{"doc_id": 0, "doc": {"person_id": 115968156, "visit_occurrence_id": 169322226, "death_date": null, "visit_concept_name": "Outpatient Visit", "visit_start_datetime": "2020-12-20 14:50:00", "visit_end_datetime": "2020-12-20 23:59:00", "visit_length_in_hours": 9.15, "integrated_visit_record": "## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-20 14:50:00, ended at 2020-12-20 23:59:00\nThe patient in this visit was 77 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred slides prepared elsewhere\n\n### Condition\n- Overlapping malignant neoplasm of male breast\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 104, "patient_first_visit_date": "2009-03-14 11:00:00", "patient_last_visit_date": "2022-11-08 16:25:00", "end_obs_date": "2021-12-20", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 1, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "recurrent", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "recurrent", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "recurrent", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "recurrent", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 6, "cumulated_visit_num": 6, "cumulated_approximate_token_count": 3919, "visit_cumulated": "## Visit\nThis visit record, was from Inpatient Visit, started at 2009-03-14 11:00:00, ended at 2009-03-15 17:02:00\nThe patient in this visit was 65 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.6 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 61 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood: 47 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 2.0 (ratio)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.6 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.67 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 251 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 26.1 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.6 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: J.CHU,Mondovi /ED @ 1153. (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 171 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 2.4 (nanogram per milliliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 233 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 16.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.3 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 9.0 (millimole per liter)\n- Prothrombin time (PT): 22.1 (second)\n- Body height: 5' 11\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Potassium [Moles/volume] in Blood: 3.3 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.77 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.6 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.04 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 86.9 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Sodium [Moles/volume] in Blood: 141 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tachypnea\n- Congestive heart failure\n- Ischemic heart disease\n- Joint pain\n- Chronic kidney disease\n- Nausea and vomiting\n- Acute subendocardial infarction\n- Hyperlipidemia\n- Hypoxemia\n- Lung field abnormal\n- Benign hypertensive renal disease with renal failure\n- Chest pain\n- Disturbance in speech\n- Hypervolemia\n- Pain in limb\n- Late effects of cerebrovascular disease\n\n### Drug\n- warfarin sodium 10 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-13\n- warfarin sodium 5 MG Oral Tablet, through Oral route, presumably until 2021-12-01. Instructions: take 5 mg by mouth. Sat and Sun schedule\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, presumably until 2021-12-03. Instructions: take 25 mg by mouth daily. \n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2009-03-13, presumably until 2009-03-13\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-15\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-13\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2009-03-14, presumably until 2009-03-15\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-14\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2009-03-13, presumably until 2009-03-13\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2009-03-15, presumably until 2009-07-10, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed for Pain. \n- baclofen 10 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2021-12-01. Instructions: take 10 mg by mouth 3 times a day. \n- lisinopril 20 MG Oral Tablet, through Oral route, presumably until 2021-12-01. Instructions: take 20 mg by mouth daily. \n- 10 ML furosemide 10 MG/ML Injection, started on 2009-03-13, presumably until 2009-03-13\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2010-03-15, with quantity of 60.0, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth 2 times a day. \n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2009-03-15, presumably until 2009-03-15\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2009-03-13, presumably until 2009-07-10. Instructions: take 300 mg by mouth 3 times a day. \n- 0.8 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2009-03-13, presumably until 2009-03-15\n- warfarin sodium 2.5 MG Oral Tablet, through Oral route, presumably until 2009-03-15. Instructions: take 2.5 mg by mouth daily. \n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-13\n- lovastatin 20 MG Oral Tablet, through Oral route. Instructions: take 20 mg by mouth every bedtime. \n- 2 ML ondansetron 2 MG/ML Injection, started on 2009-03-13, presumably until 2009-03-13\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, started on 2009-03-15, presumably until 2009-03-15\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, started on 2009-03-13, presumably until 2009-03-13\n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-15\n- 1 ML morphine sulfate 4 MG/ML Prefilled Syringe, started on 2009-03-13, presumably until 2009-03-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-05-10 00:00:00, ended at 2009-05-10 00:00:00\nThe patient in this visit was 65 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Idiopathic interstitial pneumonia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2017-01-30 00:34:00, ended at 2017-01-30 06:03:00\nThe patient in this visit was 73 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 31.9 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 229 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 144 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.2 (second)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.17 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.7 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.22 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.4 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 54 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.60 (thousand per microliter)\n- Prothrombin time (PT): 21.8 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.63 (milligram per deciliter)\n- Glucose [Mass/volume] in Blood: 262 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.2 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- MCV [Entitic volume] by Automated count: 88.2 (femtoliter)\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n\n### Condition\n- Pain in left lower limb\n- Pain in right lower limb\n- Hypoglycemia\n- Primary diagnosis: Spasm\n- Pain in lower limb\n- Essential hypertension\n\n### Drug\n- 50 ML glucose 500 MG/ML Prefilled Syringe, through Intravenous route, started on 2017-01-30, presumably until 2017-01-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2018-06-20 09:01:00, ended at 2018-06-20 13:30:00\nThe patient in this visit was 74 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.3 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.00 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 138 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.4 (percent)\n- MCV [Entitic volume] by Automated count: 88.3 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.26 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- MCH [Entitic mass] by Automated count: 29.3 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.7 (percent)\n- Prothrombin time (PT): 24.0 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 65 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 38.3 (second)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.98 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.54 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 218 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Neck pain\n- Dysarthria\n- Cerebral artery occlusion\n- Injury of muscle and tendon at neck level\n- Muscle strain\n- Spasm\n- Headache\n- Essential hypertension\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-06-20, presumably until 2018-06-20\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2018-06-20, presumably until 2018-06-20\n- lidocaine 0.05 MG/MG Medicated Patch, through Topical route, started on 2018-06-20, presumably until 2018-06-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-20 00:00:00, ended at 2020-12-20 00:00:00\nThe patient in this visit was 77 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of breast upper outer quadrant\n- Primary diagnosis: Primary malignant neoplasm of male breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-20 14:50:00, ended at 2020-12-20 23:59:00\nThe patient in this visit was 77 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred slides prepared elsewhere\n\n### Condition\n- Overlapping malignant neoplasm of male breast\n\n### Drug\n- No drugs.\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Malignant tumor of breast within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2009-03-14 11:00:00, ended at 2009-03-15 17:02:00\nThe patient in this visit was 65 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.6 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 61 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood: 47 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 2.0 (ratio)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.6 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.67 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 251 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 26.1 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.6 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: J.CHU,Mondovi /ED @ 1153. (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 171 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 2.4 (nanogram per milliliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 233 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 16.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.3 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 9.0 (millimole per liter)\n- Prothrombin time (PT): 22.1 (second)\n- Body height: 5' 11\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Potassium [Moles/volume] in Blood: 3.3 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.77 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.6 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.04 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 86.9 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Sodium [Moles/volume] in Blood: 141 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tachypnea\n- Congestive heart failure\n- Ischemic heart disease\n- Joint pain\n- Chronic kidney disease\n- Nausea and vomiting\n- Acute subendocardial infarction\n- Hyperlipidemia\n- Hypoxemia\n- Lung field abnormal\n- Benign hypertensive renal disease with renal failure\n- Chest pain\n- Disturbance in speech\n- Hypervolemia\n- Pain in limb\n- Late effects of cerebrovascular disease\n\n### Drug\n- warfarin sodium 10 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-13\n- warfarin sodium 5 MG Oral Tablet, through Oral route, presumably until 2021-12-01. Instructions: take 5 mg by mouth. Sat and Sun schedule\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, presumably until 2021-12-03. Instructions: take 25 mg by mouth daily. \n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2009-03-13, presumably until 2009-03-13\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-15\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-13\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2009-03-14, presumably until 2009-03-15\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-14\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2009-03-13, presumably until 2009-03-13\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2009-03-15, presumably until 2009-07-10, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed for Pain. \n- baclofen 10 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2021-12-01. Instructions: take 10 mg by mouth 3 times a day. \n- lisinopril 20 MG Oral Tablet, through Oral route, presumably until 2021-12-01. Instructions: take 20 mg by mouth daily. \n- 10 ML furosemide 10 MG/ML Injection, started on 2009-03-13, presumably until 2009-03-13\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2010-03-15, with quantity of 60.0, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth 2 times a day. \n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2009-03-15, presumably until 2009-03-15\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2009-03-13, presumably until 2009-07-10. Instructions: take 300 mg by mouth 3 times a day. \n- 0.8 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2009-03-13, presumably until 2009-03-15\n- warfarin sodium 2.5 MG Oral Tablet, through Oral route, presumably until 2009-03-15. Instructions: take 2.5 mg by mouth daily. \n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-13\n- lovastatin 20 MG Oral Tablet, through Oral route. Instructions: take 20 mg by mouth every bedtime. \n- 2 ML ondansetron 2 MG/ML Injection, started on 2009-03-13, presumably until 2009-03-13\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, started on 2009-03-15, presumably until 2009-03-15\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, started on 2009-03-13, presumably until 2009-03-13\n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-15\n- 1 ML morphine sulfate 4 MG/ML Prefilled Syringe, started on 2009-03-13, presumably until 2009-03-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-05-10 00:00:00, ended at 2009-05-10 00:00:00\nThe patient in this visit was 65 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Idiopathic interstitial pneumonia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2017-01-30 00:34:00, ended at 2017-01-30 06:03:00\nThe patient in this visit was 73 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 31.9 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 229 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 144 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.2 (second)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.17 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.7 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.22 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.4 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 54 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.60 (thousand per microliter)\n- Prothrombin time (PT): 21.8 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.63 (milligram per deciliter)\n- Glucose [Mass/volume] in Blood: 262 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.2 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- MCV [Entitic volume] by Automated count: 88.2 (femtoliter)\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n\n### Condition\n- Pain in left lower limb\n- Pain in right lower limb\n- Hypoglycemia\n- Primary diagnosis: Spasm\n- Pain in lower limb\n- Essential hypertension\n\n### Drug\n- 50 ML glucose 500 MG/ML Prefilled Syringe, through Intravenous route, started on 2017-01-30, presumably until 2017-01-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2018-06-20 09:01:00, ended at 2018-06-20 13:30:00\nThe patient in this visit was 74 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.3 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.00 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 138 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.4 (percent)\n- MCV [Entitic volume] by Automated count: 88.3 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.26 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- MCH [Entitic mass] by Automated count: 29.3 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.7 (percent)\n- Prothrombin time (PT): 24.0 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 65 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 38.3 (second)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.98 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.54 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 218 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Neck pain\n- Dysarthria\n- Cerebral artery occlusion\n- Injury of muscle and tendon at neck level\n- Muscle strain\n- Spasm\n- Headache\n- Essential hypertension\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-06-20, presumably until 2018-06-20\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2018-06-20, presumably until 2018-06-20\n- lidocaine 0.05 MG/MG Medicated Patch, through Topical route, started on 2018-06-20, presumably until 2018-06-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-20 00:00:00, ended at 2020-12-20 00:00:00\nThe patient in this visit was 77 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of breast upper outer quadrant\n- Primary diagnosis: Primary malignant neoplasm of male breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-20 14:50:00, ended at 2020-12-20 23:59:00\nThe patient in this visit was 77 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred slides prepared elsewhere\n\n### Condition\n- Overlapping malignant neoplasm of male breast\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Malignant tumor of breast within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of breast_cancer means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "e8f389ba77b367cd0b94b9947d1992851710e01f83c6206c3ecfe6277ecfa47d", "prompt_hash": "b06ea8d675ff151fcde6deaf5f307f568db7887648763bfa9845a274fa32a556", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 1, "doc": {"person_id": 115972392, "visit_occurrence_id": 159302851, "death_date": null, "visit_concept_name": "Telehealth", "visit_start_datetime": "2020-06-16 10:19:45", "visit_end_datetime": "2020-06-16 12:01:30", "visit_length_in_hours": 1.6958333333333333, "integrated_visit_record": "## Visit\nThis visit record, was from Telehealth, started at 2020-06-16 10:19:45, ended at 2020-06-16 12:01:30\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoporotic fracture\n\n### Drug\n- cannabidiol 100 MG/ML Oral Solution, presumably until 2020-06-16, with intended 0 refill(s)\n- ibandronic acid 150 MG Oral Tablet, through Oral route, started on 2020-06-16, presumably until 2021-06-16, with intended 0 refill(s). Instructions: take 150 mg by mouth every 30 days\n- diazepam 5 MG Oral Tablet, started on 2019-07-14, presumably until 2020-06-16, with intended 0 refill(s). Instructions: 5 mg\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2019-07-15, presumably until 2020-06-16, with intended 0 refill(s). Instructions: take 50 mg by mouth every 6 hours as needed\n- cyclobenzaprine hydrochloride 10 MG Oral Tablet, through Oral route, started on 2019-07-18, presumably until 2020-06-16, with intended 0 refill(s). Instructions: take 10 mg by mouth 3 times a day as needed\n- lactulose 667 MG/ML Oral Solution, through Oral route, started on 2019-07-17, presumably until 2020-06-16, with intended 0 refill(s). Instructions: take 40 g by mouth daily as needed\n- ondansetron 4 MG Disintegrating Oral Tablet, through Sublingual route, started on 2019-07-15, presumably until 2020-06-16, with intended 0 refill(s). Instructions: place 4 mg under the tongue and let dissolve every 8 hours as needed\n\n", "approximate_token_count": 391, "patient_first_visit_date": "2008-08-04 00:00:00", "patient_last_visit_date": "2022-11-24 00:00:00", "end_obs_date": "2021-06-16", "hypertension_type": "new", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "new", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "recurrent", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 3, "cumulated_visit_num": 3, "cumulated_approximate_token_count": 1274, "visit_cumulated": "## Visit\nThis visit record, was from Case Management Visit, started at 2008-08-04 00:00:00, ended at 2008-08-04 00:00:00\nThe patient in this visit was 60 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 37.4 (second)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Prothrombin time (PT): 13.3 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 87 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2008-08-25 06:18:00, ended at 2008-08-27 14:10:00\nThe patient in this visit was 60 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.8 (percent)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Body height: 5' 2\" (inch (US))\n- Leukocytes [#/volume] in Specimen by Automated count: 7.4 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.2 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 252 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.3 (picogram)\n- MCV [Entitic volume] by Automated count: 89.2 (femtoliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.02 (million per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2008-08-25, presumably until 2008-08-26\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2008-08-27, presumably until 2009-08-27, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day. \n- ascorbic acid 1000 MG Oral Tablet, through Oral route, presumably until 2020-06-16. Instructions: take by mouth daily. Takes more if feeling well\n- 2 ML ondansetron 2 MG/ML Injection, started on 2008-08-26, presumably until 2008-08-26\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2008-08-25, presumably until 2008-08-25\n- 1 ML promethazine hydrochloride 25 MG/ML Injection, started on 2008-08-26, presumably until 2008-08-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-16 10:19:45, ended at 2020-06-16 12:01:30\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoporotic fracture\n\n### Drug\n- cannabidiol 100 MG/ML Oral Solution, presumably until 2020-06-16, with intended 0 refill(s)\n- ibandronic acid 150 MG Oral Tablet, through Oral route, started on 2020-06-16, presumably until 2021-06-16, with intended 0 refill(s). Instructions: take 150 mg by mouth every 30 days\n- diazepam 5 MG Oral Tablet, started on 2019-07-14, presumably until 2020-06-16, with intended 0 refill(s). Instructions: 5 mg\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2019-07-15, presumably until 2020-06-16, with intended 0 refill(s). Instructions: take 50 mg by mouth every 6 hours as needed\n- cyclobenzaprine hydrochloride 10 MG Oral Tablet, through Oral route, started on 2019-07-18, presumably until 2020-06-16, with intended 0 refill(s). Instructions: take 10 mg by mouth 3 times a day as needed\n- lactulose 667 MG/ML Oral Solution, through Oral route, started on 2019-07-17, presumably until 2020-06-16, with intended 0 refill(s). Instructions: take 40 g by mouth daily as needed\n- ondansetron 4 MG Disintegrating Oral Tablet, through Sublingual route, started on 2019-07-15, presumably until 2020-06-16, with intended 0 refill(s). Instructions: place 4 mg under the tongue and let dissolve every 8 hours as needed\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Malignant tumor of breast within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-08-04 00:00:00, ended at 2008-08-04 00:00:00\nThe patient in this visit was 60 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 37.4 (second)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Prothrombin time (PT): 13.3 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 87 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2008-08-25 06:18:00, ended at 2008-08-27 14:10:00\nThe patient in this visit was 60 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.8 (percent)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Body height: 5' 2\" (inch (US))\n- Leukocytes [#/volume] in Specimen by Automated count: 7.4 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.2 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 252 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.3 (picogram)\n- MCV [Entitic volume] by Automated count: 89.2 (femtoliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.02 (million per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2008-08-25, presumably until 2008-08-26\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2008-08-27, presumably until 2009-08-27, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day. \n- ascorbic acid 1000 MG Oral Tablet, through Oral route, presumably until 2020-06-16. Instructions: take by mouth daily. Takes more if feeling well\n- 2 ML ondansetron 2 MG/ML Injection, started on 2008-08-26, presumably until 2008-08-26\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2008-08-25, presumably until 2008-08-25\n- 1 ML promethazine hydrochloride 25 MG/ML Injection, started on 2008-08-26, presumably until 2008-08-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-16 10:19:45, ended at 2020-06-16 12:01:30\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoporotic fracture\n\n### Drug\n- cannabidiol 100 MG/ML Oral Solution, presumably until 2020-06-16, with intended 0 refill(s)\n- ibandronic acid 150 MG Oral Tablet, through Oral route, started on 2020-06-16, presumably until 2021-06-16, with intended 0 refill(s). Instructions: take 150 mg by mouth every 30 days\n- diazepam 5 MG Oral Tablet, started on 2019-07-14, presumably until 2020-06-16, with intended 0 refill(s). Instructions: 5 mg\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2019-07-15, presumably until 2020-06-16, with intended 0 refill(s). Instructions: take 50 mg by mouth every 6 hours as needed\n- cyclobenzaprine hydrochloride 10 MG Oral Tablet, through Oral route, started on 2019-07-18, presumably until 2020-06-16, with intended 0 refill(s). Instructions: take 10 mg by mouth 3 times a day as needed\n- lactulose 667 MG/ML Oral Solution, through Oral route, started on 2019-07-17, presumably until 2020-06-16, with intended 0 refill(s). Instructions: take 40 g by mouth daily as needed\n- ondansetron 4 MG Disintegrating Oral Tablet, through Sublingual route, started on 2019-07-15, presumably until 2020-06-16, with intended 0 refill(s). Instructions: place 4 mg under the tongue and let dissolve every 8 hours as needed\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Malignant tumor of breast within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of breast_cancer means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "2c92333ca958bdfff3a4b813239f418ce14bbc2b45bbe8cce351b9a1b5cea3f1", "prompt_hash": "add39256bc280985cb43d1dfbb71e7d8f06ef758b354702391e646b35d2b5065", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 2, "doc": {"person_id": 115972848, "visit_occurrence_id": 193681512, "death_date": null, "visit_concept_name": "Outpatient Visit", "visit_start_datetime": "2022-01-04 19:58:00", "visit_end_datetime": "2022-01-04 23:59:00", "visit_length_in_hours": 4.016666666666667, "integrated_visit_record": "## Visit\nThis visit record, was from Outpatient Visit, started at 2022-01-04 19:58:00, ended at 2022-01-04 23:59:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n- Osteoporosis\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 145, "patient_first_visit_date": "2020-09-22 14:50:00", "patient_last_visit_date": "2023-01-21 15:20:00", "end_obs_date": "2023-01-04", "hypertension_type": "new", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "new", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "recurrent", "breast_cancer_one_year_diagnosis": 1, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 56, "cumulated_visit_num": 56, "cumulated_approximate_token_count": 7561, "visit_cumulated": "## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-22 14:50:00, ended at 2020-09-22 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred slides prepared elsewhere\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-27 13:59:00, ended at 2020-09-27 14:03:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-27 14:04:00, ended at 2020-09-27 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest; 2 views\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-10-03 12:38:31, ended at 2020-10-03 15:28:46\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-04 10:14:00, ended at 2020-10-04 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation on X-ray examination made elsewhere, written report\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-10-05 11:21:22, ended at 2020-10-05 11:41:21\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-06 10:26:00, ended at 2020-10-06 13:19:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiopharmaceutical localization of tumor, inflammatory process or distribution of radiopharmaceutical agent(s) (includes vascular flow and blood pool imaging, when performed); tomographic (SPECT) with concurrently acquired computed tomography (CT) transm\n- Bone and/or joint imaging; whole body\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-07 11:10:00, ended at 2020-10-07 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-07 11:10:00, ended at 2020-10-07 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Placement of breast localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; each additional lesion, including ultrasound guidance (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-07 11:10:00, ended at 2020-10-07 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Placement of breast localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; first lesion, including ultrasound guidance\n- Placement of breast localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; each additional lesion, including ultrasound guidance (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-10-10 00:00:00, ended at 2020-10-10 00:00:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2020-10-10, presumably until 2020-10-10\n- bacitracin 5000 UNT/ML Injectable Solution, through Intramuscular route, started on 2020-10-10, presumably until 2020-10-10\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2020-10-10, presumably until 2020-10-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-10 00:00:00, ended at 2020-10-10 00:00:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2020-10-10, presumably until 2020-10-10\n- meperidine hydrochloride 50 MG/ML Injection, started on 2020-10-10, presumably until 2020-10-10\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2020-10-10, presumably until 2020-10-10\n- cefazolin 1000 MG Injection, started on 2020-10-10, presumably until 2020-10-10\n- labetalol hydrochloride 5 MG/ML Injectable Solution, through Intravenous route, started on 2020-10-10, presumably until 2020-10-10\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2020-10-10, presumably until 2020-10-10\n- 2 ML ondansetron 2 MG/ML Injection, started on 2020-10-10, presumably until 2020-10-10\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2020-10-10, presumably until 2020-10-10\n- midazolam 1 MG/ML Injectable Solution, started on 2020-10-10, presumably until 2020-10-10\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2020-10-10, presumably until 2020-10-10\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2020-10-10, presumably until 2020-10-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-10 13:10:00, ended at 2020-10-10 21:50:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- Intraoperative identification (eg, mapping) of sentinel lymph node(s) includes injection of non-radioactive dye, when performed (List separately in addition to code for primary procedure)\n- Biopsy or excision of lymph node(s); open, deep axillary node(s)\n- Adjacent tissue transfer or rearrangement, any area; defect 30.1 sq cm to 60.0 sq cm\n- Radiological examination, surgical specimen\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Pathology consultation during surgery; first tissue block, with frozen section(s), single specimen\n- Morphometric analysis, tumor\n- Mastectomy, partial (eg, lumpectomy, tylectomy, quadrantectomy, segmentectomy)\n- Pathology consultation during surgery; each additional tissue block with frozen section(s) (List separately in addition to code for primary procedure)\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Primary malignant neoplasm of upper inner quadrant of female breast\n- Mammographic microcalcification of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-10 16:30:00, ended at 2020-10-10 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiological examination, surgical specimen\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-10-25 12:57:28, ended at 2020-10-25 14:04:03\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n- Neoplasm defined only by topography: Breast, NOS\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-10-28 15:04:13, ended at 2020-10-28 16:11:18\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.646\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-17 15:52:19, ended at 2020-11-17 16:25:10\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- anastrozole 1 MG Oral Tablet, through Oral route, started on 2020-11-17, presumably until 2021-10-31, with intended 3 refill(s). Instructions: take 1 Tab (1 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-18 00:00:00, ended at 2020-11-18 00:00:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-18 08:50:00, ended at 2020-11-18 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology treatment planning; complex\n\n### Condition\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Overlapping malignant neoplasm of female breast\n- Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-21 12:11:43, ended at 2020-11-21 12:11:58\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-23 13:48:00, ended at 2020-11-23 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology simulation-aided field setting; complex\n\n### Condition\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Overlapping malignant neoplasm of female breast\n- Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-23 13:48:00, ended at 2020-11-23 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-24 00:00:00, ended at 2020-11-24 00:00:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-24 14:15:00, ended at 2020-11-24 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- 3-dimensional radiotherapy plan, including dose-volume histograms\n- Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, onl\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Overlapping malignant neoplasm of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-29 14:06:00, ended at 2020-11-29 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment management, 5 treatments\n- Therapeutic radiology simulation-aided field setting; simple\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-30 10:14:00, ended at 2020-11-30 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n- Teletherapy isodose plan; complex (multiple treatment areas, tangential ports, the use of wedges, blocking, rotational beam, or special beam considerations), includes basic dosimetry calculation(s)\n- Therapeutic radiology port image(s)\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Overlapping malignant neoplasm of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-01 13:23:00, ended at 2020-12-01 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Overlapping malignant neoplasm of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-02 09:22:00, ended at 2020-12-02 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-04 11:20:00, ended at 2020-12-04 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-05 08:34:00, ended at 2020-12-05 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n- Radiation treatment management, 5 treatments\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-06 10:52:00, ended at 2020-12-06 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-07 07:33:00, ended at 2020-12-07 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-12 10:50:00, ended at 2020-12-12 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-13 10:42:00, ended at 2020-12-13 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-14 10:48:00, ended at 2020-12-14 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n- Radiation treatment management, 5 treatments\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-15 10:50:00, ended at 2020-12-15 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Overlapping malignant neoplasm of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-16 10:59:00, ended at 2020-12-16 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-19 10:42:00, ended at 2020-12-19 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n- Therapeutic radiology port image(s)\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-20 10:48:00, ended at 2020-12-20 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-21 10:22:00, ended at 2020-12-21 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n- Therapeutic radiology simulation-aided field setting; simple\n- Radiation treatment management, 5 treatments\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Overlapping malignant neoplasm of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-22 10:51:00, ended at 2020-12-22 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Overlapping malignant neoplasm of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-23 10:59:00, ended at 2020-12-23 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-26 10:55:00, ended at 2020-12-26 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-27 00:00:00, ended at 2020-12-27 00:00:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-01-19 13:50:04, ended at 2021-01-19 14:45:05\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n- Osteoporosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-01-27 09:00:00, ended at 2021-01-27 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.961\" (inch (US))\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Primary diagnosis: Osteoporosis\n\n### Drug\n- 100 ML zoledronic acid 0.05 MG/ML Injection, through Intravenous route, started on 2021-01-27, presumably until 2021-01-27\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2021-01-27, presumably until 2021-01-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-02-15 13:48:16, ended at 2021-02-15 14:02:19\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-28 00:00:00, ended at 2021-02-28 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-09 00:00:00, ended at 2021-03-09 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-04-20 13:41:10, ended at 2021-04-20 16:28:35\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Osteoporosis\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-21 00:00:00, ended at 2021-04-21 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n- Osteoporosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-06-28 14:40:00, ended at 2021-06-28 23:59:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic mammography, including computer-aided detection (CAD) when performed; bilateral\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-07-11 10:49:55, ended at 2021-07-11 13:05:58\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-07-28 13:47:28, ended at 2021-07-28 15:11:18\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.803\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n- Osteoporosis\n- Primary diagnosis: Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-10-31 13:10:11, ended at 2021-10-31 14:51:26\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.528\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- anastrozole 1 MG Oral Tablet, through Oral route, started on 2021-10-31, presumably until 2022-11-26, with intended 3 refill(s). Instructions: take 1 Tablet (1 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2022-01-04 19:58:00, ended at 2022-01-04 23:59:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n- Osteoporosis\n\n### Drug\n- No drugs.\n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Malignant tumor of breast within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-22 14:50:00, ended at 2020-09-22 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred slides prepared elsewhere\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-27 13:59:00, ended at 2020-09-27 14:03:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-27 14:04:00, ended at 2020-09-27 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest; 2 views\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-10-03 12:38:31, ended at 2020-10-03 15:28:46\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-04 10:14:00, ended at 2020-10-04 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation on X-ray examination made elsewhere, written report\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-10-05 11:21:22, ended at 2020-10-05 11:41:21\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-06 10:26:00, ended at 2020-10-06 13:19:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiopharmaceutical localization of tumor, inflammatory process or distribution of radiopharmaceutical agent(s) (includes vascular flow and blood pool imaging, when performed); tomographic (SPECT) with concurrently acquired computed tomography (CT) transm\n- Bone and/or joint imaging; whole body\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-07 11:10:00, ended at 2020-10-07 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-07 11:10:00, ended at 2020-10-07 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Placement of breast localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; each additional lesion, including ultrasound guidance (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-07 11:10:00, ended at 2020-10-07 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Placement of breast localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; first lesion, including ultrasound guidance\n- Placement of breast localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; each additional lesion, including ultrasound guidance (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-10-10 00:00:00, ended at 2020-10-10 00:00:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2020-10-10, presumably until 2020-10-10\n- bacitracin 5000 UNT/ML Injectable Solution, through Intramuscular route, started on 2020-10-10, presumably until 2020-10-10\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2020-10-10, presumably until 2020-10-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-10 00:00:00, ended at 2020-10-10 00:00:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2020-10-10, presumably until 2020-10-10\n- meperidine hydrochloride 50 MG/ML Injection, started on 2020-10-10, presumably until 2020-10-10\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2020-10-10, presumably until 2020-10-10\n- cefazolin 1000 MG Injection, started on 2020-10-10, presumably until 2020-10-10\n- labetalol hydrochloride 5 MG/ML Injectable Solution, through Intravenous route, started on 2020-10-10, presumably until 2020-10-10\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2020-10-10, presumably until 2020-10-10\n- 2 ML ondansetron 2 MG/ML Injection, started on 2020-10-10, presumably until 2020-10-10\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2020-10-10, presumably until 2020-10-10\n- midazolam 1 MG/ML Injectable Solution, started on 2020-10-10, presumably until 2020-10-10\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2020-10-10, presumably until 2020-10-10\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2020-10-10, presumably until 2020-10-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-10 13:10:00, ended at 2020-10-10 21:50:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- Intraoperative identification (eg, mapping) of sentinel lymph node(s) includes injection of non-radioactive dye, when performed (List separately in addition to code for primary procedure)\n- Biopsy or excision of lymph node(s); open, deep axillary node(s)\n- Adjacent tissue transfer or rearrangement, any area; defect 30.1 sq cm to 60.0 sq cm\n- Radiological examination, surgical specimen\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Pathology consultation during surgery; first tissue block, with frozen section(s), single specimen\n- Morphometric analysis, tumor\n- Mastectomy, partial (eg, lumpectomy, tylectomy, quadrantectomy, segmentectomy)\n- Pathology consultation during surgery; each additional tissue block with frozen section(s) (List separately in addition to code for primary procedure)\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Primary malignant neoplasm of upper inner quadrant of female breast\n- Mammographic microcalcification of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-10 16:30:00, ended at 2020-10-10 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiological examination, surgical specimen\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-10-25 12:57:28, ended at 2020-10-25 14:04:03\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n- Neoplasm defined only by topography: Breast, NOS\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-10-28 15:04:13, ended at 2020-10-28 16:11:18\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.646\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-17 15:52:19, ended at 2020-11-17 16:25:10\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- anastrozole 1 MG Oral Tablet, through Oral route, started on 2020-11-17, presumably until 2021-10-31, with intended 3 refill(s). Instructions: take 1 Tab (1 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-18 00:00:00, ended at 2020-11-18 00:00:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-18 08:50:00, ended at 2020-11-18 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology treatment planning; complex\n\n### Condition\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Overlapping malignant neoplasm of female breast\n- Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-21 12:11:43, ended at 2020-11-21 12:11:58\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-23 13:48:00, ended at 2020-11-23 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology simulation-aided field setting; complex\n\n### Condition\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Overlapping malignant neoplasm of female breast\n- Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-23 13:48:00, ended at 2020-11-23 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-24 00:00:00, ended at 2020-11-24 00:00:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-24 14:15:00, ended at 2020-11-24 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- 3-dimensional radiotherapy plan, including dose-volume histograms\n- Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, onl\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Overlapping malignant neoplasm of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-29 14:06:00, ended at 2020-11-29 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment management, 5 treatments\n- Therapeutic radiology simulation-aided field setting; simple\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-30 10:14:00, ended at 2020-11-30 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n- Teletherapy isodose plan; complex (multiple treatment areas, tangential ports, the use of wedges, blocking, rotational beam, or special beam considerations), includes basic dosimetry calculation(s)\n- Therapeutic radiology port image(s)\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Overlapping malignant neoplasm of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-01 13:23:00, ended at 2020-12-01 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Overlapping malignant neoplasm of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-02 09:22:00, ended at 2020-12-02 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-04 11:20:00, ended at 2020-12-04 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-05 08:34:00, ended at 2020-12-05 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n- Radiation treatment management, 5 treatments\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-06 10:52:00, ended at 2020-12-06 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-07 07:33:00, ended at 2020-12-07 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-12 10:50:00, ended at 2020-12-12 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-13 10:42:00, ended at 2020-12-13 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-14 10:48:00, ended at 2020-12-14 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n- Radiation treatment management, 5 treatments\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-15 10:50:00, ended at 2020-12-15 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Overlapping malignant neoplasm of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-16 10:59:00, ended at 2020-12-16 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-19 10:42:00, ended at 2020-12-19 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n- Therapeutic radiology port image(s)\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-20 10:48:00, ended at 2020-12-20 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Overlapping malignant neoplasm of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-21 10:22:00, ended at 2020-12-21 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n- Therapeutic radiology simulation-aided field setting; simple\n- Radiation treatment management, 5 treatments\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Overlapping malignant neoplasm of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-22 10:51:00, ended at 2020-12-22 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Overlapping malignant neoplasm of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-23 10:59:00, ended at 2020-12-23 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-26 10:55:00, ended at 2020-12-26 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, >/=1 MeV; complex\n\n### Condition\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Overlapping malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-27 00:00:00, ended at 2020-12-27 00:00:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-01-19 13:50:04, ended at 2021-01-19 14:45:05\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n- Osteoporosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-01-27 09:00:00, ended at 2021-01-27 23:59:00\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.961\" (inch (US))\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Primary diagnosis: Osteoporosis\n\n### Drug\n- 100 ML zoledronic acid 0.05 MG/ML Injection, through Intravenous route, started on 2021-01-27, presumably until 2021-01-27\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2021-01-27, presumably until 2021-01-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-02-15 13:48:16, ended at 2021-02-15 14:02:19\nThe patient in this visit was 67 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-28 00:00:00, ended at 2021-02-28 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-09 00:00:00, ended at 2021-03-09 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-04-20 13:41:10, ended at 2021-04-20 16:28:35\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Osteoporosis\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-21 00:00:00, ended at 2021-04-21 00:00:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n- Osteoporosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-06-28 14:40:00, ended at 2021-06-28 23:59:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic mammography, including computer-aided detection (CAD) when performed; bilateral\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-07-11 10:49:55, ended at 2021-07-11 13:05:58\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-07-28 13:47:28, ended at 2021-07-28 15:11:18\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.803\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n- Osteoporosis\n- Primary diagnosis: Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-10-31 13:10:11, ended at 2021-10-31 14:51:26\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.528\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of upper outer quadrant of female breast\n\n### Drug\n- anastrozole 1 MG Oral Tablet, through Oral route, started on 2021-10-31, presumably until 2022-11-26, with intended 3 refill(s). Instructions: take 1 Tablet (1 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2022-01-04 19:58:00, ended at 2022-01-04 23:59:00\nThe patient in this visit was 68 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n- Osteoporosis\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Malignant tumor of breast within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of breast_cancer means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "7ed32a537f51599798f13906e3eeed07d2004846c63de9061d12dcb4564856c8", "prompt_hash": "c23b2f74664408a53677084749c18086686795ec033c6aecf85a2c86da1ad83e", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 0.0, "f1_gu_yn": [1, 0], "recall_gu_yn": [1, 0]}
{"doc_id": 3, "doc": {"person_id": 115973365, "visit_occurrence_id": 107924426, "death_date": "2020-04-04", "visit_concept_name": "Outpatient Visit", "visit_start_datetime": "2017-08-25 08:06:00", "visit_end_datetime": "2017-08-25 23:59:00", "visit_length_in_hours": 15.883333333333333, "integrated_visit_record": "## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-25 08:06:00, ended at 2017-08-25 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 122, "patient_first_visit_date": "2014-01-11 00:00:00", "patient_last_visit_date": "2020-04-01 14:58:00", "end_obs_date": "2018-08-25", "hypertension_type": "new", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "recurrent", "type_ii_diabetes_one_year_diagnosis": 1, "breast_cancer_type": "recurrent", "breast_cancer_one_year_diagnosis": 1, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "recurrent", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 230, "cumulated_visit_num": 230, "cumulated_approximate_token_count": 52218, "visit_cumulated": "## Visit\nThis visit record, was from Case Management Visit, started at 2014-01-11 00:00:00, ended at 2014-01-11 00:00:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Breast lump\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-01-16 00:00:00, ended at 2014-01-16 00:00:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Mammography abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-17 14:20:00, ended at 2014-01-17 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Mammography; unilateral\n- Computer-aided detection (computer algorithm analysis of digital image data for lesion detection) with further review for interpretation, with or without digitization of film radiographic images; diagnostic mammography (List separately in addition to code\n\n### Condition\n- Abnormal findings on diagnostic imaging of breast\n- Mammography abnormal\n- Breast lump\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-17 14:20:00, ended at 2014-01-17 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, breast(s) (unilateral or bilateral), real time with image documentation\n\n### Condition\n- Mammography abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-17 14:20:00, ended at 2014-01-17 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, limited, joint or other nonvascular extremity structure(s) (eg, joint space, peri-articular tendon[s], muscle[s], nerve[s], other soft-tissue structure[s], or soft-tissue mass[es]), real-time with image documentation\n\n### Condition\n- Mammography abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-18 08:00:00, ended at 2014-01-18 08:05:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Carcinoma in situ of breast\n- Primary malignant neoplasm of female breast\n- Breast lump\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-18 08:06:00, ended at 2014-01-18 08:06:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Morphometric analysis, tumor\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Neoplasm of lymph nodes of upper limb\n- Primary malignant neoplasm of female breast\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-18 08:07:00, ended at 2014-01-18 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Fine needle aspiration; with imaging guidance\n- Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including ultrasound guidance\n- Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation\n\n### Condition\n- Breast lump\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-22 10:43:00, ended at 2014-01-22 13:15:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.465\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- glipizide 5 MG Oral Tablet, through Oral route, presumably until 2014-12-31. Instructions: take 5 mg by mouth Every Day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-22 13:16:00, ended at 2014-01-22 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 76.2 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.6 (percent)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.1 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 104 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 123 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.3 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.65 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.44 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 348 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.1 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 24.8 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 9.92 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.81 (million per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-23 09:34:00, ended at 2014-01-23 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.465\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- metformin hydrochloride 500 MG Oral Tablet, through Oral route. Instructions: take 500 mg by mouth daily \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-29 15:39:00, ended at 2014-01-29 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.465\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-02-01 00:00:00, ended at 2014-02-01 00:00:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 72 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-01 13:00:00, ended at 2014-02-01 13:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Antineoplastic poisoning\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-01 16:00:00, ended at 2014-02-01 16:10:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Antineoplastic poisoning\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-01 16:11:00, ended at 2014-02-01 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Magnetic resonance imaging, breast, without and/or with contrast material(s); bilateral\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Breast lump\n- Lymphadenopathy\n- Primary malignant neoplasm of female breast\n- Lung field abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-02-05 00:00:00, ended at 2014-02-05 00:00:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-06 08:56:00, ended at 2014-02-06 11:32:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-06 11:33:00, ended at 2014-02-06 11:42:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 183 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.4 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 306 (thousand per microliter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.68 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.2 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.3 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 75.2 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.94 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.38 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.72 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.2 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 24.4 (picogram)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-06 11:43:00, ended at 2014-02-06 16:14:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-06 16:15:00, ended at 2014-02-06 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 9.087\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2014-02-06, presumably until 2014-06-25, with intended 6 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed. For nausea and vomiting.\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2014-02-06, presumably until 2014-05-08, with intended 1 refill(s). Instructions: take 2 Tabs by mouth 2 times a day in the morning and noon. Take twice daily on the day before, the day of and the day after docetaxel (TAXOTERE) treatment.\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2014-02-06, presumably until 2014-06-25, with intended 6 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed. For nausea and vomiting.\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2014-02-06, presumably until 2014-06-25, with intended 6 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed. For nausea and vomiting.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-07 11:39:00, ended at 2014-02-07 15:03:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10\" (inch (US))\n\n### Procedure\n- Fluoroscopic guidance for central venous access device placement, replacement (catheter only or complete), or removal (includes fluoroscopic guidance for vascular access and catheter manipulation, any necessary contrast injections through access site or c\n- Insertion of graft for vascular access\n- Collection of venous blood by venipuncture\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Insertion of tunneled centrally inserted central venous access device, with subcutaneous port; age 5 years or older\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2014-02-07, presumably until 2014-02-07\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2014-02-07, presumably until 2014-02-07\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-02-07, presumably until 2014-02-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-11 08:57:00, ended at 2014-02-11 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 140 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 93 (unit per liter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2014-02-11, presumably until 2014-02-11\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-02-11, presumably until 2014-02-11\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-02-11, presumably until 2014-02-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-02-12 00:00:00, ended at 2014-02-12 00:00:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2014-02-12, presumably until 2015-02-12, with intended 0 refill(s). Instructions: by Topical route as needed. Apply to skin on chest port 30-60 minutes prior to chest port access.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-12 15:58:00, ended at 2014-02-12 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2014-02-12, presumably until 2014-02-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-06 09:01:00, ended at 2014-03-06 09:39:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.3 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.74 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 332 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.7 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 198 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 25.8 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.88 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.82 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 77.2 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 109 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 12.31 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.9 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-06 09:40:00, ended at 2014-03-06 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 9.087\" (inch (US))\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy follow-up\n\n### Condition\n- Type 2 diabetes mellitus without complication\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2014-03-06, presumably until 2014-03-06\n- ranitidine 150 MG Oral Tablet, through Oral route, presumably until 2014-06-25. Instructions: take 1 Tab by mouth daily as needed (stomache upset).\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-03-06, presumably until 2014-03-06\n- loratadine 10 MG Oral Tablet, through Oral route, presumably until 2014-06-25. Instructions: take 1 Tab by mouth daily as needed (after receiving neulasta).\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-07 16:50:00, ended at 2014-03-07 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2014-03-07, presumably until 2014-03-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-27 07:38:00, ended at 2014-03-27 07:50:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.12 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Neutrophils [#/volume] in Blood by Automated count: 10.81 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 402 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 120 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 198 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 161 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 8.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.58 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 26.0 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 83.6 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 17 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.4 (percent)\n- MCV [Entitic volume] by Automated count: 77.9 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 24.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.9 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Anion gap in Serum or Plasma: 18 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-27 07:51:00, ended at 2014-03-27 09:36:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 9.087\" (inch (US))\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy follow-up\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2014-03-27, presumably until 2014-03-27\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-03-27, presumably until 2014-03-27\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-03-27, presumably until 2014-03-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-27 09:37:00, ended at 2014-03-27 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-28 16:00:00, ended at 2014-03-28 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2014-03-28, presumably until 2014-03-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-17 07:54:00, ended at 2014-04-17 08:16:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.6 (percent)\n- MCH [Entitic mass] by Automated count: 23.3 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.17 (million per microliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 116 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 130 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.45 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.44 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.8 (percent)\n- MCHC [Mass/volume] by Automated count: 31.2 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 364 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 240 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 80.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 7.4 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.8 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 74.7 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 23.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.89 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Anion gap in Serum or Plasma: 16 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-17 08:17:00, ended at 2014-04-17 13:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.661\" (inch (US))\n\n### Procedure\n- Genetic counseling\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Anemia\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2014-04-17, presumably until 2014-04-17\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-04-17, presumably until 2014-04-17\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-04-17, presumably until 2014-04-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-17 14:00:00, ended at 2014-04-17 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-18 16:07:00, ended at 2014-04-18 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2014-04-18, presumably until 2014-04-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-04-22 00:00:00, ended at 2014-04-22 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-04-22 00:00:00, ended at 2014-04-22 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-23 11:08:00, ended at 2014-04-23 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 74.0 (percent)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 23.6 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.70 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.14 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 21.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 7.0 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.3 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 228 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- MCV [Entitic volume] by Automated count: 73.2 (femtoliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 353 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 156 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.3 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.97 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 249 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.77 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-04-24 00:00:00, ended at 2014-04-24 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-29 08:20:00, ended at 2014-04-29 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 21.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 144 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 30.8 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.81 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 278 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 180 (thousand per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Hemoglobin [Mass/volume] in Blood: 6.6 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 23.2 (picogram)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.3 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.5 (percent)\n- MCV [Entitic volume] by Automated count: 75.4 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 6 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.86 (million per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.2 (percent)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.23 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.25 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n\n### Procedure\n- Transfusion, blood or blood components\n\n### Condition\n- Anemia\n- Primary malignant neoplasm of female breast\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2014-04-29, presumably until 2014-04-29\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-04-29, presumably until 2014-04-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-05-02 00:00:00, ended at 2014-05-02 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-02 13:46:00, ended at 2014-05-02 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.055\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-08 07:54:00, ended at 2014-05-08 08:14:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 241 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.6 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.62 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 77.7 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.9 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 25.0 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 276 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.22 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 31.9 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 16.5 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 152 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 124 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.81 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 78.3 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.6 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Anion gap in Serum or Plasma: 15 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.50 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-08 08:15:00, ended at 2014-05-08 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.858\" (inch (US))\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2014-05-08, presumably until 2014-05-08\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2014-05-08, presumably until 2014-06-25, with intended 1 refill(s). Instructions: take 2 Tabs by mouth 2 times a day. Take twice daily on the day before, the day of and the day after docetaxel (TAXOTERE) treatment.\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-05-08, presumably until 2014-05-08\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-05-08, presumably until 2014-05-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-09 11:20:00, ended at 2014-05-09 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2014-05-09, presumably until 2014-05-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-05-20 00:00:00, ended at 2014-05-20 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 64.4 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-20 15:00:00, ended at 2014-05-20 16:18:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Antineoplastic poisoning\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-20 16:19:00, ended at 2014-05-20 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance imaging, breast, without and/or with contrast material(s); bilateral\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-21 08:25:00, ended at 2014-05-21 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, limited, joint or other nonvascular extremity structure(s) (eg, joint space, peri-articular tendon[s], muscle[s], nerve[s], other soft-tissue structure[s], or soft-tissue mass[es]), real-time with image documentation\n- Mammography; bilateral\n- Ultrasound, breast(s) (unilateral or bilateral), real time with image documentation\n- Unlisted diagnostic radiographic procedure\n\n### Condition\n- Abnormal findings on diagnostic imaging of breast\n- Breast lump\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-05-23 00:00:00, ended at 2014-05-23 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-28 10:30:00, ended at 2014-05-28 12:20:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.055\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-28 12:21:00, ended at 2014-05-28 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.055\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-29 07:50:00, ended at 2014-05-29 08:44:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 80.6 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.2 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 81.8 (femtoliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 123 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.93 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 269 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.1 (percent)\n- MCH [Entitic mass] by Automated count: 26.1 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 279 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.3 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.65 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.7 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.2 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.06 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.0 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 128 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-05-29, presumably until 2014-05-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-29 08:45:00, ended at 2014-05-29 09:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.858\" (inch (US))\n\n### Procedure\n- Counseling\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-29 10:00:00, ended at 2014-05-29 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2014-05-29, presumably until 2014-05-29\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-05-29, presumably until 2014-05-29\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-05-29, presumably until 2014-05-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-30 15:52:00, ended at 2014-05-30 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2014-05-30, presumably until 2014-05-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-06-07 00:00:00, ended at 2014-06-07 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-07 07:30:00, ended at 2014-06-07 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Lung field abnormal\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-12 11:00:00, ended at 2014-06-12 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.858\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2014-06-18 00:00:00, ended at 2014-06-18 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-18 15:10:00, ended at 2014-06-18 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Non-toxic multinodular goiter\n- Primary malignant neoplasm of female breast\n- Imaging result abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-06-19 00:00:00, ended at 2014-06-19 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-06-19 00:00:00, ended at 2014-06-19 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic multinodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-19 10:46:00, ended at 2014-06-19 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-25 10:00:00, ended at 2014-06-25 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-07-03 00:00:00, ended at 2014-07-03 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-09 14:12:00, ended at 2014-07-09 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Lymphatics and lymph nodes imaging\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-10 00:00:00, ended at 2014-07-10 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for all procedures on nerves, muscles, tendons, fascia, and bursae of shoulder and axilla\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2014-07-10, presumably until 2014-07-10\n- cefazolin 1000 MG Injection, started on 2014-07-10, presumably until 2014-07-10\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2014-07-10, presumably until 2014-07-10\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2014-07-10, presumably until 2014-07-10\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-07-10, presumably until 2014-07-10\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-07-10, presumably until 2014-07-10\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2014-07-10, presumably until 2014-07-10\n- midazolam 1 MG/ML Injectable Solution, started on 2014-07-10, presumably until 2014-07-10\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2014-07-10, presumably until 2014-07-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2014-07-10 00:00:00, ended at 2014-07-10 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2014-07-10, presumably until 2014-07-10\n- bupivacaine hydrochloride 5 MG/ML Injectable Solution, started on 2014-07-10, presumably until 2014-07-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-10 07:05:00, ended at 2014-07-11 10:55:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- Placement of breast localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; first lesion, including mammographic guidance\n- Radiological examination, surgical specimen\n- Partial mastectomy\n- Excision of axillary lymph node\n- Computed tomography guidance for needle placement (eg, biopsy, aspiration, injection, localization device), radiological supervision and interpretation\n- Biopsy or excision of lymph node(s); open, deep axillary node(s)\n- Pathology consultation during surgery; cytologic examination (eg, touch prep, squash prep), initial site\n- Unlisted procedure, breast\n- Mastectomy, partial (eg, lumpectomy, tylectomy, quadrantectomy, segmentectomy)\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n\n### Condition\n- Breast lump\n- Estrogen receptor positive tumor\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Primary malignant neoplasm of female breast\n- Gastroesophageal reflux disease\n- Non-toxic uninodular goiter\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2014-07-10, presumably until 2014-07-10\n- docusate sodium 100 MG Oral Capsule, started on 2014-07-10, presumably until 2014-12-31, with intended 0 refill(s). Instructions: 1 tab po bid.\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-07-10, presumably until 2014-07-10\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2014-07-10, presumably until 2014-10-02, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-14 08:58:00, ended at 2014-07-14 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-07-14, presumably until 2014-07-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-18 09:00:00, ended at 2014-07-18 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-31 11:00:00, ended at 2014-07-31 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.661\" (inch (US))\n\n### Procedure\n- Chemotherapy follow-up\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Primary diagnosis: Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-01 12:26:00, ended at 2014-08-01 13:29:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Special treatment procedure (eg, total body irradiation, hemibody radiation, per oral or endocavitary irradiation)\n- Therapeutic radiology simulation-aided field setting; complex\n- Therapeutic radiology treatment planning; complex\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-01 13:30:00, ended at 2014-08-01 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology simulation-aided field setting; complex\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-03 08:00:00, ended at 2014-08-03 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.52 (million per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 129 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.93 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 26.6 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 247 (thousand per microliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 268 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.3 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 44.7 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.89 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.6 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- MCV [Entitic volume] by Automated count: 81.1 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 178 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 43.7 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.34 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.0 (gram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-08-03, presumably until 2014-08-03\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-08-03, presumably until 2014-08-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-15 07:00:00, ended at 2014-08-15 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Respiratory motion management simulation (List separately in addition to code for primary procedure)\n- Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, onl\n- 3-dimensional radiotherapy plan, including dose-volume histograms\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-20 11:52:00, ended at 2014-08-20 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.055\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-22 14:45:00, ended at 2014-08-22 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n- Radiation treatment management, 5 treatments\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-23 07:15:00, ended at 2014-08-23 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-24 08:00:00, ended at 2014-08-24 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.39 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.28 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 302 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.8 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 80.5 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 200 (thousand per microliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 260 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 35.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.27 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 54.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.49 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.7 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 122 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- MCH [Entitic mass] by Automated count: 26.8 (picogram)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.1 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Type 2 diabetes mellitus without complication\n- Primary malignant neoplasm of female breast\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-08-24, presumably until 2014-08-24\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-08-24, presumably until 2014-08-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-26 07:00:00, ended at 2014-08-26 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-27 07:00:00, ended at 2014-08-27 07:29:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-27 07:30:00, ended at 2014-08-27 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computer-aided detection (computer algorithm analysis of digital image data for lesion detection) with further review for interpretation, with or without digitization of film radiographic images; diagnostic mammography (List separately in addition to code\n- Mammography; unilateral\n\n### Condition\n- Inconclusive mammography finding\n- Breast lump\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-28 07:00:00, ended at 2014-08-28 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-29 09:41:00, ended at 2014-08-29 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment management, 5 treatments\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-30 07:04:00, ended at 2014-08-30 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n- Therapeutic radiology port image(s)\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-02 07:03:00, ended at 2014-09-02 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-03 07:14:00, ended at 2014-09-03 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-04 07:01:00, ended at 2014-09-04 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-05 07:08:00, ended at 2014-09-05 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment management, 5 treatments\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-06 07:08:00, ended at 2014-09-06 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology port image(s)\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-09 07:07:00, ended at 2014-09-09 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-10 07:08:00, ended at 2014-09-10 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-11 07:07:00, ended at 2014-09-11 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-12 07:07:00, ended at 2014-09-12 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n- Radiation treatment management, 5 treatments\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-13 07:09:00, ended at 2014-09-13 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-14 08:00:00, ended at 2014-09-14 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Triglyceride [Moles/volume] in Serum or Plasma: 414 (milligram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-09-14, presumably until 2014-09-14\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-09-14, presumably until 2014-09-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-09-16 00:00:00, ended at 2014-09-16 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-16 07:10:00, ended at 2014-09-16 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n- Therapeutic radiology simulation-aided field setting; complex\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-17 06:57:00, ended at 2014-09-17 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology port image(s)\n- Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, onl\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-18 07:05:00, ended at 2014-09-18 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-19 07:05:00, ended at 2014-09-19 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment management, 5 treatments\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-20 07:07:00, ended at 2014-09-20 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-23 07:05:00, ended at 2014-09-23 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-24 07:09:00, ended at 2014-09-24 07:53:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-24 07:54:00, ended at 2014-09-24 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 61.7 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Antineoplastic poisoning\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-25 07:08:00, ended at 2014-09-25 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-26 07:09:00, ended at 2014-09-26 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment management, 5 treatments\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-27 07:15:00, ended at 2014-09-27 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-30 07:00:00, ended at 2014-09-30 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-01 07:00:00, ended at 2014-10-01 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-02 06:54:00, ended at 2014-10-02 09:11:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-02 09:12:00, ended at 2014-10-02 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.858\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- tamoxifen 20 MG Oral Tablet, through Oral route, started on 2014-10-02, presumably until 2015-05-29, with intended 1 refill(s). Instructions: take 20 mg by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-05 08:00:00, ended at 2014-10-05 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-10-05, presumably until 2014-10-05\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-10-05, presumably until 2014-10-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-15 14:00:00, ended at 2014-10-15 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.858\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Mammography abnormal\n- Breast lump\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-25 13:14:00, ended at 2014-10-25 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, breast(s) (unilateral or bilateral), real time with image documentation\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Breast lump\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-26 07:56:00, ended at 2014-10-26 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-10-26, presumably until 2014-10-26\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-10-26, presumably until 2014-10-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2014-11-13 00:00:00, ended at 2014-11-13 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 0.154 MEQ/ML Irrigation Solution, through Topical route, started on 2014-11-13, presumably until 2014-11-13\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2014-11-13, presumably until 2014-11-13\n- bupivacaine hydrochloride 5 MG/ML Injectable Solution, started on 2014-11-13, presumably until 2014-11-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-11-13 00:00:00, ended at 2014-11-13 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on the integumentary system on the extremities, anterior trunk and perineum; not otherwise specified\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Microcalcifications of the breast\n- Carcinoma in situ of breast\n\n### Drug\n- cefazolin 1000 MG Injection, started on 2014-11-13, presumably until 2014-11-13\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2014-11-13, presumably until 2014-11-13\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-11-13, presumably until 2014-11-13\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-11-13, presumably until 2014-11-13\n- midazolam 1 MG/ML Injectable Solution, started on 2014-11-13, presumably until 2014-11-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-11-13 06:33:00, ended at 2014-11-13 13:40:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11\" (inch (US))\n\n### Procedure\n- Other diagnostic procedures on breast\n- Local excision of lesion of breast\n- Other mammography\n- Radiological examination, surgical specimen\n- Placement of breast localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; first lesion, including mammographic guidance\n- Mastectomy, partial (eg, lumpectomy, tylectomy, quadrantectomy, segmentectomy)\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n\n### Condition\n- Type 2 diabetes mellitus without complication\n- Gastroesophageal reflux disease\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Breast lump\n- Primary malignant neoplasm of female breast\n- Carcinoma in situ of uterine cervix\n- Microcalcifications of the breast\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2014-11-13, presumably until 2014-12-31, with intended 0 refill(s). Instructions: take 1 Packet by mouth One Time.\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-11-13, presumably until 2014-11-13\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2014-11-13, presumably until 2014-11-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-11-16 08:00:00, ended at 2014-11-16 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.7 (percent)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 286 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 163 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.85 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 239 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Hemoglobin [Mass/volume] in Blood: 10.8 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.9 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 116 (unit per liter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.2 (picogram)\n- MCV [Entitic volume] by Automated count: 84.9 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-11-16, presumably until 2014-11-16\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-11-16, presumably until 2014-11-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-11-20 11:30:00, ended at 2014-11-20 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-11-26 14:52:00, ended at 2014-11-26 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.976\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-11-27 13:00:00, ended at 2014-11-27 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.976\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-12-07 08:00:00, ended at 2014-12-07 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2014-12-07, presumably until 2014-12-07\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-12-07, presumably until 2014-12-07\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-12-07, presumably until 2014-12-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-12-28 08:00:00, ended at 2014-12-28 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-12-28, presumably until 2014-12-28\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-12-28, presumably until 2014-12-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-12-31 11:00:00, ended at 2014-12-31 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.89\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- glipizide 5 MG Oral Tablet, through Oral route, presumably until 2017-02-23, with intended 0 refill(s). Instructions: take 5 mg by mouth Every Day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-01-01 00:00:00, ended at 2015-01-01 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-01-07 12:52:00, ended at 2015-01-07 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 62.0 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Antineoplastic poisoning\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-01-18 08:00:00, ended at 2015-01-18 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2015-01-18, presumably until 2015-01-18\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-01-18, presumably until 2015-01-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-08 08:00:00, ended at 2015-02-08 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2015-02-08, presumably until 2015-02-08\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-02-08, presumably until 2015-02-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-12 13:38:00, ended at 2015-02-12 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.606\" (inch (US))\n\n### Procedure\n- Chemotherapy follow-up\n\n### Condition\n- Non-toxic uninodular goiter\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-03-10 07:17:00, ended at 2015-03-10 12:05:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.4 (percent)\n- INR in Blood by Coagulation assay: 1.2 (ratio)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 32.5 (percent)\n- MCV [Entitic volume] by Automated count: 78.3 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.12 (thousand per microliter)\n- Body height: 5' 0\" (inch (US))\n- Glucose [Mass/volume] in Blood: 143 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.9 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.4 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.79 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.36 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 56.7 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 202 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.95 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.5 (percent)\n- MCH [Entitic mass] by Automated count: 26.2 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n- Removal of tunneled central venous access device, with subcutaneous port or pump, central or peripheral insertion\n- Removal of foreign body from skin and/or subcutaneous tissue by incision\n- Other soft tissue x-ray of chest wall\n- Fluoroscopic guidance for central venous access device placement, replacement (catheter only or complete), or removal (includes fluoroscopic guidance for vascular access and catheter manipulation, any necessary contrast injections through access site or c\n\n### Condition\n- Convalescence after chemotherapy\n- Estrogen receptor positive tumor\n- Goiter\n- Primary malignant neoplasm of female breast\n- Gastroesophageal reflux disease\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-03-10, presumably until 2015-03-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-03-26 10:43:59, ended at 2015-03-26 13:35:47\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.449\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Lymphadenopathy\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2015-03-26, presumably until 2015-04-02, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-04-03 09:41:35, ended at 2015-04-03 11:07:42\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n- General examination of patient\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Disorder of muscle\n- Anemia\n- Pure hyperglyceridemia\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- cyclobenzaprine hydrochloride 5 MG Oral Tablet, through Oral route, started on 2015-04-03, presumably until 2015-09-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed\n- 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inacti..., through Intramuscular route, started on 2015-04-03, presumably until 2015-04-03, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time\n- metformin hydrochloride 1000 MG Oral Tablet, through Oral route, started on 2015-04-03, presumably until 2015-09-24, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-04-14 08:00:11, ended at 2015-04-14 08:36:14\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of left eye: 11 (millimeter mercury column)\n- Intraocular pressure of right eye: 14 (millimeter mercury column)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-05-21 11:08:18, ended at 2015-05-21 12:25:43\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-05-29 00:00:00, ended at 2015-05-29 00:00:00\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tamoxifen 20 MG Oral Tablet, through Oral route, started on 2015-05-29, presumably until 2016-05-28, with intended 11 refill(s). Instructions: take 20 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-06-23 19:28:00, ended at 2015-06-23 23:59:00\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance imaging, breast, without and/or with contrast material(s); bilateral\n\n### Condition\n- Breast lump\n- Non-toxic multinodular goiter\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-09-10 13:04:52, ended at 2015-09-10 14:28:02\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute upper respiratory infection\n- Primary malignant neoplasm of female breast\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- codeine phosphate 2 MG/ML / guaifenesin 20 MG/ML Oral Solution, through Oral route, started on 2015-09-10, presumably until 2015-09-24, with intended 0 refill(s). Instructions: take 5-10 mL by mouth every 6 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-11-04 00:00:00, ended at 2015-11-04 00:00:00\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-11-04 10:45:00, ended at 2015-11-04 23:59:00\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic digital breast tomosynthesis; bilateral\n- Mammography; bilateral\n\n### Condition\n- Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-12-09 10:58:47, ended at 2015-12-09 11:34:31\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.45\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cough\n\n### Drug\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2015-12-09, presumably until 2016-05-31, with intended 0 refill(s). Instructions: 1 Puff by Inhalation route every 6 hours as needed Substitute with whichever inhaler is covered by her insurance\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-12-09 11:37:00, ended at 2015-12-09 23:59:00\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Cough\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-01-28 10:30:34, ended at 2016-01-28 11:24:45\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- omeprazole 20 MG Delayed Release Oral Capsule, through Oral route, started on 2016-01-28, presumably until 2016-05-31, with intended 5 refill(s). Instructions: take 20 mg by mouth as needed (Take once daily as needed for heart burn or stomach upset.)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-12 07:00:00, ended at 2016-03-12 23:59:00\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 60.2 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Disorder due to and following accidental poisoning\n- Disorder due to and following drug poisoning\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-18 21:30:00, ended at 2016-05-18 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance imaging, breast, without and/or with contrast material(s); bilateral\n\n### Condition\n- Lymphadenopathy\n- Localized enlarged lymph nodes\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-19 00:00:00, ended at 2016-05-19 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Imaging result abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-20 09:13:00, ended at 2016-05-20 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 196 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Steatosis of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-21 10:29:00, ended at 2016-05-21 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation\n- Morphometric analysis, tumor\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Fine needle aspiration; with imaging guidance\n\n### Condition\n- Lymphadenopathy\n- Secondary malignant neoplasm of lymph nodes of upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-21 14:53:15, ended at 2016-05-21 15:28:01\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Temporomandibular joint disorder\n- Acute upper respiratory infection\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-24 00:00:00, ended at 2016-05-24 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]), one or two mediastinal and/or hilar lymph node stat\n\n### Condition\n- Primary diagnosis: Imaging result abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-24 00:00:00, ended at 2016-05-24 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Imaging result abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-27 12:39:44, ended at 2016-05-27 15:41:50\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Lymphadenopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-31 13:13:07, ended at 2016-05-31 14:11:54\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-06-01 12:05:00, ended at 2016-06-01 12:05:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Non-toxic multinodular goiter\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-06-02 00:00:00, ended at 2016-06-02 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for closed chest procedures; (including bronchoscopy) not otherwise specified\n\n### Condition\n- Secondary malignant neoplasm of right lung\n- Primary malignant neoplasm of female breast\n- Localized enlarged lymph nodes\n\n### Drug\n- remifentanil 2 MG Injection, through Intravenous route, started on 2016-06-02, presumably until 2016-06-02\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2016-06-02, presumably until 2016-06-02\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2016-06-02, presumably until 2016-06-02\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-06-02, presumably until 2016-06-02\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-06-02, presumably until 2016-06-02\n- midazolam 1 MG/ML Injectable Solution, started on 2016-06-02, presumably until 2016-06-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-06-02 07:05:00, ended at 2016-06-02 09:46:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n- Glucose [Mass/volume] in Blood: 155 (milligram per deciliter)\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial needle aspiration biopsy(s), trachea, main stem and/or lobar bronchus(i)\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]), one or two mediastinal and/or hilar lymph node stat\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transendoscopic endobronchial ultrasound (EBUS) during bronchoscopic diagnostic or therapeutic intervention(s) for peripheral lesion(s) (List separately in addition to \n- Excision of Thorax Lymphatic, Percutaneous Endoscopic Approach, Diagnostic\n\n### Condition\n- Generalized enlarged lymph nodes\n- Secondary malignant neoplasm of lymph nodes of multiple sites\n- Secondary malignant neoplasm of right lung\n- Localized enlarged lymph nodes\n- Hyperlipidemia\n- Gastroesophageal reflux disease without esophagitis\n- Primary malignant neoplasm of female breast\n- Type 2 diabetes mellitus without complication\n- Non-toxic uninodular goiter\n- Secondary malignant neoplasm of intrathoracic lymph nodes\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2016-06-02, presumably until 2016-06-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-04 00:00:00, ended at 2016-06-04 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-04 00:00:00, ended at 2016-06-04 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-08 00:00:00, ended at 2016-06-08 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-09 10:01:55, ended at 2016-06-09 14:06:45\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neck pain\n- Primary diagnosis: Primary malignant neoplasm of female breast\n- Polyneuropathy\n- Infiltrating duct carcinoma, NOS, of breast, NOS\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-06-09 13:33:00, ended at 2016-06-09 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-06-09, presumably until 2016-06-09\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-06-09, presumably until 2016-06-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-06-10 00:00:00, ended at 2016-06-10 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tamoxifen 20 MG Oral Tablet, started on 2016-06-11, presumably until 2016-06-11, with intended 11 refill(s). Instructions: TAKE 20 MG BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-29 00:00:00, ended at 2016-06-29 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-30 11:34:59, ended at 2016-06-30 14:24:31\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-06-30, presumably until 2017-06-15, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2016-06-30, presumably until 2016-12-27, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-07-06 11:00:35, ended at 2016-07-06 13:19:31\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-21 08:00:00, ended at 2016-07-21 10:16:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 60.6 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Disorder due to and following accidental poisoning\n- Disorder due to and following drug poisoning\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-07-21 08:49:59, ended at 2016-07-21 13:20:39\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-21 10:17:00, ended at 2016-07-21 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-07-21, presumably until 2016-07-21\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-07-21, presumably until 2016-07-21\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-05 10:09:00, ended at 2016-08-05 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- goserelin 3.6 MG Drug Implant, through Subcutaneous route, started on 2016-08-05, presumably until 2016-08-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-12 00:00:00, ended at 2016-08-12 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-08-13 00:00:00, ended at 2016-08-13 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-14 11:25:00, ended at 2016-08-14 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.71 (million per microliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 8.0 (percent)\n- MCHC [Mass/volume] by Automated count: 32.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.40 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 42.5 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 418 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.3 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 91 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 154 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.2 (percent)\n- MCH [Entitic mass] by Automated count: 25.4 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.24 (thousand per microliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: <10.00 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.4 (percent)\n- Albumin [Mass/volume] in Urine: <5 (milligram per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 214 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 199 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 46.5 (percent)\n- MCV [Entitic volume] by Automated count: 79.4 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 112 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.44 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 4.4 (ratio)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.41 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 232 (thousand per microliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 45 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-08-14, presumably until 2016-08-14\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-08-14, presumably until 2016-08-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-09-04 08:59:00, ended at 2016-09-04 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 43.6 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.44 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 205 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.3 (percent)\n- MCH [Entitic mass] by Automated count: 25.4 (picogram)\n- MCV [Entitic volume] by Automated count: 78.6 (femtoliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.87 (million per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.32 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 97 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.00 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.88 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 176 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.3 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 46.4 (percent)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- goserelin 3.6 MG Drug Implant, through Subcutaneous route, started on 2016-09-04, presumably until 2016-09-04\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-09-04, presumably until 2016-09-04\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-09-04, presumably until 2016-09-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-09-13 07:08:00, ended at 2016-09-13 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Solitary nodule of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-09-13 07:08:00, ended at 2016-09-13 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 140 (milligram per deciliter)\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Abnormal findings on diagnostic imaging of lung\n- Localized enlarged lymph nodes\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-22 10:48:07, ended at 2016-09-22 11:32:12\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n- Joint pain\n- Neck pain\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-09-22 10:50:00, ended at 2016-09-22 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.8 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.8 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 46.9 (percent)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.44 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 45.9 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.42 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 164 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.5 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 100 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.74 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 79.0 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 25.7 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 2.66 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 165 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 73 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.16 (million per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-09-22, presumably until 2016-09-22\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-09-22, presumably until 2016-09-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-02 07:49:00, ended at 2016-10-02 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- goserelin 3.6 MG Drug Implant, through Subcutaneous route, started on 2016-10-02, presumably until 2016-10-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-16 10:06:00, ended at 2016-10-16 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.9 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 45.3 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 103 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 251 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.79 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 25.2 (picogram)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 45.6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 138 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 47 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.40 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 51 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.9 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.91 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.78 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.6 (percent)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 77.3 (femtoliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-10-16, presumably until 2016-10-16\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-10-16, presumably until 2016-10-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-30 08:30:00, ended at 2016-10-30 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- goserelin 3.6 MG Drug Implant, through Subcutaneous route, started on 2016-10-30, presumably until 2016-10-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-03 00:00:00, ended at 2016-11-03 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 70.3 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-11-03 11:00:00, ended at 2016-11-03 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Disorder due to and following drug poisoning\n- Disorder due to and following accidental poisoning\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-11-06 09:40:00, ended at 2016-11-06 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.39 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 69 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 123 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.68 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.80 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 55 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 47.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.8 (percent)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.14 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.8 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 118 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 320 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.8 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 24.9 (picogram)\n- MCV [Entitic volume] by Automated count: 76.3 (femtoliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 44.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-11-06, presumably until 2016-11-06\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-11-06, presumably until 2016-11-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-11-19 14:56:51, ended at 2016-11-19 16:37:46\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; manual screening under physician supervision\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n- Noninflammatory cervical disorder\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-11-27 09:50:00, ended at 2016-11-27 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Monocytes [#/volume] in Blood by Automated count: 0.33 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 154 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.40 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 76.3 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 71 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 31.9 (percent)\n- MCHC [Mass/volume] by Automated count: 32.2 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.07 (million per microliter)\n- Globulin [Mass/volume] in Serum: 5.2 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.6 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 292 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.9 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 24.5 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 131 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.93 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.5 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.57 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- goserelin 3.6 MG Drug Implant, through Subcutaneous route, started on 2016-11-27, presumably until 2016-11-27\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-11-27, presumably until 2016-11-27\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-11-27, presumably until 2016-11-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-01 09:56:07, ended at 2016-12-01 10:51:26\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-17 08:19:06, ended at 2016-12-17 09:34:57\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient\n\n### Condition\n- Muscle pain\n- Primary diagnosis: Neck pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-18 08:30:00, ended at 2016-12-18 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 168 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 76.3 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.26 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 64 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.5 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 65 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.73 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.3 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.17 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.9 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 158 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.5 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.43 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 40.7 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 49.2 (percent)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.43 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 24.2 (picogram)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.6 (percent)\n- MCHC [Mass/volume] by Automated count: 31.7 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 103 (thousand per microliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-12-18, presumably until 2016-12-18\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, presumably until 2017-02-23, with intended 0 refill(s). Instructions: inject subcutaneous (under the skin) 3 times a day Breakfast 4 units, lunch and dinner 6 units\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-12-18, presumably until 2016-12-18\n- insulin glargine 100 UNT/ML Injectable Solution, through Subcutaneous route, presumably until 2019-06-20, with intended 0 refill(s). Instructions: inject 16 Units subcutaneous (under the skin) daily in the evening \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-24 08:09:00, ended at 2016-12-24 15:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-24 08:09:00, ended at 2016-12-24 15:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 143 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n- Localized enlarged lymph nodes\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-24 16:00:00, ended at 2016-12-24 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- goserelin 3.6 MG Drug Implant, through Subcutaneous route, started on 2016-12-24, presumably until 2016-12-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-29 12:58:45, ended at 2016-12-29 16:57:34\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-08 08:30:00, ended at 2017-01-08 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 75.8 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.39 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.04 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 31.8 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 266 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 59 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.07 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 44.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 185 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 67 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.2 (percent)\n- MCH [Entitic mass] by Automated count: 24.1 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 83 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.5 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.24 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.9 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 41.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.14 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-13 00:00:00, ended at 2017-01-13 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for intraperitoneal procedures in lower abdomen including laparoscopy; not otherwise specified\n\n### Condition\n- Type 2 diabetes mellitus without complication\n- Gastroesophageal reflux disease without esophagitis\n- Primary malignant neoplasm of female breast\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, started on 2017-01-13, presumably until 2017-01-13\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2017-01-13, presumably until 2017-01-13\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2017-01-13, presumably until 2017-01-13\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-01-13, presumably until 2017-01-13\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-01-13, presumably until 2017-01-13\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-01-13, presumably until 2017-01-13\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-01-13, presumably until 2017-01-13\n- midazolam 1 MG/ML Injectable Solution, started on 2017-01-13, presumably until 2017-01-13\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2017-01-13, presumably until 2017-01-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-01-13 00:00:00, ended at 2017-01-13 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 5 MG/ML Injectable Solution, started on 2017-01-13, presumably until 2017-01-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-13 13:12:00, ended at 2017-01-13 22:24:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n- Glucose [Mass/volume] in Blood: 155 (milligram per deciliter)\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Collection of venous blood by venipuncture\n- Resection of Bilateral Fallopian Tubes, Percutaneous Endoscopic Approach\n- Resection of Bilateral Ovaries, Percutaneous Endoscopic Approach\n- Laparoscopy, surgical; with removal of adnexal structures (partial or total oophorectomy and/or salpingectomy)\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n- Disorder of female genital organs\n- Follicular cyst of left ovary\n- Pure hyperglyceridemia\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Simple goiter\n- Type 2 diabetes mellitus without complication\n- Follicular cyst of right ovary\n- Primary malignant neoplasm of female breast\n- Secondary malignant neoplasm of intrathoracic lymph nodes\n\n### Drug\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-01-13, presumably until 2017-03-16, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2017-01-13, presumably until 2017-01-13\n- ibuprofen 600 MG Oral Tablet, through Oral route, started on 2017-01-13, presumably until 2017-03-16, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2017-01-13, presumably until 2017-01-13\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-01-13, presumably until 2017-01-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-24 11:11:08, ended at 2017-01-24 12:57:59\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.843\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-26 14:06:02, ended at 2017-01-26 16:27:37\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.843\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n- Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- anastrozole 1 MG Oral Tablet, through Oral route, started on 2017-01-26, presumably until 2017-02-25, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-29 08:30:00, ended at 2017-01-29 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 143 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.6 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 75.3 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.91 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 97 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.46 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 130 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.7 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.42 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 39.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 156 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.3 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 253 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.09 (million per microliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 8.0 (percent)\n- MCH [Entitic mass] by Automated count: 24.6 (picogram)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 52.5 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n- Primary malignant neoplasm of female breast\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-01-29, presumably until 2017-01-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-02-19 08:30:00, ended at 2017-02-19 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 195 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 188 (unit per liter)\n- MCV [Entitic volume] by Automated count: 76.0 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 87 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 285 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.1 (percent)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.5 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.33 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 37.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.89 (thousand per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.43 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.6 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 238 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.2 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.87 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.0 (percent)\n- MCH [Entitic mass] by Automated count: 25.0 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 53.4 (percent)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-02-19, presumably until 2017-02-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-02-23 13:58:57, ended at 2017-02-23 15:22:25\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.843\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n- Secondary malignant neoplasm of intrathoracic lymph nodes\n\n### Drug\n- anastrozole 1 MG Oral Tablet, through Oral route, started on 2017-02-25, presumably until 2017-05-23, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-12 07:49:00, ended at 2017-03-12 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 250 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.8 (percent)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 24.7 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 49.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 90 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 262 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 275 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.80 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 75.9 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.25 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.8 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.6 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.9 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.46 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.82 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.41 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 261 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.7 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 38.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-03-12, presumably until 2017-03-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-03-15 00:00:00, ended at 2017-03-15 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-16 10:40:00, ended at 2017-03-16 11:58:02\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.843\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Elevated level of transaminase and lactic acid dehydrogenase\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-17 14:25:00, ended at 2017-03-17 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; complete study\n- Ultrasound, abdominal, real time with image documentation; complete\n\n### Condition\n- Elevated level of transaminase and lactic acid dehydrogenase\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-23 09:38:18, ended at 2017-03-23 12:35:44\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.843\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Elevated level of transaminase and lactic acid dehydrogenase\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-03-31 00:00:00, ended at 2017-03-31 00:00:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-02 08:26:00, ended at 2017-04-02 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- MCV [Entitic volume] by Automated count: 77.1 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 79 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 39.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.47 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 49.6 (percent)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 256 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 25.0 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.52 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.3 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 80 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.4 (percent)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.17 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 89 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.46 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.0 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 211 (unit per liter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-04-02, presumably until 2017-04-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-04-06 00:00:00, ended at 2017-04-06 00:00:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 63.4 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-06 09:00:00, ended at 2017-04-06 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Poisoning by drug AND/OR medicinal substance\n- Accidental poisoning\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-04-06 09:39:31, ended at 2017-04-06 11:12:22\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.843\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-04-09 00:00:00, ended at 2017-04-09 00:00:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver function tests abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-23 08:30:00, ended at 2017-04-23 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 73 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.4 (percent)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.6 (percent)\n- MCV [Entitic volume] by Automated count: 78.0 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.99 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.51 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.3 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 37.1 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 103 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.25 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.82 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 270 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 239 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.4 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.9 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.4 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 50.7 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 94 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.2 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.46 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 25.3 (picogram)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-04-23, presumably until 2017-04-23\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-29 12:41:00, ended at 2017-04-29 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 112 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Localized enlarged lymph nodes\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-29 12:41:00, ended at 2017-04-29 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Localized enlarged lymph nodes\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-05-14 08:24:00, ended at 2017-05-14 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-05-23 00:00:00, ended at 2017-05-23 00:00:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- anastrozole 1 MG Oral Tablet, through Oral route, started on 2017-05-23, presumably until 2018-02-01, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-04 08:10:00, ended at 2017-06-04 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-06-04, presumably until 2017-06-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-15 13:27:45, ended at 2017-06-15 14:24:51\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.843\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-25 08:10:00, ended at 2017-06-25 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 66 (unit per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.16 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.2 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.3 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.56 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 40.4 (percent)\n- MCV [Entitic volume] by Automated count: 78.9 (femtoliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.6 (gram per deciliter)\n- Prothrombin time (PT): 13.0 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 182 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.84 (million per microliter)\n- MCH [Entitic mass] by Automated count: 26.0 (picogram)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 47.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.46 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 239 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.32 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 115 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 36.9 (second)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.29 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-06-25, presumably until 2017-06-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-07-16 08:06:00, ended at 2017-07-16 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-07-16, presumably until 2017-07-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-07-21 00:00:00, ended at 2017-07-21 00:00:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-03 09:00:00, ended at 2017-08-03 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 60.8 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Poisoning by drug AND/OR medicinal substance\n- Accidental poisoning\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-06 08:10:00, ended at 2017-08-06 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-08-06, presumably until 2017-08-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-25 08:06:00, ended at 2017-08-25 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 112 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Localized enlarged lymph nodes\n- Primary malignant neoplasm of female breast\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-25 08:06:00, ended at 2017-08-25 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Malignant tumor of breast within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-01-11 00:00:00, ended at 2014-01-11 00:00:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Breast lump\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-01-16 00:00:00, ended at 2014-01-16 00:00:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Mammography abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-17 14:20:00, ended at 2014-01-17 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Mammography; unilateral\n- Computer-aided detection (computer algorithm analysis of digital image data for lesion detection) with further review for interpretation, with or without digitization of film radiographic images; diagnostic mammography (List separately in addition to code\n\n### Condition\n- Abnormal findings on diagnostic imaging of breast\n- Mammography abnormal\n- Breast lump\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-17 14:20:00, ended at 2014-01-17 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, breast(s) (unilateral or bilateral), real time with image documentation\n\n### Condition\n- Mammography abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-17 14:20:00, ended at 2014-01-17 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, limited, joint or other nonvascular extremity structure(s) (eg, joint space, peri-articular tendon[s], muscle[s], nerve[s], other soft-tissue structure[s], or soft-tissue mass[es]), real-time with image documentation\n\n### Condition\n- Mammography abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-18 08:00:00, ended at 2014-01-18 08:05:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Carcinoma in situ of breast\n- Primary malignant neoplasm of female breast\n- Breast lump\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-18 08:06:00, ended at 2014-01-18 08:06:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Morphometric analysis, tumor\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Neoplasm of lymph nodes of upper limb\n- Primary malignant neoplasm of female breast\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-18 08:07:00, ended at 2014-01-18 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Fine needle aspiration; with imaging guidance\n- Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including ultrasound guidance\n- Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation\n\n### Condition\n- Breast lump\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-22 10:43:00, ended at 2014-01-22 13:15:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.465\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- glipizide 5 MG Oral Tablet, through Oral route, presumably until 2014-12-31. Instructions: take 5 mg by mouth Every Day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-22 13:16:00, ended at 2014-01-22 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 76.2 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.6 (percent)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.1 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 104 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 123 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.3 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.65 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.44 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 348 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.1 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 24.8 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 9.92 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.81 (million per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-23 09:34:00, ended at 2014-01-23 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.465\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- metformin hydrochloride 500 MG Oral Tablet, through Oral route. Instructions: take 500 mg by mouth daily \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-29 15:39:00, ended at 2014-01-29 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.465\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-02-01 00:00:00, ended at 2014-02-01 00:00:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 72 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-01 13:00:00, ended at 2014-02-01 13:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Antineoplastic poisoning\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-01 16:00:00, ended at 2014-02-01 16:10:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Antineoplastic poisoning\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-01 16:11:00, ended at 2014-02-01 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Magnetic resonance imaging, breast, without and/or with contrast material(s); bilateral\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Breast lump\n- Lymphadenopathy\n- Primary malignant neoplasm of female breast\n- Lung field abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-02-05 00:00:00, ended at 2014-02-05 00:00:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-06 08:56:00, ended at 2014-02-06 11:32:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-06 11:33:00, ended at 2014-02-06 11:42:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 183 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.4 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 306 (thousand per microliter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.68 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.2 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.3 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 75.2 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.94 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.38 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.72 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.2 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 24.4 (picogram)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-06 11:43:00, ended at 2014-02-06 16:14:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-06 16:15:00, ended at 2014-02-06 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 9.087\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2014-02-06, presumably until 2014-06-25, with intended 6 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed. For nausea and vomiting.\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2014-02-06, presumably until 2014-05-08, with intended 1 refill(s). Instructions: take 2 Tabs by mouth 2 times a day in the morning and noon. Take twice daily on the day before, the day of and the day after docetaxel (TAXOTERE) treatment.\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2014-02-06, presumably until 2014-06-25, with intended 6 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed. For nausea and vomiting.\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2014-02-06, presumably until 2014-06-25, with intended 6 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed. For nausea and vomiting.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-07 11:39:00, ended at 2014-02-07 15:03:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10\" (inch (US))\n\n### Procedure\n- Fluoroscopic guidance for central venous access device placement, replacement (catheter only or complete), or removal (includes fluoroscopic guidance for vascular access and catheter manipulation, any necessary contrast injections through access site or c\n- Insertion of graft for vascular access\n- Collection of venous blood by venipuncture\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Insertion of tunneled centrally inserted central venous access device, with subcutaneous port; age 5 years or older\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2014-02-07, presumably until 2014-02-07\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2014-02-07, presumably until 2014-02-07\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-02-07, presumably until 2014-02-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-11 08:57:00, ended at 2014-02-11 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 140 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 93 (unit per liter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2014-02-11, presumably until 2014-02-11\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-02-11, presumably until 2014-02-11\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-02-11, presumably until 2014-02-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-02-12 00:00:00, ended at 2014-02-12 00:00:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2014-02-12, presumably until 2015-02-12, with intended 0 refill(s). Instructions: by Topical route as needed. Apply to skin on chest port 30-60 minutes prior to chest port access.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-12 15:58:00, ended at 2014-02-12 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2014-02-12, presumably until 2014-02-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-06 09:01:00, ended at 2014-03-06 09:39:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.3 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.74 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 332 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.7 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 198 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 25.8 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.88 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.82 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 77.2 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 109 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 12.31 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.9 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-06 09:40:00, ended at 2014-03-06 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 9.087\" (inch (US))\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy follow-up\n\n### Condition\n- Type 2 diabetes mellitus without complication\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2014-03-06, presumably until 2014-03-06\n- ranitidine 150 MG Oral Tablet, through Oral route, presumably until 2014-06-25. Instructions: take 1 Tab by mouth daily as needed (stomache upset).\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-03-06, presumably until 2014-03-06\n- loratadine 10 MG Oral Tablet, through Oral route, presumably until 2014-06-25. Instructions: take 1 Tab by mouth daily as needed (after receiving neulasta).\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-07 16:50:00, ended at 2014-03-07 23:59:00\nThe patient in this visit was 40 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2014-03-07, presumably until 2014-03-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-27 07:38:00, ended at 2014-03-27 07:50:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.12 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Neutrophils [#/volume] in Blood by Automated count: 10.81 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 402 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 120 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 198 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 161 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 8.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.58 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 26.0 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 83.6 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 17 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.4 (percent)\n- MCV [Entitic volume] by Automated count: 77.9 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 24.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.9 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Anion gap in Serum or Plasma: 18 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-27 07:51:00, ended at 2014-03-27 09:36:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 9.087\" (inch (US))\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy follow-up\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2014-03-27, presumably until 2014-03-27\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-03-27, presumably until 2014-03-27\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-03-27, presumably until 2014-03-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-27 09:37:00, ended at 2014-03-27 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-28 16:00:00, ended at 2014-03-28 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2014-03-28, presumably until 2014-03-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-17 07:54:00, ended at 2014-04-17 08:16:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.6 (percent)\n- MCH [Entitic mass] by Automated count: 23.3 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.17 (million per microliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 116 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 130 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.45 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.44 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.8 (percent)\n- MCHC [Mass/volume] by Automated count: 31.2 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 364 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 240 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 80.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 7.4 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.8 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 74.7 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 23.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.89 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Anion gap in Serum or Plasma: 16 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-17 08:17:00, ended at 2014-04-17 13:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.661\" (inch (US))\n\n### Procedure\n- Genetic counseling\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Anemia\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2014-04-17, presumably until 2014-04-17\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-04-17, presumably until 2014-04-17\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-04-17, presumably until 2014-04-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-17 14:00:00, ended at 2014-04-17 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-18 16:07:00, ended at 2014-04-18 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2014-04-18, presumably until 2014-04-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-04-22 00:00:00, ended at 2014-04-22 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-04-22 00:00:00, ended at 2014-04-22 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-23 11:08:00, ended at 2014-04-23 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 74.0 (percent)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 23.6 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.70 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.14 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 21.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 7.0 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.3 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 228 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- MCV [Entitic volume] by Automated count: 73.2 (femtoliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 353 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 156 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.3 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.97 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 249 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.77 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-04-24 00:00:00, ended at 2014-04-24 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-29 08:20:00, ended at 2014-04-29 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 21.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 144 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 30.8 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.81 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 278 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 180 (thousand per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Hemoglobin [Mass/volume] in Blood: 6.6 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 23.2 (picogram)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.3 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.5 (percent)\n- MCV [Entitic volume] by Automated count: 75.4 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 6 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.86 (million per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.2 (percent)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.23 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.25 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n\n### Procedure\n- Transfusion, blood or blood components\n\n### Condition\n- Anemia\n- Primary malignant neoplasm of female breast\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2014-04-29, presumably until 2014-04-29\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-04-29, presumably until 2014-04-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-05-02 00:00:00, ended at 2014-05-02 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-02 13:46:00, ended at 2014-05-02 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.055\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-08 07:54:00, ended at 2014-05-08 08:14:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 241 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.6 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.62 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 77.7 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.9 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 25.0 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 276 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.22 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 31.9 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 16.5 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 152 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 124 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.81 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 78.3 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.6 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Anion gap in Serum or Plasma: 15 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.50 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-08 08:15:00, ended at 2014-05-08 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.858\" (inch (US))\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2014-05-08, presumably until 2014-05-08\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2014-05-08, presumably until 2014-06-25, with intended 1 refill(s). Instructions: take 2 Tabs by mouth 2 times a day. Take twice daily on the day before, the day of and the day after docetaxel (TAXOTERE) treatment.\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-05-08, presumably until 2014-05-08\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-05-08, presumably until 2014-05-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-09 11:20:00, ended at 2014-05-09 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2014-05-09, presumably until 2014-05-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-05-20 00:00:00, ended at 2014-05-20 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 64.4 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-20 15:00:00, ended at 2014-05-20 16:18:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Antineoplastic poisoning\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-20 16:19:00, ended at 2014-05-20 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance imaging, breast, without and/or with contrast material(s); bilateral\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-21 08:25:00, ended at 2014-05-21 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, limited, joint or other nonvascular extremity structure(s) (eg, joint space, peri-articular tendon[s], muscle[s], nerve[s], other soft-tissue structure[s], or soft-tissue mass[es]), real-time with image documentation\n- Mammography; bilateral\n- Ultrasound, breast(s) (unilateral or bilateral), real time with image documentation\n- Unlisted diagnostic radiographic procedure\n\n### Condition\n- Abnormal findings on diagnostic imaging of breast\n- Breast lump\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-05-23 00:00:00, ended at 2014-05-23 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-28 10:30:00, ended at 2014-05-28 12:20:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.055\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-28 12:21:00, ended at 2014-05-28 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.055\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-29 07:50:00, ended at 2014-05-29 08:44:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 80.6 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.2 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 81.8 (femtoliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 123 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.93 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 269 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.1 (percent)\n- MCH [Entitic mass] by Automated count: 26.1 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 279 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.3 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.65 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.7 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.2 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.06 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.0 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 128 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-05-29, presumably until 2014-05-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-29 08:45:00, ended at 2014-05-29 09:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.858\" (inch (US))\n\n### Procedure\n- Counseling\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-29 10:00:00, ended at 2014-05-29 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2014-05-29, presumably until 2014-05-29\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-05-29, presumably until 2014-05-29\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-05-29, presumably until 2014-05-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-30 15:52:00, ended at 2014-05-30 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2014-05-30, presumably until 2014-05-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-06-07 00:00:00, ended at 2014-06-07 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-07 07:30:00, ended at 2014-06-07 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Lung field abnormal\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-12 11:00:00, ended at 2014-06-12 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.858\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2014-06-18 00:00:00, ended at 2014-06-18 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-18 15:10:00, ended at 2014-06-18 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Non-toxic multinodular goiter\n- Primary malignant neoplasm of female breast\n- Imaging result abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-06-19 00:00:00, ended at 2014-06-19 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-06-19 00:00:00, ended at 2014-06-19 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic multinodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-19 10:46:00, ended at 2014-06-19 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-25 10:00:00, ended at 2014-06-25 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-07-03 00:00:00, ended at 2014-07-03 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-09 14:12:00, ended at 2014-07-09 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Lymphatics and lymph nodes imaging\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-10 00:00:00, ended at 2014-07-10 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for all procedures on nerves, muscles, tendons, fascia, and bursae of shoulder and axilla\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2014-07-10, presumably until 2014-07-10\n- cefazolin 1000 MG Injection, started on 2014-07-10, presumably until 2014-07-10\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2014-07-10, presumably until 2014-07-10\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2014-07-10, presumably until 2014-07-10\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-07-10, presumably until 2014-07-10\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-07-10, presumably until 2014-07-10\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2014-07-10, presumably until 2014-07-10\n- midazolam 1 MG/ML Injectable Solution, started on 2014-07-10, presumably until 2014-07-10\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2014-07-10, presumably until 2014-07-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2014-07-10 00:00:00, ended at 2014-07-10 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2014-07-10, presumably until 2014-07-10\n- bupivacaine hydrochloride 5 MG/ML Injectable Solution, started on 2014-07-10, presumably until 2014-07-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-10 07:05:00, ended at 2014-07-11 10:55:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- Placement of breast localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; first lesion, including mammographic guidance\n- Radiological examination, surgical specimen\n- Partial mastectomy\n- Excision of axillary lymph node\n- Computed tomography guidance for needle placement (eg, biopsy, aspiration, injection, localization device), radiological supervision and interpretation\n- Biopsy or excision of lymph node(s); open, deep axillary node(s)\n- Pathology consultation during surgery; cytologic examination (eg, touch prep, squash prep), initial site\n- Unlisted procedure, breast\n- Mastectomy, partial (eg, lumpectomy, tylectomy, quadrantectomy, segmentectomy)\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n\n### Condition\n- Breast lump\n- Estrogen receptor positive tumor\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Primary malignant neoplasm of female breast\n- Gastroesophageal reflux disease\n- Non-toxic uninodular goiter\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2014-07-10, presumably until 2014-07-10\n- docusate sodium 100 MG Oral Capsule, started on 2014-07-10, presumably until 2014-12-31, with intended 0 refill(s). Instructions: 1 tab po bid.\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-07-10, presumably until 2014-07-10\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2014-07-10, presumably until 2014-10-02, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-14 08:58:00, ended at 2014-07-14 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-07-14, presumably until 2014-07-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-18 09:00:00, ended at 2014-07-18 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-31 11:00:00, ended at 2014-07-31 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.661\" (inch (US))\n\n### Procedure\n- Chemotherapy follow-up\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Primary diagnosis: Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-01 12:26:00, ended at 2014-08-01 13:29:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Special treatment procedure (eg, total body irradiation, hemibody radiation, per oral or endocavitary irradiation)\n- Therapeutic radiology simulation-aided field setting; complex\n- Therapeutic radiology treatment planning; complex\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-01 13:30:00, ended at 2014-08-01 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology simulation-aided field setting; complex\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-03 08:00:00, ended at 2014-08-03 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.52 (million per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 129 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.93 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 26.6 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 247 (thousand per microliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 268 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.3 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 44.7 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.89 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.6 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- MCV [Entitic volume] by Automated count: 81.1 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 178 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 43.7 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.34 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.0 (gram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-08-03, presumably until 2014-08-03\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-08-03, presumably until 2014-08-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-15 07:00:00, ended at 2014-08-15 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Respiratory motion management simulation (List separately in addition to code for primary procedure)\n- Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, onl\n- 3-dimensional radiotherapy plan, including dose-volume histograms\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-20 11:52:00, ended at 2014-08-20 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.055\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-22 14:45:00, ended at 2014-08-22 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n- Radiation treatment management, 5 treatments\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-23 07:15:00, ended at 2014-08-23 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-24 08:00:00, ended at 2014-08-24 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.39 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.28 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 302 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.8 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 80.5 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 200 (thousand per microliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 260 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 35.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.27 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 54.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.49 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.7 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 122 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- MCH [Entitic mass] by Automated count: 26.8 (picogram)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.1 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Type 2 diabetes mellitus without complication\n- Primary malignant neoplasm of female breast\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-08-24, presumably until 2014-08-24\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-08-24, presumably until 2014-08-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-26 07:00:00, ended at 2014-08-26 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-27 07:00:00, ended at 2014-08-27 07:29:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-27 07:30:00, ended at 2014-08-27 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computer-aided detection (computer algorithm analysis of digital image data for lesion detection) with further review for interpretation, with or without digitization of film radiographic images; diagnostic mammography (List separately in addition to code\n- Mammography; unilateral\n\n### Condition\n- Inconclusive mammography finding\n- Breast lump\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-28 07:00:00, ended at 2014-08-28 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-29 09:41:00, ended at 2014-08-29 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment management, 5 treatments\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-30 07:04:00, ended at 2014-08-30 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n- Therapeutic radiology port image(s)\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-02 07:03:00, ended at 2014-09-02 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-03 07:14:00, ended at 2014-09-03 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-04 07:01:00, ended at 2014-09-04 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-05 07:08:00, ended at 2014-09-05 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment management, 5 treatments\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-06 07:08:00, ended at 2014-09-06 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology port image(s)\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-09 07:07:00, ended at 2014-09-09 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-10 07:08:00, ended at 2014-09-10 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-11 07:07:00, ended at 2014-09-11 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-12 07:07:00, ended at 2014-09-12 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n- Radiation treatment management, 5 treatments\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-13 07:09:00, ended at 2014-09-13 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-14 08:00:00, ended at 2014-09-14 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Triglyceride [Moles/volume] in Serum or Plasma: 414 (milligram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-09-14, presumably until 2014-09-14\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-09-14, presumably until 2014-09-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-09-16 00:00:00, ended at 2014-09-16 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-16 07:10:00, ended at 2014-09-16 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n- Therapeutic radiology simulation-aided field setting; complex\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-17 06:57:00, ended at 2014-09-17 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology port image(s)\n- Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, onl\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-18 07:05:00, ended at 2014-09-18 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-19 07:05:00, ended at 2014-09-19 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment management, 5 treatments\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-20 07:07:00, ended at 2014-09-20 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-23 07:05:00, ended at 2014-09-23 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-24 07:09:00, ended at 2014-09-24 07:53:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-24 07:54:00, ended at 2014-09-24 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 61.7 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Antineoplastic poisoning\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-25 07:08:00, ended at 2014-09-25 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-26 07:09:00, ended at 2014-09-26 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment management, 5 treatments\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-27 07:15:00, ended at 2014-09-27 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-30 07:00:00, ended at 2014-09-30 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-01 07:00:00, ended at 2014-10-01 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-02 06:54:00, ended at 2014-10-02 09:11:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-02 09:12:00, ended at 2014-10-02 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.858\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- tamoxifen 20 MG Oral Tablet, through Oral route, started on 2014-10-02, presumably until 2015-05-29, with intended 1 refill(s). Instructions: take 20 mg by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-05 08:00:00, ended at 2014-10-05 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-10-05, presumably until 2014-10-05\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-10-05, presumably until 2014-10-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-15 14:00:00, ended at 2014-10-15 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.858\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Mammography abnormal\n- Breast lump\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-25 13:14:00, ended at 2014-10-25 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, breast(s) (unilateral or bilateral), real time with image documentation\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Breast lump\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-26 07:56:00, ended at 2014-10-26 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-10-26, presumably until 2014-10-26\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-10-26, presumably until 2014-10-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2014-11-13 00:00:00, ended at 2014-11-13 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 0.154 MEQ/ML Irrigation Solution, through Topical route, started on 2014-11-13, presumably until 2014-11-13\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2014-11-13, presumably until 2014-11-13\n- bupivacaine hydrochloride 5 MG/ML Injectable Solution, started on 2014-11-13, presumably until 2014-11-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-11-13 00:00:00, ended at 2014-11-13 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on the integumentary system on the extremities, anterior trunk and perineum; not otherwise specified\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Microcalcifications of the breast\n- Carcinoma in situ of breast\n\n### Drug\n- cefazolin 1000 MG Injection, started on 2014-11-13, presumably until 2014-11-13\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2014-11-13, presumably until 2014-11-13\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-11-13, presumably until 2014-11-13\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-11-13, presumably until 2014-11-13\n- midazolam 1 MG/ML Injectable Solution, started on 2014-11-13, presumably until 2014-11-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-11-13 06:33:00, ended at 2014-11-13 13:40:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11\" (inch (US))\n\n### Procedure\n- Other diagnostic procedures on breast\n- Local excision of lesion of breast\n- Other mammography\n- Radiological examination, surgical specimen\n- Placement of breast localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; first lesion, including mammographic guidance\n- Mastectomy, partial (eg, lumpectomy, tylectomy, quadrantectomy, segmentectomy)\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n\n### Condition\n- Type 2 diabetes mellitus without complication\n- Gastroesophageal reflux disease\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Breast lump\n- Primary malignant neoplasm of female breast\n- Carcinoma in situ of uterine cervix\n- Microcalcifications of the breast\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2014-11-13, presumably until 2014-12-31, with intended 0 refill(s). Instructions: take 1 Packet by mouth One Time.\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-11-13, presumably until 2014-11-13\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2014-11-13, presumably until 2014-11-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-11-16 08:00:00, ended at 2014-11-16 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.7 (percent)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 286 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 163 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.85 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 239 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Hemoglobin [Mass/volume] in Blood: 10.8 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.9 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 116 (unit per liter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.2 (picogram)\n- MCV [Entitic volume] by Automated count: 84.9 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-11-16, presumably until 2014-11-16\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-11-16, presumably until 2014-11-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-11-20 11:30:00, ended at 2014-11-20 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-11-26 14:52:00, ended at 2014-11-26 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.976\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-11-27 13:00:00, ended at 2014-11-27 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.976\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-12-07 08:00:00, ended at 2014-12-07 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2014-12-07, presumably until 2014-12-07\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-12-07, presumably until 2014-12-07\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-12-07, presumably until 2014-12-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-12-28 08:00:00, ended at 2014-12-28 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-12-28, presumably until 2014-12-28\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-12-28, presumably until 2014-12-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-12-31 11:00:00, ended at 2014-12-31 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 10.89\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- glipizide 5 MG Oral Tablet, through Oral route, presumably until 2017-02-23, with intended 0 refill(s). Instructions: take 5 mg by mouth Every Day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-01-01 00:00:00, ended at 2015-01-01 00:00:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-01-07 12:52:00, ended at 2015-01-07 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 62.0 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Antineoplastic poisoning\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-01-18 08:00:00, ended at 2015-01-18 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2015-01-18, presumably until 2015-01-18\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-01-18, presumably until 2015-01-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-08 08:00:00, ended at 2015-02-08 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2015-02-08, presumably until 2015-02-08\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-02-08, presumably until 2015-02-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-12 13:38:00, ended at 2015-02-12 23:59:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.606\" (inch (US))\n\n### Procedure\n- Chemotherapy follow-up\n\n### Condition\n- Non-toxic uninodular goiter\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-03-10 07:17:00, ended at 2015-03-10 12:05:00\nThe patient in this visit was 41 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.4 (percent)\n- INR in Blood by Coagulation assay: 1.2 (ratio)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 32.5 (percent)\n- MCV [Entitic volume] by Automated count: 78.3 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.12 (thousand per microliter)\n- Body height: 5' 0\" (inch (US))\n- Glucose [Mass/volume] in Blood: 143 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.9 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.4 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.79 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.36 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 56.7 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 202 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.95 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.5 (percent)\n- MCH [Entitic mass] by Automated count: 26.2 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n- Removal of tunneled central venous access device, with subcutaneous port or pump, central or peripheral insertion\n- Removal of foreign body from skin and/or subcutaneous tissue by incision\n- Other soft tissue x-ray of chest wall\n- Fluoroscopic guidance for central venous access device placement, replacement (catheter only or complete), or removal (includes fluoroscopic guidance for vascular access and catheter manipulation, any necessary contrast injections through access site or c\n\n### Condition\n- Convalescence after chemotherapy\n- Estrogen receptor positive tumor\n- Goiter\n- Primary malignant neoplasm of female breast\n- Gastroesophageal reflux disease\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-03-10, presumably until 2015-03-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-03-26 10:43:59, ended at 2015-03-26 13:35:47\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.449\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Lymphadenopathy\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2015-03-26, presumably until 2015-04-02, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-04-03 09:41:35, ended at 2015-04-03 11:07:42\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n- General examination of patient\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Disorder of muscle\n- Anemia\n- Pure hyperglyceridemia\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- cyclobenzaprine hydrochloride 5 MG Oral Tablet, through Oral route, started on 2015-04-03, presumably until 2015-09-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed\n- 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inacti..., through Intramuscular route, started on 2015-04-03, presumably until 2015-04-03, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time\n- metformin hydrochloride 1000 MG Oral Tablet, through Oral route, started on 2015-04-03, presumably until 2015-09-24, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-04-14 08:00:11, ended at 2015-04-14 08:36:14\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of left eye: 11 (millimeter mercury column)\n- Intraocular pressure of right eye: 14 (millimeter mercury column)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-05-21 11:08:18, ended at 2015-05-21 12:25:43\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-05-29 00:00:00, ended at 2015-05-29 00:00:00\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tamoxifen 20 MG Oral Tablet, through Oral route, started on 2015-05-29, presumably until 2016-05-28, with intended 11 refill(s). Instructions: take 20 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-06-23 19:28:00, ended at 2015-06-23 23:59:00\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance imaging, breast, without and/or with contrast material(s); bilateral\n\n### Condition\n- Breast lump\n- Non-toxic multinodular goiter\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-09-10 13:04:52, ended at 2015-09-10 14:28:02\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute upper respiratory infection\n- Primary malignant neoplasm of female breast\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- codeine phosphate 2 MG/ML / guaifenesin 20 MG/ML Oral Solution, through Oral route, started on 2015-09-10, presumably until 2015-09-24, with intended 0 refill(s). Instructions: take 5-10 mL by mouth every 6 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-11-04 00:00:00, ended at 2015-11-04 00:00:00\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-11-04 10:45:00, ended at 2015-11-04 23:59:00\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic digital breast tomosynthesis; bilateral\n- Mammography; bilateral\n\n### Condition\n- Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-12-09 10:58:47, ended at 2015-12-09 11:34:31\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.45\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cough\n\n### Drug\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2015-12-09, presumably until 2016-05-31, with intended 0 refill(s). Instructions: 1 Puff by Inhalation route every 6 hours as needed Substitute with whichever inhaler is covered by her insurance\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-12-09 11:37:00, ended at 2015-12-09 23:59:00\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Cough\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-01-28 10:30:34, ended at 2016-01-28 11:24:45\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- omeprazole 20 MG Delayed Release Oral Capsule, through Oral route, started on 2016-01-28, presumably until 2016-05-31, with intended 5 refill(s). Instructions: take 20 mg by mouth as needed (Take once daily as needed for heart burn or stomach upset.)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-12 07:00:00, ended at 2016-03-12 23:59:00\nThe patient in this visit was 42 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 60.2 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Disorder due to and following accidental poisoning\n- Disorder due to and following drug poisoning\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-18 21:30:00, ended at 2016-05-18 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance imaging, breast, without and/or with contrast material(s); bilateral\n\n### Condition\n- Lymphadenopathy\n- Localized enlarged lymph nodes\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-19 00:00:00, ended at 2016-05-19 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Imaging result abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-20 09:13:00, ended at 2016-05-20 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 196 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Steatosis of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-21 10:29:00, ended at 2016-05-21 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation\n- Morphometric analysis, tumor\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Fine needle aspiration; with imaging guidance\n\n### Condition\n- Lymphadenopathy\n- Secondary malignant neoplasm of lymph nodes of upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-21 14:53:15, ended at 2016-05-21 15:28:01\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Temporomandibular joint disorder\n- Acute upper respiratory infection\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-24 00:00:00, ended at 2016-05-24 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]), one or two mediastinal and/or hilar lymph node stat\n\n### Condition\n- Primary diagnosis: Imaging result abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-24 00:00:00, ended at 2016-05-24 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Imaging result abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-27 12:39:44, ended at 2016-05-27 15:41:50\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Lymphadenopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-31 13:13:07, ended at 2016-05-31 14:11:54\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-06-01 12:05:00, ended at 2016-06-01 12:05:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Non-toxic multinodular goiter\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-06-02 00:00:00, ended at 2016-06-02 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for closed chest procedures; (including bronchoscopy) not otherwise specified\n\n### Condition\n- Secondary malignant neoplasm of right lung\n- Primary malignant neoplasm of female breast\n- Localized enlarged lymph nodes\n\n### Drug\n- remifentanil 2 MG Injection, through Intravenous route, started on 2016-06-02, presumably until 2016-06-02\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2016-06-02, presumably until 2016-06-02\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2016-06-02, presumably until 2016-06-02\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-06-02, presumably until 2016-06-02\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-06-02, presumably until 2016-06-02\n- midazolam 1 MG/ML Injectable Solution, started on 2016-06-02, presumably until 2016-06-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-06-02 07:05:00, ended at 2016-06-02 09:46:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n- Glucose [Mass/volume] in Blood: 155 (milligram per deciliter)\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial needle aspiration biopsy(s), trachea, main stem and/or lobar bronchus(i)\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]), one or two mediastinal and/or hilar lymph node stat\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transendoscopic endobronchial ultrasound (EBUS) during bronchoscopic diagnostic or therapeutic intervention(s) for peripheral lesion(s) (List separately in addition to \n- Excision of Thorax Lymphatic, Percutaneous Endoscopic Approach, Diagnostic\n\n### Condition\n- Generalized enlarged lymph nodes\n- Secondary malignant neoplasm of lymph nodes of multiple sites\n- Secondary malignant neoplasm of right lung\n- Localized enlarged lymph nodes\n- Hyperlipidemia\n- Gastroesophageal reflux disease without esophagitis\n- Primary malignant neoplasm of female breast\n- Type 2 diabetes mellitus without complication\n- Non-toxic uninodular goiter\n- Secondary malignant neoplasm of intrathoracic lymph nodes\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2016-06-02, presumably until 2016-06-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-04 00:00:00, ended at 2016-06-04 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-04 00:00:00, ended at 2016-06-04 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-08 00:00:00, ended at 2016-06-08 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-09 10:01:55, ended at 2016-06-09 14:06:45\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neck pain\n- Primary diagnosis: Primary malignant neoplasm of female breast\n- Polyneuropathy\n- Infiltrating duct carcinoma, NOS, of breast, NOS\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-06-09 13:33:00, ended at 2016-06-09 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-06-09, presumably until 2016-06-09\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-06-09, presumably until 2016-06-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-06-10 00:00:00, ended at 2016-06-10 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tamoxifen 20 MG Oral Tablet, started on 2016-06-11, presumably until 2016-06-11, with intended 11 refill(s). Instructions: TAKE 20 MG BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-29 00:00:00, ended at 2016-06-29 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-30 11:34:59, ended at 2016-06-30 14:24:31\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-06-30, presumably until 2017-06-15, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2016-06-30, presumably until 2016-12-27, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-07-06 11:00:35, ended at 2016-07-06 13:19:31\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-21 08:00:00, ended at 2016-07-21 10:16:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 60.6 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Disorder due to and following accidental poisoning\n- Disorder due to and following drug poisoning\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-07-21 08:49:59, ended at 2016-07-21 13:20:39\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-21 10:17:00, ended at 2016-07-21 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-07-21, presumably until 2016-07-21\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-07-21, presumably until 2016-07-21\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-05 10:09:00, ended at 2016-08-05 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- goserelin 3.6 MG Drug Implant, through Subcutaneous route, started on 2016-08-05, presumably until 2016-08-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-12 00:00:00, ended at 2016-08-12 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-08-13 00:00:00, ended at 2016-08-13 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-14 11:25:00, ended at 2016-08-14 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.71 (million per microliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 8.0 (percent)\n- MCHC [Mass/volume] by Automated count: 32.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.40 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 42.5 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 418 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.3 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 91 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 154 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.2 (percent)\n- MCH [Entitic mass] by Automated count: 25.4 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.24 (thousand per microliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: <10.00 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.4 (percent)\n- Albumin [Mass/volume] in Urine: <5 (milligram per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 214 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 199 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 46.5 (percent)\n- MCV [Entitic volume] by Automated count: 79.4 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 112 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.44 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 4.4 (ratio)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.41 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 232 (thousand per microliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 45 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-08-14, presumably until 2016-08-14\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-08-14, presumably until 2016-08-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-09-04 08:59:00, ended at 2016-09-04 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 43.6 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.44 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 205 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.3 (percent)\n- MCH [Entitic mass] by Automated count: 25.4 (picogram)\n- MCV [Entitic volume] by Automated count: 78.6 (femtoliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.87 (million per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.32 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 97 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.00 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.88 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 176 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.3 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 46.4 (percent)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- goserelin 3.6 MG Drug Implant, through Subcutaneous route, started on 2016-09-04, presumably until 2016-09-04\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-09-04, presumably until 2016-09-04\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-09-04, presumably until 2016-09-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-09-13 07:08:00, ended at 2016-09-13 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Solitary nodule of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-09-13 07:08:00, ended at 2016-09-13 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 140 (milligram per deciliter)\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Abnormal findings on diagnostic imaging of lung\n- Localized enlarged lymph nodes\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-22 10:48:07, ended at 2016-09-22 11:32:12\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n- Joint pain\n- Neck pain\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-09-22 10:50:00, ended at 2016-09-22 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.8 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.8 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 46.9 (percent)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.44 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 45.9 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.42 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 164 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.5 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 100 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.74 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 79.0 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 25.7 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 2.66 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 165 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 73 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.16 (million per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-09-22, presumably until 2016-09-22\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-09-22, presumably until 2016-09-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-02 07:49:00, ended at 2016-10-02 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- goserelin 3.6 MG Drug Implant, through Subcutaneous route, started on 2016-10-02, presumably until 2016-10-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-16 10:06:00, ended at 2016-10-16 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.9 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 45.3 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 103 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 251 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.79 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 25.2 (picogram)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 45.6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 138 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 47 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.40 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 51 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.9 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.91 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.78 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.6 (percent)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 77.3 (femtoliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-10-16, presumably until 2016-10-16\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-10-16, presumably until 2016-10-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-30 08:30:00, ended at 2016-10-30 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- goserelin 3.6 MG Drug Implant, through Subcutaneous route, started on 2016-10-30, presumably until 2016-10-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-03 00:00:00, ended at 2016-11-03 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 70.3 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-11-03 11:00:00, ended at 2016-11-03 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Disorder due to and following drug poisoning\n- Disorder due to and following accidental poisoning\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-11-06 09:40:00, ended at 2016-11-06 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.39 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 69 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 123 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.68 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.80 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 55 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 47.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.8 (percent)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.14 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.8 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 118 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 320 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.8 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 24.9 (picogram)\n- MCV [Entitic volume] by Automated count: 76.3 (femtoliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 44.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-11-06, presumably until 2016-11-06\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-11-06, presumably until 2016-11-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-11-19 14:56:51, ended at 2016-11-19 16:37:46\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; manual screening under physician supervision\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n- Noninflammatory cervical disorder\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-11-27 09:50:00, ended at 2016-11-27 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Monocytes [#/volume] in Blood by Automated count: 0.33 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 154 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.40 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 76.3 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 71 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 31.9 (percent)\n- MCHC [Mass/volume] by Automated count: 32.2 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.07 (million per microliter)\n- Globulin [Mass/volume] in Serum: 5.2 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.6 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 292 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.9 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 24.5 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 131 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.93 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.5 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.57 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- goserelin 3.6 MG Drug Implant, through Subcutaneous route, started on 2016-11-27, presumably until 2016-11-27\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-11-27, presumably until 2016-11-27\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-11-27, presumably until 2016-11-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-01 09:56:07, ended at 2016-12-01 10:51:26\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-17 08:19:06, ended at 2016-12-17 09:34:57\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient\n\n### Condition\n- Muscle pain\n- Primary diagnosis: Neck pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-18 08:30:00, ended at 2016-12-18 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 168 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 76.3 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.26 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 64 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.5 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 65 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.73 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.3 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.17 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.9 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 158 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.5 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.43 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 40.7 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 49.2 (percent)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.43 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 24.2 (picogram)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.6 (percent)\n- MCHC [Mass/volume] by Automated count: 31.7 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 103 (thousand per microliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-12-18, presumably until 2016-12-18\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, presumably until 2017-02-23, with intended 0 refill(s). Instructions: inject subcutaneous (under the skin) 3 times a day Breakfast 4 units, lunch and dinner 6 units\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-12-18, presumably until 2016-12-18\n- insulin glargine 100 UNT/ML Injectable Solution, through Subcutaneous route, presumably until 2019-06-20, with intended 0 refill(s). Instructions: inject 16 Units subcutaneous (under the skin) daily in the evening \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-24 08:09:00, ended at 2016-12-24 15:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-24 08:09:00, ended at 2016-12-24 15:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 143 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n- Localized enlarged lymph nodes\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-24 16:00:00, ended at 2016-12-24 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- goserelin 3.6 MG Drug Implant, through Subcutaneous route, started on 2016-12-24, presumably until 2016-12-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-29 12:58:45, ended at 2016-12-29 16:57:34\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-08 08:30:00, ended at 2017-01-08 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 75.8 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.39 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.04 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 31.8 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 266 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 59 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.07 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 44.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 185 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 67 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.2 (percent)\n- MCH [Entitic mass] by Automated count: 24.1 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 83 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.5 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.24 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.9 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 41.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.14 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-13 00:00:00, ended at 2017-01-13 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for intraperitoneal procedures in lower abdomen including laparoscopy; not otherwise specified\n\n### Condition\n- Type 2 diabetes mellitus without complication\n- Gastroesophageal reflux disease without esophagitis\n- Primary malignant neoplasm of female breast\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, started on 2017-01-13, presumably until 2017-01-13\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2017-01-13, presumably until 2017-01-13\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2017-01-13, presumably until 2017-01-13\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-01-13, presumably until 2017-01-13\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-01-13, presumably until 2017-01-13\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-01-13, presumably until 2017-01-13\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-01-13, presumably until 2017-01-13\n- midazolam 1 MG/ML Injectable Solution, started on 2017-01-13, presumably until 2017-01-13\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2017-01-13, presumably until 2017-01-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-01-13 00:00:00, ended at 2017-01-13 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 5 MG/ML Injectable Solution, started on 2017-01-13, presumably until 2017-01-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-13 13:12:00, ended at 2017-01-13 22:24:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n- Glucose [Mass/volume] in Blood: 155 (milligram per deciliter)\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Collection of venous blood by venipuncture\n- Resection of Bilateral Fallopian Tubes, Percutaneous Endoscopic Approach\n- Resection of Bilateral Ovaries, Percutaneous Endoscopic Approach\n- Laparoscopy, surgical; with removal of adnexal structures (partial or total oophorectomy and/or salpingectomy)\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n- Disorder of female genital organs\n- Follicular cyst of left ovary\n- Pure hyperglyceridemia\n- Secondary malignant neoplasm of lymph nodes of upper limb\n- Simple goiter\n- Type 2 diabetes mellitus without complication\n- Follicular cyst of right ovary\n- Primary malignant neoplasm of female breast\n- Secondary malignant neoplasm of intrathoracic lymph nodes\n\n### Drug\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-01-13, presumably until 2017-03-16, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2017-01-13, presumably until 2017-01-13\n- ibuprofen 600 MG Oral Tablet, through Oral route, started on 2017-01-13, presumably until 2017-03-16, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2017-01-13, presumably until 2017-01-13\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-01-13, presumably until 2017-01-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-24 11:11:08, ended at 2017-01-24 12:57:59\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.843\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-26 14:06:02, ended at 2017-01-26 16:27:37\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.843\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n- Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- anastrozole 1 MG Oral Tablet, through Oral route, started on 2017-01-26, presumably until 2017-02-25, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-29 08:30:00, ended at 2017-01-29 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 143 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.6 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 75.3 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.91 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 97 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.46 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 130 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.7 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.42 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 39.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 156 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.3 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 253 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.09 (million per microliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 8.0 (percent)\n- MCH [Entitic mass] by Automated count: 24.6 (picogram)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 52.5 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n- Primary malignant neoplasm of female breast\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-01-29, presumably until 2017-01-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-02-19 08:30:00, ended at 2017-02-19 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 195 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 188 (unit per liter)\n- MCV [Entitic volume] by Automated count: 76.0 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 87 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 285 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.1 (percent)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.5 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.33 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 37.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.89 (thousand per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.43 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.6 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 238 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.2 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.87 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.0 (percent)\n- MCH [Entitic mass] by Automated count: 25.0 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 53.4 (percent)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-02-19, presumably until 2017-02-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-02-23 13:58:57, ended at 2017-02-23 15:22:25\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.843\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n- Secondary malignant neoplasm of intrathoracic lymph nodes\n\n### Drug\n- anastrozole 1 MG Oral Tablet, through Oral route, started on 2017-02-25, presumably until 2017-05-23, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-12 07:49:00, ended at 2017-03-12 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 250 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.8 (percent)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 24.7 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 49.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 90 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 262 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 275 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.80 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 75.9 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.25 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.8 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.6 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.9 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.46 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.82 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.41 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 261 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.7 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 38.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-03-12, presumably until 2017-03-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-03-15 00:00:00, ended at 2017-03-15 00:00:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-16 10:40:00, ended at 2017-03-16 11:58:02\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.843\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Elevated level of transaminase and lactic acid dehydrogenase\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-17 14:25:00, ended at 2017-03-17 23:59:00\nThe patient in this visit was 43 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; complete study\n- Ultrasound, abdominal, real time with image documentation; complete\n\n### Condition\n- Elevated level of transaminase and lactic acid dehydrogenase\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-23 09:38:18, ended at 2017-03-23 12:35:44\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.843\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Elevated level of transaminase and lactic acid dehydrogenase\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-03-31 00:00:00, ended at 2017-03-31 00:00:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-02 08:26:00, ended at 2017-04-02 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- MCV [Entitic volume] by Automated count: 77.1 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 79 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 39.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.47 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 49.6 (percent)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 256 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 25.0 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.52 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.3 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 80 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.4 (percent)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.17 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 89 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.46 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.0 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 211 (unit per liter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-04-02, presumably until 2017-04-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-04-06 00:00:00, ended at 2017-04-06 00:00:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 63.4 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-06 09:00:00, ended at 2017-04-06 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Poisoning by drug AND/OR medicinal substance\n- Accidental poisoning\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-04-06 09:39:31, ended at 2017-04-06 11:12:22\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.843\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-04-09 00:00:00, ended at 2017-04-09 00:00:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver function tests abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-23 08:30:00, ended at 2017-04-23 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 73 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.4 (percent)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.6 (percent)\n- MCV [Entitic volume] by Automated count: 78.0 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.99 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.51 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.3 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 37.1 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 103 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.25 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.82 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 270 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 239 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.4 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.9 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.4 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 50.7 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 94 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.2 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.46 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 25.3 (picogram)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-04-23, presumably until 2017-04-23\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-29 12:41:00, ended at 2017-04-29 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 112 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Localized enlarged lymph nodes\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-29 12:41:00, ended at 2017-04-29 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Localized enlarged lymph nodes\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-05-14 08:24:00, ended at 2017-05-14 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-05-23 00:00:00, ended at 2017-05-23 00:00:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- anastrozole 1 MG Oral Tablet, through Oral route, started on 2017-05-23, presumably until 2018-02-01, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-04 08:10:00, ended at 2017-06-04 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-06-04, presumably until 2017-06-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-15 13:27:45, ended at 2017-06-15 14:24:51\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 4' 11.843\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-25 08:10:00, ended at 2017-06-25 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 66 (unit per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.16 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.2 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.3 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.56 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 40.4 (percent)\n- MCV [Entitic volume] by Automated count: 78.9 (femtoliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.6 (gram per deciliter)\n- Prothrombin time (PT): 13.0 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 182 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.84 (million per microliter)\n- MCH [Entitic mass] by Automated count: 26.0 (picogram)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 47.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.46 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 239 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.32 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 115 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 36.9 (second)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.29 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-06-25, presumably until 2017-06-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-07-16 08:06:00, ended at 2017-07-16 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-07-16, presumably until 2017-07-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-07-21 00:00:00, ended at 2017-07-21 00:00:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-03 09:00:00, ended at 2017-08-03 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 60.8 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Poisoning by drug AND/OR medicinal substance\n- Accidental poisoning\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-06 08:10:00, ended at 2017-08-06 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Malignant neoplasm of nipple and areola of female breast\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-08-06, presumably until 2017-08-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-25 08:06:00, ended at 2017-08-25 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 112 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Localized enlarged lymph nodes\n- Primary malignant neoplasm of female breast\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-25 08:06:00, ended at 2017-08-25 23:59:00\nThe patient in this visit was 44 years old, unknown race, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Malignant tumor of breast within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of breast_cancer means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["Yes"]], "filtered_resps": ["Yes"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "753e5a08ec775d919e02bd9d795ea43b95a37f1b864e67a988567ea0199defa4", "prompt_hash": "aecd3798e9d70cd429c1026506f51a185f8b12aea05a48b40b13d25416eae5fe", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 1.0, "f1_gu_yn": [1, 1], "recall_gu_yn": [1, 1]}
{"doc_id": 4, "doc": {"person_id": 115967390, "visit_occurrence_id": 186042705, "death_date": null, "visit_concept_name": "Telehealth", "visit_start_datetime": "2021-08-31 00:00:00", "visit_end_datetime": "2021-08-31 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Telehealth, started at 2021-08-31 00:00:00, ended at 2021-08-31 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2021-08-31, presumably until 2022-08-25, with intended 3 refill(s). Instructions: take 1 Tablet (0.5 mg total) by mouth daily in the evening Rx 2/2: Dose is 1 mg in am and 1.5 mg every evening\n\n", "approximate_token_count": 157, "patient_first_visit_date": "2013-08-12 00:00:00", "patient_last_visit_date": "2023-01-27 00:00:00", "end_obs_date": "2022-08-31", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 1, "obesity_type": "recurrent", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 1, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "recurrent", "chronic_kidney_disease_one_year_diagnosis": 1, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "recurrent", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "recurrent", "type_ii_diabetes_one_year_diagnosis": 1, "breast_cancer_type": "recurrent", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "recurrent", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "recurrent", "heart_failure_one_year_diagnosis": 1, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 643, "cumulated_visit_num": 643, "cumulated_approximate_token_count": 135939, "visit_cumulated": "## Visit\nThis visit record, was from Case Management Visit, started at 2013-08-12 00:00:00, ended at 2013-08-12 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-08-14 00:00:00, ended at 2013-08-14 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-09-02 00:00:00, ended at 2013-09-02 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Electrocardiogram abnormal\n- Primary diagnosis: Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-09-02 00:00:00, ended at 2013-09-02 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 35 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-02 07:51:00, ended at 2013-09-02 11:39:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Primary cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-09-02 09:05:39, ended at 2013-09-02 11:27:09\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Chronic ischemic heart disease\n- Primary diagnosis: Congestive heart failure\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- 24 HR isosorbide mononitrate 30 MG Extended Release Oral Tablet, through Oral route, presumably until 2013-10-02. Instructions: take 30 mg by mouth every morning.\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2013-09-02, presumably until 2014-04-25, with intended 6 refill(s). Instructions: take 3 Tabs by mouth Every Day. Two am and one pm\n- ticagrelor 90 MG Oral Tablet, through Oral route, presumably until 2014-05-23. Instructions: take 90 mg by mouth 2 times a day.\n- aspirin 325 MG Oral Tablet, through Oral route, presumably until 2014-05-23. Instructions: take 325 mg by mouth daily.\n- spironolactone 25 MG Oral Tablet, through Oral route, started on 2013-09-02, presumably until 2013-09-25, with intended 6 refill(s). Instructions: take 25 mg by mouth daily.\n- losartan potassium 100 MG Oral Tablet, through Oral route, presumably until 2014-05-23. Instructions: take 100 mg by mouth daily.\n- insulin glargine 100 UNT/ML Injectable Solution, through Subcutaneous route, presumably until 2013-11-05. Instructions: inject 30 Units subcutaneous (under the skin) Evening.\n- carvedilol 12.5 MG Oral Tablet, through Oral route, started on 2013-09-02, presumably until 2013-10-02, with intended 6 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-02 11:40:00, ended at 2013-09-02 11:40:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 49 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.31 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.3 (thousand per microliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.4 (nanogram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.5 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.61 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.75 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Prothrombin time (PT): 13.2 (second)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 5.6 (ratio)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 242 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 266 (milligram per deciliter)\n- Triiodothyronine (T3) [Mass/volume] in Serum or Plasma: 113 (nanogram per deciliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 276 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.26 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.0 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 29 (milligram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 14.5 (percent)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 82.7 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 248 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 182 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 27.7 (picogram)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.88 (milli-international unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 313 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.6 (gram per deciliter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Congestive heart failure\n- Type 2 diabetes mellitus without complication\n- Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-02 11:41:00, ended at 2013-09-02 23:59:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-09-03 00:00:00, ended at 2013-09-03 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-09-03 00:00:00, ended at 2013-09-03 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-09-03 00:00:00, ended at 2013-09-03 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic ischemic heart disease\n- Coronary atherosclerosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-05 13:30:00, ended at 2013-09-05 13:30:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Chronic ischemic heart disease\n- Coronary arteriosclerosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-05 13:30:00, ended at 2013-09-05 13:30:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of extracranial arteries; complete bilateral study\n\n### Condition\n- Chronic ischemic heart disease\n- Coronary atherosclerosis\n- Disorder of carotid artery\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-05 13:31:00, ended at 2013-09-05 23:59:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of lower extremity arteries or arterial bypass grafts; unilateral or limited study\n\n### Condition\n- Coronary atherosclerosis\n- Chronic ischemic heart disease\n- Intermittent claudication\n- Atherosclerosis of arteries of the extremities\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-11 06:56:00, ended at 2013-09-11 06:56:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Postprocedural state finding\n- Lung field abnormal\n- Old myocardial infarction\n- Chronic ischemic heart disease\n- Coronary arteriosclerosis\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-11 06:57:00, ended at 2013-09-11 23:59:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Chronic ischemic heart disease\n- Lung field abnormal\n- Coronary arteriosclerosis\n- Heart disease\n- Old myocardial infarction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-09-18 00:00:00, ended at 2013-09-18 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-02 08:00:00, ended at 2013-10-02 10:59:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Cardiopulmonary exercise testing, including measurements of minute ventilation, CO2 production, O2 uptake, and electrocardiographic recordings\n\n### Condition\n- Dyspnea\n- Congestive heart failure\n- Combined systolic and diastolic dysfunction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-10-02 09:15:59, ended at 2013-10-02 10:38:57\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n- Chronic ischemic heart disease\n- Primary diagnosis: Congestive heart failure\n\n### Drug\n- 24 HR isosorbide mononitrate 60 MG Extended Release Oral Tablet, through Oral route, started on 2013-10-02, presumably until 2013-11-08, with intended 9 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n- carvedilol 25 MG Oral Tablet, through Oral route, started on 2013-10-02, presumably until 2013-11-08, with intended 6 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-02 11:00:00, ended at 2013-10-02 14:51:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pulmonary stress testing; simple (eg, 6-minute walk test, prolonged exercise test for bronchospasm with pre- and post-spirometry and oximetry)\n\n### Condition\n- Congestive heart failure\n- Abnormal breathing\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-10-02 11:16:02, ended at 2013-10-02 14:45:58\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of nervous system due to diabetes mellitus\n- Primary diagnosis: Diabetic - poor control\n- Primary diagnosis: Diabetes mellitus without complication\n\n### Drug\n- 3 ML insulin lispro 25 UNT/ML / insulin lispro protamine, human 75 UNT/ML Pen Injector, through Subcutaneous route, started on 2013-10-02, presumably until 2014-05-19, with intended 6 refill(s). Instructions: inject 15-20 Units subcutaneous (under the skin) 2 times a day before meals. Before breakfast take 15 units, before dinner take 20 units.\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, started on 2013-10-02, presumably until 2013-10-31, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-02 14:52:00, ended at 2013-10-02 23:59:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Cardiopulmonary exercise testing, including measurements of minute ventilation, CO2 production, O2 uptake, and electrocardiographic recordings\n- Bioimpedance-derived physiologic cardiovascular analysis\n\n### Condition\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-10-08 00:00:00, ended at 2013-10-08 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-10-09 00:00:00, ended at 2013-10-09 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-09 12:00:00, ended at 2013-10-09 13:16:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-10-09 12:05:57, ended at 2013-10-09 12:53:16\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Congestive heart failure\n- Electrocardiogram abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-09 13:17:00, ended at 2013-10-09 23:59:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 136 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-10-31 00:00:00, ended at 2013-10-31 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of nervous system due to diabetes mellitus\n- Primary diagnosis: Polyneuropathy due to diabetes mellitus\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, started on 2013-10-31, presumably until 2013-11-08, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-11-01 00:00:00, ended at 2013-11-01 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Heart failure\n- Primary diagnosis: Primary cardiomyopathy\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-11-05 06:01:00, ended at 2013-11-05 17:24:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n- Hemoglobin A1c/Hemoglobin.total in Blood: 10.6 (percent)\n- Sodium [Moles/volume] in Blood: 141 (millimole per liter)\n- Potassium [Moles/volume] in Blood: 4.3 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 11.2 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood: 33 (percent)\n\n### Procedure\n- Catheterization of right heart\n- Coronary arteriography using two catheters\n- Collection of venous blood by venipuncture\n- Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right heart catheterization\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n\n### Condition\n- Primary diagnosis: Congestive heart failure\n- Coronary arteriosclerosis\n- Diabetic - poor control\n- Old myocardial infarction\n- Angina pectoris\n- Chronic ischemic heart disease\n- Type 2 diabetes mellitus without complication\n- Diabetes mellitus without complication\n\n### Drug\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2013-11-05, presumably until 2013-11-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-11-08 09:17:24, ended at 2013-11-08 10:30:56\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congestive heart failure\n- Chronic ischemic heart disease\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- carvedilol 25 MG Oral Tablet, through Oral route, started on 2013-11-08, presumably until 2014-01-10, with intended 6 refill(s). Instructions: take 2 Tabs by mouth 2 times a day with meals.\n- 24 HR isosorbide mononitrate 120 MG Extended Release Oral Tablet, through Oral route, started on 2013-11-08, presumably until 2014-04-25, with intended 6 refill(s). Instructions: take 1 Tab by mouth every morning.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-11-22 00:00:00, ended at 2013-11-22 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for transvenous insertion or replacement of pacing cardioverter-defibrillator\n\n### Condition\n- Primary cardiomyopathy\n\n### Drug\n- 1 ML ketorolac tromethamine 30 MG/ML Injection, started on 2013-11-22, presumably until 2013-11-22\n- cefazolin 1000 MG Injection, started on 2013-11-22, presumably until 2013-11-22\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-11-22, presumably until 2013-11-22\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2013-11-22, presumably until 2013-11-22\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-11-22, presumably until 2013-11-22\n- midazolam 1 MG/ML Injectable Solution, started on 2013-11-22, presumably until 2013-11-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-11-22 06:14:00, ended at 2013-11-23 11:24:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocyte distribution width [Ratio] by Automated count: 14.4 (percent)\n- Hemoglobin [Mass/volume] in Blood by calculation: 10.5 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 194 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood: 31 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.46 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.4 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 58 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.4 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- Potassium [Moles/volume] in Blood: 4.3 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 36 (milliliter per minute per square meter)\n- MCV [Entitic volume] by Automated count: 82.1 (femtoliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Prothrombin time (PT): 14.0 (second)\n- Sodium [Moles/volume] in Blood: 140 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 29.3 (second)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 134 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- MCH [Entitic mass] by Automated count: 27.1 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Body height: 5' 5\" (inch (US))\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n\n### Procedure\n- Radiologic examination, chest; single view, frontal\n- Implantation or replacement of automatic cardioverter/defibrillator, total system [AICD]\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Insertion or replacement of permanent implantable defibrillator system, with transvenous lead(s), single or dual chamber\n- Collection of venous blood by venipuncture\n\n### Condition\n- Essential hypertension\n- Coronary arteriosclerosis\n- Imaging of thorax abnormal\n- Congestive heart failure\n- Type 2 diabetes mellitus without complication\n- Old myocardial infarction\n- Chronic ischemic heart disease\n\n### Drug\n- losartan potassium 50 MG Oral Tablet, through Oral route, started on 2013-11-23, presumably until 2013-11-23\n- ketorolac tromethamine 10 MG Oral Tablet, through Oral route, started on 2013-11-22, presumably until 2013-11-23\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2013-11-22, presumably until 2013-11-22\n- ticagrelor 90 MG Oral Tablet, through Oral route, started on 2013-11-22, presumably until 2013-11-23\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-11-22, presumably until 2013-11-22\n- aspirin 325 MG Oral Tablet, through Oral route, started on 2013-11-23, presumably until 2013-11-23\n- cefazolin 1000 MG Injection, through Intravenous route, started on 2013-11-22, presumably until 2013-11-22\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, started on 2013-11-23, presumably until 2013-11-23\n- furosemide 40 MG Oral Tablet, through Oral route, started on 2013-11-23, presumably until 2013-11-23\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2013-11-23, presumably until 2013-12-24, with intended 0 refill(s). Instructions: take 1 Cap by mouth 3 times a day.\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2013-11-22, presumably until 2013-11-23\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-11-22, presumably until 2013-11-22\n- 24 HR isosorbide mononitrate 60 MG Extended Release Oral Tablet, through Oral route, started on 2013-11-23, presumably until 2013-11-23\n- carvedilol 25 MG Oral Tablet, through Oral route, started on 2013-11-23, presumably until 2013-11-23\n- insulin glargine 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2013-11-22, presumably until 2013-11-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-12-09 11:17:31, ended at 2013-12-09 11:47:10\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Congestive heart failure\n- Primary cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-01-10 00:00:00, ended at 2014-01-10 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congestive heart failure\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-01-28 00:00:00, ended at 2014-01-28 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congestive heart failure\n- Primary cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-01-30 10:21:05, ended at 2014-01-30 11:21:24\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Congestive heart failure\n- Diabetic - poor control\n- Primary diagnosis: Pulmonary tuberculosis\n- Diabetes mellitus without complication\n\n### Drug\n- vitamin B6 50 MG Oral Tablet, through Oral route, started on 2014-01-30, presumably until 2015-01-30, with intended 8 refill(s). Instructions: take 1 Tab by mouth daily.\n- isoniazid 300 MG Oral Tablet, through Oral route, started on 2014-01-30, presumably until 2015-01-30, with intended 8 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-30 11:27:00, ended at 2014-01-30 23:59:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 47 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.4 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.8 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.74 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 35 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.04 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 42 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.3 (percent)\n- MCH [Entitic mass] by Automated count: 26.8 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 213 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.35 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 80.1 (femtoliter)\n- Glucose [Mass/volume] in Serum or Plasma: 187 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.8 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.75 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 240 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.7 (percent)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Pulmonary tuberculosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-02-25 00:00:00, ended at 2014-02-25 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congestive heart failure\n- Primary diagnosis: Diastolic heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-02-26 11:23:48, ended at 2014-02-26 11:47:02\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diabetes mellitus without complication\n- Primary diagnosis: Diabetic - poor control\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-26 11:48:00, ended at 2014-02-26 11:49:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n- Collection of venous blood by venipuncture\n\n### Condition\n- Congestive heart failure\n- Diastolic heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-26 11:50:00, ended at 2014-02-26 23:59:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin A1c/Hemoglobin.total in Blood: 9.4 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diabetes mellitus without complication\n- Diabetic - poor control\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-03-04 10:35:43, ended at 2014-03-04 11:12:18\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diabetes mellitus without complication\n- Diabetic - poor control\n- Congestive heart failure\n- Primary diagnosis: Pulmonary tuberculosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-03-06 00:00:00, ended at 2014-03-06 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic ischemic heart disease\n- Primary diagnosis: Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-03-06 00:00:00, ended at 2014-03-06 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Primary diagnosis: Congestive heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-03-13 00:00:00, ended at 2014-03-13 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary tuberculosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-13 09:22:00, ended at 2014-03-13 23:59:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n\n### Condition\n- Heart failure\n- Primary cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-03-21 00:00:00, ended at 2014-03-21 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 30 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-21 12:22:00, ended at 2014-03-21 13:24:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-21 13:25:00, ended at 2014-03-21 23:59:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n- Computed tomography, abdomen and pelvis; without contrast material\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Lung field abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-21 13:25:00, ended at 2014-03-21 23:59:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-03-25 12:37:51, ended at 2014-03-25 13:49:16\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic systolic heart failure\n- Primary diagnosis: Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-04-04 00:00:00, ended at 2014-04-04 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-04-04 09:56:20, ended at 2014-04-04 11:38:39\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diabetes mellitus without complication\n- Type 2 diabetes mellitus without complication\n- Chronic ischemic heart disease\n- Primary diagnosis: Congestive heart failure\n- Diabetic - poor control\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2014-04-04, presumably until 2014-05-23, with intended 6 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-04-25 00:00:00, ended at 2014-04-25 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n- Primary diagnosis: Congestive heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2014-04-25, presumably until 2014-05-19, with intended 6 refill(s). Instructions: take 2 Tabs by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-04-25 12:28:00, ended at 2014-04-25 14:22:05\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic ischemic heart disease\n- Type 2 diabetes mellitus without complication\n- Primary diagnosis: Congestive heart failure\n\n### Drug\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2014-04-25, presumably until 2014-04-25, with intended 6 refill(s). Instructions: take 2 Tabs by mouth 2 times a day. Two am and one pm\n- 24 HR isosorbide mononitrate 120 MG Extended Release Oral Tablet, started on 2014-04-25, presumably until 2014-05-19, with intended 6 refill(s). Instructions: Pt sent home with hand written prescription for 240 mg tablet pill - to take one tablet in evening or two of 120 each pm together\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-25 14:27:00, ended at 2014-04-25 23:59:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.24 (milli-international unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 219 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Triiodothyronine (T3) [Mass/volume] in Serum or Plasma: 96 (nanogram per deciliter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.8 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 35 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 260 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 10.2 (percent)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.4 (nanogram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 50 (milliliter per minute per square meter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic ischemic heart disease\n- Type 2 diabetes mellitus without complication\n- Congestive heart failure\n- Primary cardiomyopathy\n- Pulmonary tuberculosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-05-14 00:00:00, ended at 2014-05-14 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Polyneuropathy due to diabetes mellitus\n- Primary diagnosis: Disorder of nervous system due to diabetes mellitus\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, started on 2014-05-14, presumably until 2014-07-18, with intended 3 refill(s). Instructions: take 1 Cap by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2014-05-17 19:59:00, ended at 2014-05-23 16:30:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Iron [Mass/volume] in Serum or Plasma: 26 (microgram per deciliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 235 (microgram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.7 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Manual count: 1.2 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 40 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Eosinophils/100 leukocytes in Blood by Manual count: 4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.6 (percent)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 19 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Body height: 5' 5\" (inch (US))\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- INR in Platelet poor plasma by Coagulation assay: 1.4 (ratio)\n- Leukocytes [#/volume] in Specimen by Automated count: 13.8 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 26.8 (picogram)\n- Monocytes/100 leukocytes in Blood by Manual count: 10 (percent)\n- Neutrophils [#/volume] in Blood by Manual count: 7.9 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 388 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.59 (milli-international unit per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.7 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.12 (million per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.6 (percent)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 11 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.5 (thousand per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 468 (nanogram per milliliter)\n- Lactate [Moles/volume] in Blood: 1.6 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.45 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 2.3 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.82 (thousand per microliter)\n- Prothrombin time (PT): 16.2 (second)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.46 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.5 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 83 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 13.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 8.0 (gram per deciliter)\n- Left ventricular Ejection fraction: 28.7 (percent)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 207 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 24.5 (percent)\n- MCV [Entitic volume] by Automated count: 81.3 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: <15 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 64 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 39.0 (second)\n\n### Procedure\n- Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes\n- Hospital discharge day management; 30 minutes or less\n- Catheterization of right heart\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Collection of venous blood by venipuncture\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Procedure on single vessel\n- Critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes (List separately in addition to code for primary service)\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Right heart catheterization including measurement(s) of oxygen saturation and cardiac output, when performed\n- Central venous catheter placement with guidance\n- Physical therapy evaluation\n- Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right heart catheterization\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Medical decision making that is straightforward or o\n- Coronary arteriography using two catheters\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Revision of automatic implantable cardioverter/defibrillator\n- Percutaneous transluminal coronary angioplasty\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Radiologic examination, esophagus, including scout chest radiograph(s) and delayed image(s), when performed; single-contrast (eg, barium) study\n- Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, without imaging guidance; age 5 years or older\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Radiologic examination, chest; single view, frontal\n- Insertion of drug-eluting coronary artery stent\n- Insertion of one vascular stent\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch\n\n### Condition\n- Diabetic - poor control\n- Fever\n- Helicobacter-associated disease\n- Essential hypertension\n- Hyperosmolality and or hypernatremia\n- Hypo-osmolality and or hyponatremia\n- Iron deficiency anemia\n- Long QT syndrome\n- Chest pain\n- Eye / vision finding\n- Atrial fibrillation\n- Primary diagnosis: Congestive heart failure\n- Diabetes mellitus without complication\n- Infective pneumonia\n- Leukocytosis\n- Coronary arteriosclerosis\n- Disorder of esophagus\n- Cardiomegaly\n- Chronic ischemic heart disease\n- Disorder of function of stomach\n- Disorder of lung\n- Hypovolemia\n- Lung field abnormal\n- Nonspecific tuberculin test reaction\n- Preinfarction syndrome\n- Primary diagnosis: Acute on chronic systolic heart failure\n- Acute renal failure syndrome\n- Electrocardiogram abnormal\n- Old myocardial infarction\n\n### Drug\n- amoxicillin 500 MG Oral Capsule, through Oral route, started on 2014-05-23, presumably until 2014-05-23, with intended 0 refill(s). Instructions: take 2 Caps by mouth Q12H.\n- furosemide 20 MG Oral Tablet, through Oral route, presumably until 2014-05-23. Instructions: take 40 mg by mouth every morning.\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2014-05-23, presumably until 2015-05-23, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2014-05-21, presumably until 2014-05-21\n- ceftriaxone 1000 MG Injection, through Intravenous route, started on 2014-05-18, presumably until 2014-05-18\n- diazepam 5 MG Oral Tablet, through Oral route, started on 2014-05-22, presumably until 2014-05-22\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2014-05-17, presumably until 2014-05-22\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2014-05-22, presumably until 2014-05-22\n- 3 ML insulin lispro 25 UNT/ML / insulin lispro protamine, human 75 UNT/ML Pen Injector, through Subcutaneous route, started on 2014-05-23, presumably until 2014-11-11, with intended 11 refill(s). Instructions: inject 10-20 Units subcutaneous (under the skin) 3 times a day. 10 units every morning, 15 units in afternoon, 20 units every evening\n- tetracycline hydrochloride 500 MG Oral Capsule, through Oral route, started on 2014-05-23, presumably until 2015-05-23, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day.\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2014-05-18, presumably until 2014-05-18\n- aspirin 325 MG Oral Tablet, through Oral route, started on 2014-05-22, presumably until 2014-05-22\n- bismuth subsalicylate 35 MG/ML Oral Suspension, through Oral route, started on 2014-05-23, presumably until 2014-06-13, with intended 0 refill(s). Instructions: take 15 mL by mouth 4 times a day.\n- metronidazole 250 MG Oral Tablet, through Oral route, started on 2014-05-23, presumably until 2015-05-23, with intended 0 refill(s). Instructions: take 1 Tab by mouth 4 times a day.\n- trazodone hydrochloride 50 MG Oral Tablet, through Oral route, started on 2014-05-18, presumably until 2014-05-18\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2014-05-21, presumably until 2014-05-21\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, started on 2014-05-22, presumably until 2014-05-23\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2014-05-19, presumably until 2014-05-19\n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2014-05-17, presumably until 2014-05-17\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2014-05-21, presumably until 2014-05-22\n- vitamin B6 50 MG Oral Tablet, through Oral route, started on 2014-05-18, presumably until 2014-05-23\n- insulin detemir 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2014-05-18, presumably until 2014-05-23\n- isoniazid 300 MG Oral Tablet, through Oral route, started on 2014-05-18, presumably until 2014-05-23\n- insulin isophane, human 100 UNT/ML Injectable Suspension, through Subcutaneous route, started on 2014-05-18, presumably until 2014-05-18\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2014-05-18, presumably until 2014-05-19\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2014-05-19, presumably until 2014-05-22\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2014-05-20, presumably until 2014-05-21\n- atorvastatin 80 MG Oral Tablet, through Oral route, started on 2014-05-23, presumably until 2015-05-23, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily in the evening.\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2014-05-18, presumably until 2014-05-23\n- erythromycin 0.005 MG/MG Ophthalmic Ointment, through Intraocular route, started on 2014-05-20, presumably until 2014-05-23\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2014-05-17, presumably until 2014-05-18\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2014-05-20, presumably until 2014-05-21\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2014-05-22, presumably until 2014-05-22\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2014-05-19, presumably until 2014-05-19\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2014-05-20, presumably until 2014-09-01, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-05-17, presumably until 2014-05-22\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2014-05-22, presumably until 2014-05-22\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-05-18, presumably until 2014-05-18\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, through Intravenous route, started on 2014-05-18, presumably until 2014-05-18\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2014-05-22, presumably until 2014-05-22\n- benzonatate 100 MG Oral Capsule, through Oral route, started on 2014-05-18, presumably until 2014-05-21\n- 100 ML potassium chloride 0.2 MEQ/ML Injection, through Intravenous route, started on 2014-05-19, presumably until 2014-05-19\n- glucose 50 MG/ML Injection, through Intravenous route, started on 2014-05-18, presumably until 2014-05-18\n- ketorolac tromethamine 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-05-20, presumably until 2014-06-13, with intended 0 refill(s). Instructions: instill 1 Drop to right eye 4 times a day.\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2014-05-18, presumably until 2014-05-18\n- 24 HR isosorbide mononitrate 120 MG Extended Release Oral Tablet, through Oral route, presumably until 2014-05-23. Instructions: take 120 mg by mouth Every Day.\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2014-05-18, presumably until 2014-05-22\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, started on 2014-05-18, presumably until 2014-05-18\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2014-05-19, presumably until 2015-05-23, with intended 11 refill(s). Instructions: take 1 Tab by mouth every morning with breakfast.\n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2014-05-23, presumably until 2015-06-22, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily.\n- 1 ML morphine sulfate 4 MG/ML Prefilled Syringe, through Intravenous route, started on 2014-05-18, presumably until 2014-05-19\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2014-05-22, presumably until 2014-05-22\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2014-05-20, presumably until 2014-05-22\n- clarithromycin 500 MG Oral Tablet, through Oral route, started on 2014-05-23, presumably until 2014-05-23, with intended 0 refill(s). Instructions: take 1 Tab by mouth Q12H.\n- tetracycline hydrochloride 250 MG Oral Capsule, through Oral route, started on 2014-05-23, presumably until 2014-05-23, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day.\n- losartan potassium 25 MG Oral Tablet, through Oral route, started on 2014-05-23, presumably until 2014-09-01, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-05-27 00:00:00, ended at 2014-05-27 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic ischemic heart disease\n- Helicobacter-associated disease\n- Acute on chronic combined systolic and diastolic heart failure\n- Diabetes mellitus without complication\n- Diabetic - poor control\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-13 11:45:00, ended at 2014-06-13 23:59:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 249 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 11.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Congestive heart failure\n- Type 2 diabetes mellitus without complication\n- Chronic combined systolic and diastolic heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-07-18 00:00:00, ended at 2014-07-18 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of nervous system due to diabetes mellitus\n- Polyneuropathy due to diabetes mellitus\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, started on 2014-07-18, presumably until 2014-11-23, with intended 2 refill(s). Instructions: take 1 Cap by mouth daily. appt needed for additional refills\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-09-01 10:15:49, ended at 2014-09-01 11:57:22\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Revision of automatic implantable cardioverter/defibrillator\n- Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care \n\n### Condition\n- Primary diagnosis: Cardiomyopathy associated with another disorder\n\n### Drug\n- losartan potassium 25 MG Oral Tablet, through Oral route, started on 2014-09-01, presumably until 2015-09-01, with intended 3 refill(s). Instructions: take 1 tablet by mouth every bedtime.\n- carvedilol 6.25 MG Oral Tablet, through Oral route, started on 2014-09-01, presumably until 2015-06-10, with intended 3 refill(s). Instructions: take 1 tablet by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-01 12:05:00, ended at 2014-09-01 23:59:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 281 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 13.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Cardiomyopathy associated with another disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-11-06 00:00:00, ended at 2014-11-06 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diabetes mellitus without complication\n- Primary diagnosis: Diabetic - poor control\n\n### Drug\n- 3 ML insulin lispro 25 UNT/ML / insulin lispro protamine, human 75 UNT/ML Pen Injector, started on 2014-11-11, presumably until 2016-03-10, with intended 2 refill(s). Instructions: Inject SQ 3 times per day 10 minutes before each meal, Before breakfast: take 10 units, Before Lunch: 15 units, Before dinner: take 20 units\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-11-23 00:00:00, ended at 2014-11-23 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, started on 2014-11-23, presumably until 2014-12-15, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-11-24 00:00:00, ended at 2014-11-24 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, started on 2014-11-24, presumably until 2014-11-24, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-12-15 00:00:00, ended at 2014-12-15 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, started on 2014-12-15, presumably until 2015-04-20, with intended 1 refill(s). Instructions: take 1 Cap by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-04-20 00:00:00, ended at 2015-04-20 00:00:00\nThe patient in this visit was 52 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Mononeuritis\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, started on 2015-04-21, presumably until 2015-09-15, with intended 3 refill(s). Instructions: TAKE ONE CAPSULE BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-06-09 00:00:00, ended at 2015-06-09 00:00:00\nThe patient in this visit was 52 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR isosorbide mononitrate 60 MG Extended Release Oral Tablet, started on 2015-06-12, presumably until 2018-07-19, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY NIGHT AT BEDTIME\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-06-10 09:43:13, ended at 2015-06-10 14:27:42\nThe patient in this visit was 52 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care \n- Revision of automatic implantable cardioverter/defibrillator\n\n### Condition\n- Chronic ischemic heart disease\n- Primary diagnosis: Congestive heart failure\n- Flatulence, eructation and gas pain\n- Primary diagnosis: Chronic combined systolic and diastolic heart failure\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, presumably until 2015-06-10, with intended 0 refill(s). Instructions: take 40 mg by mouth Evening\n- aspirin 325 MG Oral Tablet, through Oral route, presumably until 2018-07-19, with intended 0 refill(s). Instructions: take 325 mg by mouth Evening\n- furosemide 40 MG Oral Tablet, through Oral route, started on 2015-06-10, presumably until 2016-06-16, with intended 6 refill(s). Instructions: take 1 Tab by mouth daily\n- atorvastatin 80 MG Oral Tablet, through Oral route, presumably until 2018-07-19, with intended 0 refill(s). Instructions: take 80 mg by mouth Evening\n- carvedilol 6.25 MG Oral Tablet, through Oral route, started on 2015-06-10, presumably until 2016-03-25, with intended 6 refill(s). Instructions: take 2 Tabs by mouth 2 times a day\n- 24 HR isosorbide mononitrate 60 MG Extended Release Oral Tablet, through Oral route, started on 2015-06-10, presumably until 2015-06-12, with intended 6 refill(s). Instructions: take 1 Tab by mouth every morning\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, started on 2012-08-19, presumably until 2016-10-28, with intended 0 refill(s). Instructions: place 0.4 mg under the tongue and let dissolve\n- clopidogrel 75 MG Oral Tablet, through Oral route, presumably until 2015-06-22, with intended 0 refill(s). Instructions: take by mouth Evening\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-06-18 11:16:53, ended at 2015-06-18 12:18:27\nThe patient in this visit was 52 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus without complication\n\n### Drug\n- 3 ML liraglutide 6 MG/ML Pen Injector, through Subcutaneous route, started on 2015-06-18, presumably until 2016-03-25, with intended 6 refill(s). Instructions: inject 1.2 mg subcutaneous (under the skin) daily with lunch\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-06-18 12:30:00, ended at 2015-06-18 23:59:00\nThe patient in this visit was 52 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 32 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 15.0 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 130 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 152 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 438 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 92 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-06-22 00:00:00, ended at 2015-06-22 00:00:00\nThe patient in this visit was 52 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- clopidogrel 75 MG Oral Tablet, started on 2015-06-22, presumably until 2016-07-12, with intended 11 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-09-02 00:00:00, ended at 2015-09-02 00:00:00\nThe patient in this visit was 52 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- losartan potassium 25 MG Oral Tablet, started on 2015-09-04, presumably until 2016-09-11, with intended 11 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-09-15 00:00:00, ended at 2015-09-15 00:00:00\nThe patient in this visit was 52 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diabetes mellitus without complication\n- Primary diagnosis: Diabetic - poor control\n- Peripheral nerve disease\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, started on 2015-09-24, presumably until 2016-05-23, with intended 5 refill(s). Instructions: TAKE ONE CAPSULE BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-01-28 00:00:00, ended at 2016-01-28 00:00:00\nThe patient in this visit was 52 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- famotidine 20 MG Oral Tablet, started on 2016-01-29, presumably until 2016-01-29, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n- 12 HR ranolazine 500 MG Extended Release Oral Tablet, started on 2016-01-29, presumably until 2016-01-29, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY 12 HOURS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-02-02 00:00:00, ended at 2016-02-02 00:00:00\nThe patient in this visit was 52 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-02-16 10:27:52, ended at 2016-02-16 12:43:21\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congestive heart failure\n- Type 2 diabetes mellitus\n- Primary diagnosis: Chronic combined systolic and diastolic heart failure\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-02-16 12:49:00, ended at 2016-02-16 23:59:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 130 (unit per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 284 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 6.0 (ratio)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 237 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 12.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Albumin [Mass/volume] in Urine: 3480 (milligram per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 181 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 114.00 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Microalbumin/Creatinine [Mass Ratio] in Urine: >3000 (milligram per gram)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 47 (milligram per deciliter)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 3.9 (ratio)\n- Glucose [Mass/volume] in Serum or Plasma: 236 (milligram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.12 (micro-international unit per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 281 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Chronic combined systolic and diastolic heart failure\n- Congestive heart failure\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-02-23 00:00:00, ended at 2016-02-23 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperglycemia due to type 2 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n\n### Drug\n- 0.65 ML exenatide 3.08 MG/ML Pen Injector, started on 2016-02-23, presumably until 2016-06-15, with intended 11 refill(s). Instructions: Inject contents of syringe SQ once a week\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-03-10 00:00:00, ended at 2016-03-10 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- 3 ML insulin lispro 25 UNT/ML / insulin lispro protamine, human 75 UNT/ML Pen Injector, started on 2016-03-11, presumably until 2017-03-11, with intended 11 refill(s). Instructions: INJECT SUBCUTANEOUSLY 15 UNITS BEFORE BREAKFAST AND 30 UNITS BEFORE DINNER. INJECT 10 MINUTES BEFORE EACH MEAL\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-03-11 00:00:00, ended at 2016-03-11 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-03-25 00:00:00, ended at 2016-03-25 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic combined systolic and diastolic heart failure\n- Hyperglycemia due to type 2 diabetes mellitus\n- Congestive heart failure\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-25 09:38:00, ended at 2016-03-25 13:08:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 28.1 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Type 2 diabetes mellitus\n- Chronic ischemic heart disease\n- Hyperglycemia due to type 2 diabetes mellitus\n- Chronic combined systolic and diastolic heart failure\n- Congestive heart failure\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-03-25 11:54:13, ended at 2016-03-25 13:05:42\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperglycemia due to type 2 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n\n### Drug\n- 3 ML liraglutide 6 MG/ML Pen Injector, through Subcutaneous route, started on 2016-03-28, presumably until 2017-08-23, with intended 11 refill(s). Instructions: inject 0.6 mg subcutaneous (under the skin) Every Day Failed Bydureon\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-25 13:09:00, ended at 2016-03-25 13:09:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-25 13:10:00, ended at 2016-03-25 23:59:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 5.1 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 57 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 65 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Anabasine [Mass/volume] in Urine: <2.0 (nanogram per milliliter)\n- Prealbumin [Mass/volume] in Serum or Plasma: 29 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.5 (gram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Nornicotine [Mass/volume] in Urine: <2.0 (nanogram per milliliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.48 (micro-international unit per milliliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Cotinine [Mass/volume] in Urine: <5.0 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 42 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 205 (unit per liter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 8.6 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma: 1619 (picogram per milliliter)\n- Nicotine [Mass/volume] in Urine: <2.0 (nanogram per milliliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic combined systolic and diastolic heart failure\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-05-23 00:00:00, ended at 2016-05-23 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neuralgia\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, started on 2016-05-23, presumably until 2016-07-26, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-31 08:21:00, ended at 2016-05-31 10:37:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n- Solitary nodule of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-31 09:04:07, ended at 2016-05-31 16:25:59\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care \n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-31 10:38:00, ended at 2016-05-31 23:59:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-06-15 00:00:00, ended at 2016-06-15 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperglycemia due to type 2 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-15 09:39:45, ended at 2016-06-15 14:39:47\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- 3 ML insulin lispro 25 UNT/ML / insulin lispro protamine, human 75 UNT/ML Pen Injector, started on 2016-06-15, presumably until 2016-06-15, with intended 11 refill(s). Instructions: INJECT SUBCUTANEOUSLY 15 UNITS BEFORE BREAKFAST AND 30 UNITS BEFORE DINNER. INJECT 10 MINUTES BEFORE EACH MEAL\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-15 10:21:51, ended at 2016-06-15 12:10:36\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care \n\n### Condition\n- Type 2 diabetes mellitus\n- Chronic ischemic heart disease\n- Primary diagnosis: Heart failure\n- Complication due to diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-06-15 12:33:00, ended at 2016-06-15 23:59:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 45 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.34 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 63 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 6.1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Complication due to diabetes mellitus\n- Chronic ischemic heart disease\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-06-16 00:00:00, ended at 2016-06-16 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic combined systolic and diastolic heart failure\n- Congestive heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- furosemide 40 MG Oral Tablet, started on 2016-06-17, presumably until 2016-07-06, with intended 4 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-07-06 00:00:00, ended at 2016-07-06 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Congestive heart failure\n- Chronic combined systolic and diastolic heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- furosemide 40 MG Oral Tablet, through Oral route, started on 2016-07-06, presumably until 2017-07-23, with intended 4 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-07-12 00:00:00, ended at 2016-07-12 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- clopidogrel 75 MG Oral Tablet, started on 2016-07-13, presumably until 2016-08-11, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-07-26 00:00:00, ended at 2016-07-26 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n- Neuralgia\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, started on 2016-07-27, presumably until 2016-08-23, with intended 11 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-08-11 00:00:00, ended at 2016-08-11 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- clopidogrel 75 MG Oral Tablet, started on 2016-08-11, presumably until 2017-08-10, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-08-23 00:00:00, ended at 2016-08-23 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Disorder of endocrine system\n- Polyneuropathy associated with another disorder\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n- duloxetine 30 MG Delayed Release Oral Capsule, started on 2016-08-24, presumably until 2017-09-26, with intended 3 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-23 00:00:00, ended at 2016-08-23 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of endocrine system\n- Polyneuropathy associated with another disorder\n- Primary diagnosis: Hyperglycemia due to type 2 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n\n### Drug\n- duloxetine 30 MG Delayed Release Oral Capsule, through Oral route, started on 2016-08-23, presumably until 2016-08-23, with intended 3 refill(s). Instructions: take 1 Cap by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-09-11 00:00:00, ended at 2016-09-11 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- losartan potassium 25 MG Oral Tablet, started on 2016-09-13, presumably until 2017-06-13, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-28 09:45:50, ended at 2016-10-28 11:48:28\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care \n\n### Condition\n- Chronic ischemic heart disease\n- Diabetes mellitus\n- Heart failure\n- Complication due to diabetes mellitus\n\n### Drug\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, started on 2016-10-28, presumably until 2018-07-19, with intended 6 refill(s). Instructions: place 1 Tab under the tongue and let dissolve as needed for Chest pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-28 12:00:00, ended at 2016-10-28 23:59:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Monocytes/100 leukocytes in Blood by Automated count: 7.8 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.4 (percent)\n- Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma: 1027 (picogram per milliliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.57 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 249 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 26 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.22 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.0 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.7 (percent)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 6.8 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.5 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.12 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.2 (percent)\n- MCV [Entitic volume] by Automated count: 81.5 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.37 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.39 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 85 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 26.9 (picogram)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.3 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.86 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic ischemic heart disease\n- Diabetes mellitus\n- Complication due to diabetes mellitus\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-11-14 09:19:16, ended at 2016-11-14 10:03:25\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Heart failure\n- Chronic ischemic heart disease\n- Cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-11-14 10:12:00, ended at 2016-11-14 23:59:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.43 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 42 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma: 853 (picogram per milliliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 121 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-11-14 10:35:21, ended at 2016-11-14 13:17:37\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperglycemia due to type 2 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Chronic kidney disease due to type 2 diabetes mellitus\n\n### Drug\n- empagliflozin 10 MG Oral Tablet, through Oral route, started on 2016-11-14, presumably until 2017-06-11, with intended 6 refill(s). Instructions: take 1 Tab by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-12-19 00:00:00, ended at 2016-12-19 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Polyneuropathy associated with another disorder\n- Disorder of endocrine system\n- Type 2 diabetes mellitus\n\n### Drug\n- duloxetine 30 MG Delayed Release Oral Capsule, started on 2016-12-20, presumably until 2016-12-20, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-20 00:00:00, ended at 2017-02-20 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Creatinine [Mass/volume] in Urine: 55.60 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.01 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 25.8 (picogram)\n- Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma: 731 (picogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.41 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.6 (percent)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 17.6 (percent)\n- MCV [Entitic volume] by Automated count: 81.7 (femtoliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.89 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 31.6 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.4 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 252 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Albumin [Mass/volume] in Urine: 32 (milligram per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.26 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.6 (gram per deciliter)\n- Microalbumin/Creatinine [Mass Ratio] in Urine: 58 (milligram per gram)\n- Neutrophils [#/volume] in Blood by Automated count: 8.20 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 71.7 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.3 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 80 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 7.6 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.87 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Heart failure\n- Complication due to diabetes mellitus\n- Type 2 diabetes mellitus\n- Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-02-20 11:16:07, ended at 2017-02-20 13:53:56\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care \n\n### Condition\n- Primary diagnosis: Heart failure\n- Type 2 diabetes mellitus\n- Chronic ischemic heart disease\n- Complication due to diabetes mellitus\n\n### Drug\n- amoxicillin 500 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2017-02-16, presumably until 2017-02-23, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-02-20 13:55:00, ended at 2017-02-20 23:59:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic ischemic heart disease\n- Complication due to diabetes mellitus\n- Heart failure\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-10 10:12:00, ended at 2017-03-10 12:59:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, retroperitoneal (eg, renal, aorta, nodes), real time with image documentation; complete\n\n### Condition\n- Type 2 diabetes mellitus\n- Chronic ischemic heart disease\n- Heart failure\n- Complication due to diabetes mellitus\n- Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-10 11:21:26, ended at 2017-03-10 13:19:48\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic ischemic heart disease\n- Complication due to diabetes mellitus\n- Type 2 diabetes mellitus\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-10 13:00:00, ended at 2017-03-10 23:59:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.28 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 157 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 8.0 (percent)\n- Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma: 1332 (picogram per milliliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 5.1 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 26 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 193 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.7 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Heart failure\n- Chronic ischemic heart disease\n- Complication due to diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-03-11 00:00:00, ended at 2017-03-11 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n- 3 ML insulin lispro 25 UNT/ML / insulin lispro protamine, human 75 UNT/ML Pen Injector, started on 2017-03-14, presumably until 2017-08-23, with intended 11 refill(s). Instructions: Humalog 75/25 insulin mix  Before breakfast: take 15  Before lunch: 25 unit     Before dinner: take 30 units      \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-28 13:12:00, ended at 2017-03-28 17:44:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n- Glucose [Mass/volume] in Blood: 95 (milligram per deciliter)\n- Left ventricular Ejection fraction: 28.0 (percent)\n- Sodium [Moles/volume] in Blood: 142 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 14.3 (gram per deciliter)\n- Potassium [Moles/volume] in Blood: 3.4 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood: 42 (percent)\n- INR in Blood by Coagulation assay: 1.0 (ratio)\n\n### Procedure\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Collection of blood specimen from a completely implantable venous access device\n- Insertion of Monitoring Device into Right Ventricle, Percutaneous Approach\n- Measurement of Cardiac Sampling and Pressure, Right Heart, Percutaneous Approach\n- Right heart catheterization including measurement(s) of oxygen saturation and cardiac output, when performed\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Monitoring of Cardiac Output, Percutaneous Approach\n- Collection of venous blood by venipuncture\n\n### Condition\n- Type 2 diabetes mellitus\n- Generalized ischemic myocardial dysfunction\n- Essential hypertension\n- Type 2 diabetes mellitus without complication\n- Heart failure\n- Chronic ischemic heart disease\n- Complication due to diabetes mellitus\n- Hypertensive heart failure\n- Cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-04-28 00:00:00, ended at 2017-04-28 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Complication due to diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-05-19 09:20:25, ended at 2017-05-19 10:27:05\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care \n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2017-04-14, presumably until 2017-11-10, with intended 0 refill(s). Instructions: take 10 mg by mouth daily\n- methotrexate 2.5 MG Oral Tablet, through Oral route, started on 2017-04-14, presumably until 2018-07-19, with intended 0 refill(s). Instructions: take 15 mg by mouth every 7 days \n- folic acid 1 MG Oral Tablet, through Oral route, started on 2017-04-18, presumably until 2018-07-19, with intended 0 refill(s). Instructions: take 1 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-06-11 00:00:00, ended at 2017-06-11 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- empagliflozin 10 MG Oral Tablet, started on 2017-06-13, presumably until 2018-07-19, with intended 11 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-06-13 00:00:00, ended at 2017-06-13 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- losartan potassium 25 MG Oral Tablet, started on 2017-06-13, presumably until 2017-09-18, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-06-16 00:00:00, ended at 2017-06-16 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-06-18 00:00:00, ended at 2017-06-18 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Chronic ischemic heart disease\n- Complication due to diabetes mellitus\n\n### Drug\n- carvedilol 12.5 MG Oral Tablet, started on 2017-06-18, presumably until 2017-08-23, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-26 09:50:15, ended at 2017-06-26 10:30:17\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic ischemic heart disease\n- Primary diagnosis: Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-26 10:39:00, ended at 2017-06-26 23:59:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin A1c/Hemoglobin.total in Blood: 9.8 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.9 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 32 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 143 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.61 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 275 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.1 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n- Complication due to diabetes mellitus\n- Type 2 diabetes mellitus\n- Heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-07-12 00:00:00, ended at 2017-07-12 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-07-12 00:00:00, ended at 2017-07-12 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n- 3 ML liraglutide 6 MG/ML Pen Injector, started on 2017-07-13, presumably until 2018-05-31, with intended 11 refill(s). Instructions: INJECT 1.2 MG SUBCUTANEOUS EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-07-17 00:00:00, ended at 2017-07-17 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary diabetes mellitus\n- Severe hyperglycemia due to diabetes mellitus\n- Complication due to diabetes mellitus\n- Kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-07-23 00:00:00, ended at 2017-07-23 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Congestive heart failure\n- Chronic combined systolic and diastolic heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- furosemide 40 MG Oral Tablet, started on 2017-07-23, presumably until 2017-10-04, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-08-10 00:00:00, ended at 2017-08-10 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- clopidogrel 75 MG Oral Tablet, started on 2017-08-10, presumably until 2018-06-01, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-08-23 00:00:00, ended at 2017-08-23 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-08-23 00:00:00, ended at 2017-08-23 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Complication due to diabetes mellitus\n- Chronic ischemic heart disease\n- Type 2 diabetes mellitus\n\n### Drug\n- carvedilol 25 MG Oral Tablet, started on 2017-08-23, presumably until 2018-07-19, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-23 09:57:58, ended at 2017-08-23 12:23:51\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.567\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- 3 ML insulin lispro 25 UNT/ML / insulin lispro protamine, human 75 UNT/ML Pen Injector, started on 2017-08-23, presumably until 2018-07-19, with intended 11 refill(s). Instructions: Humalog 75/25 insulin mix Before breakfast: take 18 Before lunch: 26 units  Before dinner: take 26 units\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-23 11:13:50, ended at 2017-08-23 13:17:06\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.5\" (inch (US))\n\n### Procedure\n- Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care \n\n### Condition\n- Chronic ischemic heart disease\n- Complication due to diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- carvedilol 25 MG Oral Tablet, through Oral route, started on 2017-08-23, presumably until 2017-08-23, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-08 00:00:00, ended at 2017-09-08 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-09-12 00:00:00, ended at 2017-09-12 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-09-18 00:00:00, ended at 2017-09-18 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sacubitril 24 MG / valsartan 26 MG Oral Tablet, through Oral route, started on 2017-09-18, presumably until 2018-06-01, with intended 0 refill(s). Instructions: take 24-26 mg by mouth 2 times a day \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-09-23 00:00:00, ended at 2017-09-23 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n- Neuralgia\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, started on 2017-09-26, presumably until 2018-05-04, with intended 6 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-04 13:06:00, ended at 2017-10-04 13:06:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-04 13:07:00, ended at 2017-10-04 23:59:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 146 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.8 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 243 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.2 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 27.5 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 8.6 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.61 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.31 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.7 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 168 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.80 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.20 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22.5 (percent)\n- Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma: 500 (picogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 42 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Globulin [Mass/volume] in Serum: 5.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.8 (percent)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 7.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.49 (micro-international unit per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 83.0 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.56 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Type 2 diabetes mellitus\n- Chronic combined systolic and diastolic heart failure\n- Heart failure\n- Chronic ischemic heart disease\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Congestive heart failure\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-10-23 00:00:00, ended at 2017-10-23 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Congestive heart failure\n- Chronic combined systolic and diastolic heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- furosemide 40 MG Oral Tablet, through Oral route, started on 2017-10-23, presumably until 2017-10-25, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day Take 80mg in the morning, 40mg in the evening\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-10 10:13:57, ended at 2017-11-10 11:24:08\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care \n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-12-13 00:00:00, ended at 2017-12-13 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2017-12-13, presumably until 2017-12-13, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-01-16 00:00:00, ended at 2018-01-16 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2018-01-17, presumably until 2018-01-17, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-17 08:03:00, ended at 2018-01-17 09:18:03\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care \n\n### Condition\n- Complication due to diabetes mellitus\n- Type 2 diabetes mellitus\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-17 09:21:00, ended at 2018-01-17 09:21:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 9.0 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 5.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 146 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 7.3 (percent)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 85.2 (femtoliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.8 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 159 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.30 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.0 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 257 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.74 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.53 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.74 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.4 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.7 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.1 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.12 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 49 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.6 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Secondary diabetes mellitus\n- Complication due to diabetes mellitus\n- Severe hyperglycemia due to diabetes mellitus\n- Kidney disease\n- Type 2 diabetes mellitus\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-17 09:22:00, ended at 2018-01-17 23:59:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Complication due to diabetes mellitus\n- Heart failure\n- Secondary diabetes mellitus\n- Severe hyperglycemia due to diabetes mellitus\n- Type 2 diabetes mellitus\n- Kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-02-07 00:00:00, ended at 2018-02-07 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2018-02-08, presumably until 2018-02-08, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-03-14 11:26:56, ended at 2018-03-14 13:55:49\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 30 (calculated)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Body height: 5' 4\" (inch (US))\n- Creatinine [Mass/volume] in Serum or Plasma: 1.88 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 206 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 57 (milligram per deciliter)\n\n### Procedure\n- Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter; single, dual, or multiple lead transvenous imp\n\n### Condition\n- Type 2 diabetes mellitus\n- Chronic ischemic heart disease\n- Complication due to diabetes mellitus\n- Primary diagnosis: Heart failure\n\n### Drug\n- digoxin 0.125 MG Oral Tablet, through Oral route, started on 2018-03-14, presumably until 2018-06-01, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-14 14:02:00, ended at 2018-03-14 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma: 567 (picogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 7.9 (percent)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 40 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.66 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Complication due to diabetes mellitus\n- Type 2 diabetes mellitus\n- Heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-03-22 00:00:00, ended at 2018-03-22 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 185 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.58 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 41 (milligram per deciliter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 26 (calculated)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-28 13:52:00, ended at 2018-03-28 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 41 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 110 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.52 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Type 2 diabetes mellitus\n- Heart failure\n- Complication due to diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-06 00:00:00, ended at 2018-04-06 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 122 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.56 (milligram per deciliter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 26 (calculated)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 41 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-13 00:00:00, ended at 2018-04-13 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 26 (calculated)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.49 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 146 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-20 00:00:00, ended at 2018-04-20 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 23 (calculated)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.67 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 122 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-27 00:00:00, ended at 2018-04-27 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 102 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 34 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.53 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 22 (calculated)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-05-04 00:00:00, ended at 2018-05-04 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 18 (calculated)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.58 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 253 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-04 00:00:00, ended at 2018-05-04 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neuralgia\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, started on 2018-05-08, presumably until 2018-07-19, with intended 6 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-05-11 00:00:00, ended at 2018-05-11 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 153 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.55 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 15 (calculated)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-23 00:00:00, ended at 2018-05-23 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic combined systolic and diastolic heart failure\n- Congestive heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- spironolactone 25 MG Oral Tablet, started on 2018-05-23, presumably until 2018-07-19, with intended 6 refill(s). Instructions: TAKE 1/2 TABLET BY MOUTH DAILY\n- furosemide 80 MG Oral Tablet, started on 2018-05-23, presumably until 2018-06-01, with intended 6 refill(s). Instructions: TAKE 1 TABLET BY MOUTH IN THE MORNING AND IN THE AFTERNOON\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-23 09:48:00, ended at 2018-05-23 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 188 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 29 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.52 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic combined systolic and diastolic heart failure\n- Chronic ischemic heart disease\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-05-28 00:00:00, ended at 2018-05-28 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.78 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 34 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 19 (calculated)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 373 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic ischemic heart disease\n- Chronic combined systolic and diastolic heart failure\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-31 00:00:00, ended at 2018-05-31 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- 3 ML liraglutide 6 MG/ML Pen Injector, started on 2018-06-05, presumably until 2018-07-19, with intended 11 refill(s). Instructions: INJECT 1.2 MG SUBCUTANEOUS EVERY DAY  90 day supply if insurance allows\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-06-01 00:00:00, ended at 2018-06-01 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Congestive heart failure\n- Chronic ischemic heart disease\n- Chronic combined systolic and diastolic heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-06-01 00:00:00, ended at 2018-06-01 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic combined systolic and diastolic heart failure\n- Chronic ischemic heart disease\n- Congestive heart failure\n- Primary diagnosis: Heart failure\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2018-06-01, presumably until 2018-07-19, with intended 3 refill(s). Instructions: take 1 Tab by mouth 3 times a day\n- digoxin 0.125 MG Oral Tablet, through Oral route, started on 2018-06-01, presumably until 2018-07-19, with intended 11 refill(s). Instructions: take 0.5 Tabs by mouth daily\n- furosemide 80 MG Oral Tablet, started on 2018-06-01, presumably until 2018-07-19, with intended 6 refill(s). Instructions: Take 80 mg (one tablet) in the morning and 40 mg (half of a tablet) in the afternoon.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-06-04 00:00:00, ended at 2018-06-04 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic combined systolic and diastolic heart failure\n- Congestive heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-06-06 00:00:00, ended at 2018-06-06 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for heart transplant or heart/lung transplant\n- Insertion of non-tunneled centrally inserted central venous catheter; age 5 years or older\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging)\n- Insertion and placement of flow directed catheter (eg, Swan-Ganz) for monitoring purposes\n- Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n\n### Condition\n- Heart failure\n- Atrial fibrillation\n- Cardiomyopathy\n- Essential hypertension\n- Transplanted heart present\n\n### Drug\n- 10 ML calcium chloride 100 MG/ML Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-07\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-06\n- 10 ML epinephrine 0.1 MG/ML Prefilled Syringe, through Intravenous route, started on 2018-06-06, presumably until 2018-06-07\n- 5 ML protamine sulfate (USP) 10 MG/ML Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-07\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2018-06-06, presumably until 2018-06-07\n- 2 ML magnesium sulfate 500 MG/ML Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-06\n- 250 ML norepinephrine 0.016 MG/ML Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-06\n- 10 ML furosemide 10 MG/ML Injection, started on 2018-06-06, presumably until 2018-06-07\n- 50 ML clevidipine 0.5 MG/ML Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-07\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2018-06-06, presumably until 2018-06-06\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2018-06-06, presumably until 2018-06-06\n- vasopressin (USP) 20 UNT/ML Injectable Solution, through Intravenous route, started on 2018-06-07, presumably until 2018-06-07\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2018-06-06, presumably until 2018-06-06\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-07\n- ketamine 100 MG/ML Injectable Solution, started on 2018-06-06, presumably until 2018-06-06\n- 10 ML tranexamic acid 100 MG/ML Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-06\n- 2 ML dexmedetomidine 0.1 MG/ML Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-06\n- midazolam 1 MG/ML Injectable Solution, started on 2018-06-06, presumably until 2018-06-06\n- 1 ML sufentanil 0.05 MG/ML Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-06-06 15:50:00, ended at 2018-07-19 16:03:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Base excess in Blood by calculation: 7 (millimole per liter)\n- C peptide [Mass/volume] in Serum or Plasma: 0.2 (nanogram per milliliter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 45.5 (millimeter mercury column)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 24.8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 9.5 (gram per deciliter)\n- Lactate [Moles/volume] in Blood: >15.0 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.6 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 94.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 6.7 (millimole per liter)\n- Sodium [Moles/volume] in Blood: 142 (millimole per liter)\n- Body height: 5' 5\" (inch (US))\n- Eosinophils [#/volume] in Blood by Manual count: 0.27 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.82 (million per microliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 259 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.8 (percent)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 5 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.20 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Phosphate [Mass/volume] in Serum or Plasma: 6.5 (milligram per deciliter)\n- Prothrombin time (PT): 26.1 (second)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.70 (micro-international unit per milliliter)\n- Ammonia [Mass/volume] in Plasma: 42 (micromole per liter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 3.8 (milligram per deciliter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.44 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Creatinine renal clearance in 24 hour Urine and Serum or Plasma: 21 (milliliter per minute)\n- Left ventricular Ejection fraction: 57.7 (percent)\n- Leukocytes [#/volume] in Body fluid by Manual count: 8 (milli-international unit per milliliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 88 (percent)\n- Platelets [#/volume] in Blood by Automated count: 97 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.6 (gram per deciliter)\n- Urate [Mass/volume] in Serum or Plasma: <2.0 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: >150 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Bicarbonate [Moles/volume] in Specimen: 30.4 (millimole per liter)\n- Calcium.ionized [Moles/volume] in Mixed venous blood: 0.64 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.49 (thousand per microliter)\n- Hydroxyitraconazole [Mass/volume] in Serum or Plasma: <0.1 (microgram per milliliter)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 2.00 (thousand per microliter)\n- Myoglobin [Mass/volume] in Urine: 143 (microgram per liter)\n- Procalcitonin [Mass/volume] in Serum or Plasma: 8.53 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 97 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 3.31 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood: 28 (percent)\n- Heparin unfractionated [Units/volume] in Platelet poor plasma: <0.10 (unit per milliliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 6 - 10 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.1 (thousand per microliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 395 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Manual count: 2.30 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 99.3 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 4.2 (milligram per deciliter)\n- Potassium [Moles/volume] in Blood: 4.8 (millimole per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 310 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: >3500 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Base excess in Arterial blood by calculation: 4.3 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.22 (thousand per microliter)\n- Body weight Stated: 92.0 (kilogram)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 284 (unit per liter)\n- Glucose [Mass/volume] in Blood: >500 (milligram per deciliter)\n- Itraconazole [Mass/volume] in Serum or Plasma: <0.1 (microgram per milliliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 804 (unit per liter)\n- Monocytes [#/volume] in Blood by Manual count: 2.71 (thousand per microliter)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 97 (millimeter mercury column)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Tacrolimus [Mass/volume] in Blood: 9.9 (nanogram per milliliter)\n- Aldolase [Enzymatic activity/volume] in Serum or Plasma: 13.5 (unit per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 1.60 (milligram per deciliter)\n- Body height Stated: 165 (centimeter)\n- Calcium.ionized [Moles/volume] in Blood: 1.08 (millimole per liter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 45.6 (millimeter mercury column)\n- Ferritin [Mass/volume] in Serum or Plasma: 250.1 (nanogram per milliliter)\n- Globulin [Mass/volume] in Serum: 5.2 (gram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 7.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.90 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 150 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 68.8 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 80 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 51 - 100 (per high power field)\n- Iron [Mass/volume] in Serum or Plasma: 28 (microgram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.4 (percent)\n- Oxygen [Partial pressure] in Arterial blood: 93.5 (millimeter mercury column)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 15.5 (microgram per milliliter)\n- Lidocaine [Mass/volume] in Serum or Plasma: <0.5 (microgram per milliliter)\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Evaluation of oral and pharyngeal swallowing function\n- Measurement of Cardiac Sampling and Pressure, Right Heart, Percutaneous Approach\n- Introduction of Other Therapeutic Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Medical decision making that is straightforward or o\n- Hemodialysis procedure with single evaluation by a physician or other qualified health care professional\n- Critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes (List separately in addition to code for primary service)\n- Controlled ventilation procedure and therapy, initiation and management\n- Continuous inhalation treatment with aerosol medication for acute airway obstruction; each additional hour (List separately in addition to code for primary procedure)\n- Respiratory Ventilation, Greater than 96 Consecutive Hours\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Right heart catheterization including measurement(s) of oxygen saturation and cardiac output, when performed\n- Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies) requiring repeated evaluations by a physician or other qualified health care professional, with or without substantial re\n- Occupational therapy evaluation, high complexity, requiring these components: An occupational profile and medical and therapy history, which includes review of medical and/or therapy records and extensive additional review of physical, cognitive, or psych\n- Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording \n- Excision of Right Ventricle, Percutaneous Approach, Diagnostic\n- Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, without imaging guidance; age 5 years or older\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Transplantation of Heart, Allogeneic, Open Approach\n- Fluoroscopic guidance for central venous access device placement, replacement (catheter only or complete), or removal (includes fluoroscopic guidance for vascular access and catheter manipulation, any necessary contrast injections through access site or c\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Treatment of swallowing dysfunction and/or oral function for feeding\n- Radiologic examination, chest; single view\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Duplex scan of lower extremity arteries or arterial bypass grafts; unilateral or limited study\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of \n- Insertion of non-tunneled centrally inserted central venous catheter; age 5 years or older\n- Physical therapy evaluation: moderate complexity, requiring these components: A history of present problem with 1-2 personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures in\n- Collection of venous blood by venipuncture\n- Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right heart catheterization\n- Performance of Cardiac Output, Continuous\n- Endomyocardial biopsy\n- Insertion of Infusion Device into Right Atrium, Percutaneous Approach\n- Computed tomography, thorax, diagnostic; without contrast material\n- Flexible endoscopic evaluation of swallowing by cine or video recording\n- Removal of Cardiac Lead from Heart, Open Approach\n- Insertion of Infusion Device into Right Internal Jugular Vein, Percutaneous Approach\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Fluoroscopy of Multiple Coronary Arteries using Low Osmolar Contrast\n- Performance of Urinary Filtration, Intermittent, Less than 6 Hours Per Day\n- Insertion of tunneled centrally inserted central venous catheter, without subcutaneous port or pump; age 5 years or older\n- Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies), with single evaluation by a physician or other qualified health care professional\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Insertion of Infusion Device into Superior Vena Cava, Percutaneous Approach\n- Insertion of Tunneled Vascular Access Device into Chest Subcutaneous Tissue and Fascia, Percutaneous Approach\n- Computed tomography, head or brain; without contrast material\n- Insertion and placement of flow directed catheter (eg, Swan-Ganz) for monitoring purposes\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Performance of Urinary Filtration, Continuous, Greater than 18 hours Per Day\n- Continuous inhalation treatment with aerosol medication for acute airway obstruction; first hour\n- Introduction of Vasopressor into Peripheral Vein, Percutaneous Approach\n- Duplex scan of lower extremity arteries or arterial bypass grafts; complete bilateral study\n- Insertion of Monitoring Device into Right Pulmonary Artery, Percutaneous Approach\n\n### Condition\n- Acute on chronic hypercapnic respiratory failure\n- Aortocoronary bypass graft present\n- Disorders of both mitral and tricuspid valves\n- Infection due to Escherichia coli\n- Iron deficiency anemia\n- Long QT syndrome\n- Pain at rest of left lower limb co-occurrent and due to atherosclerosis\n- Pleural effusion\n- Pulmonary hypertension\n- Aberrant premature complexes\n- Acute posthemorrhagic anemia\n- Atrial fibrillation\n- Conduction disorder of the heart\n- Diabetes mellitus without complication\n- Disorder of cardiovascular system\n- Disorder of transplanted heart\n- Hepatic failure\n- Hyperkalemia\n- Intermittent claudication of bilateral lower limbs co-occurrent and due to atherosclerosis\n- Supraventricular tachycardia\n- Ventricular tachycardia\n- Acute hypoxemic respiratory failure\n- Anemia in chronic kidney disease\n- Atherosclerosis of artery of lower limb\n- Cardiogenic shock\n- Cardiomegaly\n- Cardiomyopathy\n- Chronic total occlusion of coronary artery\n- Coronary artery graft present\n- Hypo-osmolality and or hyponatremia\n- Hypoglycemia due to type 2 diabetes mellitus\n- Rheumatic disease of heart valve\n- Skin sensation disturbance\n- Transplanted heart present\n- Abnormal findings on diagnostic imaging of lung\n- Acquired absence of organ\n- Congestive heart failure\n- Critical illness myopathy\n- Delirium\n- Diastolic heart failure\n- Edema, generalized\n- Electrocardiogram abnormal\n- Generalized ischemic myocardial dysfunction\n- Hypertensive heart and renal disease with (congestive) heart failure\n- Late effect of complications of procedure\n- Late effect of medical and surgical care complication\n- Localized edema\n- Muscle pain\n- Muscle weakness\n- Old myocardial infarction\n- Right bundle branch block\n- Sepsis\n- Septic shock\n- Ventricular premature complex\n- Acidosis\n- Acute renal failure syndrome\n- Acute tubular necrosis\n- Altered mental status\n- Bacterial infection due to Pseudomonas\n- Cardiac transplant failure\n- Chronic ischemic heart disease\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Metabolic encephalopathy\n- Moderate protein-calorie malnutrition (weight for age 60-74 percent of standard)\n- Acute on chronic combined systolic and diastolic heart failure\n- Angina co-occurrent and due to coronary arteriosclerosis\n- Blood coagulation disorder\n- Chronic kidney disease stage 3\n- Complication of anesthesia\n- Gastroesophageal reflux disease without esophagitis\n- Primary diagnosis: Heart failure\n- Hyperglycemia\n- Hyperglycemia due to type 2 diabetes mellitus\n- Hyperosmolality and or hypernatremia\n- Hypertensive heart and chronic kidney disease\n- Leukocytosis\n- Low blood pressure\n- Persistent pain following procedure\n- Acute on chronic hypoxemic respiratory failure\n- Acute pulmonary edema\n- Atelectasis\n- Cardiac arrhythmia\n- Chronic passive congestion of liver\n- Disorder of digestive system\n- Disorder of immune function\n- Disorientated\n- Postoperative shock\n- Rest pain\n- Vocal cord paralysis\n- Atrial flutter\n- Bradycardia\n- Complication due to diabetes mellitus\n- End-stage renal disease\n- Finding of urine output\n- Hyperosmolarity\n- Left bundle branch block\n- Obesity\n- Pneumonia due to Pseudomonas\n- Pneumothorax\n- Rheumatoid arthritis\n- Shock\n- Chronic pulmonary edema\n- Disorder of plasma protein metabolism\n- Type 2 diabetes mellitus\n- Urinary tract infectious disease\n\n### Drug\n- glycerin, started on 2018-06-11, presumably until 2018-06-11\n- acyclovir 200 MG Oral Capsule, through Oral route, started on 2018-07-02, presumably until 2018-12-17, with intended 11 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2018-06-28, presumably until 2018-07-12, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- albuterol 0.83 MG/ML Inhalation Solution, through Inhalation, started on 2018-06-11, presumably until 2018-06-23\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2018-06-07, presumably until 2018-06-15\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2018-06-08, presumably until 2018-06-11\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2018-06-09, presumably until 2018-06-11\n- 100 ML milrinone lactate 0.2 MG/ML Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-15\n- 250 ML dopamine hydrochloride 3.2 MG/ML Injection, through Intravenous route, started on 2018-06-15, presumably until 2018-06-15\n- 3 ML insulin isophane, human 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2018-07-03, presumably until 2018-07-19, with intended 5 refill(s). Instructions: inject 33 Units subcutaneous (under the skin) 2 times a day\n- gabapentin 50 MG/ML Oral Solution, through Oral route, started on 2018-06-18, presumably until 2018-07-02\n- sodium citrate, through Intravenous route, started on 2018-06-09, presumably until 2018-06-25\n- 10 ML epinephrine 0.1 MG/ML Prefilled Syringe, through Intravenous route, started on 2018-06-07, presumably until 2018-06-07\n- chlorhexidine gluconate 1.2 MG/ML Mouthwash, through Submucosal route, started on 2018-06-07, presumably until 2018-06-15\n- haloperidol 5 MG/ML Injectable Solution, started on 2018-06-11, presumably until 2018-06-12\n- chlorothiazide 50 MG/ML Oral Suspension, through Oral route, started on 2018-06-08, presumably until 2018-06-17\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-07-04, presumably until 2019-07-04, with intended 11 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast\n- 50 ML albumin human, USP 250 MG/ML Injection, through Intravenous route, started on 2018-06-07, presumably until 2018-06-19\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2018-06-17, presumably until 2018-06-23\n- magnesium citrate 58.2 MG/ML Oral Solution, through Oral route, started on 2018-06-11, presumably until 2018-06-11\n- docusate sodium 10 MG/ML Oral Solution, through Oral route, started on 2018-06-08, presumably until 2018-06-15\n- 3 ML insulin lispro 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2018-07-03, presumably until 2018-07-09, with intended 5 refill(s). Instructions: inject 22 Units subcutaneous (under the skin) 3 times a day before meals Additionally, inject 0-12 units subcutaneously 4 times a day before meals and at bedtime per sliding scale.\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2018-06-07, presumably until 2018-06-28\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-06-26, presumably until 2018-06-28\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2018-07-03, presumably until 2018-08-24, with intended 2 refill(s). Instructions: take 2 Tabs by mouth daily Or as directed per prednisone taper card.\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2018-06-28, presumably until 2018-06-30\n- aspirin 325 MG Oral Tablet, through Oral route, started on 2018-07-19, presumably until 2018-07-19\n- amphotericin B 50 MG Injection, started on 2018-06-07, presumably until 2018-06-07\n- mineral oil 0.425 MG/MG / petrolatum 0.568 MG/MG Ophthalmic Ointment, through Intraocular route, started on 2018-06-11, presumably until 2018-06-11\n- mineral oil 0.15 MG/MG / petrolatum 0.83 MG/MG Ophthalmic Ointment, through Intraocular route, started on 2018-06-09, presumably until 2018-06-15\n- 1 ML epoetin alfa 10000 UNT/ML Injection, through Subcutaneous route, started on 2018-06-29, presumably until 2018-08-16, with intended 0 refill(s). Instructions: inject 1 mL subcutaneous (under the skin) every Tuesday, Thursday and Saturday\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2018-06-29, presumably until 2018-06-29\n- midodrine hydrochloride 10 MG Oral Tablet, through Oral route, started on 2018-07-09, presumably until 2018-07-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-06-15, presumably until 2018-06-15\n- cefazolin 1000 MG Injection, started on 2018-06-07, presumably until 2018-06-07\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, started on 2018-06-12, presumably until 2018-06-15\n- prednisone 1 MG/ML Oral Solution, through Oral route, started on 2018-06-08, presumably until 2018-07-02\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2018-06-23, presumably until 2018-06-23\n- 5 ML iron sucrose 20 MG/ML Injection, through Intravenous route, started on 2018-06-29, presumably until 2018-08-16, with intended 0 refill(s). Instructions: 5 mL by Intravenous route every Tuesday, Thursday and Saturday For 9 doses.\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2018-06-07, presumably until 2018-06-07\n- 250 ML norepinephrine 0.016 MG/ML Injection, through Intravenous route, started on 2018-06-10, presumably until 2018-06-16\n- tacrolimus 5 MG Oral Capsule, through Oral route, started on 2018-06-08, presumably until 2018-07-02\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2018-07-03, presumably until 2018-08-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime\n- 10 ML calcium chloride 100 MG/ML Prefilled Syringe, through Intravenous route, started on 2018-06-07, presumably until 2018-06-07\n- insulin isophane, human 100 UNT/ML Injectable Suspension, through Subcutaneous route, started on 2018-06-07, presumably until 2018-07-19\n- nystatin 100000 UNT/ML Oral Suspension, through Oral route, started on 2018-06-08, presumably until 2019-05-31, with intended 11 refill(s). Instructions: 5 mL by Swish & Swallow route 3 times a day\n- lansoprazole 30 MG Disintegrating Oral Tablet, through Oral route, started on 2018-06-29, presumably until 2018-07-02\n- 10 ML furosemide 10 MG/ML Injection, started on 2018-06-07, presumably until 2018-06-30\n- 250 ML dopamine hydrochloride 1.6 MG/ML Injection, through Intravenous route, started on 2018-06-21, presumably until 2018-07-05\n- midodrine hydrochloride 5 MG Oral Tablet, through Oral route, started on 2018-06-21, presumably until 2018-08-02, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2018-06-12, presumably until 2018-07-19\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, through Subcutaneous route, started on 2018-06-20, presumably until 2018-08-02, with intended 0 refill(s). Instructions: inject 0.5 mL subcutaneous (under the skin) every 8 hours\n- citric acid, through Intravenous route, started on 2018-06-09, presumably until 2018-06-25\n- chlorothiazide 500 MG Injection, through Intravenous route, started on 2018-06-08, presumably until 2018-06-21\n- potassium chloride 1.33 MEQ/ML Oral Solution, through Oral route, started on 2018-06-16, presumably until 2018-06-28\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2018-06-08, presumably until 2018-08-29, with intended 0 refill(s). Instructions: inject 23 Units subcutaneous (under the skin) 3 times a day with meals\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2018-06-07, presumably until 2018-06-24\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2018-06-19, presumably until 2018-06-21\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2018-06-08, presumably until 2018-06-13\n- hydroxyzine hydrochloride 2 MG/ML Oral Solution, through Oral route, started on 2018-06-12, presumably until 2018-06-12\n- 50 ML sodium bicarbonate 84 MG/ML Prefilled Syringe, through Intravenous route, started on 2018-06-07, presumably until 2018-06-15\n- 50 ML glucose 500 MG/ML Prefilled Syringe, through Intravenous route, started on 2018-06-17, presumably until 2018-06-23\n- 50 ML potassium chloride 0.4 MEQ/ML Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-07\n- acetaminophen 32 MG/ML Oral Solution, through Oral route, started on 2018-06-09, presumably until 2018-06-26\n- spironolactone 25 MG Oral Tablet, through Oral route, started on 2018-06-07, presumably until 2018-06-07\n- tacrolimus 0.5 MG Oral Capsule, through Oral route, started on 2018-07-03, presumably until 2018-07-30, with intended 11 refill(s). Instructions: take 1 Cap by mouth daily\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-06-21, presumably until 2018-06-25\n- sennosides, USP 35.2 MG/ML Oral Solution, through Oral route, started on 2018-06-08, presumably until 2018-06-13\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-07-18, presumably until 2018-07-18\n- venlafaxine 25 MG Oral Tablet, through Oral route, started on 2018-06-19, presumably until 2018-08-02, with intended 0 refill(s). Instructions: take 1 Tab by mouth DAILY\n- furosemide 80 MG Oral Tablet, through Oral route, started on 2018-06-07, presumably until 2018-06-07\n- albuterol 2 MG Oral Tablet, through Oral route, started on 2018-06-15, presumably until 2018-07-19, with intended 11 refill(s). Instructions: take 2 Tabs by mouth 3 times a day\n- albuterol 0.4 MG/ML Oral Solution, through Oral route, started on 2018-06-21, presumably until 2018-07-02\n- sulfamethoxazole 400 MG / trimethoprim 80 MG Oral Tablet, through Oral route, started on 2018-06-08, presumably until 2018-08-29, with intended 11 refill(s). Instructions: take 1 Tab by mouth every day\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2018-07-05, presumably until 2018-07-05\n- gabapentin 100 MG Oral Capsule, through Oral route, started on 2018-07-02, presumably until 2018-07-19, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n- insulin glargine 100 UNT/ML Injectable Solution, started on 2018-07-19, presumably until 2018-08-16, with intended 0 refill(s). Instructions: On 07/19/2018, inject 15 units subcutaneously (under the skin) in the evening once. Then on 07/20/2018, inject 15 units SQ in the morning once. Then starting on 07/21/2018, inject 30 units SQ once daily in the morning thereafter.\n- itraconazole 10 MG/ML Oral Solution, through Oral route, started on 2018-06-21, presumably until 2018-09-10, with intended 2 refill(s). Instructions: Take 20 mL (200 mg) by mouth every morning and 10 mL (100 mg) every evening on an empty stomach.\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-06-28, presumably until 2019-07-03, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals\n- lidocaine 0.05 MG/MG Medicated Patch, through Transdermal route, started on 2018-07-05, presumably until 2018-09-27, with intended 0 refill(s). Instructions: apply 1 Patch to skin daily Apply patch to upper back  for up to 12 hours in any 24 hour period.\n- glucose 50 MG/ML Injection, through Intravenous route, started on 2018-06-09, presumably until 2018-06-12\n- 100 ML propofol 10 MG/ML Injection, through Intravenous route, started on 2018-06-07, presumably until 2018-06-07\n- midodrine hydrochloride 2.5 MG Oral Tablet, through Oral route, started on 2018-07-03, presumably until 2018-07-17\n- 10 ML atropine sulfate 0.1 MG/ML Prefilled Syringe, started on 2018-06-21, presumably until 2018-06-21\n- 100 ML clevidipine 0.5 MG/ML Injection, through Intravenous route, started on 2018-06-07, presumably until 2018-06-13\n- bumetanide 0.25 MG/ML Injectable Solution, through Intravenous route, started on 2018-06-08, presumably until 2018-06-08\n- albuterol 5 MG/ML Inhalation Solution, through Inhalation, started on 2018-06-10, presumably until 2018-06-11\n- prednisone 20 MG Oral Tablet, through Oral route, started on 2018-07-03, presumably until 2018-07-19\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2018-06-11, presumably until 2018-06-11\n- mycophenolate mofetil 500 MG Oral Tablet, through Oral route, started on 2018-07-02, presumably until 2018-10-03, with intended 11 refill(s). Instructions: take 2 Tabs by mouth 2 times a day\n- modafinil 100 MG Oral Tablet, through Oral route, started on 2018-06-15, presumably until 2018-07-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- acyclovir 40 MG/ML Oral Suspension, through Oral route, started on 2018-06-08, presumably until 2018-07-02\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-06-29, presumably until 2018-11-03, with intended 11 refill(s). Instructions: take 1 Tab by mouth every morning with breakfast\n- glucose 4000 MG Chewable Tablet, through Oral route, started on 2018-07-03, presumably until 2018-08-16, with intended 0 refill(s). Instructions: take 4 Tabs by mouth as needed for Low blood sugar\n- midazolam 1 MG/ML Injectable Solution, started on 2018-06-09, presumably until 2018-06-09\n- 100 ML dexmedetomidine 0.004 MG/ML Injection, through Intravenous route, started on 2018-06-07, presumably until 2018-06-08\n- methylprednisolone 125 MG Injection, started on 2018-06-07, presumably until 2018-06-07\n- melatonin 3 MG Disintegrating Oral Tablet, through Oral route, started on 2018-06-18, presumably until 2018-07-18\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2018-07-03, presumably until 2018-07-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-06-08 00:00:00, ended at 2018-06-08 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic combined systolic and diastolic heart failure\n- Chronic ischemic heart disease\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-06-11 00:00:00, ended at 2018-06-11 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic combined systolic and diastolic heart failure\n- Congestive heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-14 00:00:00, ended at 2018-06-14 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Complication due to diabetes mellitus\n- Chronic ischemic heart disease\n- Type 2 diabetes mellitus\n\n### Drug\n- carvedilol 12.5 MG Oral Tablet, started on 2018-06-14, presumably until 2018-06-14, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-06-19 00:00:00, ended at 2018-06-19 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-06-19, presumably until 2018-06-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-06-26 00:00:00, ended at 2018-06-26 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-06-26, presumably until 2018-06-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-06-28 00:00:00, ended at 2018-06-28 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-06-28, presumably until 2018-06-28\n- midazolam 1 MG/ML Injectable Solution, started on 2018-06-28, presumably until 2018-06-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-07-03 00:00:00, ended at 2018-07-03 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-07-03, presumably until 2018-07-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-07-06 00:00:00, ended at 2018-07-06 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Peripheral vascular disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-07-10 00:00:00, ended at 2018-07-10 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-07-10, presumably until 2018-07-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-07-18 00:00:00, ended at 2018-07-18 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-07-18, presumably until 2018-07-18\n- 2 ML verapamil hydrochloride 2.5 MG/ML Injection, through Intravenous route, started on 2018-07-18, presumably until 2018-07-18\n- iodixanol, through Intravenous route, started on 2018-07-18, presumably until 2018-07-18\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2018-07-18, presumably until 2018-07-18\n- 250 ML nitroglycerin 0.1 MG/ML Injection, through Intravenous route, started on 2018-07-18, presumably until 2018-07-18\n- midazolam 1 MG/ML Injectable Solution, started on 2018-07-18, presumably until 2018-07-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-07-27 00:00:00, ended at 2018-07-27 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- tacrolimus 1 MG Oral Capsule, through Oral route, presumably until 2018-08-14, with intended 0 refill(s). Instructions: take 1 mg by mouth 2 times a day Total dose of 1mg AM, 1mg PM\n- amlodipine 2.5 MG Oral Tablet, through Oral route, presumably until 2018-08-16, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n- tacrolimus 0.5 MG Oral Capsule, through Oral route, started on 2018-07-30, presumably until 2018-08-14, with intended 11 refill(s). Instructions: take 1 Cap by mouth 2 times a day Total dose of 0.5mg AM, 1mg PM\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-08-01 00:00:00, ended at 2018-08-01 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pure hypercholesterolemia\n- Primary diagnosis: Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-08-02 00:00:00, ended at 2018-08-02 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-08-02, presumably until 2018-08-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-08-02 00:00:00, ended at 2018-08-02 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- clopidogrel 75 MG Oral Tablet, started on 2018-08-02, presumably until 2018-08-02, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-08-02 10:49:54, ended at 2018-08-02 12:42:30\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-02 12:51:00, ended at 2018-08-02 13:22:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.8 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 2.2 (ratio)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.56 (thousand per microliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 119 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.48 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Itraconazole [Mass/volume] in Serum or Plasma: 1.0 (microgram per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.7 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.3 (percent)\n- MCHC [Mass/volume] by Automated count: 30.5 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Hydroxyitraconazole [Mass/volume] in Serum or Plasma: 1.4 (microgram per milliliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 91.7 (percent)\n- Tacrolimus [Mass/volume] in Blood: 10.9 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 62 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 94 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 218 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 100 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 264 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 10.75 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 197 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.26 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.26 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 100.6 (femtoliter)\n- Chloride [Moles/volume] in Serum or Plasma: 96 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 30.6 (picogram)\n- Triglyceride [Moles/volume] in Serum or Plasma: 153 (milligram per deciliter)\n\n### Procedure\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n\n### Condition\n- Disorder of transplanted heart\n- Pure hypercholesterolemia\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-02 13:23:00, ended at 2018-08-02 14:57:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Excision of Right Ventricle, Percutaneous Approach, Diagnostic\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Right heart catheterization including measurement(s) of oxygen saturation and cardiac output, when performed\n- Endomyocardial biopsy\n- Measurement of Cardiac Sampling and Pressure, Right Heart, Percutaneous Approach\n\n### Condition\n- Transplanted heart present\n- Obesity\n- Disorder of transplanted heart\n- Pure hypercholesterolemia\n- Essential hypertension\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-13 09:08:00, ended at 2018-08-13 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 134 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 97.0 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.44 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.8 (picogram)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.1 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 30.7 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.01 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 206 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 80 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.9 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 8.53 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.19 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.8 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.4 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 67 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.18 (million per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Tacrolimus [Mass/volume] in Blood: 4.6 (nanogram per milliliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-08-14 00:00:00, ended at 2018-08-14 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n\n### Drug\n- tacrolimus 1 MG Oral Capsule, through Oral route, started on 2018-08-14, presumably until 2018-08-17, with intended 3 refill(s). Instructions: take 1 Cap by mouth 2 times a day Total dose of 1mg AM, 1mg PM\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-08-15 00:00:00, ended at 2018-08-15 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-08-16 00:00:00, ended at 2018-08-16 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Endomyocardial biopsy\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-08-16, presumably until 2018-08-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-16 12:53:00, ended at 2018-08-16 14:48:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Excision of Right Ventricle, Percutaneous Approach, Diagnostic\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n\n### Condition\n- Transplanted heart present\n- Chronic kidney disease\n- Acute deep venous thrombosis of internal jugular vein\n- Disorder of transplanted heart\n- Essential hypertension\n- Embolism from thrombosis of vein of lower extremity\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-08-17 00:00:00, ended at 2018-08-17 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal level of blood mineral\n- Disorder of transplanted heart\n\n### Drug\n- tacrolimus 1 MG Oral Capsule, started on 2018-08-17, presumably until 2018-09-10, with intended 3 refill(s). Instructions: Total dose of 0.5mg AM, 1mg PM\n- tacrolimus 0.5 MG Oral Capsule, started on 2018-08-17, presumably until 2018-09-10, with intended 3 refill(s). Instructions: Total dose: 0.5mg in the am, 1mg in the pm.\n- magnesium amino acid chelate 133 MG Oral Tablet, through Oral route, started on 2018-08-17, presumably until 2018-09-27, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-17 09:51:00, ended at 2018-08-17 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 89 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.3 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.0 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.34 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.34 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 13.3 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.6 (percent)\n- MCH [Entitic mass] by Automated count: 29.9 (picogram)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Tacrolimus [Mass/volume] in Blood: 15.9 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.83 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 30.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 97.7 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.0 (percent)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 56 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 11.68 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 87.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 173 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-08-20 00:00:00, ended at 2018-08-20 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- apixaban 2.5 MG Oral Tablet, through Oral route, started on 2018-08-20, presumably until 2018-11-27, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-08-20 00:00:00, ended at 2018-08-20 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-20 13:50:00, ended at 2018-08-20 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study\n\n### Condition\n- Disorder of transplanted heart\n- Embolism from thrombosis of vein of lower extremity\n- Acute deep venous thrombosis of internal jugular vein\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-08-23 00:00:00, ended at 2018-08-23 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease\n- Disorder of transplanted heart\n- Essential hypertension\n\n### Drug\n- furosemide 40 MG Oral Tablet, through Oral route, started on 2018-08-23, presumably until 2018-08-29, with intended 11 refill(s). Instructions: take 2 Tabs by mouth 2 times a day\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2018-08-23, presumably until 2018-08-24, with intended 11 refill(s). Instructions: take 2 Tabs by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-23 08:00:00, ended at 2018-08-23 10:42:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 60.4 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n- Essential hypertension\n- Edema\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-08-23 09:14:30, ended at 2018-08-23 10:36:05\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Edema\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-23 10:43:00, ended at 2018-08-23 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 52 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.6 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.93 (thousand per microliter)\n- Tacrolimus [Mass/volume] in Blood: 7.7 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.40 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.2 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.40 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 196 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 67 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.78 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 83.1 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 112 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 148 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.9 (picogram)\n- MCV [Entitic volume] by Automated count: 94.4 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 133 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 31.7 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 11.80 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.2 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-08-24 00:00:00, ended at 2018-08-24 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease\n- Transplanted heart present\n- Disorder of transplanted heart\n- Essential hypertension\n\n### Drug\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2018-08-24, presumably until 2018-09-17, with intended 2 refill(s). Instructions: take 1.5 Tabs by mouth daily\n- amlodipine 10 MG Oral Tablet, through Oral route, started on 2018-08-24, presumably until 2018-08-28, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-24 12:02:00, ended at 2018-08-24 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording \n\n### Condition\n- Peripheral vascular disease\n- Gangrenous disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-08-24 12:03:48, ended at 2018-08-24 13:17:41\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Peripheral vascular disease\n- Gangrenous disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-27 08:35:00, ended at 2018-08-27 10:39:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 73 (milligram per deciliter)\n- INR in Blood by Coagulation assay: 1.1 (ratio)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n- Removal of tunneled central venous catheter, without subcutaneous port or pump\n\n### Condition\n- Transplanted heart present\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2018-08-27, presumably until 2018-08-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-08-28 00:00:00, ended at 2018-08-28 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- bumetanide 2 MG Oral Tablet, through Oral route, started on 2018-08-28, presumably until 2018-09-10, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- clonidine hydrochloride 0.1 MG Oral Tablet, through Oral route, started on 2018-08-28, presumably until 2018-09-10, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2018-08-28 17:48:00, ended at 2018-09-10 13:53:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 145 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.6 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 95.1 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 89.6 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 5.6 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.82 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma: 9149 (picogram per milliliter)\n- Platelets [#/volume] in Blood by Automated count: 284 (thousand per microliter)\n- Tacrolimus [Mass/volume] in Blood: 9.5 (nanogram per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.9 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.78 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.08 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 66 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.59 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Glucose [Mass/volume] in Blood: 99 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.28 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.42 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.5 (percent)\n- Left ventricular Ejection fraction: 60.3 (percent)\n- MCH [Entitic mass] by Automated count: 30.9 (picogram)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.027 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Base excess in Blood by calculation: 1 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Body height: 5' 5\" (inch (US))\n- Erythrocyte distribution width [Ratio] by Automated count: 18.8 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.8 (milligram per deciliter)\n\n### Procedure\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Occupational therapy evaluation, moderate complexity, requiring these components: An occupational profile and medical and therapy history, which includes an expanded review of medical and/or therapy records and additional review of physical, cognitive, or\n- Physical therapy evaluation: moderate complexity, requiring these components: A history of present problem with 1-2 personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures in\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Introduction of Vasopressor into Peripheral Vein, Percutaneous Approach\n- Excision of Right Ventricle, Percutaneous Approach, Diagnostic\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Medical decision making that is straightforward or o\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Hospital discharge day management; 30 minutes or less\n- Collection of venous blood by venipuncture\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of \n- Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination\n- Radiologic examination, chest; 2 views\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Abdominal distension, gaseous\n- Disorder of transplanted heart\n- Dyspnea\n- Leukocytosis\n- Essential hypertension\n- Gangrene due to type 2 diabetes mellitus\n- Hypoglycemia due to type 2 diabetes mellitus\n- Peripheral angiopathy due to diabetes mellitus\n- Anemia in chronic kidney disease\n- Coag./bleeding tests abnormal\n- Congestive heart failure\n- Disorder of nervous system due to type 2 diabetes mellitus\n- Hypertensive heart and renal disease with (congestive) heart failure\n- Late effect of complications of procedure\n- Tricuspid incompetence, non-rheumatic\n- Chest pain\n- Disorder of digestive system\n- Electrocardiogram abnormal\n- Hyperglycemia due to type 2 diabetes mellitus\n- Long QT syndrome\n- Thrombus due to any device, implant AND/OR graft\n- Type 2 diabetes mellitus\n- Alkalosis\n- Disorder of eye due to type 2 diabetes mellitus\n- Gangrenous disorder\n- Heart failure\n- Acute on chronic diastolic heart failure\n- Diastolic heart failure\n- Transplanted heart present\n- Acute deep venous thrombosis of internal jugular vein\n- Cardiac transplant failure\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Constipation\n- Primary diagnosis: Hypervolemia\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Obesity\n- Valvular endocarditis\n- Acquired absence of organ\n- Acute renal failure syndrome\n- Allergic disposition\n- Pleural effusion\n- Chronic kidney disease stage 4\n\n### Drug\n- bumetanide 2 MG Oral Tablet, through Oral route, started on 2018-08-31, presumably until 2018-09-10\n- chlorothiazide 500 MG Oral Tablet, through Oral route, started on 2018-09-06, presumably until 2019-09-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- acyclovir 200 MG Oral Capsule, through Oral route, started on 2018-08-28, presumably until 2018-09-10\n- 250 ML dobutamine 1 MG/ML Injection, through Intravenous route, started on 2018-09-04, presumably until 2018-09-09\n- 24 HR isosorbide mononitrate 30 MG Extended Release Oral Tablet, through Oral route, started on 2018-09-09, presumably until 2019-09-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- clonidine hydrochloride 0.3 MG Oral Tablet, through Oral route, started on 2018-09-10, presumably until 2019-09-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2018-09-04, presumably until 2018-09-04\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-08-29, presumably until 2018-09-10\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2018-09-07, presumably until 2018-11-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- tacrolimus 1 MG Oral Capsule, through Oral route, started on 2018-08-28, presumably until 2018-09-10\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-08-28, presumably until 2018-09-06\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2018-08-29, presumably until 2018-08-29\n- prednisone 2.5 MG Oral Tablet, through Oral route, started on 2018-08-30, presumably until 2018-09-10\n- amlodipine 10 MG Oral Tablet, through Oral route, started on 2018-08-30, presumably until 2019-09-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- hydralazine hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-08-28, presumably until 2018-09-09\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2018-08-29, presumably until 2018-09-10\n- apixaban 2.5 MG Oral Tablet, through Oral route, started on 2018-08-28, presumably until 2018-08-28\n- apixaban 5 MG Oral Tablet, through Oral route, started on 2018-08-31, presumably until 2018-09-10\n- clonidine hydrochloride 0.1 MG Oral Tablet, through Oral route, started on 2018-08-31, presumably until 2018-09-10\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2018-08-29, presumably until 2018-08-29\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2018-08-29, presumably until 2018-08-29\n- magnesium hydroxide 80 MG/ML Oral Suspension, through Oral route, started on 2018-09-03, presumably until 2018-09-09\n- insulin isophane, human 100 UNT/ML Injectable Suspension, through Subcutaneous route, started on 2018-08-29, presumably until 2018-09-10\n- nystatin 100000 UNT/ML Oral Suspension, through Oral route, started on 2018-08-29, presumably until 2018-09-10\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-09-01, presumably until 2018-09-04\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2018-08-29, presumably until 2018-09-10\n- chlorothiazide 500 MG Injection, through Intravenous route, started on 2018-09-02, presumably until 2018-09-05\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-08-30, presumably until 2018-09-10\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2018-08-29, presumably until 2018-09-10\n- 100 ML magnesium sulfate 10 MG/ML Injection, through Intravenous route, started on 2018-09-02, presumably until 2018-09-02\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2018-09-02, presumably until 2018-09-02\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2018-08-30, presumably until 2018-09-04\n- tacrolimus 0.5 MG Oral Capsule, through Oral route, started on 2018-08-29, presumably until 2019-09-10, with intended 0 refill(s). Instructions: take 5 Caps by mouth 2 times a day\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2018-08-29, presumably until 2018-09-03\n- sulfamethoxazole 400 MG / trimethoprim 80 MG Oral Tablet, through Oral route, started on 2018-08-29, presumably until 2019-07-05, with intended 0 refill(s). Instructions: take 1 Tab by mouth every other day\n- itraconazole 10 MG/ML Oral Solution, through Oral route, started on 2018-08-28, presumably until 2018-09-03\n- magnesium amino acid chelate 133 MG Oral Tablet, through Oral route, started on 2018-08-28, presumably until 2018-09-10\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-08-29, presumably until 2018-09-10\n- lidocaine 0.05 MG/MG Medicated Patch, through Topical route, started on 2018-08-29, presumably until 2018-09-09\n- bumetanide 1 MG Oral Tablet, through Oral route, started on 2018-08-31, presumably until 2019-09-10, with intended 0 refill(s). Instructions: take 5 Tabs by mouth 2 times a day\n- bumetanide 0.25 MG/ML Injectable Solution, through Intravenous route, started on 2018-08-28, presumably until 2018-09-02\n- mycophenolate mofetil 500 MG Oral Tablet, through Oral route, started on 2018-08-28, presumably until 2018-09-10\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-08-29, presumably until 2018-09-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-08-30 00:00:00, ended at 2018-08-30 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Endomyocardial biopsy\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-08-30, presumably until 2018-08-30\n- midazolam 1 MG/ML Injectable Solution, started on 2018-08-30, presumably until 2018-08-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-09-05 00:00:00, ended at 2018-09-05 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-09-10 00:00:00, ended at 2018-09-10 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- chlorothiazide 500 MG Oral Tablet, through Oral route, started on 2018-09-10, presumably until 2018-09-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- 24 HR isosorbide mononitrate 30 MG Extended Release Oral Tablet, through Oral route, started on 2018-09-10, presumably until 2018-09-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning\n- clonidine hydrochloride 0.1 MG Oral Tablet, through Oral route, started on 2018-09-10, presumably until 2019-09-10, with intended 0 refill(s). Instructions: take 3 Tabs by mouth 2 times a day\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2018-09-10, presumably until 2019-01-20, with intended 0 refill(s). Instructions: take 2 Tabs by mouth daily\n- tacrolimus 0.5 MG Oral Capsule, through Oral route, started on 2018-09-10, presumably until 2018-09-18, with intended 0 refill(s). Instructions: take 5 Caps by mouth 2 times a day\n- bumetanide 1 MG Oral Tablet, through Oral route, started on 2018-09-10, presumably until 2018-09-27, with intended 0 refill(s). Instructions: take 5 Tabs by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-09-11 00:00:00, ended at 2018-09-11 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Hyperosmolarity\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-09-11 00:00:00, ended at 2018-09-11 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Complication due to diabetes mellitus\n\n### Drug\n- 3 ML insulin isophane, human 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2018-09-11, presumably until 2019-11-27, with intended 11 refill(s). Instructions: inject 22 Units subcutaneous (under the skin) 2 times a day 22 units AM, 22 units PM\n- 3 ML insulin lispro 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2018-09-11, presumably until 2019-11-21, with intended 11 refill(s). Instructions: inject 17 Units subcutaneous (under the skin) 3 times a day with meals\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-11 13:10:09, ended at 2018-09-11 13:10:51\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Hyperosmolarity\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-09-12 00:00:00, ended at 2018-09-12 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-13 09:23:00, ended at 2018-09-13 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 97 (unit per liter)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 110 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.01 (million per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 79.9 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.29 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.15 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 11.26 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.09 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 171 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.1 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Tacrolimus [Mass/volume] in Blood: 7.8 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.5 (percent)\n- MCH [Entitic mass] by Automated count: 29.1 (picogram)\n- MCV [Entitic volume] by Automated count: 90.6 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.26 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 378 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hypomagnesemia\n- Transplanted heart present\n- Disorder of transplanted heart\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-09-13 09:42:41, ended at 2018-09-13 11:15:45\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Primary diagnosis: Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- chlorothiazide 500 MG Oral Tablet, through Oral route, started on 2018-09-13, presumably until 2018-09-18, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- 24 HR isosorbide mononitrate 30 MG Extended Release Oral Tablet, through Oral route, started on 2018-09-13, presumably until 2019-09-13, with intended 11 refill(s). Instructions: take 1 Tab by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-09-14 00:00:00, ended at 2018-09-14 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydralazine hydrochloride 10 MG Oral Tablet, through Oral route, started on 2018-09-14, presumably until 2018-09-28, with intended 11 refill(s). Instructions: take 1 Tab by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-09-17 00:00:00, ended at 2018-09-17 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-09-17, presumably until 2019-01-20, with intended 3 refill(s). Instructions: take 1.5 Tabs by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-09-18 00:00:00, ended at 2018-09-18 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tacrolimus 0.5 MG Oral Capsule, through Oral route, started on 2018-09-18, presumably until 2018-10-10, with intended 0 refill(s). Instructions: take 5 Caps by mouth 2 times a day Take 5 capsules in AM and 6 capsules in PM\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-18 08:57:00, ended at 2018-09-18 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 105 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.00 (million per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.5 (picogram)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.4 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.2 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.58 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- MCHC [Mass/volume] by Automated count: 31.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.5 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 337 (thousand per microliter)\n- Tacrolimus [Mass/volume] in Blood: 4.9 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 173 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.2 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.4 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.16 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 11.69 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 93 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 33 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.1 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 1.01 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-09-21 00:00:00, ended at 2018-09-21 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- everolimus 0.75 MG Oral Tablet, through Oral route, started on 2018-09-21, presumably until 2018-09-28, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day Cytotoxic. Take with  food. Swallow whole. do not break, chew or crush tablets.  Z94.1  DOT: 06/06/2018\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-09-21 00:00:00, ended at 2018-09-21 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-21 08:44:00, ended at 2018-09-21 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- MCV [Entitic volume] by Automated count: 90.1 (femtoliter)\n- Tacrolimus [Mass/volume] in Blood: 8.6 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.5 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.1 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 174 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.3 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.8 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.02 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.95 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.98 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 313 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 87 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.26 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 12.12 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 93 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.3 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.3 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 28.8 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-09-24 00:00:00, ended at 2018-09-24 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Blood chemistry abnormal\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-27 09:28:00, ended at 2018-09-27 09:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Lymphocytes [#/volume] in Blood by Automated count: 1.84 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 28.7 (picogram)\n- Tacrolimus [Mass/volume] in Blood: 7.3 (nanogram per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.86 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 48 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.0 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.0 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.8 (percent)\n- MCHC [Mass/volume] by Automated count: 31.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.1 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.03 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Everolimus [Mass/volume] in Blood: 2.5 (nanogram per milliliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.1 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 13.1 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.97 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 271 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 68 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-27 10:00:00, ended at 2018-09-27 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 69.6 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Disorder of immune function\n- Hypomagnesemia\n- Transplanted heart present\n- Disorder of transplanted heart\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-09-28 00:00:00, ended at 2018-09-28 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- bumetanide 2 MG Oral Tablet, through Oral route, started on 2018-09-28, presumably until 2018-10-01, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- everolimus 0.5 MG Oral Tablet, started on 2018-09-28, presumably until 2018-10-03, with intended 3 refill(s). Instructions: Take 1mg twice daily. Cytotoxic. Take with  food. Swallow whole. do not break, chew or crush tablets.  Z94.1  DOT: 06/06/2018\n- hydralazine hydrochloride 10 MG Oral Tablet, through Oral route, started on 2018-09-28, presumably until 2018-11-27, with intended 3 refill(s). Instructions: take 2 Tabs by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-28 09:47:00, ended at 2018-09-28 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-01 00:00:00, ended at 2018-10-01 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- bumetanide 2 MG Oral Tablet, through Oral route, started on 2018-10-01, presumably until 2018-10-03, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day 2nd prescription, please dispense!\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-10-01 09:40:00, ended at 2018-10-01 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.0 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.3 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Everolimus [Mass/volume] in Blood: 3.5 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 231 (thousand per microliter)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.1 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 81.6 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 10.0 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.70 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.6 (milligram per deciliter)\n- Tacrolimus [Mass/volume] in Blood: 8.3 (nanogram per milliliter)\n- MCH [Entitic mass] by Automated count: 28.9 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.81 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.1 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 47 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 133 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 116 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.3 (femtoliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.17 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.23 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-10-03 00:00:00, ended at 2018-10-03 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- bumetanide 2 MG Oral Tablet, through Oral route, started on 2018-10-03, presumably until 2018-11-27, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily 2nd prescription, please dispense!\n- everolimus 0.5 MG Oral Tablet, started on 2018-10-03, presumably until 2018-11-28, with intended 3 refill(s). Instructions: Take 1mg in the AM, 1.5mg in the PM. Cytotoxic. Take with  food. Swallow whole. do not break, chew or crush tablets.  Z94.1  DOT: 06/06/2018\n- mycophenolate mofetil 500 MG Oral Tablet, through Oral route, started on 2018-10-03, presumably until 2018-10-23, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-08 00:00:00, ended at 2018-10-08 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.2 (calculated)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1000 (cells per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 40 (cells per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 85.6 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Tacrolimus [Mass/volume] in Blood by LC/MS/MS: 10.5 (microgram per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 230 (cells per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.1 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 18 (calculated)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 11 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 94 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.8 (percent)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7920 (cells per microliter)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 11.9 (femtoliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.60 (million per liter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter calculated)\n- Lymphocytes [#/volume] in Blood by Automated count: 810 (cells per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 79.2 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 42 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.29 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.0 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.1 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 370 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-10 00:00:00, ended at 2018-10-10 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tacrolimus 0.5 MG Oral Capsule, through Oral route, started on 2018-10-10, presumably until 2018-10-11, with intended 11 refill(s). Instructions: take 5 Caps by mouth 2 times a day Take 5 capsules in AM and 6 capsules in PM\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-11 00:00:00, ended at 2018-10-11 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tacrolimus 1 MG Oral Capsule, started on 2018-10-11, presumably until 2018-12-07, with intended 11 refill(s). Instructions: Take 2.5mg in Am and 3 mg in PM\n- tacrolimus 0.5 MG Oral Capsule, started on 2018-10-11, presumably until 2018-12-07, with intended 11 refill(s). Instructions: Take 0.5 mg in AM and as directed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-12 00:00:00, ended at 2018-10-12 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-12 00:00:00, ended at 2018-10-12 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-15 00:00:00, ended at 2018-10-15 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-19 00:00:00, ended at 2018-10-19 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-22 00:00:00, ended at 2018-10-22 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-22 00:00:00, ended at 2018-10-22 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2018-10-22, presumably until 2018-10-29, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day for 7 days\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-10-22, presumably until 2018-11-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-10-22 07:58:00, ended at 2018-10-22 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 162 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 15.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 31.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 83.9 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 52 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 128 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.3 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.4 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 99 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Tacrolimus [Mass/volume] in Blood: 12.2 (nanogram per milliliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 218 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.5 (percent)\n- Everolimus [Mass/volume] in Blood: 6.2 (nanogram per milliliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.11 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 12.56 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 399 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 31 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 214 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 26.5 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 1.28 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.64 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.1 (percent)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 133 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 4.1 (ratio)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.59 (million per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.3 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n\n### Condition\n- Systolic heart failure\n- Transplanted heart present\n- Congestive heart failure\n- Gangrenous disorder\n- Hypomagnesemia\n- Blood chemistry abnormal\n- Disorder of transplanted heart\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-10-22 10:35:07, ended at 2018-10-22 11:46:40\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Gangrenous disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-23 00:00:00, ended at 2018-10-23 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- C reactive protein [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-23 00:00:00, ended at 2018-10-23 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-26 00:00:00, ended at 2018-10-26 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-29 00:00:00, ended at 2018-10-29 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-02 00:00:00, ended at 2018-11-02 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-11-02 00:00:00, ended at 2018-11-02 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with transluminal angioplasty\n- Angiography, extremity, unilateral, radiological supervision and interpretation\n- Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed\n- Amputation, toe; interphalangeal joint\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-02 00:00:00, ended at 2018-11-02 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for diagnostic arteriography/venography\n\n### Condition\n- Atherosclerosis of artery of lower limb\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Chronic occlusion of artery of extremity\n- Type 2 diabetes mellitus\n- Foot ulcer due to type 2 diabetes mellitus\n- Gangrene of left lower limb due to atherosclerosis\n- Peripheral angiopathy due to diabetes mellitus\n- Gangrene due to type 2 diabetes mellitus\n\n### Drug\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2018-11-02, presumably until 2018-11-02\n- cefazolin 1000 MG Injection, started on 2018-11-02, presumably until 2018-11-02\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2018-11-02, presumably until 2018-11-02\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-11-02, presumably until 2018-11-02\n- ketamine 100 MG/ML Injectable Solution, started on 2018-11-02, presumably until 2018-11-02\n- 2 ML dexmedetomidine 0.1 MG/ML Injection, through Intravenous route, started on 2018-11-02, presumably until 2018-11-02\n- midazolam 1 MG/ML Injectable Solution, started on 2018-11-02, presumably until 2018-11-02\n- 2 ML alfentanil 0.5 MG/ML Injection, started on 2018-11-02, presumably until 2018-11-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-02 00:00:00, ended at 2018-11-02 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent pain following procedure\n\n### Drug\n- 30 ML mepivacaine hydrochloride 15 MG/ML Injection, started on 2018-11-02, presumably until 2018-11-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-02 09:33:00, ended at 2018-11-03 14:20:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 124 (milligram per deciliter)\n- INR in Blood by Coagulation assay: 1.7 (ratio)\n- Hematocrit [Volume Fraction] of Blood: 29 (percent)\n- Potassium [Moles/volume] in Blood: 3.5 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 9.9 (gram per deciliter)\n- Sodium [Moles/volume] in Blood: 140 (millimole per liter)\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Selective catheter placement, arterial system; initial third order or more selective abdominal, pelvic, or lower extremity artery branch, within a vascular family\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Amputation, toe; metatarsophalangeal joint\n- Detachment at Right 1st Toe, Complete, Open Approach\n- Collection of venous blood by venipuncture\n- Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed\n- Dilation of Right Anterior Tibial Artery, Percutaneous Approach\n- Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with transluminal angioplasty\n- Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach\n- Angiography, extremity, unilateral, radiological supervision and interpretation\n- Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements f\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Fluoroscopy of Right Lower Extremity Arteries\n- Intravenous infusion, hydration; initial, 31 minutes to 1 hour\n\n### Condition\n- Chronic kidney disease\n- Chronic kidney disease stage 3\n- Foot ulcer due to type 2 diabetes mellitus\n- Gangrenous disorder\n- Peripheral angiopathy due to diabetes mellitus\n- Gangrene of left lower limb due to atherosclerosis\n- Primary diagnosis: Peripheral vascular disease\n- Type 2 diabetes mellitus\n- Chronic occlusion of artery of extremity\n- Gangrene due to type 2 diabetes mellitus\n- Acute renal failure syndrome\n- Atherosclerosis of artery of lower limb\n- Dissection of artery of lower limb\n- Transplanted heart present\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Chronic kidney disease due to hypertension\n\n### Drug\n- bumetanide 2 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- amoxicillin 500 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours for 5 days\n- acyclovir 200 MG Oral Capsule, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- 24 HR isosorbide mononitrate 30 MG Extended Release Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- sodium iodide, through Topical route, started on 2018-08-12, presumably until 2019-02-14, with intended 0 refill(s). Instructions: 1 Spray by Topical route 2 times a day\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- apixaban 2.5 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- clonidine hydrochloride 0.1 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-11-02, presumably until 2018-11-02\n- hydralazine hydrochloride 10 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- povidone-iodine, through Topical route, started on 2018-08-12, presumably until 2019-02-14, with intended 0 refill(s). Instructions: 1 Spray by Topical route 2 times a day\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- potassium iodide, through Topical route, started on 2018-08-12, presumably until 2019-02-14, with intended 0 refill(s). Instructions: 1 Spray by Topical route 2 times a day\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-11-02, presumably until 2018-11-02\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-11-02, presumably until 2018-11-02\n- iodine, through Topical route, started on 2018-08-12, presumably until 2019-02-14, with intended 0 refill(s). Instructions: 1 Spray by Topical route 2 times a day\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2019-04-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2018-11-02, presumably until 2018-11-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-05 00:00:00, ended at 2018-11-05 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-09 00:00:00, ended at 2018-11-09 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-12 00:00:00, ended at 2018-11-12 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- MCH [Entitic mass] by Automated count: 24.9 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 7065 (cells per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.4 (percent)\n- MCV [Entitic volume] by Automated count: 79.3 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 78.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 16 (calculated)\n- Basophils [#/volume] in Blood by Automated count: 36 (cells per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.68 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 837 (cells per microliter)\n- Platelets [#/volume] in Blood by Automated count: 395 (thousand per microliter)\n- Tacrolimus [Mass/volume] in Blood by LC/MS/MS: 10.3 (microgram per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.5 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 252 (cells per microliter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter calculated)\n- Glucose [Mass/volume] in Serum or Plasma: 130 (milligram per deciliter)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.3 (calculated)\n- Hemoglobin [Mass/volume] in Blood: 8.9 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 140 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.0 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 810 (cells per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.58 (million per liter)\n- MCHC [Mass/volume] by Automated count: 31.3 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 12.4 (femtoliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-16 00:00:00, ended at 2018-11-16 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Drug-induced constipation\n\n### Drug\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2018-11-16, presumably until 2018-11-26, with intended 11 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2018-11-16, presumably until 2018-11-26, with intended 5 refill(s). Instructions: take 17 g by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-16 00:00:00, ended at 2018-11-16 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-19 00:00:00, ended at 2018-11-19 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-23 00:00:00, ended at 2018-11-23 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Peripheral vascular disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-23 00:00:00, ended at 2018-11-23 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Pure hypercholesterolemia\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-23 00:00:00, ended at 2018-11-23 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-26 00:00:00, ended at 2018-11-26 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-26 09:57:00, ended at 2018-11-26 10:28:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 70.3 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study\n\n### Condition\n- Chronic kidney disease\n- Disorder of transplanted heart\n- Hyperlipidemia\n- Pure hypercholesterolemia\n- Essential hypertension\n- Hypomagnesemia\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-26 10:29:00, ended at 2018-11-26 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin [Mass/volume] in Blood: 9.1 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 75.3 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 47 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 3.8 (ratio)\n- Eosinophils [#/volume] in Blood by Automated count: 0.30 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 235 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.13 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 115 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.02 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.76 (million per microliter)\n- MCV [Entitic volume] by Automated count: 79.0 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 364 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.6 (percent)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.7 (percent)\n- MCH [Entitic mass] by Automated count: 24.3 (picogram)\n- Tacrolimus [Mass/volume] in Blood: 4.3 (nanogram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 110 (milligram per deciliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 133 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Everolimus [Mass/volume] in Blood: 1.7 (nanogram per milliliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 179 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 180 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 30.7 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n\n### Procedure\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n- Collection of venous blood by venipuncture\n\n### Condition\n- Transplanted heart present\n- Hypomagnesemia\n- Pure hypercholesterolemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-11-26 11:10:25, ended at 2018-11-26 12:19:19\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Transplanted heart present\n- Essential hypertension\n- Hyperlipidemia\n- Chronic kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-11-27 00:00:00, ended at 2018-11-27 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Absence of toe\n- Primary diagnosis: Acquired absence of organ\n- Disorder of transplanted heart\n- Hyperlipidemia\n\n### Drug\n- bumetanide 2 MG Oral Tablet, through Oral route, started on 2018-11-27, presumably until 2019-07-05, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day 2nd prescription, please dispense!\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, started on 2018-11-27, presumably until 2019-02-14, with intended 11 refill(s). Instructions: Take 40mEq in the AM, 20mEq in the PM.\n- hydralazine hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-11-27, presumably until 2019-11-22, with intended 3 refill(s). Instructions: take 1 Tab by mouth 3 times a day\n- pravastatin sodium 40 MG Oral Tablet, through Oral route, presumably until 2019-07-05, with intended 11 refill(s). Instructions: take 1 Tab by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-11-28 00:00:00, ended at 2018-11-28 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n\n### Drug\n- everolimus 0.5 MG Oral Tablet, started on 2018-11-28, presumably until 2018-12-07, with intended 3 refill(s). Instructions: Take 1.5mg BID; Cytotoxic. Take with  food. Swallow whole. do not break, chew or crush tablets.  Z94.1  DOT: 06/06/2018\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-30 00:00:00, ended at 2018-11-30 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-03 00:00:00, ended at 2018-12-03 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-03 10:32:00, ended at 2018-12-03 10:49:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.1 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 78.3 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 120 (unit per liter)\n- Everolimus [Mass/volume] in Blood: 7.9 (nanogram per milliliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.23 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 373 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- MCH [Entitic mass] by Automated count: 24.7 (picogram)\n- Tacrolimus [Mass/volume] in Blood: 11.8 (nanogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.73 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.98 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.0 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.2 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.73 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 125 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.2 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.1 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.9 (percent)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 31.6 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-03 10:50:00, ended at 2018-12-03 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording \n- Duplex scan of lower extremity arteries or arterial bypass grafts; unilateral or limited study\n\n### Condition\n- Peripheral vascular disease\n- Disorder of transplanted heart\n- Transplanted heart present\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-12-03 10:50:06, ended at 2018-12-03 12:27:12\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Peripheral vascular disease\n\n### Drug\n- collagenase 0.25 UNT/MG Topical Ointment, through Topical route, started on 2018-12-03, presumably until 2019-02-14, with intended 0 refill(s). Instructions: by Topical route daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-05 00:00:00, ended at 2018-12-05 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Peripheral vascular disease\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-12-05, presumably until 2018-12-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-07 00:00:00, ended at 2018-12-07 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-12-07 00:00:00, ended at 2018-12-07 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n\n### Drug\n- tacrolimus 1 MG Oral Capsule, started on 2018-12-07, presumably until 2019-01-20, with intended 11 refill(s). Instructions: Take 2mg in Am and 2 mg in PM\n- everolimus 0.5 MG Oral Tablet, started on 2018-12-07, presumably until 2019-01-20, with intended 3 refill(s). Instructions: Take 1mg BID; Cytotoxic. Take with  food. Swallow whole. do not break, chew or crush tablets.  Z94.1  DOT: 06/06/2018\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-10 00:00:00, ended at 2018-12-10 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.3 (calculated)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter calculated)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 12.3 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.2 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 783 (cells per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Tacrolimus [Mass/volume] in Blood by LC/MS/MS: 6.2 (microgram per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 249 (cells per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.63 (million per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.8 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 76.6 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.5 (percent)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 9 (calculated)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 6 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 8.7 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.16 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.3 (percent)\n- MCH [Entitic mass] by Automated count: 24.0 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 3602 (cells per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 119 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.5 (percent)\n- MCHC [Mass/volume] by Automated count: 31.3 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1114 (cells per microliter)\n- Basophils [#/volume] in Blood by Automated count: 52 (cells per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 62.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 370 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-14 00:00:00, ended at 2018-12-14 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2019-02-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-14 00:00:00, ended at 2018-12-14 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-17 00:00:00, ended at 2018-12-17 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.11 (million per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 163 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4744 (cells per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 9 (calculated)\n- Basophils [#/volume] in Blood by Automated count: 40 (cells per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 23.1 (picogram)\n- MCV [Entitic volume] by Automated count: 76.9 (femtoliter)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 12.0 (femtoliter)\n- Tacrolimus [Mass/volume] in Blood by LC/MS/MS: 3.9 (microgram per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.1 (percent)\n- Everolimus [Mass/volume] in Blood: 4.0 (nanogram per milliliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 998 (cells per microliter)\n- Platelets [#/volume] in Blood by Automated count: 355 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.71 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.9 (percent)\n- MCHC [Mass/volume] by Automated count: 30.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 650 (cells per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 8 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 268 (cells per microliter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter calculated)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.6 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 70.8 (percent)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.3 (calculated)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 112 (unit per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.7 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-19 00:00:00, ended at 2018-12-19 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-21 00:00:00, ended at 2018-12-21 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-24 00:00:00, ended at 2018-12-24 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-25 00:00:00, ended at 2018-12-25 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-28 00:00:00, ended at 2018-12-28 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-31 00:00:00, ended at 2018-12-31 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-04 00:00:00, ended at 2019-01-04 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-07 00:00:00, ended at 2019-01-07 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.4 (percent)\n- MCH [Entitic mass] by Automated count: 22.6 (picogram)\n- MCV [Entitic volume] by Automated count: 77.1 (femtoliter)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 13.0 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter calculated)\n- Glucose [Mass/volume] in Serum or Plasma: 328 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.3 (percent)\n- MCHC [Mass/volume] by Automated count: 29.3 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.1 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 865 (cells per microliter)\n- Tacrolimus [Mass/volume] in Blood by LC/MS/MS: 1.2 (microgram per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 94 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 59 (cells per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.70 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 370 (cells per microliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 714 (cells per microliter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 16 (calculated)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.1 (calculated)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.33 (million per liter)\n- Platelets [#/volume] in Blood by Automated count: 319 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.4 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6392 (cells per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.4 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.5 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-11 00:00:00, ended at 2019-01-11 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-11 00:00:00, ended at 2019-01-11 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2019-01-12 23:47:00, ended at 2019-01-20 14:28:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: 34.10 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 31.0 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.6 (millimole per liter)\n- Tacrolimus [Mass/volume] in Blood: 8.4 (nanogram per milliliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 3.731 (nanogram per milliliter)\n- Albumin [Mass/volume] in Urine: 203 (milligram per liter)\n- Body height: 5' 5\" (inch (US))\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.13 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma: >70000 (picogram per milliliter)\n- Platelets [#/volume] in Blood by Automated count: 273 (thousand per microliter)\n- Prothrombin time (PT): 14.3 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 95.8 (second)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.67 (million per microliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 10.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.6 (thousand per microliter)\n- Microalbumin/Creatinine [Mass Ratio] in Urine: 595 (milligram per gram)\n- Sodium/Creatinine [Molar ratio] in Urine: <20 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Anion gap in Serum or Plasma: 21 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 375 (milligram per deciliter)\n- Lactate [Moles/volume] in Blood: 1.9 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 23.2 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 85.9 (percent)\n- Salicylates [Presence] in Urine: <0.3 (milligram per deciliter)\n- Base excess in Arterial blood by calculation: -8.0 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.20 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Glucose [Mass/volume] in Blood: 96 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.9 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 60 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Everolimus [Mass/volume] in Blood: 9.3 (nanogram per milliliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCV [Entitic volume] by Automated count: 76.7 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.93 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 79 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 3.88 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.0 (percent)\n- Heparin unfractionated [Units/volume] in Platelet poor plasma: <0.10 (unit per milliliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Bicarbonate [Moles/volume] in Specimen: 18.6 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Left ventricular Ejection fraction: 41.4 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.5 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Ultrasound, retroperitoneal (eg, renal, aorta, nodes), real time with image documentation; complete\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Collection of venous blood by venipuncture\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements f\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging)\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes (List separately in addition to code for primary service)\n- Radiologic examination, chest; single view\n- Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right heart catheterization\n- Hospital discharge day management; 30 minutes or less\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Excision of Right Ventricle, Percutaneous Approach, Diagnostic\n- Fluoroscopy of Multiple Coronary Arteries using Low Osmolar Contrast\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Medical decision making that is straightforward or o\n- Endomyocardial biopsy\n\n### Condition\n- Cardiac transplant failure\n- Chronic kidney disease stage 3\n- Open wound of foot\n- Renal disorder due to type 2 diabetes mellitus\n- Sepsis\n- Acute on chronic combined systolic and diastolic heart failure\n- Acute tubular necrosis\n- Anemia in chronic kidney disease\n- Electrocardiogram abnormal\n- Hyperglycemia due to type 2 diabetes mellitus\n- Obesity\n- Peripheral vascular disease\n- Severe protein-calorie malnutrition (Gomez: less than 60 percent of standard weight)\n- Tachycardia\n- Transplanted heart present\n- Acidosis\n- Acute non-ST segment elevation myocardial infarction\n- Acute renal failure syndrome\n- Cardiogenic shock\n- Coronary thrombosis not resulting in myocardial infarction\n- Chronic pulmonary edema\n- Hyperkalemia\n- Localized edema\n- Pulmonary hypertension\n- Viral pneumonia\n- Atherosclerosis of coronary artery without angina pectoris\n- Blood coagulation disorder\n- Cardiomegaly\n- Chronic kidney disease stage 4\n- Hypertensive heart and renal disease with (congestive) heart failure\n- Acquired absence of organ\n- Acute ischemic heart disease\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Disorder of immune function\n- Heart disease\n- Old myocardial infarction\n- Atrial fibrillation\n- Cardiac transplant rejection\n- Primary diagnosis: Chronic ischemic heart disease\n- Disorder of transplanted heart\n- Hypokalemia\n- Late effect of complications of procedure\n- Septic shock\n- Absence of toe\n- Acute on chronic hypoxemic respiratory failure\n- Congestive heart failure\n- Hypo-osmolality and or hyponatremia\n- Pneumonia and influenza\n- Takotsubo cardiomyopathy\n- Type 2 diabetes mellitus\n- Upper respiratory tract infection due to Influenza\n- Backache\n- Dehydration\n\n### Drug\n- bumetanide 2 MG Oral Tablet, through Oral route, started on 2019-01-20, presumably until 2019-01-20\n- sodium bicarbonate 650 MG Oral Tablet, through Oral route, started on 2019-01-15, presumably until 2019-01-19\n- chlorothiazide 500 MG Oral Tablet, through Oral route, started on 2019-01-14, presumably until 2019-01-15\n- acyclovir 200 MG Oral Capsule, through Oral route, started on 2019-01-15, presumably until 2019-03-06, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day for 30 days\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Cartridge, started on 2019-01-17, presumably until 2019-01-18\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2019-01-17, presumably until 2019-01-17\n- methylprednisolone 40 MG Injection, started on 2019-01-13, presumably until 2019-01-15\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-20\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2019-01-13, presumably until 2019-01-14\n- tacrolimus 1 MG Oral Capsule, through Oral route, started on 2019-01-13, presumably until 2019-01-15\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-13\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-13\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-13\n- aspirin 325 MG Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-14\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-19\n- dextromethorphan hydrobromide 2 MG/ML / guaifenesin 20 MG/ML Oral Solution, through Oral route, started on 2019-01-13, presumably until 2019-01-13\n- clonidine hydrochloride 0.1 MG Oral Tablet, through Oral route, started on 2019-01-20, presumably until 2019-01-20\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2019-01-17, presumably until 2019-01-20\n- insulin isophane, human 100 UNT/ML Injectable Suspension, through Subcutaneous route, started on 2019-01-14, presumably until 2019-01-20\n- 250 ML dopamine hydrochloride 1.6 MG/ML Injection, through Intravenous route, started on 2019-01-13, presumably until 2019-01-19\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2019-01-13, presumably until 2019-01-13\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2019-01-15, presumably until 2019-01-16\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-02-01, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2019-01-13, presumably until 2019-01-13\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2019-01-18, presumably until 2020-01-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning with breakfast\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2019-01-14, presumably until 2019-01-15\n- tacrolimus 0.5 MG Oral Capsule, through Oral route, started on 2019-01-18, presumably until 2019-02-15, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-01-13, presumably until 2019-01-19\n- everolimus 0.75 MG Oral Tablet, through Oral route, started on 2019-01-20, presumably until 2019-02-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day Cytotoxic. Take with or without food. Swallow whole. do not break, chew or crush tablets.\n- lidocaine hydrochloride 0.02 MG/MG Topical Gel, through Submucosal route, started on 2019-01-13, presumably until 2019-01-13\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2019-01-13, presumably until 2019-01-13\n- oseltamivir 6 MG/ML Oral Suspension, through Oral route, started on 2019-01-13, presumably until 2019-01-16\n- benzonatate 100 MG Oral Capsule, through Oral route, started on 2019-01-13, presumably until 2019-01-13\n- sulfamethoxazole 400 MG / trimethoprim 80 MG Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-19\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-20\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-19\n- bumetanide 0.25 MG/ML Injectable Solution, through Intravenous route, started on 2019-01-13, presumably until 2019-01-19\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-19\n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-20\n- ondansetron 8 MG Disintegrating Oral Tablet, through Oral route, started on 2019-01-16, presumably until 2019-01-16\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2019-01-13, presumably until 2019-01-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2019-01-13 00:00:00, ended at 2019-01-13 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2019-01-13, presumably until 2019-01-13\n- iodixanol, through Intravenous route, started on 2019-01-13, presumably until 2019-01-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-14 00:00:00, ended at 2019-01-14 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-18 00:00:00, ended at 2019-01-18 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-21 00:00:00, ended at 2019-01-21 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-23 00:00:00, ended at 2019-01-23 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2019-01-23, presumably until 2019-02-19, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day Cytotoxic. Take with or without food. Swallow whole. do not break, chew or crush tablets.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-25 00:00:00, ended at 2019-01-25 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-28 00:00:00, ended at 2019-01-28 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-02-01 00:00:00, ended at 2019-02-01 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-02-01, presumably until 2019-02-19, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-01 00:00:00, ended at 2019-02-01 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-04 00:00:00, ended at 2019-02-04 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-08 00:00:00, ended at 2019-02-08 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-11 00:00:00, ended at 2019-02-11 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-13 00:00:00, ended at 2019-02-13 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-14 00:00:00, ended at 2019-02-14 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-02-14 08:38:00, ended at 2019-02-14 10:14:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 4.28 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.9 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.1 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.5 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 23.4 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 5.44 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 312 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.42 (milligram per deciliter)\n- Everolimus [Mass/volume] in Blood: 2.6 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.4 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.3 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 85 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 94 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.00 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 79.2 (femtoliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.6 (percent)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 51 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 15 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 29.5 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.9 (percent)\n- Tacrolimus [Mass/volume] in Blood: 1.7 (nanogram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n\n### Condition\n- Essential hypertension\n- Disorder of transplanted heart\n- Transplanted heart present\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-14 09:01:55, ended at 2019-02-14 10:07:14\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2019-02-14 10:15:00, ended at 2019-02-14 23:59:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 68.0 (percent)\n\n### Procedure\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging)\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-15 00:00:00, ended at 2019-02-15 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-02-15 00:00:00, ended at 2019-02-15 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- tacrolimus 1 MG Oral Capsule, through Oral route, started on 2019-02-15, presumably until 2019-10-04, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day Total dose of 1mg Am, 1.5mg PM\n- tacrolimus 0.5 MG Oral Capsule, through Oral route, started on 2019-02-15, presumably until 2019-10-04, with intended 1 refill(s). Instructions: take 1 Cap by mouth PM Total dose of 1mg AM, 1.5mg PM; Z94.1, Fax: 999-999-9999\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-18 00:00:00, ended at 2019-02-18 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-02-19 00:00:00, ended at 2019-02-19 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n\n### Drug\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2019-02-19, presumably until 2019-05-01, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day Take 0.5 mg in AM and 1 mg in PM\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-19 00:00:00, ended at 2019-02-19 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 2.5 MG Oral Tablet, through Oral route, started on 2019-02-19, presumably until 2019-04-03, with intended 6 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-22 00:00:00, ended at 2019-02-22 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-25 00:00:00, ended at 2019-02-25 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-01 00:00:00, ended at 2019-03-01 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-04 00:00:00, ended at 2019-03-04 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.4 (percent)\n- MCV [Entitic volume] by Automated count: 76.2 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 200 (cells per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 842 (cells per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4802 (cells per microliter)\n- Tacrolimus [Mass/volume] in Blood by LC/MS/MS: 3.4 (microgram per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 24 (calculated)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter calculated)\n- Lymphocytes [#/volume] in Blood by Automated count: 987 (cells per microliter)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.0 (calculated)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.05 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.9 (thousand per microliter)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 12.5 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 50 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.2 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 69 (cells per microliter)\n- MCHC [Mass/volume] by Automated count: 31.3 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 85 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 82 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.2 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.86 (million per liter)\n- MCH [Entitic mass] by Automated count: 23.8 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 301 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.0 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.3 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-03-06 00:00:00, ended at 2019-03-06 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- acyclovir 200 MG Oral Capsule, through Oral route, started on 2019-03-06, presumably until 2019-07-05, with intended 6 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-08 00:00:00, ended at 2019-03-08 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-11 00:00:00, ended at 2019-03-11 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-11 00:00:00, ended at 2019-03-11 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-15 00:00:00, ended at 2019-03-15 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-18 00:00:00, ended at 2019-03-18 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-22 00:00:00, ended at 2019-03-22 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-25 00:00:00, ended at 2019-03-25 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-29 00:00:00, ended at 2019-03-29 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-01 00:00:00, ended at 2019-04-01 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-03 00:00:00, ended at 2019-04-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- prednisone 2.5 MG Oral Tablet, through Oral route, started on 2019-04-03, presumably until 2019-10-03, with intended 6 refill(s). Instructions: take 1 Tab (2.5 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-04-03 00:00:00, ended at 2019-04-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-04-03 00:00:00, ended at 2019-04-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-04-04 00:00:00, ended at 2019-04-04 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperglycemia due to type 2 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-05 00:00:00, ended at 2019-04-05 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-08 00:00:00, ended at 2019-04-08 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-12 00:00:00, ended at 2019-04-12 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-15 00:00:00, ended at 2019-04-15 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-19 00:00:00, ended at 2019-04-19 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-22 00:00:00, ended at 2019-04-22 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-26 00:00:00, ended at 2019-04-26 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-26 00:00:00, ended at 2019-04-26 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-29 00:00:00, ended at 2019-04-29 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-29 09:45:00, ended at 2019-04-29 23:59:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 91 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 29.8 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.89 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 330 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.2 (percent)\n- MCV [Entitic volume] by Automated count: 82.0 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.8 (percent)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.0 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.7 (percent)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.2 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.1 (thousand per microliter)\n- Tacrolimus [Mass/volume] in Blood: 2.7 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 69 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.4 (percent)\n- Everolimus [Mass/volume] in Blood: 1.8 (nanogram per milliliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.11 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.17 (million per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.5 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 24.5 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 4.01 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n- Essential hypertension\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-04-30 00:00:00, ended at 2019-04-30 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-04-30 00:00:00, ended at 2019-04-30 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-05-01 00:00:00, ended at 2019-05-01 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n\n### Drug\n- everolimus 1 MG Oral Tablet, through Oral route, started on 2019-05-01, presumably until 2019-07-09, with intended 11 refill(s). Instructions: take 1 mg by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-05-03 00:00:00, ended at 2019-05-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-05-06 00:00:00, ended at 2019-05-06 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-05-06 00:00:00, ended at 2019-05-06 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.5 (percent)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 12.2 (femtoliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.90 (million per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 951 (cells per microliter)\n- MCV [Entitic volume] by Automated count: 77.4 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.2 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Tacrolimus [Mass/volume] in Blood by LC/MS/MS: 3.0 (microgram per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 161 (cells per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4904 (cells per microliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter calculated)\n- Potassium [Moles/volume] in Serum or Plasma: 5.2 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 22 (calculated)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.45 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 24.4 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.6 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.2 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 40 (cells per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 127 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 31.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 643 (cells per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 54 (milligram per deciliter)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.2 (calculated)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 299 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-05-10 00:00:00, ended at 2019-05-10 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-05-13 00:00:00, ended at 2019-05-13 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-05-17 00:00:00, ended at 2019-05-17 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-05-20 00:00:00, ended at 2019-05-20 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-05-24 00:00:00, ended at 2019-05-24 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-05-27 00:00:00, ended at 2019-05-27 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-05-31 00:00:00, ended at 2019-05-31 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-31 09:30:00, ended at 2019-05-31 23:59:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of lower extremity arteries or arterial bypass grafts; unilateral or limited study\n- Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording \n\n### Condition\n- Gangrenous disorder\n- Peripheral vascular disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-31 09:30:15, ended at 2019-05-31 11:29:56\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Gangrenous disorder\n- Primary diagnosis: Peripheral vascular disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-03 00:00:00, ended at 2019-06-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-07 00:00:00, ended at 2019-06-07 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-10 00:00:00, ended at 2019-06-10 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-14 00:00:00, ended at 2019-06-14 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-17 00:00:00, ended at 2019-06-17 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-21 00:00:00, ended at 2019-06-21 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-24 00:00:00, ended at 2019-06-24 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-28 00:00:00, ended at 2019-06-28 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-01 00:00:00, ended at 2019-07-01 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-03 00:00:00, ended at 2019-07-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Fatigue\n- Pure hypercholesterolemia\n- Type 1 diabetes mellitus without complication\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-03 00:00:00, ended at 2019-07-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-03 00:00:00, ended at 2019-07-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-04 00:00:00, ended at 2019-07-04 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Iron saturation [Mass Fraction] in Serum or Plasma: 9 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Iron deficiency anemia\n\n### Drug\n- rosuvastatin calcium 20 MG Oral Tablet, through Oral route, presumably until 2019-07-12, with intended 11 refill(s). Instructions: take 1 Tab (20 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-04 07:37:00, ended at 2019-07-04 09:47:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 4.0 (ratio)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.10 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hemoglobin [Mass/volume] in Blood: 10.2 (gram per deciliter)\n- Tacrolimus [Mass/volume] in Blood: 2.8 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.2 (percent)\n- Everolimus [Mass/volume] in Blood: 2.7 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 20.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 242 (thousand per microliter)\n- Protein/Creatinine [Mass Ratio] in Urine: 0.89 (milligram per milligram)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Cholesterol [Mass/volume] in Serum or Plasma: 259 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.22 (million per microliter)\n- MCH [Entitic mass] by Automated count: 24.2 (picogram)\n- MCV [Entitic volume] by Automated count: 78.9 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.16 (thousand per microliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 202 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 100 (unit per liter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 9.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.3 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.10 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 52 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 116 (unit per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 60.1 (percent)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 171 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 30.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 158 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.3 (thousand per microliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 49.0 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 65 (milligram per deciliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 194 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 55.28 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n\n### Condition\n- Pure hypercholesterolemia\n- Fatigue\n- Disorder of transplanted heart\n- Transplanted heart present\n- Type 1 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-07-04 08:10:26, ended at 2019-07-04 09:43:16\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Acute ST segment elevation myocardial infarction\n- Disorder of transplanted heart\n- Transplanted heart present\n- Conduction disorder of the heart\n- Electrocardiogram abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-04 09:48:00, ended at 2019-07-04 23:59:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 67.2 (percent)\n\n### Procedure\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; supervision only, without interpretation and report\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; tracing only, without interpretation and report\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation \n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; interpretation and report only\n\n### Condition\n- Cardiomegaly\n- Pure hypercholesterolemia\n- Transplanted heart present\n- Disorder of transplanted heart\n- Type 1 diabetes mellitus without complication\n- Iron deficiency anemia\n- Fatigue\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-05 00:00:00, ended at 2019-07-05 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-07-05 00:00:00, ended at 2019-07-05 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Primary diagnosis: Transplanted heart present\n\n### Drug\n- bumetanide 2 MG Oral Tablet, through Oral route, started on 2019-07-05, presumably until 2019-10-04, with intended 3 refill(s). Instructions: take 1 Tab (2 mg total) by mouth daily 2nd prescription, please dispense!\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2019-07-05, presumably until 2020-07-30, with intended 3 refill(s). Instructions: take 1 Tab by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-08 00:00:00, ended at 2019-07-08 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-09 00:00:00, ended at 2019-07-09 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2019-07-09, presumably until 2019-10-22, with intended 11 refill(s). Instructions: take 1 Tab (0.5 mg total) by mouth 2 times a day Take 1 mg in AM and 1.5mg in PM.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-07-09 00:00:00, ended at 2019-07-09 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n\n### Drug\n- everolimus 1 MG Oral Tablet, through Oral route, started on 2019-07-09, presumably until 2019-12-23, with intended 11 refill(s). Instructions: take 2 mg by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-07-12 00:00:00, ended at 2019-07-12 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n\n### Drug\n- rosuvastatin calcium 20 MG Oral Tablet, through Oral route, started on 2019-07-12, presumably until 2020-08-21, with intended 11 refill(s). Instructions: take 1 Tab (20 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-12 00:00:00, ended at 2019-07-12 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-15 00:00:00, ended at 2019-07-15 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-19 00:00:00, ended at 2019-07-19 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-22 00:00:00, ended at 2019-07-22 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-25 00:00:00, ended at 2019-07-25 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-26 00:00:00, ended at 2019-07-26 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-29 00:00:00, ended at 2019-07-29 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2019-07-31 00:00:00, ended at 2019-07-31 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Endomyocardial biopsy\n\n### Condition\n- Transplanted heart present\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2019-07-31, presumably until 2019-07-31\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-31 00:00:00, ended at 2019-07-31 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-31 11:18:00, ended at 2019-07-31 12:26:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 253 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 30.7 (gram per deciliter)\n- Tacrolimus [Mass/volume] in Blood: 4.4 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.5 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.24 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.0 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.6 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.28 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 68 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Everolimus [Mass/volume] in Blood: 5.6 (nanogram per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 24.6 (picogram)\n- MCV [Entitic volume] by Automated count: 79.9 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.88 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 213 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 17.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 104 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.48 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.8 (percent)\n\n### Procedure\n- Endomyocardial biopsy\n- Excision of Right Ventricle, Percutaneous Approach, Diagnostic\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Collection of venous blood by venipuncture\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n- Cardiac transplant rejection\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-01 00:00:00, ended at 2019-08-01 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2019-08-01, presumably until 2020-09-04, with intended 11 refill(s). Instructions: take 1 Cap (250 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-02 00:00:00, ended at 2019-08-02 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-05 00:00:00, ended at 2019-08-05 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-09 00:00:00, ended at 2019-08-09 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-12 00:00:00, ended at 2019-08-12 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-16 00:00:00, ended at 2019-08-16 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-19 00:00:00, ended at 2019-08-19 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-23 00:00:00, ended at 2019-08-23 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-26 00:00:00, ended at 2019-08-26 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-30 00:00:00, ended at 2019-08-30 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-02 00:00:00, ended at 2019-09-02 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-06 00:00:00, ended at 2019-09-06 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-09 00:00:00, ended at 2019-09-09 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-11 00:00:00, ended at 2019-09-11 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-13 00:00:00, ended at 2019-09-13 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-13 00:00:00, ended at 2019-09-13 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-16 00:00:00, ended at 2019-09-16 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-10-02 00:00:00, ended at 2019-10-02 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-10-03 00:00:00, ended at 2019-10-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- mycophenolate mofetil 500 MG Oral Tablet, through Oral route, started on 2019-10-03, presumably until 2020-10-16, with intended 11 refill(s). Instructions: take 2 Tabs (1,000 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-10-03 00:00:00, ended at 2019-10-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-03 09:51:00, ended at 2019-10-03 10:28:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 63.7 (percent)\n\n### Procedure\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging)\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study\n\n### Condition\n- Disorder of transplanted heart\n- Pure hypercholesterolemia\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-03 10:29:00, ended at 2019-10-03 23:59:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.80 (million per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67.5 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 77 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.46 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 54 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.82 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- Tacrolimus [Mass/volume] in Blood: 1.0 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.0 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 184 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 30.7 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.19 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 81.3 (femtoliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.9 (percent)\n- MCH [Entitic mass] by Automated count: 25.0 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 172 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-03 11:26:41, ended at 2019-10-03 12:14:25\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pure hypercholesterolemia\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- clonidine hydrochloride 0.1 MG Oral Tablet, through Oral route, presumably until 2020-10-20, with intended 11 refill(s). Instructions: take 0.1-0.2 mg by mouth as directed Take 0.1mg QAM and 0.2mg QPM\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-10-04 00:00:00, ended at 2019-10-04 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- bumetanide 1 MG Oral Tablet, through Oral route, started on 2019-10-04, presumably until 2019-11-26, with intended 3 refill(s). Instructions: take 1 Tab (1 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2019-10-15 00:00:00, ended at 2019-10-15 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2019-10-15, presumably until 2019-10-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-15 09:46:00, ended at 2019-10-15 12:19:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 85 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 158 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.49 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.4 (percent)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Anion gap in Serum or Plasma: 15 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 79.9 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.65 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.1 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22.0 (percent)\n- MCH [Entitic mass] by Automated count: 25.1 (picogram)\n- MCHC [Mass/volume] by Automated count: 31.5 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 40 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.02 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.33 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 64.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 264 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.1 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Endomyocardial biopsy\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n\n### Condition\n- Acquired absence of organ\n- Absence of toe\n- Chronic kidney disease due to hypertension\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Chronic kidney disease\n- Disorder of transplanted heart\n- Hyperlipidemia\n- Type 2 diabetes mellitus\n- Transplanted heart present\n- Cardiac transplant rejection\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-10-16 00:00:00, ended at 2019-10-16 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Everolimus [Mass/volume] in Blood: 9.4 (nanogram per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-10-19 00:00:00, ended at 2019-10-19 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-10-22 00:00:00, ended at 2019-10-22 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2019-10-22, presumably until 2020-04-24, with intended 11 refill(s). Instructions: take 1 mg by mouth 2 times a day \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-11-21 00:00:00, ended at 2019-11-21 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Complication due to diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- 3 ML insulin lispro 100 UNT/ML Pen Injector, started on 2019-11-22, presumably until 2022-06-10, with intended 11 refill(s). Instructions: INJECT 17 UNITS SUB-CUTANEOUSLY( UNDER THE SKIN) THREE TIMES DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-11-22 00:00:00, ended at 2019-11-22 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydralazine hydrochloride 100 MG Oral Tablet, through Oral route, started on 2019-11-22, presumably until 2021-06-04, with intended 11 refill(s). Instructions: take 1 Tab (100 mg total) by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-11-22 00:00:00, ended at 2019-11-22 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Complication due to diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- 3 ML insulin lispro 100 UNT/ML Pen Injector, started on 2019-11-22, presumably until 2019-11-22, with intended 11 refill(s). Instructions: INJECT 17 UNITS UNDER THE SKIN(UNDER THE SKIN) THREE TIMES DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-11-26 00:00:00, ended at 2019-11-26 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- 24 HR isosorbide mononitrate 30 MG Extended Release Oral Tablet, through Oral route, presumably until 2019-12-23, with intended 2 refill(s). Instructions: take 1 Tab (30 mg total) by mouth as directed\n- bumetanide 1 MG Oral Tablet, through Oral route, started on 2019-11-26, presumably until 2020-09-10, with intended 3 refill(s). Instructions: take 2 Tabs (2 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-11-27 00:00:00, ended at 2019-11-27 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Complication due to diabetes mellitus\n\n### Drug\n- 3 ML insulin isophane, human 100 UNT/ML Pen Injector, started on 2019-11-27, presumably until 2021-02-02, with intended 6 refill(s). Instructions: Inject subcutaneously 22 units AM, 22 units PM\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-04 00:00:00, ended at 2019-12-04 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Peripheral vascular disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-12-07 00:00:00, ended at 2019-12-07 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperosmolarity\n- Type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-10 00:00:00, ended at 2019-12-10 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Hyperosmolarity\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-20 00:00:00, ended at 2019-12-20 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-23 09:55:00, ended at 2019-12-23 23:59:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.99 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 46 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 17 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.8 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 25.3 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 3.69 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.19 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 30.3 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 209 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.67 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.3 (percent)\n- MCV [Entitic volume] by Automated count: 83.5 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.7 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 89 (unit per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.2 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.13 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.1 (gram per deciliter)\n\n### Procedure\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n- Collection of venous blood by venipuncture\n\n### Condition\n- Pure hypercholesterolemia\n- Disorder of transplanted heart\n- Hyperlipidemia\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-23 10:19:13, ended at 2019-12-23 11:39:05\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n- Everolimus [Mass/volume] in Blood: 1.4 (nanogram per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Pure hypercholesterolemia\n- Transplanted heart present\n\n### Drug\n- 24 HR isosorbide mononitrate 30 MG Extended Release Oral Tablet, through Oral route, started on 2019-12-23, presumably until 2020-12-10, with intended 3 refill(s). Instructions: take 1 Tab (30 mg total) by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-24 00:00:00, ended at 2019-12-24 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.4 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 224 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 45 (milligram per deciliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- C reactive protein [Mass/volume] in Serum or Plasma by High sensitivity method: 3.0 (milligram per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.3 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 827 (cells per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 157 (milligram per deciliter)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.2 (calculated)\n- MCHC [Mass/volume] by Automated count: 31.7 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3631 (cells per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 233 (cells per microliter)\n- Homocysteine [Moles/volume] in Serum or Plasma: 12.3 (micromole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.6 (percent)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 13.5 (femtoliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.05 (million per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.1 (percent)\n- MCH [Entitic mass] by Automated count: 25.9 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 42 (cells per microliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 77 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter calculated)\n- Monocytes [#/volume] in Blood by Automated count: 567 (cells per microliter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 27 (calculated)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 86 (unit per liter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 51 (milligram per deciliter)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 1.5 (ratio)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.66 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 116 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 81.7 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 159 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 3.1 (ratio)\n- Lipoprotein a [Mass/volume] in Serum or Plasma: 221.8 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hyperlipidemia\n- Hypomagnesemia\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2019-12-24, presumably until 2020-10-06, with intended 3 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-26 00:00:00, ended at 2019-12-26 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-30 00:00:00, ended at 2019-12-30 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-01-02 00:00:00, ended at 2020-01-02 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperosmolarity\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-03 00:00:00, ended at 2020-01-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-06 00:00:00, ended at 2020-01-06 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-10 00:00:00, ended at 2020-01-10 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-10 08:12:00, ended at 2020-01-10 09:59:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of lower extremity arteries or arterial bypass grafts; unilateral or limited study\n- Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording \n\n### Condition\n- Peripheral vascular disease\n- Disorder of soft tissue\n- Localized edema\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-10 08:12:54, ended at 2020-01-10 14:56:11\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Peripheral vascular disease\n- Disorder of soft tissue\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-10 10:00:00, ended at 2020-01-10 23:59:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study\n\n### Condition\n- Localized edema\n- Disorder of soft tissue\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-13 00:00:00, ended at 2020-01-13 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-17 00:00:00, ended at 2020-01-17 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-20 00:00:00, ended at 2020-01-20 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-24 00:00:00, ended at 2020-01-24 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-27 00:00:00, ended at 2020-01-27 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-31 00:00:00, ended at 2020-01-31 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-03 00:00:00, ended at 2020-02-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-07 00:00:00, ended at 2020-02-07 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-10 00:00:00, ended at 2020-02-10 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-14 00:00:00, ended at 2020-02-14 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-17 00:00:00, ended at 2020-02-17 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-21 00:00:00, ended at 2020-02-21 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-24 00:00:00, ended at 2020-02-24 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-28 00:00:00, ended at 2020-02-28 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-02 00:00:00, ended at 2020-03-02 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-06 00:00:00, ended at 2020-03-06 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-09 00:00:00, ended at 2020-03-09 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-13 00:00:00, ended at 2020-03-13 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-16 00:00:00, ended at 2020-03-16 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-20 00:00:00, ended at 2020-03-20 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-23 00:00:00, ended at 2020-03-23 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-27 00:00:00, ended at 2020-03-27 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-30 00:00:00, ended at 2020-03-30 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-30 00:00:00, ended at 2020-03-30 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperosmolarity\n- Primary diagnosis: Type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-03 00:00:00, ended at 2020-04-03 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-06 00:00:00, ended at 2020-04-06 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-10 00:00:00, ended at 2020-04-10 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-13 00:00:00, ended at 2020-04-13 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 148 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.9 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 31.7 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 214 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 44 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 3202 (cells per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 26 (calculated)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 49 (cells per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.18 (million per liter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter calculated)\n- MCH [Entitic mass] by Automated count: 25.1 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.3 (calculated)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 80 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.1 (percent)\n- MCV [Entitic volume] by Automated count: 79.2 (femtoliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.69 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 259 (cells per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.8 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.1 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.5 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.4 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 751 (cells per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1139 (cells per microliter)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 13.0 (femtoliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-15 14:40:50, ended at 2020-04-15 15:07:23\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperosmolarity\n- Primary diagnosis: Type 2 diabetes mellitus\n\n### Drug\n- 0.5 ML dulaglutide 1.5 MG/ML Auto-Injector, through Subcutaneous route, started on 2020-04-15, presumably until 2020-11-03, with intended 11 refill(s). Instructions: inject 0.75 mg subcutaneous (under the skin) once a week\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-17 00:00:00, ended at 2020-04-17 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-20 00:00:00, ended at 2020-04-20 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-21 00:00:00, ended at 2020-04-21 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.6 (percent)\n- Everolimus [Mass/volume] in Blood: 1.9 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 10.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 25.3 (picogram)\n- MCV [Entitic volume] by Automated count: 79.8 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 31.7 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.9 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3819 (cells per microliter)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 12.7 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 239 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 102 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 202 (cells per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 34 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.15 (million per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 16.8 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 610 (cells per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.1 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 19 (calculated)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.75 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 28 (cells per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 941 (cells per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-24 00:00:00, ended at 2020-04-24 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2020-04-24, presumably until 2020-07-16, with intended 11 refill(s). Instructions: take 3 Tabs (1.5 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-24 00:00:00, ended at 2020-04-24 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-27 00:00:00, ended at 2020-04-27 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-01 00:00:00, ended at 2020-05-01 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-04 00:00:00, ended at 2020-05-04 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-06 00:00:00, ended at 2020-05-06 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-06 00:00:00, ended at 2020-05-06 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-06 00:00:00, ended at 2020-05-06 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-08 00:00:00, ended at 2020-05-08 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-11 00:00:00, ended at 2020-05-11 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-15 00:00:00, ended at 2020-05-15 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-18 00:00:00, ended at 2020-05-18 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-22 00:00:00, ended at 2020-05-22 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-25 00:00:00, ended at 2020-05-25 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-29 00:00:00, ended at 2020-05-29 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-01 00:00:00, ended at 2020-06-01 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-05 00:00:00, ended at 2020-06-05 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-08 00:00:00, ended at 2020-06-08 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-12 00:00:00, ended at 2020-06-12 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-15 00:00:00, ended at 2020-06-15 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-16 00:00:00, ended at 2020-07-16 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2020-07-16, presumably until 2021-04-27, with intended 11 refill(s). Instructions: take 1 Tab (0.5 mg total) by mouth 2 times a day Total dose of 1.5mg twice daily\n- everolimus 1 MG Oral Tablet, through Oral route, started on 2020-07-16, presumably until 2020-07-29, with intended 11 refill(s). Instructions: take 1 Tab (1 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-23 10:45:04, ended at 2020-07-23 11:09:56\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose mean value [Mass/volume] in Blood Estimated from glycated hemoglobin: 183 (milligram per deciliter calculated)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 7.3 (percent hemoglobin)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Complication due to diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n- Postprocedural asymptomatic ovarian failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-24 00:00:00, ended at 2020-07-24 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 109 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.9 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1056 (cells per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 622 (cells per microliter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 16 (calculated)\n- Neutrophils [#/volume] in Blood by Automated count: 3625 (cells per microliter)\n- Platelets [#/volume] in Blood by Automated count: 223 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.09 (million per liter)\n- MCH [Entitic mass] by Automated count: 26.2 (picogram)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.2 (percent)\n- MCV [Entitic volume] by Automated count: 80.4 (femtoliter)\n- Basophils [#/volume] in Blood by Automated count: 39 (cells per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 160 (cells per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.9 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.34 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.3 (percent)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 12.3 (femtoliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.7 (gram per deciliter)\n- Everolimus [Mass/volume] in Blood: 2.7 (nanogram per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-29 00:00:00, ended at 2020-07-29 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-07-29 00:00:00, ended at 2020-07-29 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n\n### Drug\n- ferrous sulfate 325 MG Oral Tablet, started on 2020-07-30, presumably until 2022-06-09, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-29 00:00:00, ended at 2020-07-29 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- everolimus 1 MG Oral Tablet, through Oral route, started on 2020-07-29, presumably until 2021-04-29, with intended 11 refill(s). Instructions: take 1-2 Tabs (1-2 mg total) by mouth 2 times a day Take 1.5 mg in AM and 2 mg in PM\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-13 00:00:00, ended at 2020-08-13 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.44 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 181 (cells per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.7 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.8 (percent)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.5 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.4 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.12 (million per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 36 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 69 (cells per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.9 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 902 (cells per microliter)\n- MCV [Entitic volume] by Automated count: 79.6 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3136 (cells per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 64 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 613 (cells per microliter)\n- Platelets [#/volume] in Blood by Automated count: 205 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 25 (calculated)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.8 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Everolimus [Mass/volume] in Blood: 3.2 (nanogram per milliliter)\n- MCH [Entitic mass] by Automated count: 26.2 (picogram)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 12.5 (femtoliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-21 00:00:00, ended at 2020-08-21 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Primary diagnosis: Transplanted heart present\n- Pure hypercholesterolemia\n\n### Drug\n- rosuvastatin calcium 20 MG Oral Tablet, through Oral route, started on 2020-08-21, presumably until 2021-02-02, with intended 3 refill(s). Instructions: take 1 Tab (20 mg total) by mouth daily\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2020-08-21, presumably until 2021-09-28, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-09-03 00:00:00, ended at 2020-09-03 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- docusate sodium 250 MG Oral Capsule, started on 2020-09-04, presumably until 2021-05-03, with intended 11 refill(s). Instructions: TAKE 1 CAPSULE(250 MG) BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-09-09 00:00:00, ended at 2020-09-09 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Peripheral vascular disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-09-10 00:00:00, ended at 2020-09-10 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- bumetanide 1 MG Oral Tablet, through Oral route, started on 2020-09-10, presumably until 2021-02-26, with intended 3 refill(s). Instructions: take 2 Tabs (2 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-11 12:09:00, ended at 2020-09-11 23:59:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of lower extremity arteries or arterial bypass grafts; unilateral or limited study\n- Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording \n\n### Condition\n- Peripheral vascular disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-09-25 00:00:00, ended at 2020-09-25 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-02 00:00:00, ended at 2020-10-02 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-05 00:00:00, ended at 2020-10-05 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-06 00:00:00, ended at 2020-10-06 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Primary diagnosis: Transplanted heart present\n\n### Drug\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2020-10-06, presumably until 2021-02-26, with intended 3 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-10-07 00:00:00, ended at 2020-10-07 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperosmolarity\n- Type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-09 00:00:00, ended at 2020-10-09 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-12 00:00:00, ended at 2020-10-12 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-10-12 00:00:00, ended at 2020-10-12 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- mycophenolate mofetil 500 MG Oral Tablet, started on 2020-10-16, presumably until 2020-10-16, with intended 11 refill(s). Instructions: TAKE 2 TABLETS BY MOUTH 2 TIMES A DAY.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-16 00:00:00, ended at 2020-10-16 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Blood glucose abnormal\n- Pure hypercholesterolemia\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-16 00:00:00, ended at 2020-10-16 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- mycophenolate mofetil 500 MG Oral Tablet, through Oral route, started on 2020-10-16, presumably until 2021-11-18, with intended 11 refill(s). Instructions: take 2 Tabs (1,000 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-19 00:00:00, ended at 2020-10-19 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-19 06:12:00, ended at 2020-10-19 06:50:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 187 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 25.8 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.16 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.49 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 26.48 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.57 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 116 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.0 (percent)\n- MCHC [Mass/volume] by Automated count: 31.2 (gram per deciliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 78.0 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 106 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.6 (percent)\n- Everolimus [Mass/volume] in Blood: 7.6 (nanogram per milliliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 7.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.8 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.04 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 82.7 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 220 (thousand per microliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 236 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.49 (micro-international unit per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 88 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.49 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Cholesterol [Mass/volume] in Serum or Plasma: 169 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 53 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 84 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.8 (percent)\n- Anion gap in Serum or Plasma: 15 (millimole per liter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 3.2 (ratio)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.9 (thousand per microliter)\n- Protein/Creatinine [Mass Ratio] in Urine: 2.95 (milligram per milligram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 30 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 74.3 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n\n### Procedure\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n- Pure hypercholesterolemia\n- Blood glucose abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-19 06:51:00, ended at 2020-10-19 07:12:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest; 2 views\n\n### Condition\n- Blood glucose abnormal\n- Transplanted heart present\n- Disorder of transplanted heart\n- Pure hypercholesterolemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-19 07:13:00, ended at 2020-10-19 10:34:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 68.9 (percent)\n\n### Procedure\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; tracing only, without interpretation and report\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; supervision only, without interpretation and report\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; interpretation and report only\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation \n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n- Blood glucose abnormal\n- Pure hypercholesterolemia\n- Cardiomegaly\n\n### Drug\n- 250 ML dobutamine 1 MG/ML Injection, through Intravenous route, started on 2020-10-19, presumably until 2020-10-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-10-19 09:24:19, ended at 2020-10-19 11:16:33\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Blood glucose abnormal\n- Pure hypercholesterolemia\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-19 10:35:00, ended at 2020-10-19 23:59:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-20 00:00:00, ended at 2020-10-20 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- clonidine hydrochloride 0.2 MG Oral Tablet, through Oral route, started on 2020-10-20, presumably until 2022-06-10, with intended 3 refill(s). Instructions: take 1 Tab (0.2 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-23 00:00:00, ended at 2020-10-23 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-26 00:00:00, ended at 2020-10-26 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-30 00:00:00, ended at 2020-10-30 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-02 00:00:00, ended at 2020-11-02 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-03 13:19:42, ended at 2020-11-03 14:16:55\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Complication due to diabetes mellitus\n\n### Drug\n- 0.5 ML dulaglutide 3 MG/ML Auto-Injector, through Subcutaneous route, started on 2020-11-03, presumably until 2021-09-06, with intended 4 refill(s). Instructions: inject 1.5 mg subcutaneous (under the skin) once a week\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-06 00:00:00, ended at 2020-11-06 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-09 00:00:00, ended at 2020-11-09 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-11-11 00:00:00, ended at 2020-11-11 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, started on 2020-11-11, presumably until 2020-11-25, with intended 0 refill(s). Instructions: Take 2L by mouth night before and 2L morning of procedure. Stop fluids 4hr before procedure. Instructions are forwarded to patient.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-13 00:00:00, ended at 2020-11-13 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-16 00:00:00, ended at 2020-11-16 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-20 00:00:00, ended at 2020-11-20 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-23 00:00:00, ended at 2020-11-23 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-27 00:00:00, ended at 2020-11-27 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-30 00:00:00, ended at 2020-11-30 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-02 08:00:00, ended at 2020-12-02 08:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-04 00:00:00, ended at 2020-12-04 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-07 00:00:00, ended at 2020-12-07 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-08 00:00:00, ended at 2020-12-08 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-09 00:00:00, ended at 2020-12-09 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-10 00:00:00, ended at 2020-12-10 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- 24 HR isosorbide mononitrate 30 MG Extended Release Oral Tablet, through Oral route, started on 2020-12-10, presumably until 2021-09-06, with intended 3 refill(s). Instructions: take 1 Tab (30 mg total) by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-11 00:00:00, ended at 2020-12-11 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-14 00:00:00, ended at 2020-12-14 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-12-17 08:46:02, ended at 2020-12-17 09:44:25\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Unlisted procedure, dentoalveolar structures\n- Alveoloplasty, each quadrant (specify)\n\n### Condition\n- Transplanted heart present\n- Dental caries\n- Primary diagnosis: Diastolic heart failure\n- Periapical abscess\n- Type 2 diabetes mellitus without complication\n- Primary diagnosis: Congestive heart failure\n- Primary diagnosis: Valvular endocarditis\n\n### Drug\n- chlorhexidine gluconate 1.2 MG/ML Mouthwash, through Oral route, started on 2020-12-17, presumably until 2021-02-25, with intended 3 refill(s). Instructions: take 15 mL by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-18 00:00:00, ended at 2020-12-18 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-21 00:00:00, ended at 2020-12-21 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-23 08:55:59, ended at 2020-12-23 09:01:45\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-25 00:00:00, ended at 2020-12-25 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-28 00:00:00, ended at 2020-12-28 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-01 00:00:00, ended at 2021-01-01 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-04 00:00:00, ended at 2021-01-04 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-01-05 00:00:00, ended at 2021-01-05 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Complication due to diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-01-07 00:00:00, ended at 2021-01-07 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-08 00:00:00, ended at 2021-01-08 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-11 00:00:00, ended at 2021-01-11 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-15 00:00:00, ended at 2021-01-15 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-18 00:00:00, ended at 2021-01-18 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-22 00:00:00, ended at 2021-01-22 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-25 00:00:00, ended at 2021-01-25 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-29 00:00:00, ended at 2021-01-29 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-01 00:00:00, ended at 2021-02-01 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-02 00:00:00, ended at 2021-02-02 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Pure hypercholesterolemia\n- Transplanted heart present\n\n### Drug\n- rosuvastatin calcium 20 MG Oral Tablet, through Oral route, started on 2021-02-02, presumably until 2021-12-15, with intended 3 refill(s). Instructions: take 1 Tab (20 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-02-02 00:00:00, ended at 2021-02-02 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Complication due to diabetes mellitus\n\n### Drug\n- 3 ML insulin isophane, human 100 UNT/ML Pen Injector, started on 2021-02-03, presumably until 2022-06-10, with intended 6 refill(s). Instructions: Inject subcutaneously 14 units twice daily. (Total 28 units per day).\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-05 00:00:00, ended at 2021-02-05 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-08 00:00:00, ended at 2021-02-08 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-12 00:00:00, ended at 2021-02-12 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-15 00:00:00, ended at 2021-02-15 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-19 00:00:00, ended at 2021-02-19 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-22 00:00:00, ended at 2021-02-22 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-24 00:00:00, ended at 2021-02-24 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-25 00:00:00, ended at 2021-02-25 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-02-25 09:03:00, ended at 2021-02-25 09:34:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 15 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.1 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.74 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 17.5 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.6 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.33 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 82.6 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.62 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 227 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.48 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 42 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- Everolimus [Mass/volume] in Blood: 2.9 (nanogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 151 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.9 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.47 (million per microliter)\n- MCH [Entitic mass] by Automated count: 26.2 (picogram)\n- MCHC [Mass/volume] by Automated count: 31.7 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-02-25 09:35:00, ended at 2021-02-25 23:59:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 75.0 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study\n\n### Condition\n- Transplanted heart present\n- Essential hypertension\n- Diabetes mellitus without complication\n- Hypomagnesemia\n- Disorder of transplanted heart\n- Hyperlipidemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-02-25 10:02:17, ended at 2021-02-25 11:09:14\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Transplanted heart present\n- Disorder of transplanted heart\n- Essential hypertension\n- Hyperlipidemia\n- Diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-02-26 00:00:00, ended at 2021-02-26 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- amlodipine 10 MG Oral Tablet, through Oral route, started on 2021-02-26, presumably until 2022-03-24, with intended 3 refill(s). Instructions: take 1 Tab (10 mg total) by mouth daily\n- bumetanide 1 MG Oral Tablet, through Oral route, started on 2021-02-26, presumably until 2021-10-04, with intended 3 refill(s). Instructions: take 1 Tab (1 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-26 00:00:00, ended at 2021-02-26 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-01 00:00:00, ended at 2021-03-01 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-05 00:00:00, ended at 2021-03-05 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-08 00:00:00, ended at 2021-03-08 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-12 00:00:00, ended at 2021-03-12 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-15 00:00:00, ended at 2021-03-15 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-19 00:00:00, ended at 2021-03-19 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-22 00:00:00, ended at 2021-03-22 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-26 00:00:00, ended at 2021-03-26 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-29 00:00:00, ended at 2021-03-29 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-02 00:00:00, ended at 2021-04-02 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-05 00:00:00, ended at 2021-04-05 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-09 00:00:00, ended at 2021-04-09 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-12 00:00:00, ended at 2021-04-12 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-16 00:00:00, ended at 2021-04-16 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-19 00:00:00, ended at 2021-04-19 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-23 00:00:00, ended at 2021-04-23 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-26 00:00:00, ended at 2021-04-26 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-04-27 00:00:00, ended at 2021-04-27 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2021-04-28, presumably until 2021-04-29, with intended 11 refill(s). Instructions: take 1 Tablet (0.5 mg total) by mouth 2 times a day Total dose of 1.5mg twice daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-04-29 00:00:00, ended at 2021-04-29 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2021-04-29, presumably until 2021-05-11, with intended 3 refill(s). Instructions: take 1 Tablet (0.5 mg total) by mouth 2 times a day Total dose of 1.5mg BID, Rx 2 of 2. Fax 999-999-9999.\n- everolimus 1 MG Oral Tablet, through Oral route, started on 2021-04-29, presumably until 2021-05-11, with intended 3 refill(s). Instructions: take 1 Tablet (1 mg total) by mouth 2 times a day Take 1.5 mg BID. Rx 1 of 2. Fax 999-999-9999.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-30 00:00:00, ended at 2021-04-30 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-03 00:00:00, ended at 2021-05-03 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2021-05-03, presumably until 2022-05-05, with intended 11 refill(s). Instructions: take 1 Capsule (250 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-03 00:00:00, ended at 2021-05-03 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.7 (percent)\n- MCH [Entitic mass] by Automated count: 26.5 (picogram)\n- MCV [Entitic volume] by Automated count: 79.8 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 37 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.2 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1097 (cells per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 17.7 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 676 (cells per microliter)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 12.4 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 24 (calculated)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.4 (calculated)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 69 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 37 (cells per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 217 (cells per microliter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter calculated)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67.3 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.56 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.2 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4173 (cells per microliter)\n- Platelets [#/volume] in Blood by Automated count: 192 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Everolimus [Mass/volume] in Blood: 13.8 (nanogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.41 (million per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.9 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-07 00:00:00, ended at 2021-05-07 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2021-05-07, presumably until 2021-09-14, with intended 3 refill(s). Instructions: take 1-2 Tablets by mouth daily as needed for Constipation\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-07 00:00:00, ended at 2021-05-07 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-10 00:00:00, ended at 2021-05-10 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-05-11 00:00:00, ended at 2021-05-11 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n\n### Drug\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2021-05-11, presumably until 2021-05-26, with intended 3 refill(s). Instructions: take 1 Tablet (0.5 mg total) by mouth PM Total dose of 1mg in am and 1.5mg in pm, Rx 2 of 2. Fax 999-999-9999.\n- everolimus 1 MG Oral Tablet, through Oral route, started on 2021-05-11, presumably until 2021-05-26, with intended 3 refill(s). Instructions: take 1 Tablet (1 mg total) by mouth 2 times a day Total dose of 1mg in am and 1.5mg in pm, Rx 1 of 2. Fax 999-999-9999.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-14 00:00:00, ended at 2021-05-14 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-17 00:00:00, ended at 2021-05-17 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-17 00:00:00, ended at 2021-05-17 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-20 00:00:00, ended at 2021-05-20 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-21 00:00:00, ended at 2021-05-21 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-24 00:00:00, ended at 2021-05-24 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-05-24 09:06:00, ended at 2021-05-24 11:19:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.45 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 137 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 25.6 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 3.12 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.38 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 31.0 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 79 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.19 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.62 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 212 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.2 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 31 (milligram per deciliter)\n- Everolimus [Mass/volume] in Blood: 8.0 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 11.2 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 82.4 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.9 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.94 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-05-24 10:07:28, ended at 2021-05-24 11:42:39\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-05-24 11:20:00, ended at 2021-05-24 23:59:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging)\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-25 00:00:00, ended at 2021-05-25 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Capsule, through Oral route, started on 2021-05-25, presumably until 2021-08-30, with intended 0 refill(s). Instructions: take 25 mg by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-05-25 00:00:00, ended at 2021-05-25 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n\n### Drug\n- everolimus 1 MG Oral Tablet, through Oral route, started on 2021-05-26, presumably until 2022-05-23, with intended 3 refill(s). Instructions: take 1 mg by mouth 2 times a day Rx 1/2: Total dose of 1mg in am and 1.5 mg in pm.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-25 00:00:00, ended at 2021-05-25 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-28 00:00:00, ended at 2021-05-28 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-31 00:00:00, ended at 2021-05-31 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-04 00:00:00, ended at 2021-06-04 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-04 00:00:00, ended at 2021-06-04 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Essential hypertension\n\n### Drug\n- hydralazine hydrochloride 100 MG Oral Tablet, through Oral route, started on 2021-06-04, presumably until 2022-06-09, with intended 3 refill(s). Instructions: take 1 Tablet (100 mg total) by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-07 00:00:00, ended at 2021-06-07 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-11 00:00:00, ended at 2021-06-11 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-14 00:00:00, ended at 2021-06-14 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-18 00:00:00, ended at 2021-06-18 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-21 00:00:00, ended at 2021-06-21 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-25 00:00:00, ended at 2021-06-25 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-28 00:00:00, ended at 2021-06-28 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-07-02 00:00:00, ended at 2021-07-02 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-07-05 00:00:00, ended at 2021-07-05 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-07-09 00:00:00, ended at 2021-07-09 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-07-12 00:00:00, ended at 2021-07-12 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-07-16 00:00:00, ended at 2021-07-16 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-07-19 00:00:00, ended at 2021-07-19 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-07-23 00:00:00, ended at 2021-07-23 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-07-26 00:00:00, ended at 2021-07-26 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-07-30 00:00:00, ended at 2021-07-30 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-02 00:00:00, ended at 2021-08-02 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-06 00:00:00, ended at 2021-08-06 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-09 00:00:00, ended at 2021-08-09 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-13 00:00:00, ended at 2021-08-13 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-16 00:00:00, ended at 2021-08-16 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-20 00:00:00, ended at 2021-08-20 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-23 00:00:00, ended at 2021-08-23 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-08-24 00:00:00, ended at 2021-08-24 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-27 00:00:00, ended at 2021-08-27 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of thyroid gland\n- Disorder of transplanted heart\n- Primary diagnosis: Impaired glucose tolerance\n- Hyperlipidemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-30 00:00:00, ended at 2021-08-30 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-08-30 06:47:00, ended at 2021-08-30 07:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.13 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.9 (percent)\n- Protein/Creatinine [Mass Ratio] in Urine: 4.36 (milligram per milligram)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- Everolimus [Mass/volume] in Blood: 3.5 (nanogram per milliliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 7.2 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 3 - 5 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.9 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 122 (unit per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 170 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.0 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 31.8 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 190 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.22 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 82.5 (femtoliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 143 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- Creatinine [Mass/volume] in Urine: 25.45 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.52 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.3 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 4.0 (ratio)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.58 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 20.0 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 111.0 (milligram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 3.00 (micro-international unit per milliliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 323 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.1 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 90 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.96 (million per microliter)\n- MCH [Entitic mass] by Automated count: 26.2 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 70.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 245 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 47 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.49 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.2 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n\n### Condition\n- Disorder of thyroid gland\n- Disorder of transplanted heart\n- Transplanted heart present\n- Hyperlipidemia\n- Impaired glucose tolerance\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-08-30 07:01:00, ended at 2021-08-30 23:59:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 61.4 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation \n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; supervision only, without interpretation and report\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; interpretation and report only\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; tracing only, without interpretation and report\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n\n### Condition\n- Transplanted heart present\n- Type 2 diabetes mellitus\n- Cardiomegaly\n- Disorder of transplanted heart\n- Hyperglycemia due to type 2 diabetes mellitus\n- Ventricular premature complex\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-08-30 10:28:13, ended at 2021-08-30 11:49:46\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Hyperlipidemia\n- Electrocardiogram abnormal\n- Primary diagnosis: Essential hypertension\n- Chronic kidney disease\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-08-31 00:00:00, ended at 2021-08-31 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2021-08-31, presumably until 2022-08-25, with intended 3 refill(s). Instructions: take 1 Tablet (0.5 mg total) by mouth daily in the evening Rx 2/2: Dose is 1 mg in am and 1.5 mg every evening\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Malignant tumor of breast within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-08-12 00:00:00, ended at 2013-08-12 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-08-14 00:00:00, ended at 2013-08-14 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-09-02 00:00:00, ended at 2013-09-02 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Electrocardiogram abnormal\n- Primary diagnosis: Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-09-02 00:00:00, ended at 2013-09-02 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 35 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-02 07:51:00, ended at 2013-09-02 11:39:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Primary cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-09-02 09:05:39, ended at 2013-09-02 11:27:09\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Chronic ischemic heart disease\n- Primary diagnosis: Congestive heart failure\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- 24 HR isosorbide mononitrate 30 MG Extended Release Oral Tablet, through Oral route, presumably until 2013-10-02. Instructions: take 30 mg by mouth every morning.\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2013-09-02, presumably until 2014-04-25, with intended 6 refill(s). Instructions: take 3 Tabs by mouth Every Day. Two am and one pm\n- ticagrelor 90 MG Oral Tablet, through Oral route, presumably until 2014-05-23. Instructions: take 90 mg by mouth 2 times a day.\n- aspirin 325 MG Oral Tablet, through Oral route, presumably until 2014-05-23. Instructions: take 325 mg by mouth daily.\n- spironolactone 25 MG Oral Tablet, through Oral route, started on 2013-09-02, presumably until 2013-09-25, with intended 6 refill(s). Instructions: take 25 mg by mouth daily.\n- losartan potassium 100 MG Oral Tablet, through Oral route, presumably until 2014-05-23. Instructions: take 100 mg by mouth daily.\n- insulin glargine 100 UNT/ML Injectable Solution, through Subcutaneous route, presumably until 2013-11-05. Instructions: inject 30 Units subcutaneous (under the skin) Evening.\n- carvedilol 12.5 MG Oral Tablet, through Oral route, started on 2013-09-02, presumably until 2013-10-02, with intended 6 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-02 11:40:00, ended at 2013-09-02 11:40:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 49 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.31 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.3 (thousand per microliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.4 (nanogram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.5 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.61 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.75 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Prothrombin time (PT): 13.2 (second)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 5.6 (ratio)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 242 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 266 (milligram per deciliter)\n- Triiodothyronine (T3) [Mass/volume] in Serum or Plasma: 113 (nanogram per deciliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 276 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.26 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.0 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 29 (milligram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 14.5 (percent)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 82.7 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 248 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 182 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 27.7 (picogram)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.88 (milli-international unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 313 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.6 (gram per deciliter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Congestive heart failure\n- Type 2 diabetes mellitus without complication\n- Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-02 11:41:00, ended at 2013-09-02 23:59:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-09-03 00:00:00, ended at 2013-09-03 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-09-03 00:00:00, ended at 2013-09-03 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-09-03 00:00:00, ended at 2013-09-03 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic ischemic heart disease\n- Coronary atherosclerosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-05 13:30:00, ended at 2013-09-05 13:30:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Chronic ischemic heart disease\n- Coronary arteriosclerosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-05 13:30:00, ended at 2013-09-05 13:30:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of extracranial arteries; complete bilateral study\n\n### Condition\n- Chronic ischemic heart disease\n- Coronary atherosclerosis\n- Disorder of carotid artery\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-05 13:31:00, ended at 2013-09-05 23:59:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of lower extremity arteries or arterial bypass grafts; unilateral or limited study\n\n### Condition\n- Coronary atherosclerosis\n- Chronic ischemic heart disease\n- Intermittent claudication\n- Atherosclerosis of arteries of the extremities\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-11 06:56:00, ended at 2013-09-11 06:56:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Postprocedural state finding\n- Lung field abnormal\n- Old myocardial infarction\n- Chronic ischemic heart disease\n- Coronary arteriosclerosis\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-11 06:57:00, ended at 2013-09-11 23:59:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Chronic ischemic heart disease\n- Lung field abnormal\n- Coronary arteriosclerosis\n- Heart disease\n- Old myocardial infarction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-09-18 00:00:00, ended at 2013-09-18 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-02 08:00:00, ended at 2013-10-02 10:59:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Cardiopulmonary exercise testing, including measurements of minute ventilation, CO2 production, O2 uptake, and electrocardiographic recordings\n\n### Condition\n- Dyspnea\n- Congestive heart failure\n- Combined systolic and diastolic dysfunction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-10-02 09:15:59, ended at 2013-10-02 10:38:57\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n- Chronic ischemic heart disease\n- Primary diagnosis: Congestive heart failure\n\n### Drug\n- 24 HR isosorbide mononitrate 60 MG Extended Release Oral Tablet, through Oral route, started on 2013-10-02, presumably until 2013-11-08, with intended 9 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n- carvedilol 25 MG Oral Tablet, through Oral route, started on 2013-10-02, presumably until 2013-11-08, with intended 6 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-02 11:00:00, ended at 2013-10-02 14:51:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pulmonary stress testing; simple (eg, 6-minute walk test, prolonged exercise test for bronchospasm with pre- and post-spirometry and oximetry)\n\n### Condition\n- Congestive heart failure\n- Abnormal breathing\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-10-02 11:16:02, ended at 2013-10-02 14:45:58\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of nervous system due to diabetes mellitus\n- Primary diagnosis: Diabetic - poor control\n- Primary diagnosis: Diabetes mellitus without complication\n\n### Drug\n- 3 ML insulin lispro 25 UNT/ML / insulin lispro protamine, human 75 UNT/ML Pen Injector, through Subcutaneous route, started on 2013-10-02, presumably until 2014-05-19, with intended 6 refill(s). Instructions: inject 15-20 Units subcutaneous (under the skin) 2 times a day before meals. Before breakfast take 15 units, before dinner take 20 units.\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, started on 2013-10-02, presumably until 2013-10-31, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-02 14:52:00, ended at 2013-10-02 23:59:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Cardiopulmonary exercise testing, including measurements of minute ventilation, CO2 production, O2 uptake, and electrocardiographic recordings\n- Bioimpedance-derived physiologic cardiovascular analysis\n\n### Condition\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-10-08 00:00:00, ended at 2013-10-08 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-10-09 00:00:00, ended at 2013-10-09 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-09 12:00:00, ended at 2013-10-09 13:16:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-10-09 12:05:57, ended at 2013-10-09 12:53:16\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Congestive heart failure\n- Electrocardiogram abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-09 13:17:00, ended at 2013-10-09 23:59:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 136 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-10-31 00:00:00, ended at 2013-10-31 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of nervous system due to diabetes mellitus\n- Primary diagnosis: Polyneuropathy due to diabetes mellitus\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, started on 2013-10-31, presumably until 2013-11-08, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-11-01 00:00:00, ended at 2013-11-01 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Heart failure\n- Primary diagnosis: Primary cardiomyopathy\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-11-05 06:01:00, ended at 2013-11-05 17:24:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n- Hemoglobin A1c/Hemoglobin.total in Blood: 10.6 (percent)\n- Sodium [Moles/volume] in Blood: 141 (millimole per liter)\n- Potassium [Moles/volume] in Blood: 4.3 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 11.2 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood: 33 (percent)\n\n### Procedure\n- Catheterization of right heart\n- Coronary arteriography using two catheters\n- Collection of venous blood by venipuncture\n- Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right heart catheterization\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n\n### Condition\n- Primary diagnosis: Congestive heart failure\n- Coronary arteriosclerosis\n- Diabetic - poor control\n- Old myocardial infarction\n- Angina pectoris\n- Chronic ischemic heart disease\n- Type 2 diabetes mellitus without complication\n- Diabetes mellitus without complication\n\n### Drug\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2013-11-05, presumably until 2013-11-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-11-08 09:17:24, ended at 2013-11-08 10:30:56\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congestive heart failure\n- Chronic ischemic heart disease\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- carvedilol 25 MG Oral Tablet, through Oral route, started on 2013-11-08, presumably until 2014-01-10, with intended 6 refill(s). Instructions: take 2 Tabs by mouth 2 times a day with meals.\n- 24 HR isosorbide mononitrate 120 MG Extended Release Oral Tablet, through Oral route, started on 2013-11-08, presumably until 2014-04-25, with intended 6 refill(s). Instructions: take 1 Tab by mouth every morning.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-11-22 00:00:00, ended at 2013-11-22 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for transvenous insertion or replacement of pacing cardioverter-defibrillator\n\n### Condition\n- Primary cardiomyopathy\n\n### Drug\n- 1 ML ketorolac tromethamine 30 MG/ML Injection, started on 2013-11-22, presumably until 2013-11-22\n- cefazolin 1000 MG Injection, started on 2013-11-22, presumably until 2013-11-22\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-11-22, presumably until 2013-11-22\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2013-11-22, presumably until 2013-11-22\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-11-22, presumably until 2013-11-22\n- midazolam 1 MG/ML Injectable Solution, started on 2013-11-22, presumably until 2013-11-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-11-22 06:14:00, ended at 2013-11-23 11:24:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocyte distribution width [Ratio] by Automated count: 14.4 (percent)\n- Hemoglobin [Mass/volume] in Blood by calculation: 10.5 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 194 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood: 31 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.46 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.4 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 58 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.4 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- Potassium [Moles/volume] in Blood: 4.3 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 36 (milliliter per minute per square meter)\n- MCV [Entitic volume] by Automated count: 82.1 (femtoliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Prothrombin time (PT): 14.0 (second)\n- Sodium [Moles/volume] in Blood: 140 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 29.3 (second)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 134 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- MCH [Entitic mass] by Automated count: 27.1 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Body height: 5' 5\" (inch (US))\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n\n### Procedure\n- Radiologic examination, chest; single view, frontal\n- Implantation or replacement of automatic cardioverter/defibrillator, total system [AICD]\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Insertion or replacement of permanent implantable defibrillator system, with transvenous lead(s), single or dual chamber\n- Collection of venous blood by venipuncture\n\n### Condition\n- Essential hypertension\n- Coronary arteriosclerosis\n- Imaging of thorax abnormal\n- Congestive heart failure\n- Type 2 diabetes mellitus without complication\n- Old myocardial infarction\n- Chronic ischemic heart disease\n\n### Drug\n- losartan potassium 50 MG Oral Tablet, through Oral route, started on 2013-11-23, presumably until 2013-11-23\n- ketorolac tromethamine 10 MG Oral Tablet, through Oral route, started on 2013-11-22, presumably until 2013-11-23\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2013-11-22, presumably until 2013-11-22\n- ticagrelor 90 MG Oral Tablet, through Oral route, started on 2013-11-22, presumably until 2013-11-23\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-11-22, presumably until 2013-11-22\n- aspirin 325 MG Oral Tablet, through Oral route, started on 2013-11-23, presumably until 2013-11-23\n- cefazolin 1000 MG Injection, through Intravenous route, started on 2013-11-22, presumably until 2013-11-22\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, started on 2013-11-23, presumably until 2013-11-23\n- furosemide 40 MG Oral Tablet, through Oral route, started on 2013-11-23, presumably until 2013-11-23\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2013-11-23, presumably until 2013-12-24, with intended 0 refill(s). Instructions: take 1 Cap by mouth 3 times a day.\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2013-11-22, presumably until 2013-11-23\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-11-22, presumably until 2013-11-22\n- 24 HR isosorbide mononitrate 60 MG Extended Release Oral Tablet, through Oral route, started on 2013-11-23, presumably until 2013-11-23\n- carvedilol 25 MG Oral Tablet, through Oral route, started on 2013-11-23, presumably until 2013-11-23\n- insulin glargine 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2013-11-22, presumably until 2013-11-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-12-09 11:17:31, ended at 2013-12-09 11:47:10\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Congestive heart failure\n- Primary cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-01-10 00:00:00, ended at 2014-01-10 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congestive heart failure\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-01-28 00:00:00, ended at 2014-01-28 00:00:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congestive heart failure\n- Primary cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-01-30 10:21:05, ended at 2014-01-30 11:21:24\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Congestive heart failure\n- Diabetic - poor control\n- Primary diagnosis: Pulmonary tuberculosis\n- Diabetes mellitus without complication\n\n### Drug\n- vitamin B6 50 MG Oral Tablet, through Oral route, started on 2014-01-30, presumably until 2015-01-30, with intended 8 refill(s). Instructions: take 1 Tab by mouth daily.\n- isoniazid 300 MG Oral Tablet, through Oral route, started on 2014-01-30, presumably until 2015-01-30, with intended 8 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-30 11:27:00, ended at 2014-01-30 23:59:00\nThe patient in this visit was 50 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 47 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.4 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.8 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.74 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 35 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.04 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 42 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.3 (percent)\n- MCH [Entitic mass] by Automated count: 26.8 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 213 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.35 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 80.1 (femtoliter)\n- Glucose [Mass/volume] in Serum or Plasma: 187 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.8 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.75 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 240 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.7 (percent)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Pulmonary tuberculosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-02-25 00:00:00, ended at 2014-02-25 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congestive heart failure\n- Primary diagnosis: Diastolic heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-02-26 11:23:48, ended at 2014-02-26 11:47:02\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diabetes mellitus without complication\n- Primary diagnosis: Diabetic - poor control\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-26 11:48:00, ended at 2014-02-26 11:49:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n- Collection of venous blood by venipuncture\n\n### Condition\n- Congestive heart failure\n- Diastolic heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-26 11:50:00, ended at 2014-02-26 23:59:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin A1c/Hemoglobin.total in Blood: 9.4 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diabetes mellitus without complication\n- Diabetic - poor control\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-03-04 10:35:43, ended at 2014-03-04 11:12:18\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diabetes mellitus without complication\n- Diabetic - poor control\n- Congestive heart failure\n- Primary diagnosis: Pulmonary tuberculosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-03-06 00:00:00, ended at 2014-03-06 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic ischemic heart disease\n- Primary diagnosis: Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-03-06 00:00:00, ended at 2014-03-06 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Primary diagnosis: Congestive heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-03-13 00:00:00, ended at 2014-03-13 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary tuberculosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-13 09:22:00, ended at 2014-03-13 23:59:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n\n### Condition\n- Heart failure\n- Primary cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-03-21 00:00:00, ended at 2014-03-21 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 30 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-21 12:22:00, ended at 2014-03-21 13:24:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-21 13:25:00, ended at 2014-03-21 23:59:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n- Computed tomography, abdomen and pelvis; without contrast material\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Lung field abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-21 13:25:00, ended at 2014-03-21 23:59:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-03-25 12:37:51, ended at 2014-03-25 13:49:16\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic systolic heart failure\n- Primary diagnosis: Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-04-04 00:00:00, ended at 2014-04-04 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-04-04 09:56:20, ended at 2014-04-04 11:38:39\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diabetes mellitus without complication\n- Type 2 diabetes mellitus without complication\n- Chronic ischemic heart disease\n- Primary diagnosis: Congestive heart failure\n- Diabetic - poor control\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2014-04-04, presumably until 2014-05-23, with intended 6 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-04-25 00:00:00, ended at 2014-04-25 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n- Primary diagnosis: Congestive heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2014-04-25, presumably until 2014-05-19, with intended 6 refill(s). Instructions: take 2 Tabs by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-04-25 12:28:00, ended at 2014-04-25 14:22:05\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic ischemic heart disease\n- Type 2 diabetes mellitus without complication\n- Primary diagnosis: Congestive heart failure\n\n### Drug\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2014-04-25, presumably until 2014-04-25, with intended 6 refill(s). Instructions: take 2 Tabs by mouth 2 times a day. Two am and one pm\n- 24 HR isosorbide mononitrate 120 MG Extended Release Oral Tablet, started on 2014-04-25, presumably until 2014-05-19, with intended 6 refill(s). Instructions: Pt sent home with hand written prescription for 240 mg tablet pill - to take one tablet in evening or two of 120 each pm together\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-25 14:27:00, ended at 2014-04-25 23:59:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.24 (milli-international unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 219 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Triiodothyronine (T3) [Mass/volume] in Serum or Plasma: 96 (nanogram per deciliter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.8 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 35 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 260 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 10.2 (percent)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.4 (nanogram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 50 (milliliter per minute per square meter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic ischemic heart disease\n- Type 2 diabetes mellitus without complication\n- Congestive heart failure\n- Primary cardiomyopathy\n- Pulmonary tuberculosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-05-14 00:00:00, ended at 2014-05-14 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Polyneuropathy due to diabetes mellitus\n- Primary diagnosis: Disorder of nervous system due to diabetes mellitus\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, started on 2014-05-14, presumably until 2014-07-18, with intended 3 refill(s). Instructions: take 1 Cap by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2014-05-17 19:59:00, ended at 2014-05-23 16:30:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Iron [Mass/volume] in Serum or Plasma: 26 (microgram per deciliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 235 (microgram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.7 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Manual count: 1.2 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 40 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Eosinophils/100 leukocytes in Blood by Manual count: 4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.6 (percent)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 19 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Body height: 5' 5\" (inch (US))\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- INR in Platelet poor plasma by Coagulation assay: 1.4 (ratio)\n- Leukocytes [#/volume] in Specimen by Automated count: 13.8 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 26.8 (picogram)\n- Monocytes/100 leukocytes in Blood by Manual count: 10 (percent)\n- Neutrophils [#/volume] in Blood by Manual count: 7.9 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 388 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.59 (milli-international unit per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.7 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.12 (million per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.6 (percent)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 11 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.5 (thousand per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 468 (nanogram per milliliter)\n- Lactate [Moles/volume] in Blood: 1.6 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.45 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 2.3 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.82 (thousand per microliter)\n- Prothrombin time (PT): 16.2 (second)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.46 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.5 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 83 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 13.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 8.0 (gram per deciliter)\n- Left ventricular Ejection fraction: 28.7 (percent)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 207 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 24.5 (percent)\n- MCV [Entitic volume] by Automated count: 81.3 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: <15 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 64 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 39.0 (second)\n\n### Procedure\n- Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes\n- Hospital discharge day management; 30 minutes or less\n- Catheterization of right heart\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Collection of venous blood by venipuncture\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Procedure on single vessel\n- Critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes (List separately in addition to code for primary service)\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Right heart catheterization including measurement(s) of oxygen saturation and cardiac output, when performed\n- Central venous catheter placement with guidance\n- Physical therapy evaluation\n- Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right heart catheterization\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Medical decision making that is straightforward or o\n- Coronary arteriography using two catheters\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Revision of automatic implantable cardioverter/defibrillator\n- Percutaneous transluminal coronary angioplasty\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Radiologic examination, esophagus, including scout chest radiograph(s) and delayed image(s), when performed; single-contrast (eg, barium) study\n- Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, without imaging guidance; age 5 years or older\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Radiologic examination, chest; single view, frontal\n- Insertion of drug-eluting coronary artery stent\n- Insertion of one vascular stent\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch\n\n### Condition\n- Diabetic - poor control\n- Fever\n- Helicobacter-associated disease\n- Essential hypertension\n- Hyperosmolality and or hypernatremia\n- Hypo-osmolality and or hyponatremia\n- Iron deficiency anemia\n- Long QT syndrome\n- Chest pain\n- Eye / vision finding\n- Atrial fibrillation\n- Primary diagnosis: Congestive heart failure\n- Diabetes mellitus without complication\n- Infective pneumonia\n- Leukocytosis\n- Coronary arteriosclerosis\n- Disorder of esophagus\n- Cardiomegaly\n- Chronic ischemic heart disease\n- Disorder of function of stomach\n- Disorder of lung\n- Hypovolemia\n- Lung field abnormal\n- Nonspecific tuberculin test reaction\n- Preinfarction syndrome\n- Primary diagnosis: Acute on chronic systolic heart failure\n- Acute renal failure syndrome\n- Electrocardiogram abnormal\n- Old myocardial infarction\n\n### Drug\n- amoxicillin 500 MG Oral Capsule, through Oral route, started on 2014-05-23, presumably until 2014-05-23, with intended 0 refill(s). Instructions: take 2 Caps by mouth Q12H.\n- furosemide 20 MG Oral Tablet, through Oral route, presumably until 2014-05-23. Instructions: take 40 mg by mouth every morning.\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2014-05-23, presumably until 2015-05-23, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2014-05-21, presumably until 2014-05-21\n- ceftriaxone 1000 MG Injection, through Intravenous route, started on 2014-05-18, presumably until 2014-05-18\n- diazepam 5 MG Oral Tablet, through Oral route, started on 2014-05-22, presumably until 2014-05-22\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2014-05-17, presumably until 2014-05-22\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2014-05-22, presumably until 2014-05-22\n- 3 ML insulin lispro 25 UNT/ML / insulin lispro protamine, human 75 UNT/ML Pen Injector, through Subcutaneous route, started on 2014-05-23, presumably until 2014-11-11, with intended 11 refill(s). Instructions: inject 10-20 Units subcutaneous (under the skin) 3 times a day. 10 units every morning, 15 units in afternoon, 20 units every evening\n- tetracycline hydrochloride 500 MG Oral Capsule, through Oral route, started on 2014-05-23, presumably until 2015-05-23, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day.\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2014-05-18, presumably until 2014-05-18\n- aspirin 325 MG Oral Tablet, through Oral route, started on 2014-05-22, presumably until 2014-05-22\n- bismuth subsalicylate 35 MG/ML Oral Suspension, through Oral route, started on 2014-05-23, presumably until 2014-06-13, with intended 0 refill(s). Instructions: take 15 mL by mouth 4 times a day.\n- metronidazole 250 MG Oral Tablet, through Oral route, started on 2014-05-23, presumably until 2015-05-23, with intended 0 refill(s). Instructions: take 1 Tab by mouth 4 times a day.\n- trazodone hydrochloride 50 MG Oral Tablet, through Oral route, started on 2014-05-18, presumably until 2014-05-18\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2014-05-21, presumably until 2014-05-21\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, started on 2014-05-22, presumably until 2014-05-23\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2014-05-19, presumably until 2014-05-19\n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2014-05-17, presumably until 2014-05-17\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2014-05-21, presumably until 2014-05-22\n- vitamin B6 50 MG Oral Tablet, through Oral route, started on 2014-05-18, presumably until 2014-05-23\n- insulin detemir 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2014-05-18, presumably until 2014-05-23\n- isoniazid 300 MG Oral Tablet, through Oral route, started on 2014-05-18, presumably until 2014-05-23\n- insulin isophane, human 100 UNT/ML Injectable Suspension, through Subcutaneous route, started on 2014-05-18, presumably until 2014-05-18\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2014-05-18, presumably until 2014-05-19\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2014-05-19, presumably until 2014-05-22\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2014-05-20, presumably until 2014-05-21\n- atorvastatin 80 MG Oral Tablet, through Oral route, started on 2014-05-23, presumably until 2015-05-23, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily in the evening.\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2014-05-18, presumably until 2014-05-23\n- erythromycin 0.005 MG/MG Ophthalmic Ointment, through Intraocular route, started on 2014-05-20, presumably until 2014-05-23\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2014-05-17, presumably until 2014-05-18\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2014-05-20, presumably until 2014-05-21\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2014-05-22, presumably until 2014-05-22\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2014-05-19, presumably until 2014-05-19\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2014-05-20, presumably until 2014-09-01, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-05-17, presumably until 2014-05-22\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2014-05-22, presumably until 2014-05-22\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-05-18, presumably until 2014-05-18\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, through Intravenous route, started on 2014-05-18, presumably until 2014-05-18\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2014-05-22, presumably until 2014-05-22\n- benzonatate 100 MG Oral Capsule, through Oral route, started on 2014-05-18, presumably until 2014-05-21\n- 100 ML potassium chloride 0.2 MEQ/ML Injection, through Intravenous route, started on 2014-05-19, presumably until 2014-05-19\n- glucose 50 MG/ML Injection, through Intravenous route, started on 2014-05-18, presumably until 2014-05-18\n- ketorolac tromethamine 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-05-20, presumably until 2014-06-13, with intended 0 refill(s). Instructions: instill 1 Drop to right eye 4 times a day.\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2014-05-18, presumably until 2014-05-18\n- 24 HR isosorbide mononitrate 120 MG Extended Release Oral Tablet, through Oral route, presumably until 2014-05-23. Instructions: take 120 mg by mouth Every Day.\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2014-05-18, presumably until 2014-05-22\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, started on 2014-05-18, presumably until 2014-05-18\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2014-05-19, presumably until 2015-05-23, with intended 11 refill(s). Instructions: take 1 Tab by mouth every morning with breakfast.\n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2014-05-23, presumably until 2015-06-22, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily.\n- 1 ML morphine sulfate 4 MG/ML Prefilled Syringe, through Intravenous route, started on 2014-05-18, presumably until 2014-05-19\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2014-05-22, presumably until 2014-05-22\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2014-05-20, presumably until 2014-05-22\n- clarithromycin 500 MG Oral Tablet, through Oral route, started on 2014-05-23, presumably until 2014-05-23, with intended 0 refill(s). Instructions: take 1 Tab by mouth Q12H.\n- tetracycline hydrochloride 250 MG Oral Capsule, through Oral route, started on 2014-05-23, presumably until 2014-05-23, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day.\n- losartan potassium 25 MG Oral Tablet, through Oral route, started on 2014-05-23, presumably until 2014-09-01, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-05-27 00:00:00, ended at 2014-05-27 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic ischemic heart disease\n- Helicobacter-associated disease\n- Acute on chronic combined systolic and diastolic heart failure\n- Diabetes mellitus without complication\n- Diabetic - poor control\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-13 11:45:00, ended at 2014-06-13 23:59:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 249 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 11.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Congestive heart failure\n- Type 2 diabetes mellitus without complication\n- Chronic combined systolic and diastolic heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-07-18 00:00:00, ended at 2014-07-18 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of nervous system due to diabetes mellitus\n- Polyneuropathy due to diabetes mellitus\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, started on 2014-07-18, presumably until 2014-11-23, with intended 2 refill(s). Instructions: take 1 Cap by mouth daily. appt needed for additional refills\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-09-01 10:15:49, ended at 2014-09-01 11:57:22\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Revision of automatic implantable cardioverter/defibrillator\n- Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care \n\n### Condition\n- Primary diagnosis: Cardiomyopathy associated with another disorder\n\n### Drug\n- losartan potassium 25 MG Oral Tablet, through Oral route, started on 2014-09-01, presumably until 2015-09-01, with intended 3 refill(s). Instructions: take 1 tablet by mouth every bedtime.\n- carvedilol 6.25 MG Oral Tablet, through Oral route, started on 2014-09-01, presumably until 2015-06-10, with intended 3 refill(s). Instructions: take 1 tablet by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-01 12:05:00, ended at 2014-09-01 23:59:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 281 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 13.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Cardiomyopathy associated with another disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-11-06 00:00:00, ended at 2014-11-06 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diabetes mellitus without complication\n- Primary diagnosis: Diabetic - poor control\n\n### Drug\n- 3 ML insulin lispro 25 UNT/ML / insulin lispro protamine, human 75 UNT/ML Pen Injector, started on 2014-11-11, presumably until 2016-03-10, with intended 2 refill(s). Instructions: Inject SQ 3 times per day 10 minutes before each meal, Before breakfast: take 10 units, Before Lunch: 15 units, Before dinner: take 20 units\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-11-23 00:00:00, ended at 2014-11-23 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, started on 2014-11-23, presumably until 2014-12-15, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-11-24 00:00:00, ended at 2014-11-24 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, started on 2014-11-24, presumably until 2014-11-24, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-12-15 00:00:00, ended at 2014-12-15 00:00:00\nThe patient in this visit was 51 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, started on 2014-12-15, presumably until 2015-04-20, with intended 1 refill(s). Instructions: take 1 Cap by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-04-20 00:00:00, ended at 2015-04-20 00:00:00\nThe patient in this visit was 52 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Mononeuritis\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, started on 2015-04-21, presumably until 2015-09-15, with intended 3 refill(s). Instructions: TAKE ONE CAPSULE BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-06-09 00:00:00, ended at 2015-06-09 00:00:00\nThe patient in this visit was 52 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR isosorbide mononitrate 60 MG Extended Release Oral Tablet, started on 2015-06-12, presumably until 2018-07-19, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY NIGHT AT BEDTIME\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-06-10 09:43:13, ended at 2015-06-10 14:27:42\nThe patient in this visit was 52 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care \n- Revision of automatic implantable cardioverter/defibrillator\n\n### Condition\n- Chronic ischemic heart disease\n- Primary diagnosis: Congestive heart failure\n- Flatulence, eructation and gas pain\n- Primary diagnosis: Chronic combined systolic and diastolic heart failure\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, presumably until 2015-06-10, with intended 0 refill(s). Instructions: take 40 mg by mouth Evening\n- aspirin 325 MG Oral Tablet, through Oral route, presumably until 2018-07-19, with intended 0 refill(s). Instructions: take 325 mg by mouth Evening\n- furosemide 40 MG Oral Tablet, through Oral route, started on 2015-06-10, presumably until 2016-06-16, with intended 6 refill(s). Instructions: take 1 Tab by mouth daily\n- atorvastatin 80 MG Oral Tablet, through Oral route, presumably until 2018-07-19, with intended 0 refill(s). Instructions: take 80 mg by mouth Evening\n- carvedilol 6.25 MG Oral Tablet, through Oral route, started on 2015-06-10, presumably until 2016-03-25, with intended 6 refill(s). Instructions: take 2 Tabs by mouth 2 times a day\n- 24 HR isosorbide mononitrate 60 MG Extended Release Oral Tablet, through Oral route, started on 2015-06-10, presumably until 2015-06-12, with intended 6 refill(s). Instructions: take 1 Tab by mouth every morning\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, started on 2012-08-19, presumably until 2016-10-28, with intended 0 refill(s). Instructions: place 0.4 mg under the tongue and let dissolve\n- clopidogrel 75 MG Oral Tablet, through Oral route, presumably until 2015-06-22, with intended 0 refill(s). Instructions: take by mouth Evening\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-06-18 11:16:53, ended at 2015-06-18 12:18:27\nThe patient in this visit was 52 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus without complication\n\n### Drug\n- 3 ML liraglutide 6 MG/ML Pen Injector, through Subcutaneous route, started on 2015-06-18, presumably until 2016-03-25, with intended 6 refill(s). Instructions: inject 1.2 mg subcutaneous (under the skin) daily with lunch\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-06-18 12:30:00, ended at 2015-06-18 23:59:00\nThe patient in this visit was 52 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 32 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 15.0 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 130 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 152 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 438 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 92 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-06-22 00:00:00, ended at 2015-06-22 00:00:00\nThe patient in this visit was 52 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- clopidogrel 75 MG Oral Tablet, started on 2015-06-22, presumably until 2016-07-12, with intended 11 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-09-02 00:00:00, ended at 2015-09-02 00:00:00\nThe patient in this visit was 52 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- losartan potassium 25 MG Oral Tablet, started on 2015-09-04, presumably until 2016-09-11, with intended 11 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-09-15 00:00:00, ended at 2015-09-15 00:00:00\nThe patient in this visit was 52 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diabetes mellitus without complication\n- Primary diagnosis: Diabetic - poor control\n- Peripheral nerve disease\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, started on 2015-09-24, presumably until 2016-05-23, with intended 5 refill(s). Instructions: TAKE ONE CAPSULE BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-01-28 00:00:00, ended at 2016-01-28 00:00:00\nThe patient in this visit was 52 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- famotidine 20 MG Oral Tablet, started on 2016-01-29, presumably until 2016-01-29, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n- 12 HR ranolazine 500 MG Extended Release Oral Tablet, started on 2016-01-29, presumably until 2016-01-29, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY 12 HOURS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-02-02 00:00:00, ended at 2016-02-02 00:00:00\nThe patient in this visit was 52 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-02-16 10:27:52, ended at 2016-02-16 12:43:21\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congestive heart failure\n- Type 2 diabetes mellitus\n- Primary diagnosis: Chronic combined systolic and diastolic heart failure\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-02-16 12:49:00, ended at 2016-02-16 23:59:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 130 (unit per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 284 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 6.0 (ratio)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 237 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 12.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Albumin [Mass/volume] in Urine: 3480 (milligram per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 181 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 114.00 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Microalbumin/Creatinine [Mass Ratio] in Urine: >3000 (milligram per gram)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 47 (milligram per deciliter)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 3.9 (ratio)\n- Glucose [Mass/volume] in Serum or Plasma: 236 (milligram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.12 (micro-international unit per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 281 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Chronic combined systolic and diastolic heart failure\n- Congestive heart failure\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-02-23 00:00:00, ended at 2016-02-23 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperglycemia due to type 2 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n\n### Drug\n- 0.65 ML exenatide 3.08 MG/ML Pen Injector, started on 2016-02-23, presumably until 2016-06-15, with intended 11 refill(s). Instructions: Inject contents of syringe SQ once a week\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-03-10 00:00:00, ended at 2016-03-10 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- 3 ML insulin lispro 25 UNT/ML / insulin lispro protamine, human 75 UNT/ML Pen Injector, started on 2016-03-11, presumably until 2017-03-11, with intended 11 refill(s). Instructions: INJECT SUBCUTANEOUSLY 15 UNITS BEFORE BREAKFAST AND 30 UNITS BEFORE DINNER. INJECT 10 MINUTES BEFORE EACH MEAL\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-03-11 00:00:00, ended at 2016-03-11 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-03-25 00:00:00, ended at 2016-03-25 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic combined systolic and diastolic heart failure\n- Hyperglycemia due to type 2 diabetes mellitus\n- Congestive heart failure\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-25 09:38:00, ended at 2016-03-25 13:08:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 28.1 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Type 2 diabetes mellitus\n- Chronic ischemic heart disease\n- Hyperglycemia due to type 2 diabetes mellitus\n- Chronic combined systolic and diastolic heart failure\n- Congestive heart failure\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-03-25 11:54:13, ended at 2016-03-25 13:05:42\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperglycemia due to type 2 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n\n### Drug\n- 3 ML liraglutide 6 MG/ML Pen Injector, through Subcutaneous route, started on 2016-03-28, presumably until 2017-08-23, with intended 11 refill(s). Instructions: inject 0.6 mg subcutaneous (under the skin) Every Day Failed Bydureon\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-25 13:09:00, ended at 2016-03-25 13:09:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-25 13:10:00, ended at 2016-03-25 23:59:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 5.1 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 57 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 65 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Anabasine [Mass/volume] in Urine: <2.0 (nanogram per milliliter)\n- Prealbumin [Mass/volume] in Serum or Plasma: 29 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.5 (gram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Nornicotine [Mass/volume] in Urine: <2.0 (nanogram per milliliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.48 (micro-international unit per milliliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Cotinine [Mass/volume] in Urine: <5.0 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 42 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 205 (unit per liter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 8.6 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma: 1619 (picogram per milliliter)\n- Nicotine [Mass/volume] in Urine: <2.0 (nanogram per milliliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic combined systolic and diastolic heart failure\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-05-23 00:00:00, ended at 2016-05-23 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neuralgia\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, started on 2016-05-23, presumably until 2016-07-26, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-31 08:21:00, ended at 2016-05-31 10:37:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n- Solitary nodule of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-31 09:04:07, ended at 2016-05-31 16:25:59\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care \n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-31 10:38:00, ended at 2016-05-31 23:59:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-06-15 00:00:00, ended at 2016-06-15 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperglycemia due to type 2 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-15 09:39:45, ended at 2016-06-15 14:39:47\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- 3 ML insulin lispro 25 UNT/ML / insulin lispro protamine, human 75 UNT/ML Pen Injector, started on 2016-06-15, presumably until 2016-06-15, with intended 11 refill(s). Instructions: INJECT SUBCUTANEOUSLY 15 UNITS BEFORE BREAKFAST AND 30 UNITS BEFORE DINNER. INJECT 10 MINUTES BEFORE EACH MEAL\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-15 10:21:51, ended at 2016-06-15 12:10:36\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care \n\n### Condition\n- Type 2 diabetes mellitus\n- Chronic ischemic heart disease\n- Primary diagnosis: Heart failure\n- Complication due to diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-06-15 12:33:00, ended at 2016-06-15 23:59:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 45 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.34 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 63 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 6.1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Complication due to diabetes mellitus\n- Chronic ischemic heart disease\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-06-16 00:00:00, ended at 2016-06-16 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic combined systolic and diastolic heart failure\n- Congestive heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- furosemide 40 MG Oral Tablet, started on 2016-06-17, presumably until 2016-07-06, with intended 4 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-07-06 00:00:00, ended at 2016-07-06 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Congestive heart failure\n- Chronic combined systolic and diastolic heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- furosemide 40 MG Oral Tablet, through Oral route, started on 2016-07-06, presumably until 2017-07-23, with intended 4 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-07-12 00:00:00, ended at 2016-07-12 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- clopidogrel 75 MG Oral Tablet, started on 2016-07-13, presumably until 2016-08-11, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-07-26 00:00:00, ended at 2016-07-26 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n- Neuralgia\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, started on 2016-07-27, presumably until 2016-08-23, with intended 11 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-08-11 00:00:00, ended at 2016-08-11 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- clopidogrel 75 MG Oral Tablet, started on 2016-08-11, presumably until 2017-08-10, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-08-23 00:00:00, ended at 2016-08-23 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Disorder of endocrine system\n- Polyneuropathy associated with another disorder\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n- duloxetine 30 MG Delayed Release Oral Capsule, started on 2016-08-24, presumably until 2017-09-26, with intended 3 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-23 00:00:00, ended at 2016-08-23 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of endocrine system\n- Polyneuropathy associated with another disorder\n- Primary diagnosis: Hyperglycemia due to type 2 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n\n### Drug\n- duloxetine 30 MG Delayed Release Oral Capsule, through Oral route, started on 2016-08-23, presumably until 2016-08-23, with intended 3 refill(s). Instructions: take 1 Cap by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-09-11 00:00:00, ended at 2016-09-11 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- losartan potassium 25 MG Oral Tablet, started on 2016-09-13, presumably until 2017-06-13, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-28 09:45:50, ended at 2016-10-28 11:48:28\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care \n\n### Condition\n- Chronic ischemic heart disease\n- Diabetes mellitus\n- Heart failure\n- Complication due to diabetes mellitus\n\n### Drug\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, started on 2016-10-28, presumably until 2018-07-19, with intended 6 refill(s). Instructions: place 1 Tab under the tongue and let dissolve as needed for Chest pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-28 12:00:00, ended at 2016-10-28 23:59:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Monocytes/100 leukocytes in Blood by Automated count: 7.8 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.4 (percent)\n- Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma: 1027 (picogram per milliliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.57 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 249 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 26 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.22 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.0 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.7 (percent)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 6.8 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.5 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.12 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.2 (percent)\n- MCV [Entitic volume] by Automated count: 81.5 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.37 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.39 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 85 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 26.9 (picogram)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.3 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.86 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic ischemic heart disease\n- Diabetes mellitus\n- Complication due to diabetes mellitus\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-11-14 09:19:16, ended at 2016-11-14 10:03:25\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Heart failure\n- Chronic ischemic heart disease\n- Cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-11-14 10:12:00, ended at 2016-11-14 23:59:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.43 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 42 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma: 853 (picogram per milliliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 121 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-11-14 10:35:21, ended at 2016-11-14 13:17:37\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperglycemia due to type 2 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Chronic kidney disease due to type 2 diabetes mellitus\n\n### Drug\n- empagliflozin 10 MG Oral Tablet, through Oral route, started on 2016-11-14, presumably until 2017-06-11, with intended 6 refill(s). Instructions: take 1 Tab by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-12-19 00:00:00, ended at 2016-12-19 00:00:00\nThe patient in this visit was 53 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Polyneuropathy associated with another disorder\n- Disorder of endocrine system\n- Type 2 diabetes mellitus\n\n### Drug\n- duloxetine 30 MG Delayed Release Oral Capsule, started on 2016-12-20, presumably until 2016-12-20, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-20 00:00:00, ended at 2017-02-20 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Creatinine [Mass/volume] in Urine: 55.60 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.01 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 25.8 (picogram)\n- Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma: 731 (picogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.41 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.6 (percent)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 17.6 (percent)\n- MCV [Entitic volume] by Automated count: 81.7 (femtoliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.89 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 31.6 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.4 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 252 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Albumin [Mass/volume] in Urine: 32 (milligram per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.26 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.6 (gram per deciliter)\n- Microalbumin/Creatinine [Mass Ratio] in Urine: 58 (milligram per gram)\n- Neutrophils [#/volume] in Blood by Automated count: 8.20 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 71.7 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.3 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 80 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 7.6 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.87 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Heart failure\n- Complication due to diabetes mellitus\n- Type 2 diabetes mellitus\n- Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-02-20 11:16:07, ended at 2017-02-20 13:53:56\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care \n\n### Condition\n- Primary diagnosis: Heart failure\n- Type 2 diabetes mellitus\n- Chronic ischemic heart disease\n- Complication due to diabetes mellitus\n\n### Drug\n- amoxicillin 500 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2017-02-16, presumably until 2017-02-23, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-02-20 13:55:00, ended at 2017-02-20 23:59:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic ischemic heart disease\n- Complication due to diabetes mellitus\n- Heart failure\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-10 10:12:00, ended at 2017-03-10 12:59:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, retroperitoneal (eg, renal, aorta, nodes), real time with image documentation; complete\n\n### Condition\n- Type 2 diabetes mellitus\n- Chronic ischemic heart disease\n- Heart failure\n- Complication due to diabetes mellitus\n- Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-10 11:21:26, ended at 2017-03-10 13:19:48\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic ischemic heart disease\n- Complication due to diabetes mellitus\n- Type 2 diabetes mellitus\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-10 13:00:00, ended at 2017-03-10 23:59:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.28 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 157 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 8.0 (percent)\n- Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma: 1332 (picogram per milliliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 5.1 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 26 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 193 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.7 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Heart failure\n- Chronic ischemic heart disease\n- Complication due to diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-03-11 00:00:00, ended at 2017-03-11 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n- 3 ML insulin lispro 25 UNT/ML / insulin lispro protamine, human 75 UNT/ML Pen Injector, started on 2017-03-14, presumably until 2017-08-23, with intended 11 refill(s). Instructions: Humalog 75/25 insulin mix  Before breakfast: take 15  Before lunch: 25 unit     Before dinner: take 30 units      \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-28 13:12:00, ended at 2017-03-28 17:44:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n- Glucose [Mass/volume] in Blood: 95 (milligram per deciliter)\n- Left ventricular Ejection fraction: 28.0 (percent)\n- Sodium [Moles/volume] in Blood: 142 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 14.3 (gram per deciliter)\n- Potassium [Moles/volume] in Blood: 3.4 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood: 42 (percent)\n- INR in Blood by Coagulation assay: 1.0 (ratio)\n\n### Procedure\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Collection of blood specimen from a completely implantable venous access device\n- Insertion of Monitoring Device into Right Ventricle, Percutaneous Approach\n- Measurement of Cardiac Sampling and Pressure, Right Heart, Percutaneous Approach\n- Right heart catheterization including measurement(s) of oxygen saturation and cardiac output, when performed\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Monitoring of Cardiac Output, Percutaneous Approach\n- Collection of venous blood by venipuncture\n\n### Condition\n- Type 2 diabetes mellitus\n- Generalized ischemic myocardial dysfunction\n- Essential hypertension\n- Type 2 diabetes mellitus without complication\n- Heart failure\n- Chronic ischemic heart disease\n- Complication due to diabetes mellitus\n- Hypertensive heart failure\n- Cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-04-28 00:00:00, ended at 2017-04-28 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Complication due to diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-05-19 09:20:25, ended at 2017-05-19 10:27:05\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care \n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2017-04-14, presumably until 2017-11-10, with intended 0 refill(s). Instructions: take 10 mg by mouth daily\n- methotrexate 2.5 MG Oral Tablet, through Oral route, started on 2017-04-14, presumably until 2018-07-19, with intended 0 refill(s). Instructions: take 15 mg by mouth every 7 days \n- folic acid 1 MG Oral Tablet, through Oral route, started on 2017-04-18, presumably until 2018-07-19, with intended 0 refill(s). Instructions: take 1 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-06-11 00:00:00, ended at 2017-06-11 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- empagliflozin 10 MG Oral Tablet, started on 2017-06-13, presumably until 2018-07-19, with intended 11 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-06-13 00:00:00, ended at 2017-06-13 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- losartan potassium 25 MG Oral Tablet, started on 2017-06-13, presumably until 2017-09-18, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-06-16 00:00:00, ended at 2017-06-16 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-06-18 00:00:00, ended at 2017-06-18 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Chronic ischemic heart disease\n- Complication due to diabetes mellitus\n\n### Drug\n- carvedilol 12.5 MG Oral Tablet, started on 2017-06-18, presumably until 2017-08-23, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-26 09:50:15, ended at 2017-06-26 10:30:17\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic ischemic heart disease\n- Primary diagnosis: Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-26 10:39:00, ended at 2017-06-26 23:59:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin A1c/Hemoglobin.total in Blood: 9.8 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.9 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 32 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 143 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.61 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 275 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.1 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n- Complication due to diabetes mellitus\n- Type 2 diabetes mellitus\n- Heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-07-12 00:00:00, ended at 2017-07-12 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-07-12 00:00:00, ended at 2017-07-12 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n- 3 ML liraglutide 6 MG/ML Pen Injector, started on 2017-07-13, presumably until 2018-05-31, with intended 11 refill(s). Instructions: INJECT 1.2 MG SUBCUTANEOUS EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-07-17 00:00:00, ended at 2017-07-17 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary diabetes mellitus\n- Severe hyperglycemia due to diabetes mellitus\n- Complication due to diabetes mellitus\n- Kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-07-23 00:00:00, ended at 2017-07-23 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Congestive heart failure\n- Chronic combined systolic and diastolic heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- furosemide 40 MG Oral Tablet, started on 2017-07-23, presumably until 2017-10-04, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-08-10 00:00:00, ended at 2017-08-10 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- clopidogrel 75 MG Oral Tablet, started on 2017-08-10, presumably until 2018-06-01, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-08-23 00:00:00, ended at 2017-08-23 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-08-23 00:00:00, ended at 2017-08-23 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Complication due to diabetes mellitus\n- Chronic ischemic heart disease\n- Type 2 diabetes mellitus\n\n### Drug\n- carvedilol 25 MG Oral Tablet, started on 2017-08-23, presumably until 2018-07-19, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-23 09:57:58, ended at 2017-08-23 12:23:51\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.567\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- 3 ML insulin lispro 25 UNT/ML / insulin lispro protamine, human 75 UNT/ML Pen Injector, started on 2017-08-23, presumably until 2018-07-19, with intended 11 refill(s). Instructions: Humalog 75/25 insulin mix Before breakfast: take 18 Before lunch: 26 units  Before dinner: take 26 units\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-23 11:13:50, ended at 2017-08-23 13:17:06\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.5\" (inch (US))\n\n### Procedure\n- Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care \n\n### Condition\n- Chronic ischemic heart disease\n- Complication due to diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- carvedilol 25 MG Oral Tablet, through Oral route, started on 2017-08-23, presumably until 2017-08-23, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-08 00:00:00, ended at 2017-09-08 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-09-12 00:00:00, ended at 2017-09-12 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-09-18 00:00:00, ended at 2017-09-18 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sacubitril 24 MG / valsartan 26 MG Oral Tablet, through Oral route, started on 2017-09-18, presumably until 2018-06-01, with intended 0 refill(s). Instructions: take 24-26 mg by mouth 2 times a day \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-09-23 00:00:00, ended at 2017-09-23 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n- Neuralgia\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, started on 2017-09-26, presumably until 2018-05-04, with intended 6 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-04 13:06:00, ended at 2017-10-04 13:06:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-04 13:07:00, ended at 2017-10-04 23:59:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 146 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.8 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 243 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.2 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 27.5 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 8.6 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.61 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.31 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.7 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 168 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.80 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.20 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22.5 (percent)\n- Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma: 500 (picogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 42 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Globulin [Mass/volume] in Serum: 5.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.8 (percent)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 7.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.49 (micro-international unit per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 83.0 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.56 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Type 2 diabetes mellitus\n- Chronic combined systolic and diastolic heart failure\n- Heart failure\n- Chronic ischemic heart disease\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Congestive heart failure\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-10-23 00:00:00, ended at 2017-10-23 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Congestive heart failure\n- Chronic combined systolic and diastolic heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- furosemide 40 MG Oral Tablet, through Oral route, started on 2017-10-23, presumably until 2017-10-25, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day Take 80mg in the morning, 40mg in the evening\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-10 10:13:57, ended at 2017-11-10 11:24:08\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care \n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-12-13 00:00:00, ended at 2017-12-13 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2017-12-13, presumably until 2017-12-13, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-01-16 00:00:00, ended at 2018-01-16 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2018-01-17, presumably until 2018-01-17, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-17 08:03:00, ended at 2018-01-17 09:18:03\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care \n\n### Condition\n- Complication due to diabetes mellitus\n- Type 2 diabetes mellitus\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-17 09:21:00, ended at 2018-01-17 09:21:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 9.0 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 5.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 146 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 7.3 (percent)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 85.2 (femtoliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.8 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 159 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.30 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.0 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 257 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.74 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.53 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.74 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.4 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.7 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.1 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.12 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 49 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.6 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Secondary diabetes mellitus\n- Complication due to diabetes mellitus\n- Severe hyperglycemia due to diabetes mellitus\n- Kidney disease\n- Type 2 diabetes mellitus\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-17 09:22:00, ended at 2018-01-17 23:59:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Complication due to diabetes mellitus\n- Heart failure\n- Secondary diabetes mellitus\n- Severe hyperglycemia due to diabetes mellitus\n- Type 2 diabetes mellitus\n- Kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-02-07 00:00:00, ended at 2018-02-07 00:00:00\nThe patient in this visit was 54 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2018-02-08, presumably until 2018-02-08, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-03-14 11:26:56, ended at 2018-03-14 13:55:49\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 30 (calculated)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Body height: 5' 4\" (inch (US))\n- Creatinine [Mass/volume] in Serum or Plasma: 1.88 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 206 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 57 (milligram per deciliter)\n\n### Procedure\n- Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter; single, dual, or multiple lead transvenous imp\n\n### Condition\n- Type 2 diabetes mellitus\n- Chronic ischemic heart disease\n- Complication due to diabetes mellitus\n- Primary diagnosis: Heart failure\n\n### Drug\n- digoxin 0.125 MG Oral Tablet, through Oral route, started on 2018-03-14, presumably until 2018-06-01, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-14 14:02:00, ended at 2018-03-14 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma: 567 (picogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 7.9 (percent)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 40 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.66 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Complication due to diabetes mellitus\n- Type 2 diabetes mellitus\n- Heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-03-22 00:00:00, ended at 2018-03-22 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 185 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.58 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 41 (milligram per deciliter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 26 (calculated)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-28 13:52:00, ended at 2018-03-28 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 41 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 110 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.52 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Type 2 diabetes mellitus\n- Heart failure\n- Complication due to diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-06 00:00:00, ended at 2018-04-06 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 122 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.56 (milligram per deciliter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 26 (calculated)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 41 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-13 00:00:00, ended at 2018-04-13 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 26 (calculated)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.49 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 146 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-20 00:00:00, ended at 2018-04-20 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 23 (calculated)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.67 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 122 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-27 00:00:00, ended at 2018-04-27 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 102 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 34 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.53 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 22 (calculated)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-05-04 00:00:00, ended at 2018-05-04 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 18 (calculated)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.58 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 253 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-04 00:00:00, ended at 2018-05-04 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neuralgia\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, started on 2018-05-08, presumably until 2018-07-19, with intended 6 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-05-11 00:00:00, ended at 2018-05-11 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 153 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.55 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 15 (calculated)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-23 00:00:00, ended at 2018-05-23 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic combined systolic and diastolic heart failure\n- Congestive heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- spironolactone 25 MG Oral Tablet, started on 2018-05-23, presumably until 2018-07-19, with intended 6 refill(s). Instructions: TAKE 1/2 TABLET BY MOUTH DAILY\n- furosemide 80 MG Oral Tablet, started on 2018-05-23, presumably until 2018-06-01, with intended 6 refill(s). Instructions: TAKE 1 TABLET BY MOUTH IN THE MORNING AND IN THE AFTERNOON\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-23 09:48:00, ended at 2018-05-23 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 188 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 29 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.52 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic combined systolic and diastolic heart failure\n- Chronic ischemic heart disease\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-05-28 00:00:00, ended at 2018-05-28 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.78 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 34 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 19 (calculated)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 373 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic ischemic heart disease\n- Chronic combined systolic and diastolic heart failure\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-31 00:00:00, ended at 2018-05-31 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- 3 ML liraglutide 6 MG/ML Pen Injector, started on 2018-06-05, presumably until 2018-07-19, with intended 11 refill(s). Instructions: INJECT 1.2 MG SUBCUTANEOUS EVERY DAY  90 day supply if insurance allows\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-06-01 00:00:00, ended at 2018-06-01 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Congestive heart failure\n- Chronic ischemic heart disease\n- Chronic combined systolic and diastolic heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-06-01 00:00:00, ended at 2018-06-01 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic combined systolic and diastolic heart failure\n- Chronic ischemic heart disease\n- Congestive heart failure\n- Primary diagnosis: Heart failure\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2018-06-01, presumably until 2018-07-19, with intended 3 refill(s). Instructions: take 1 Tab by mouth 3 times a day\n- digoxin 0.125 MG Oral Tablet, through Oral route, started on 2018-06-01, presumably until 2018-07-19, with intended 11 refill(s). Instructions: take 0.5 Tabs by mouth daily\n- furosemide 80 MG Oral Tablet, started on 2018-06-01, presumably until 2018-07-19, with intended 6 refill(s). Instructions: Take 80 mg (one tablet) in the morning and 40 mg (half of a tablet) in the afternoon.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-06-04 00:00:00, ended at 2018-06-04 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic combined systolic and diastolic heart failure\n- Congestive heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-06-06 00:00:00, ended at 2018-06-06 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for heart transplant or heart/lung transplant\n- Insertion of non-tunneled centrally inserted central venous catheter; age 5 years or older\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging)\n- Insertion and placement of flow directed catheter (eg, Swan-Ganz) for monitoring purposes\n- Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n\n### Condition\n- Heart failure\n- Atrial fibrillation\n- Cardiomyopathy\n- Essential hypertension\n- Transplanted heart present\n\n### Drug\n- 10 ML calcium chloride 100 MG/ML Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-07\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-06\n- 10 ML epinephrine 0.1 MG/ML Prefilled Syringe, through Intravenous route, started on 2018-06-06, presumably until 2018-06-07\n- 5 ML protamine sulfate (USP) 10 MG/ML Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-07\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2018-06-06, presumably until 2018-06-07\n- 2 ML magnesium sulfate 500 MG/ML Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-06\n- 250 ML norepinephrine 0.016 MG/ML Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-06\n- 10 ML furosemide 10 MG/ML Injection, started on 2018-06-06, presumably until 2018-06-07\n- 50 ML clevidipine 0.5 MG/ML Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-07\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2018-06-06, presumably until 2018-06-06\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2018-06-06, presumably until 2018-06-06\n- vasopressin (USP) 20 UNT/ML Injectable Solution, through Intravenous route, started on 2018-06-07, presumably until 2018-06-07\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2018-06-06, presumably until 2018-06-06\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-07\n- ketamine 100 MG/ML Injectable Solution, started on 2018-06-06, presumably until 2018-06-06\n- 10 ML tranexamic acid 100 MG/ML Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-06\n- 2 ML dexmedetomidine 0.1 MG/ML Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-06\n- midazolam 1 MG/ML Injectable Solution, started on 2018-06-06, presumably until 2018-06-06\n- 1 ML sufentanil 0.05 MG/ML Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-06-06 15:50:00, ended at 2018-07-19 16:03:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Base excess in Blood by calculation: 7 (millimole per liter)\n- C peptide [Mass/volume] in Serum or Plasma: 0.2 (nanogram per milliliter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 45.5 (millimeter mercury column)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 24.8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 9.5 (gram per deciliter)\n- Lactate [Moles/volume] in Blood: >15.0 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.6 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 94.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 6.7 (millimole per liter)\n- Sodium [Moles/volume] in Blood: 142 (millimole per liter)\n- Body height: 5' 5\" (inch (US))\n- Eosinophils [#/volume] in Blood by Manual count: 0.27 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.82 (million per microliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 259 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.8 (percent)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 5 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.20 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Phosphate [Mass/volume] in Serum or Plasma: 6.5 (milligram per deciliter)\n- Prothrombin time (PT): 26.1 (second)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.70 (micro-international unit per milliliter)\n- Ammonia [Mass/volume] in Plasma: 42 (micromole per liter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 3.8 (milligram per deciliter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.44 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Creatinine renal clearance in 24 hour Urine and Serum or Plasma: 21 (milliliter per minute)\n- Left ventricular Ejection fraction: 57.7 (percent)\n- Leukocytes [#/volume] in Body fluid by Manual count: 8 (milli-international unit per milliliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 88 (percent)\n- Platelets [#/volume] in Blood by Automated count: 97 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.6 (gram per deciliter)\n- Urate [Mass/volume] in Serum or Plasma: <2.0 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: >150 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Bicarbonate [Moles/volume] in Specimen: 30.4 (millimole per liter)\n- Calcium.ionized [Moles/volume] in Mixed venous blood: 0.64 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.49 (thousand per microliter)\n- Hydroxyitraconazole [Mass/volume] in Serum or Plasma: <0.1 (microgram per milliliter)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 2.00 (thousand per microliter)\n- Myoglobin [Mass/volume] in Urine: 143 (microgram per liter)\n- Procalcitonin [Mass/volume] in Serum or Plasma: 8.53 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 97 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 3.31 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood: 28 (percent)\n- Heparin unfractionated [Units/volume] in Platelet poor plasma: <0.10 (unit per milliliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 6 - 10 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.1 (thousand per microliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 395 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Manual count: 2.30 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 99.3 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 4.2 (milligram per deciliter)\n- Potassium [Moles/volume] in Blood: 4.8 (millimole per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 310 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: >3500 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Base excess in Arterial blood by calculation: 4.3 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.22 (thousand per microliter)\n- Body weight Stated: 92.0 (kilogram)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 284 (unit per liter)\n- Glucose [Mass/volume] in Blood: >500 (milligram per deciliter)\n- Itraconazole [Mass/volume] in Serum or Plasma: <0.1 (microgram per milliliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 804 (unit per liter)\n- Monocytes [#/volume] in Blood by Manual count: 2.71 (thousand per microliter)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 97 (millimeter mercury column)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Tacrolimus [Mass/volume] in Blood: 9.9 (nanogram per milliliter)\n- Aldolase [Enzymatic activity/volume] in Serum or Plasma: 13.5 (unit per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 1.60 (milligram per deciliter)\n- Body height Stated: 165 (centimeter)\n- Calcium.ionized [Moles/volume] in Blood: 1.08 (millimole per liter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 45.6 (millimeter mercury column)\n- Ferritin [Mass/volume] in Serum or Plasma: 250.1 (nanogram per milliliter)\n- Globulin [Mass/volume] in Serum: 5.2 (gram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 7.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.90 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 150 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 68.8 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 80 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 51 - 100 (per high power field)\n- Iron [Mass/volume] in Serum or Plasma: 28 (microgram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.4 (percent)\n- Oxygen [Partial pressure] in Arterial blood: 93.5 (millimeter mercury column)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 15.5 (microgram per milliliter)\n- Lidocaine [Mass/volume] in Serum or Plasma: <0.5 (microgram per milliliter)\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Evaluation of oral and pharyngeal swallowing function\n- Measurement of Cardiac Sampling and Pressure, Right Heart, Percutaneous Approach\n- Introduction of Other Therapeutic Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Medical decision making that is straightforward or o\n- Hemodialysis procedure with single evaluation by a physician or other qualified health care professional\n- Critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes (List separately in addition to code for primary service)\n- Controlled ventilation procedure and therapy, initiation and management\n- Continuous inhalation treatment with aerosol medication for acute airway obstruction; each additional hour (List separately in addition to code for primary procedure)\n- Respiratory Ventilation, Greater than 96 Consecutive Hours\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Right heart catheterization including measurement(s) of oxygen saturation and cardiac output, when performed\n- Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies) requiring repeated evaluations by a physician or other qualified health care professional, with or without substantial re\n- Occupational therapy evaluation, high complexity, requiring these components: An occupational profile and medical and therapy history, which includes review of medical and/or therapy records and extensive additional review of physical, cognitive, or psych\n- Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording \n- Excision of Right Ventricle, Percutaneous Approach, Diagnostic\n- Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, without imaging guidance; age 5 years or older\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Transplantation of Heart, Allogeneic, Open Approach\n- Fluoroscopic guidance for central venous access device placement, replacement (catheter only or complete), or removal (includes fluoroscopic guidance for vascular access and catheter manipulation, any necessary contrast injections through access site or c\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Treatment of swallowing dysfunction and/or oral function for feeding\n- Radiologic examination, chest; single view\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Duplex scan of lower extremity arteries or arterial bypass grafts; unilateral or limited study\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of \n- Insertion of non-tunneled centrally inserted central venous catheter; age 5 years or older\n- Physical therapy evaluation: moderate complexity, requiring these components: A history of present problem with 1-2 personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures in\n- Collection of venous blood by venipuncture\n- Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right heart catheterization\n- Performance of Cardiac Output, Continuous\n- Endomyocardial biopsy\n- Insertion of Infusion Device into Right Atrium, Percutaneous Approach\n- Computed tomography, thorax, diagnostic; without contrast material\n- Flexible endoscopic evaluation of swallowing by cine or video recording\n- Removal of Cardiac Lead from Heart, Open Approach\n- Insertion of Infusion Device into Right Internal Jugular Vein, Percutaneous Approach\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Fluoroscopy of Multiple Coronary Arteries using Low Osmolar Contrast\n- Performance of Urinary Filtration, Intermittent, Less than 6 Hours Per Day\n- Insertion of tunneled centrally inserted central venous catheter, without subcutaneous port or pump; age 5 years or older\n- Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies), with single evaluation by a physician or other qualified health care professional\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Insertion of Infusion Device into Superior Vena Cava, Percutaneous Approach\n- Insertion of Tunneled Vascular Access Device into Chest Subcutaneous Tissue and Fascia, Percutaneous Approach\n- Computed tomography, head or brain; without contrast material\n- Insertion and placement of flow directed catheter (eg, Swan-Ganz) for monitoring purposes\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Performance of Urinary Filtration, Continuous, Greater than 18 hours Per Day\n- Continuous inhalation treatment with aerosol medication for acute airway obstruction; first hour\n- Introduction of Vasopressor into Peripheral Vein, Percutaneous Approach\n- Duplex scan of lower extremity arteries or arterial bypass grafts; complete bilateral study\n- Insertion of Monitoring Device into Right Pulmonary Artery, Percutaneous Approach\n\n### Condition\n- Acute on chronic hypercapnic respiratory failure\n- Aortocoronary bypass graft present\n- Disorders of both mitral and tricuspid valves\n- Infection due to Escherichia coli\n- Iron deficiency anemia\n- Long QT syndrome\n- Pain at rest of left lower limb co-occurrent and due to atherosclerosis\n- Pleural effusion\n- Pulmonary hypertension\n- Aberrant premature complexes\n- Acute posthemorrhagic anemia\n- Atrial fibrillation\n- Conduction disorder of the heart\n- Diabetes mellitus without complication\n- Disorder of cardiovascular system\n- Disorder of transplanted heart\n- Hepatic failure\n- Hyperkalemia\n- Intermittent claudication of bilateral lower limbs co-occurrent and due to atherosclerosis\n- Supraventricular tachycardia\n- Ventricular tachycardia\n- Acute hypoxemic respiratory failure\n- Anemia in chronic kidney disease\n- Atherosclerosis of artery of lower limb\n- Cardiogenic shock\n- Cardiomegaly\n- Cardiomyopathy\n- Chronic total occlusion of coronary artery\n- Coronary artery graft present\n- Hypo-osmolality and or hyponatremia\n- Hypoglycemia due to type 2 diabetes mellitus\n- Rheumatic disease of heart valve\n- Skin sensation disturbance\n- Transplanted heart present\n- Abnormal findings on diagnostic imaging of lung\n- Acquired absence of organ\n- Congestive heart failure\n- Critical illness myopathy\n- Delirium\n- Diastolic heart failure\n- Edema, generalized\n- Electrocardiogram abnormal\n- Generalized ischemic myocardial dysfunction\n- Hypertensive heart and renal disease with (congestive) heart failure\n- Late effect of complications of procedure\n- Late effect of medical and surgical care complication\n- Localized edema\n- Muscle pain\n- Muscle weakness\n- Old myocardial infarction\n- Right bundle branch block\n- Sepsis\n- Septic shock\n- Ventricular premature complex\n- Acidosis\n- Acute renal failure syndrome\n- Acute tubular necrosis\n- Altered mental status\n- Bacterial infection due to Pseudomonas\n- Cardiac transplant failure\n- Chronic ischemic heart disease\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Metabolic encephalopathy\n- Moderate protein-calorie malnutrition (weight for age 60-74 percent of standard)\n- Acute on chronic combined systolic and diastolic heart failure\n- Angina co-occurrent and due to coronary arteriosclerosis\n- Blood coagulation disorder\n- Chronic kidney disease stage 3\n- Complication of anesthesia\n- Gastroesophageal reflux disease without esophagitis\n- Primary diagnosis: Heart failure\n- Hyperglycemia\n- Hyperglycemia due to type 2 diabetes mellitus\n- Hyperosmolality and or hypernatremia\n- Hypertensive heart and chronic kidney disease\n- Leukocytosis\n- Low blood pressure\n- Persistent pain following procedure\n- Acute on chronic hypoxemic respiratory failure\n- Acute pulmonary edema\n- Atelectasis\n- Cardiac arrhythmia\n- Chronic passive congestion of liver\n- Disorder of digestive system\n- Disorder of immune function\n- Disorientated\n- Postoperative shock\n- Rest pain\n- Vocal cord paralysis\n- Atrial flutter\n- Bradycardia\n- Complication due to diabetes mellitus\n- End-stage renal disease\n- Finding of urine output\n- Hyperosmolarity\n- Left bundle branch block\n- Obesity\n- Pneumonia due to Pseudomonas\n- Pneumothorax\n- Rheumatoid arthritis\n- Shock\n- Chronic pulmonary edema\n- Disorder of plasma protein metabolism\n- Type 2 diabetes mellitus\n- Urinary tract infectious disease\n\n### Drug\n- glycerin, started on 2018-06-11, presumably until 2018-06-11\n- acyclovir 200 MG Oral Capsule, through Oral route, started on 2018-07-02, presumably until 2018-12-17, with intended 11 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2018-06-28, presumably until 2018-07-12, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- albuterol 0.83 MG/ML Inhalation Solution, through Inhalation, started on 2018-06-11, presumably until 2018-06-23\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2018-06-07, presumably until 2018-06-15\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2018-06-08, presumably until 2018-06-11\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2018-06-09, presumably until 2018-06-11\n- 100 ML milrinone lactate 0.2 MG/ML Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-15\n- 250 ML dopamine hydrochloride 3.2 MG/ML Injection, through Intravenous route, started on 2018-06-15, presumably until 2018-06-15\n- 3 ML insulin isophane, human 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2018-07-03, presumably until 2018-07-19, with intended 5 refill(s). Instructions: inject 33 Units subcutaneous (under the skin) 2 times a day\n- gabapentin 50 MG/ML Oral Solution, through Oral route, started on 2018-06-18, presumably until 2018-07-02\n- sodium citrate, through Intravenous route, started on 2018-06-09, presumably until 2018-06-25\n- 10 ML epinephrine 0.1 MG/ML Prefilled Syringe, through Intravenous route, started on 2018-06-07, presumably until 2018-06-07\n- chlorhexidine gluconate 1.2 MG/ML Mouthwash, through Submucosal route, started on 2018-06-07, presumably until 2018-06-15\n- haloperidol 5 MG/ML Injectable Solution, started on 2018-06-11, presumably until 2018-06-12\n- chlorothiazide 50 MG/ML Oral Suspension, through Oral route, started on 2018-06-08, presumably until 2018-06-17\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-07-04, presumably until 2019-07-04, with intended 11 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast\n- 50 ML albumin human, USP 250 MG/ML Injection, through Intravenous route, started on 2018-06-07, presumably until 2018-06-19\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2018-06-17, presumably until 2018-06-23\n- magnesium citrate 58.2 MG/ML Oral Solution, through Oral route, started on 2018-06-11, presumably until 2018-06-11\n- docusate sodium 10 MG/ML Oral Solution, through Oral route, started on 2018-06-08, presumably until 2018-06-15\n- 3 ML insulin lispro 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2018-07-03, presumably until 2018-07-09, with intended 5 refill(s). Instructions: inject 22 Units subcutaneous (under the skin) 3 times a day before meals Additionally, inject 0-12 units subcutaneously 4 times a day before meals and at bedtime per sliding scale.\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2018-06-07, presumably until 2018-06-28\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-06-26, presumably until 2018-06-28\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2018-07-03, presumably until 2018-08-24, with intended 2 refill(s). Instructions: take 2 Tabs by mouth daily Or as directed per prednisone taper card.\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2018-06-28, presumably until 2018-06-30\n- aspirin 325 MG Oral Tablet, through Oral route, started on 2018-07-19, presumably until 2018-07-19\n- amphotericin B 50 MG Injection, started on 2018-06-07, presumably until 2018-06-07\n- mineral oil 0.425 MG/MG / petrolatum 0.568 MG/MG Ophthalmic Ointment, through Intraocular route, started on 2018-06-11, presumably until 2018-06-11\n- mineral oil 0.15 MG/MG / petrolatum 0.83 MG/MG Ophthalmic Ointment, through Intraocular route, started on 2018-06-09, presumably until 2018-06-15\n- 1 ML epoetin alfa 10000 UNT/ML Injection, through Subcutaneous route, started on 2018-06-29, presumably until 2018-08-16, with intended 0 refill(s). Instructions: inject 1 mL subcutaneous (under the skin) every Tuesday, Thursday and Saturday\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2018-06-29, presumably until 2018-06-29\n- midodrine hydrochloride 10 MG Oral Tablet, through Oral route, started on 2018-07-09, presumably until 2018-07-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-06-15, presumably until 2018-06-15\n- cefazolin 1000 MG Injection, started on 2018-06-07, presumably until 2018-06-07\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, started on 2018-06-12, presumably until 2018-06-15\n- prednisone 1 MG/ML Oral Solution, through Oral route, started on 2018-06-08, presumably until 2018-07-02\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2018-06-23, presumably until 2018-06-23\n- 5 ML iron sucrose 20 MG/ML Injection, through Intravenous route, started on 2018-06-29, presumably until 2018-08-16, with intended 0 refill(s). Instructions: 5 mL by Intravenous route every Tuesday, Thursday and Saturday For 9 doses.\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2018-06-07, presumably until 2018-06-07\n- 250 ML norepinephrine 0.016 MG/ML Injection, through Intravenous route, started on 2018-06-10, presumably until 2018-06-16\n- tacrolimus 5 MG Oral Capsule, through Oral route, started on 2018-06-08, presumably until 2018-07-02\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2018-07-03, presumably until 2018-08-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime\n- 10 ML calcium chloride 100 MG/ML Prefilled Syringe, through Intravenous route, started on 2018-06-07, presumably until 2018-06-07\n- insulin isophane, human 100 UNT/ML Injectable Suspension, through Subcutaneous route, started on 2018-06-07, presumably until 2018-07-19\n- nystatin 100000 UNT/ML Oral Suspension, through Oral route, started on 2018-06-08, presumably until 2019-05-31, with intended 11 refill(s). Instructions: 5 mL by Swish & Swallow route 3 times a day\n- lansoprazole 30 MG Disintegrating Oral Tablet, through Oral route, started on 2018-06-29, presumably until 2018-07-02\n- 10 ML furosemide 10 MG/ML Injection, started on 2018-06-07, presumably until 2018-06-30\n- 250 ML dopamine hydrochloride 1.6 MG/ML Injection, through Intravenous route, started on 2018-06-21, presumably until 2018-07-05\n- midodrine hydrochloride 5 MG Oral Tablet, through Oral route, started on 2018-06-21, presumably until 2018-08-02, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2018-06-12, presumably until 2018-07-19\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, through Subcutaneous route, started on 2018-06-20, presumably until 2018-08-02, with intended 0 refill(s). Instructions: inject 0.5 mL subcutaneous (under the skin) every 8 hours\n- citric acid, through Intravenous route, started on 2018-06-09, presumably until 2018-06-25\n- chlorothiazide 500 MG Injection, through Intravenous route, started on 2018-06-08, presumably until 2018-06-21\n- potassium chloride 1.33 MEQ/ML Oral Solution, through Oral route, started on 2018-06-16, presumably until 2018-06-28\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2018-06-08, presumably until 2018-08-29, with intended 0 refill(s). Instructions: inject 23 Units subcutaneous (under the skin) 3 times a day with meals\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2018-06-07, presumably until 2018-06-24\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2018-06-19, presumably until 2018-06-21\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2018-06-08, presumably until 2018-06-13\n- hydroxyzine hydrochloride 2 MG/ML Oral Solution, through Oral route, started on 2018-06-12, presumably until 2018-06-12\n- 50 ML sodium bicarbonate 84 MG/ML Prefilled Syringe, through Intravenous route, started on 2018-06-07, presumably until 2018-06-15\n- 50 ML glucose 500 MG/ML Prefilled Syringe, through Intravenous route, started on 2018-06-17, presumably until 2018-06-23\n- 50 ML potassium chloride 0.4 MEQ/ML Injection, through Intravenous route, started on 2018-06-06, presumably until 2018-06-07\n- acetaminophen 32 MG/ML Oral Solution, through Oral route, started on 2018-06-09, presumably until 2018-06-26\n- spironolactone 25 MG Oral Tablet, through Oral route, started on 2018-06-07, presumably until 2018-06-07\n- tacrolimus 0.5 MG Oral Capsule, through Oral route, started on 2018-07-03, presumably until 2018-07-30, with intended 11 refill(s). Instructions: take 1 Cap by mouth daily\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-06-21, presumably until 2018-06-25\n- sennosides, USP 35.2 MG/ML Oral Solution, through Oral route, started on 2018-06-08, presumably until 2018-06-13\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-07-18, presumably until 2018-07-18\n- venlafaxine 25 MG Oral Tablet, through Oral route, started on 2018-06-19, presumably until 2018-08-02, with intended 0 refill(s). Instructions: take 1 Tab by mouth DAILY\n- furosemide 80 MG Oral Tablet, through Oral route, started on 2018-06-07, presumably until 2018-06-07\n- albuterol 2 MG Oral Tablet, through Oral route, started on 2018-06-15, presumably until 2018-07-19, with intended 11 refill(s). Instructions: take 2 Tabs by mouth 3 times a day\n- albuterol 0.4 MG/ML Oral Solution, through Oral route, started on 2018-06-21, presumably until 2018-07-02\n- sulfamethoxazole 400 MG / trimethoprim 80 MG Oral Tablet, through Oral route, started on 2018-06-08, presumably until 2018-08-29, with intended 11 refill(s). Instructions: take 1 Tab by mouth every day\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2018-07-05, presumably until 2018-07-05\n- gabapentin 100 MG Oral Capsule, through Oral route, started on 2018-07-02, presumably until 2018-07-19, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n- insulin glargine 100 UNT/ML Injectable Solution, started on 2018-07-19, presumably until 2018-08-16, with intended 0 refill(s). Instructions: On 07/19/2018, inject 15 units subcutaneously (under the skin) in the evening once. Then on 07/20/2018, inject 15 units SQ in the morning once. Then starting on 07/21/2018, inject 30 units SQ once daily in the morning thereafter.\n- itraconazole 10 MG/ML Oral Solution, through Oral route, started on 2018-06-21, presumably until 2018-09-10, with intended 2 refill(s). Instructions: Take 20 mL (200 mg) by mouth every morning and 10 mL (100 mg) every evening on an empty stomach.\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-06-28, presumably until 2019-07-03, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals\n- lidocaine 0.05 MG/MG Medicated Patch, through Transdermal route, started on 2018-07-05, presumably until 2018-09-27, with intended 0 refill(s). Instructions: apply 1 Patch to skin daily Apply patch to upper back  for up to 12 hours in any 24 hour period.\n- glucose 50 MG/ML Injection, through Intravenous route, started on 2018-06-09, presumably until 2018-06-12\n- 100 ML propofol 10 MG/ML Injection, through Intravenous route, started on 2018-06-07, presumably until 2018-06-07\n- midodrine hydrochloride 2.5 MG Oral Tablet, through Oral route, started on 2018-07-03, presumably until 2018-07-17\n- 10 ML atropine sulfate 0.1 MG/ML Prefilled Syringe, started on 2018-06-21, presumably until 2018-06-21\n- 100 ML clevidipine 0.5 MG/ML Injection, through Intravenous route, started on 2018-06-07, presumably until 2018-06-13\n- bumetanide 0.25 MG/ML Injectable Solution, through Intravenous route, started on 2018-06-08, presumably until 2018-06-08\n- albuterol 5 MG/ML Inhalation Solution, through Inhalation, started on 2018-06-10, presumably until 2018-06-11\n- prednisone 20 MG Oral Tablet, through Oral route, started on 2018-07-03, presumably until 2018-07-19\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2018-06-11, presumably until 2018-06-11\n- mycophenolate mofetil 500 MG Oral Tablet, through Oral route, started on 2018-07-02, presumably until 2018-10-03, with intended 11 refill(s). Instructions: take 2 Tabs by mouth 2 times a day\n- modafinil 100 MG Oral Tablet, through Oral route, started on 2018-06-15, presumably until 2018-07-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- acyclovir 40 MG/ML Oral Suspension, through Oral route, started on 2018-06-08, presumably until 2018-07-02\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-06-29, presumably until 2018-11-03, with intended 11 refill(s). Instructions: take 1 Tab by mouth every morning with breakfast\n- glucose 4000 MG Chewable Tablet, through Oral route, started on 2018-07-03, presumably until 2018-08-16, with intended 0 refill(s). Instructions: take 4 Tabs by mouth as needed for Low blood sugar\n- midazolam 1 MG/ML Injectable Solution, started on 2018-06-09, presumably until 2018-06-09\n- 100 ML dexmedetomidine 0.004 MG/ML Injection, through Intravenous route, started on 2018-06-07, presumably until 2018-06-08\n- methylprednisolone 125 MG Injection, started on 2018-06-07, presumably until 2018-06-07\n- melatonin 3 MG Disintegrating Oral Tablet, through Oral route, started on 2018-06-18, presumably until 2018-07-18\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2018-07-03, presumably until 2018-07-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-06-08 00:00:00, ended at 2018-06-08 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic combined systolic and diastolic heart failure\n- Chronic ischemic heart disease\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-06-11 00:00:00, ended at 2018-06-11 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic combined systolic and diastolic heart failure\n- Congestive heart failure\n- Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-14 00:00:00, ended at 2018-06-14 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Complication due to diabetes mellitus\n- Chronic ischemic heart disease\n- Type 2 diabetes mellitus\n\n### Drug\n- carvedilol 12.5 MG Oral Tablet, started on 2018-06-14, presumably until 2018-06-14, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-06-19 00:00:00, ended at 2018-06-19 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-06-19, presumably until 2018-06-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-06-26 00:00:00, ended at 2018-06-26 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-06-26, presumably until 2018-06-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-06-28 00:00:00, ended at 2018-06-28 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-06-28, presumably until 2018-06-28\n- midazolam 1 MG/ML Injectable Solution, started on 2018-06-28, presumably until 2018-06-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-07-03 00:00:00, ended at 2018-07-03 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-07-03, presumably until 2018-07-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-07-06 00:00:00, ended at 2018-07-06 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Peripheral vascular disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-07-10 00:00:00, ended at 2018-07-10 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-07-10, presumably until 2018-07-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-07-18 00:00:00, ended at 2018-07-18 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-07-18, presumably until 2018-07-18\n- 2 ML verapamil hydrochloride 2.5 MG/ML Injection, through Intravenous route, started on 2018-07-18, presumably until 2018-07-18\n- iodixanol, through Intravenous route, started on 2018-07-18, presumably until 2018-07-18\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2018-07-18, presumably until 2018-07-18\n- 250 ML nitroglycerin 0.1 MG/ML Injection, through Intravenous route, started on 2018-07-18, presumably until 2018-07-18\n- midazolam 1 MG/ML Injectable Solution, started on 2018-07-18, presumably until 2018-07-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-07-27 00:00:00, ended at 2018-07-27 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- tacrolimus 1 MG Oral Capsule, through Oral route, presumably until 2018-08-14, with intended 0 refill(s). Instructions: take 1 mg by mouth 2 times a day Total dose of 1mg AM, 1mg PM\n- amlodipine 2.5 MG Oral Tablet, through Oral route, presumably until 2018-08-16, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n- tacrolimus 0.5 MG Oral Capsule, through Oral route, started on 2018-07-30, presumably until 2018-08-14, with intended 11 refill(s). Instructions: take 1 Cap by mouth 2 times a day Total dose of 0.5mg AM, 1mg PM\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-08-01 00:00:00, ended at 2018-08-01 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pure hypercholesterolemia\n- Primary diagnosis: Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-08-02 00:00:00, ended at 2018-08-02 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-08-02, presumably until 2018-08-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-08-02 00:00:00, ended at 2018-08-02 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- clopidogrel 75 MG Oral Tablet, started on 2018-08-02, presumably until 2018-08-02, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-08-02 10:49:54, ended at 2018-08-02 12:42:30\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-02 12:51:00, ended at 2018-08-02 13:22:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.8 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 2.2 (ratio)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.56 (thousand per microliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 119 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.48 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Itraconazole [Mass/volume] in Serum or Plasma: 1.0 (microgram per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.7 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.3 (percent)\n- MCHC [Mass/volume] by Automated count: 30.5 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Hydroxyitraconazole [Mass/volume] in Serum or Plasma: 1.4 (microgram per milliliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 91.7 (percent)\n- Tacrolimus [Mass/volume] in Blood: 10.9 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 62 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 94 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 218 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 100 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 264 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 10.75 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 197 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.26 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.26 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 100.6 (femtoliter)\n- Chloride [Moles/volume] in Serum or Plasma: 96 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 30.6 (picogram)\n- Triglyceride [Moles/volume] in Serum or Plasma: 153 (milligram per deciliter)\n\n### Procedure\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n\n### Condition\n- Disorder of transplanted heart\n- Pure hypercholesterolemia\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-02 13:23:00, ended at 2018-08-02 14:57:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Excision of Right Ventricle, Percutaneous Approach, Diagnostic\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Right heart catheterization including measurement(s) of oxygen saturation and cardiac output, when performed\n- Endomyocardial biopsy\n- Measurement of Cardiac Sampling and Pressure, Right Heart, Percutaneous Approach\n\n### Condition\n- Transplanted heart present\n- Obesity\n- Disorder of transplanted heart\n- Pure hypercholesterolemia\n- Essential hypertension\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-13 09:08:00, ended at 2018-08-13 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 134 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 97.0 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.44 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.8 (picogram)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.1 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 30.7 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.01 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 206 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 80 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.9 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 8.53 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.19 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.8 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.4 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 67 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.18 (million per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Tacrolimus [Mass/volume] in Blood: 4.6 (nanogram per milliliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-08-14 00:00:00, ended at 2018-08-14 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n\n### Drug\n- tacrolimus 1 MG Oral Capsule, through Oral route, started on 2018-08-14, presumably until 2018-08-17, with intended 3 refill(s). Instructions: take 1 Cap by mouth 2 times a day Total dose of 1mg AM, 1mg PM\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-08-15 00:00:00, ended at 2018-08-15 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-08-16 00:00:00, ended at 2018-08-16 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Endomyocardial biopsy\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-08-16, presumably until 2018-08-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-16 12:53:00, ended at 2018-08-16 14:48:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Excision of Right Ventricle, Percutaneous Approach, Diagnostic\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n\n### Condition\n- Transplanted heart present\n- Chronic kidney disease\n- Acute deep venous thrombosis of internal jugular vein\n- Disorder of transplanted heart\n- Essential hypertension\n- Embolism from thrombosis of vein of lower extremity\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-08-17 00:00:00, ended at 2018-08-17 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal level of blood mineral\n- Disorder of transplanted heart\n\n### Drug\n- tacrolimus 1 MG Oral Capsule, started on 2018-08-17, presumably until 2018-09-10, with intended 3 refill(s). Instructions: Total dose of 0.5mg AM, 1mg PM\n- tacrolimus 0.5 MG Oral Capsule, started on 2018-08-17, presumably until 2018-09-10, with intended 3 refill(s). Instructions: Total dose: 0.5mg in the am, 1mg in the pm.\n- magnesium amino acid chelate 133 MG Oral Tablet, through Oral route, started on 2018-08-17, presumably until 2018-09-27, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-17 09:51:00, ended at 2018-08-17 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 89 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.3 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.0 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.34 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.34 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 13.3 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.6 (percent)\n- MCH [Entitic mass] by Automated count: 29.9 (picogram)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Tacrolimus [Mass/volume] in Blood: 15.9 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.83 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 30.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 97.7 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.0 (percent)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 56 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 11.68 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 87.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 173 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-08-20 00:00:00, ended at 2018-08-20 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- apixaban 2.5 MG Oral Tablet, through Oral route, started on 2018-08-20, presumably until 2018-11-27, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-08-20 00:00:00, ended at 2018-08-20 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-20 13:50:00, ended at 2018-08-20 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study\n\n### Condition\n- Disorder of transplanted heart\n- Embolism from thrombosis of vein of lower extremity\n- Acute deep venous thrombosis of internal jugular vein\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-08-23 00:00:00, ended at 2018-08-23 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease\n- Disorder of transplanted heart\n- Essential hypertension\n\n### Drug\n- furosemide 40 MG Oral Tablet, through Oral route, started on 2018-08-23, presumably until 2018-08-29, with intended 11 refill(s). Instructions: take 2 Tabs by mouth 2 times a day\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2018-08-23, presumably until 2018-08-24, with intended 11 refill(s). Instructions: take 2 Tabs by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-23 08:00:00, ended at 2018-08-23 10:42:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 60.4 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n- Essential hypertension\n- Edema\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-08-23 09:14:30, ended at 2018-08-23 10:36:05\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Edema\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-23 10:43:00, ended at 2018-08-23 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 52 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.6 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.93 (thousand per microliter)\n- Tacrolimus [Mass/volume] in Blood: 7.7 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.40 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.2 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.40 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 196 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 67 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.78 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 83.1 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 112 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 148 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.9 (picogram)\n- MCV [Entitic volume] by Automated count: 94.4 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 133 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 31.7 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 11.80 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.2 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-08-24 00:00:00, ended at 2018-08-24 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease\n- Transplanted heart present\n- Disorder of transplanted heart\n- Essential hypertension\n\n### Drug\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2018-08-24, presumably until 2018-09-17, with intended 2 refill(s). Instructions: take 1.5 Tabs by mouth daily\n- amlodipine 10 MG Oral Tablet, through Oral route, started on 2018-08-24, presumably until 2018-08-28, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-24 12:02:00, ended at 2018-08-24 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording \n\n### Condition\n- Peripheral vascular disease\n- Gangrenous disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-08-24 12:03:48, ended at 2018-08-24 13:17:41\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Peripheral vascular disease\n- Gangrenous disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-27 08:35:00, ended at 2018-08-27 10:39:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 73 (milligram per deciliter)\n- INR in Blood by Coagulation assay: 1.1 (ratio)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n- Removal of tunneled central venous catheter, without subcutaneous port or pump\n\n### Condition\n- Transplanted heart present\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2018-08-27, presumably until 2018-08-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-08-28 00:00:00, ended at 2018-08-28 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- bumetanide 2 MG Oral Tablet, through Oral route, started on 2018-08-28, presumably until 2018-09-10, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- clonidine hydrochloride 0.1 MG Oral Tablet, through Oral route, started on 2018-08-28, presumably until 2018-09-10, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2018-08-28 17:48:00, ended at 2018-09-10 13:53:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 145 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.6 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 95.1 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 89.6 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 5.6 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.82 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma: 9149 (picogram per milliliter)\n- Platelets [#/volume] in Blood by Automated count: 284 (thousand per microliter)\n- Tacrolimus [Mass/volume] in Blood: 9.5 (nanogram per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.9 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.78 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.08 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 66 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.59 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Glucose [Mass/volume] in Blood: 99 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.28 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.42 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.5 (percent)\n- Left ventricular Ejection fraction: 60.3 (percent)\n- MCH [Entitic mass] by Automated count: 30.9 (picogram)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.027 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Base excess in Blood by calculation: 1 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Body height: 5' 5\" (inch (US))\n- Erythrocyte distribution width [Ratio] by Automated count: 18.8 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.8 (milligram per deciliter)\n\n### Procedure\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Occupational therapy evaluation, moderate complexity, requiring these components: An occupational profile and medical and therapy history, which includes an expanded review of medical and/or therapy records and additional review of physical, cognitive, or\n- Physical therapy evaluation: moderate complexity, requiring these components: A history of present problem with 1-2 personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures in\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Introduction of Vasopressor into Peripheral Vein, Percutaneous Approach\n- Excision of Right Ventricle, Percutaneous Approach, Diagnostic\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Medical decision making that is straightforward or o\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Hospital discharge day management; 30 minutes or less\n- Collection of venous blood by venipuncture\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of \n- Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination\n- Radiologic examination, chest; 2 views\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Abdominal distension, gaseous\n- Disorder of transplanted heart\n- Dyspnea\n- Leukocytosis\n- Essential hypertension\n- Gangrene due to type 2 diabetes mellitus\n- Hypoglycemia due to type 2 diabetes mellitus\n- Peripheral angiopathy due to diabetes mellitus\n- Anemia in chronic kidney disease\n- Coag./bleeding tests abnormal\n- Congestive heart failure\n- Disorder of nervous system due to type 2 diabetes mellitus\n- Hypertensive heart and renal disease with (congestive) heart failure\n- Late effect of complications of procedure\n- Tricuspid incompetence, non-rheumatic\n- Chest pain\n- Disorder of digestive system\n- Electrocardiogram abnormal\n- Hyperglycemia due to type 2 diabetes mellitus\n- Long QT syndrome\n- Thrombus due to any device, implant AND/OR graft\n- Type 2 diabetes mellitus\n- Alkalosis\n- Disorder of eye due to type 2 diabetes mellitus\n- Gangrenous disorder\n- Heart failure\n- Acute on chronic diastolic heart failure\n- Diastolic heart failure\n- Transplanted heart present\n- Acute deep venous thrombosis of internal jugular vein\n- Cardiac transplant failure\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Constipation\n- Primary diagnosis: Hypervolemia\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Obesity\n- Valvular endocarditis\n- Acquired absence of organ\n- Acute renal failure syndrome\n- Allergic disposition\n- Pleural effusion\n- Chronic kidney disease stage 4\n\n### Drug\n- bumetanide 2 MG Oral Tablet, through Oral route, started on 2018-08-31, presumably until 2018-09-10\n- chlorothiazide 500 MG Oral Tablet, through Oral route, started on 2018-09-06, presumably until 2019-09-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- acyclovir 200 MG Oral Capsule, through Oral route, started on 2018-08-28, presumably until 2018-09-10\n- 250 ML dobutamine 1 MG/ML Injection, through Intravenous route, started on 2018-09-04, presumably until 2018-09-09\n- 24 HR isosorbide mononitrate 30 MG Extended Release Oral Tablet, through Oral route, started on 2018-09-09, presumably until 2019-09-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- clonidine hydrochloride 0.3 MG Oral Tablet, through Oral route, started on 2018-09-10, presumably until 2019-09-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2018-09-04, presumably until 2018-09-04\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-08-29, presumably until 2018-09-10\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2018-09-07, presumably until 2018-11-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- tacrolimus 1 MG Oral Capsule, through Oral route, started on 2018-08-28, presumably until 2018-09-10\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-08-28, presumably until 2018-09-06\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2018-08-29, presumably until 2018-08-29\n- prednisone 2.5 MG Oral Tablet, through Oral route, started on 2018-08-30, presumably until 2018-09-10\n- amlodipine 10 MG Oral Tablet, through Oral route, started on 2018-08-30, presumably until 2019-09-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- hydralazine hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-08-28, presumably until 2018-09-09\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2018-08-29, presumably until 2018-09-10\n- apixaban 2.5 MG Oral Tablet, through Oral route, started on 2018-08-28, presumably until 2018-08-28\n- apixaban 5 MG Oral Tablet, through Oral route, started on 2018-08-31, presumably until 2018-09-10\n- clonidine hydrochloride 0.1 MG Oral Tablet, through Oral route, started on 2018-08-31, presumably until 2018-09-10\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2018-08-29, presumably until 2018-08-29\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2018-08-29, presumably until 2018-08-29\n- magnesium hydroxide 80 MG/ML Oral Suspension, through Oral route, started on 2018-09-03, presumably until 2018-09-09\n- insulin isophane, human 100 UNT/ML Injectable Suspension, through Subcutaneous route, started on 2018-08-29, presumably until 2018-09-10\n- nystatin 100000 UNT/ML Oral Suspension, through Oral route, started on 2018-08-29, presumably until 2018-09-10\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-09-01, presumably until 2018-09-04\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2018-08-29, presumably until 2018-09-10\n- chlorothiazide 500 MG Injection, through Intravenous route, started on 2018-09-02, presumably until 2018-09-05\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-08-30, presumably until 2018-09-10\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2018-08-29, presumably until 2018-09-10\n- 100 ML magnesium sulfate 10 MG/ML Injection, through Intravenous route, started on 2018-09-02, presumably until 2018-09-02\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2018-09-02, presumably until 2018-09-02\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2018-08-30, presumably until 2018-09-04\n- tacrolimus 0.5 MG Oral Capsule, through Oral route, started on 2018-08-29, presumably until 2019-09-10, with intended 0 refill(s). Instructions: take 5 Caps by mouth 2 times a day\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2018-08-29, presumably until 2018-09-03\n- sulfamethoxazole 400 MG / trimethoprim 80 MG Oral Tablet, through Oral route, started on 2018-08-29, presumably until 2019-07-05, with intended 0 refill(s). Instructions: take 1 Tab by mouth every other day\n- itraconazole 10 MG/ML Oral Solution, through Oral route, started on 2018-08-28, presumably until 2018-09-03\n- magnesium amino acid chelate 133 MG Oral Tablet, through Oral route, started on 2018-08-28, presumably until 2018-09-10\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-08-29, presumably until 2018-09-10\n- lidocaine 0.05 MG/MG Medicated Patch, through Topical route, started on 2018-08-29, presumably until 2018-09-09\n- bumetanide 1 MG Oral Tablet, through Oral route, started on 2018-08-31, presumably until 2019-09-10, with intended 0 refill(s). Instructions: take 5 Tabs by mouth 2 times a day\n- bumetanide 0.25 MG/ML Injectable Solution, through Intravenous route, started on 2018-08-28, presumably until 2018-09-02\n- mycophenolate mofetil 500 MG Oral Tablet, through Oral route, started on 2018-08-28, presumably until 2018-09-10\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-08-29, presumably until 2018-09-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-08-30 00:00:00, ended at 2018-08-30 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Endomyocardial biopsy\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-08-30, presumably until 2018-08-30\n- midazolam 1 MG/ML Injectable Solution, started on 2018-08-30, presumably until 2018-08-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-09-05 00:00:00, ended at 2018-09-05 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-09-10 00:00:00, ended at 2018-09-10 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- chlorothiazide 500 MG Oral Tablet, through Oral route, started on 2018-09-10, presumably until 2018-09-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- 24 HR isosorbide mononitrate 30 MG Extended Release Oral Tablet, through Oral route, started on 2018-09-10, presumably until 2018-09-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning\n- clonidine hydrochloride 0.1 MG Oral Tablet, through Oral route, started on 2018-09-10, presumably until 2019-09-10, with intended 0 refill(s). Instructions: take 3 Tabs by mouth 2 times a day\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2018-09-10, presumably until 2019-01-20, with intended 0 refill(s). Instructions: take 2 Tabs by mouth daily\n- tacrolimus 0.5 MG Oral Capsule, through Oral route, started on 2018-09-10, presumably until 2018-09-18, with intended 0 refill(s). Instructions: take 5 Caps by mouth 2 times a day\n- bumetanide 1 MG Oral Tablet, through Oral route, started on 2018-09-10, presumably until 2018-09-27, with intended 0 refill(s). Instructions: take 5 Tabs by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-09-11 00:00:00, ended at 2018-09-11 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Hyperosmolarity\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-09-11 00:00:00, ended at 2018-09-11 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Complication due to diabetes mellitus\n\n### Drug\n- 3 ML insulin isophane, human 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2018-09-11, presumably until 2019-11-27, with intended 11 refill(s). Instructions: inject 22 Units subcutaneous (under the skin) 2 times a day 22 units AM, 22 units PM\n- 3 ML insulin lispro 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2018-09-11, presumably until 2019-11-21, with intended 11 refill(s). Instructions: inject 17 Units subcutaneous (under the skin) 3 times a day with meals\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-11 13:10:09, ended at 2018-09-11 13:10:51\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Hyperosmolarity\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-09-12 00:00:00, ended at 2018-09-12 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-13 09:23:00, ended at 2018-09-13 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 97 (unit per liter)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 110 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.01 (million per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 79.9 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.29 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.15 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 11.26 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.09 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 171 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.1 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Tacrolimus [Mass/volume] in Blood: 7.8 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.5 (percent)\n- MCH [Entitic mass] by Automated count: 29.1 (picogram)\n- MCV [Entitic volume] by Automated count: 90.6 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.26 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 378 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hypomagnesemia\n- Transplanted heart present\n- Disorder of transplanted heart\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-09-13 09:42:41, ended at 2018-09-13 11:15:45\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Primary diagnosis: Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- chlorothiazide 500 MG Oral Tablet, through Oral route, started on 2018-09-13, presumably until 2018-09-18, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- 24 HR isosorbide mononitrate 30 MG Extended Release Oral Tablet, through Oral route, started on 2018-09-13, presumably until 2019-09-13, with intended 11 refill(s). Instructions: take 1 Tab by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-09-14 00:00:00, ended at 2018-09-14 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydralazine hydrochloride 10 MG Oral Tablet, through Oral route, started on 2018-09-14, presumably until 2018-09-28, with intended 11 refill(s). Instructions: take 1 Tab by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-09-17 00:00:00, ended at 2018-09-17 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-09-17, presumably until 2019-01-20, with intended 3 refill(s). Instructions: take 1.5 Tabs by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-09-18 00:00:00, ended at 2018-09-18 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tacrolimus 0.5 MG Oral Capsule, through Oral route, started on 2018-09-18, presumably until 2018-10-10, with intended 0 refill(s). Instructions: take 5 Caps by mouth 2 times a day Take 5 capsules in AM and 6 capsules in PM\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-18 08:57:00, ended at 2018-09-18 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 105 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.00 (million per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.5 (picogram)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.4 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.2 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.58 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- MCHC [Mass/volume] by Automated count: 31.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.5 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 337 (thousand per microliter)\n- Tacrolimus [Mass/volume] in Blood: 4.9 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 173 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.2 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.4 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.16 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 11.69 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 93 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 33 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.1 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 1.01 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-09-21 00:00:00, ended at 2018-09-21 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- everolimus 0.75 MG Oral Tablet, through Oral route, started on 2018-09-21, presumably until 2018-09-28, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day Cytotoxic. Take with  food. Swallow whole. do not break, chew or crush tablets.  Z94.1  DOT: 06/06/2018\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-09-21 00:00:00, ended at 2018-09-21 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-21 08:44:00, ended at 2018-09-21 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- MCV [Entitic volume] by Automated count: 90.1 (femtoliter)\n- Tacrolimus [Mass/volume] in Blood: 8.6 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.5 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.1 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 174 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.3 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.8 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.02 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.95 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.98 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 313 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 87 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.26 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 12.12 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 93 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.3 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.3 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 28.8 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-09-24 00:00:00, ended at 2018-09-24 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Blood chemistry abnormal\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-27 09:28:00, ended at 2018-09-27 09:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Lymphocytes [#/volume] in Blood by Automated count: 1.84 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 28.7 (picogram)\n- Tacrolimus [Mass/volume] in Blood: 7.3 (nanogram per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.86 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 48 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.0 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.0 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.8 (percent)\n- MCHC [Mass/volume] by Automated count: 31.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.1 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.03 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Everolimus [Mass/volume] in Blood: 2.5 (nanogram per milliliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.1 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 13.1 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.97 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 271 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 68 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-27 10:00:00, ended at 2018-09-27 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 69.6 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Disorder of immune function\n- Hypomagnesemia\n- Transplanted heart present\n- Disorder of transplanted heart\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-09-28 00:00:00, ended at 2018-09-28 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- bumetanide 2 MG Oral Tablet, through Oral route, started on 2018-09-28, presumably until 2018-10-01, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- everolimus 0.5 MG Oral Tablet, started on 2018-09-28, presumably until 2018-10-03, with intended 3 refill(s). Instructions: Take 1mg twice daily. Cytotoxic. Take with  food. Swallow whole. do not break, chew or crush tablets.  Z94.1  DOT: 06/06/2018\n- hydralazine hydrochloride 10 MG Oral Tablet, through Oral route, started on 2018-09-28, presumably until 2018-11-27, with intended 3 refill(s). Instructions: take 2 Tabs by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-28 09:47:00, ended at 2018-09-28 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-01 00:00:00, ended at 2018-10-01 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- bumetanide 2 MG Oral Tablet, through Oral route, started on 2018-10-01, presumably until 2018-10-03, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day 2nd prescription, please dispense!\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-10-01 09:40:00, ended at 2018-10-01 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.0 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.3 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Everolimus [Mass/volume] in Blood: 3.5 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 231 (thousand per microliter)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.1 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 81.6 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 10.0 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.70 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.6 (milligram per deciliter)\n- Tacrolimus [Mass/volume] in Blood: 8.3 (nanogram per milliliter)\n- MCH [Entitic mass] by Automated count: 28.9 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.81 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.1 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 47 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 133 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 116 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.3 (femtoliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.17 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.23 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-10-03 00:00:00, ended at 2018-10-03 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- bumetanide 2 MG Oral Tablet, through Oral route, started on 2018-10-03, presumably until 2018-11-27, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily 2nd prescription, please dispense!\n- everolimus 0.5 MG Oral Tablet, started on 2018-10-03, presumably until 2018-11-28, with intended 3 refill(s). Instructions: Take 1mg in the AM, 1.5mg in the PM. Cytotoxic. Take with  food. Swallow whole. do not break, chew or crush tablets.  Z94.1  DOT: 06/06/2018\n- mycophenolate mofetil 500 MG Oral Tablet, through Oral route, started on 2018-10-03, presumably until 2018-10-23, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-08 00:00:00, ended at 2018-10-08 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.2 (calculated)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1000 (cells per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 40 (cells per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 85.6 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Tacrolimus [Mass/volume] in Blood by LC/MS/MS: 10.5 (microgram per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 230 (cells per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.1 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 18 (calculated)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 11 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 94 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.8 (percent)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7920 (cells per microliter)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 11.9 (femtoliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.60 (million per liter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter calculated)\n- Lymphocytes [#/volume] in Blood by Automated count: 810 (cells per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 79.2 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 42 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.29 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.0 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.1 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 370 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-10 00:00:00, ended at 2018-10-10 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tacrolimus 0.5 MG Oral Capsule, through Oral route, started on 2018-10-10, presumably until 2018-10-11, with intended 11 refill(s). Instructions: take 5 Caps by mouth 2 times a day Take 5 capsules in AM and 6 capsules in PM\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-11 00:00:00, ended at 2018-10-11 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tacrolimus 1 MG Oral Capsule, started on 2018-10-11, presumably until 2018-12-07, with intended 11 refill(s). Instructions: Take 2.5mg in Am and 3 mg in PM\n- tacrolimus 0.5 MG Oral Capsule, started on 2018-10-11, presumably until 2018-12-07, with intended 11 refill(s). Instructions: Take 0.5 mg in AM and as directed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-12 00:00:00, ended at 2018-10-12 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-12 00:00:00, ended at 2018-10-12 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-15 00:00:00, ended at 2018-10-15 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-19 00:00:00, ended at 2018-10-19 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-22 00:00:00, ended at 2018-10-22 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-22 00:00:00, ended at 2018-10-22 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2018-10-22, presumably until 2018-10-29, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day for 7 days\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-10-22, presumably until 2018-11-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-10-22 07:58:00, ended at 2018-10-22 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 162 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 15.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 31.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 83.9 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 52 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 128 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.3 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.4 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 99 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Tacrolimus [Mass/volume] in Blood: 12.2 (nanogram per milliliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 218 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.5 (percent)\n- Everolimus [Mass/volume] in Blood: 6.2 (nanogram per milliliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.11 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 12.56 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 399 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 31 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 214 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 26.5 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 1.28 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.64 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.1 (percent)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 133 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 4.1 (ratio)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.59 (million per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.3 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n\n### Condition\n- Systolic heart failure\n- Transplanted heart present\n- Congestive heart failure\n- Gangrenous disorder\n- Hypomagnesemia\n- Blood chemistry abnormal\n- Disorder of transplanted heart\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-10-22 10:35:07, ended at 2018-10-22 11:46:40\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Gangrenous disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-23 00:00:00, ended at 2018-10-23 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- C reactive protein [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-23 00:00:00, ended at 2018-10-23 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-26 00:00:00, ended at 2018-10-26 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-29 00:00:00, ended at 2018-10-29 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-02 00:00:00, ended at 2018-11-02 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-11-02 00:00:00, ended at 2018-11-02 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with transluminal angioplasty\n- Angiography, extremity, unilateral, radiological supervision and interpretation\n- Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed\n- Amputation, toe; interphalangeal joint\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-02 00:00:00, ended at 2018-11-02 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for diagnostic arteriography/venography\n\n### Condition\n- Atherosclerosis of artery of lower limb\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Chronic occlusion of artery of extremity\n- Type 2 diabetes mellitus\n- Foot ulcer due to type 2 diabetes mellitus\n- Gangrene of left lower limb due to atherosclerosis\n- Peripheral angiopathy due to diabetes mellitus\n- Gangrene due to type 2 diabetes mellitus\n\n### Drug\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2018-11-02, presumably until 2018-11-02\n- cefazolin 1000 MG Injection, started on 2018-11-02, presumably until 2018-11-02\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2018-11-02, presumably until 2018-11-02\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-11-02, presumably until 2018-11-02\n- ketamine 100 MG/ML Injectable Solution, started on 2018-11-02, presumably until 2018-11-02\n- 2 ML dexmedetomidine 0.1 MG/ML Injection, through Intravenous route, started on 2018-11-02, presumably until 2018-11-02\n- midazolam 1 MG/ML Injectable Solution, started on 2018-11-02, presumably until 2018-11-02\n- 2 ML alfentanil 0.5 MG/ML Injection, started on 2018-11-02, presumably until 2018-11-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-02 00:00:00, ended at 2018-11-02 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent pain following procedure\n\n### Drug\n- 30 ML mepivacaine hydrochloride 15 MG/ML Injection, started on 2018-11-02, presumably until 2018-11-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-02 09:33:00, ended at 2018-11-03 14:20:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 124 (milligram per deciliter)\n- INR in Blood by Coagulation assay: 1.7 (ratio)\n- Hematocrit [Volume Fraction] of Blood: 29 (percent)\n- Potassium [Moles/volume] in Blood: 3.5 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 9.9 (gram per deciliter)\n- Sodium [Moles/volume] in Blood: 140 (millimole per liter)\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Selective catheter placement, arterial system; initial third order or more selective abdominal, pelvic, or lower extremity artery branch, within a vascular family\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Amputation, toe; metatarsophalangeal joint\n- Detachment at Right 1st Toe, Complete, Open Approach\n- Collection of venous blood by venipuncture\n- Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed\n- Dilation of Right Anterior Tibial Artery, Percutaneous Approach\n- Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with transluminal angioplasty\n- Dilation of Right Femoral Artery with Drug-eluting Intraluminal Device, using Drug-Coated Balloon, Percutaneous Approach\n- Angiography, extremity, unilateral, radiological supervision and interpretation\n- Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements f\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Fluoroscopy of Right Lower Extremity Arteries\n- Intravenous infusion, hydration; initial, 31 minutes to 1 hour\n\n### Condition\n- Chronic kidney disease\n- Chronic kidney disease stage 3\n- Foot ulcer due to type 2 diabetes mellitus\n- Gangrenous disorder\n- Peripheral angiopathy due to diabetes mellitus\n- Gangrene of left lower limb due to atherosclerosis\n- Primary diagnosis: Peripheral vascular disease\n- Type 2 diabetes mellitus\n- Chronic occlusion of artery of extremity\n- Gangrene due to type 2 diabetes mellitus\n- Acute renal failure syndrome\n- Atherosclerosis of artery of lower limb\n- Dissection of artery of lower limb\n- Transplanted heart present\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Chronic kidney disease due to hypertension\n\n### Drug\n- bumetanide 2 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- amoxicillin 500 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours for 5 days\n- acyclovir 200 MG Oral Capsule, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- 24 HR isosorbide mononitrate 30 MG Extended Release Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- sodium iodide, through Topical route, started on 2018-08-12, presumably until 2019-02-14, with intended 0 refill(s). Instructions: 1 Spray by Topical route 2 times a day\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- apixaban 2.5 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- clonidine hydrochloride 0.1 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-11-02, presumably until 2018-11-02\n- hydralazine hydrochloride 10 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- povidone-iodine, through Topical route, started on 2018-08-12, presumably until 2019-02-14, with intended 0 refill(s). Instructions: 1 Spray by Topical route 2 times a day\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- potassium iodide, through Topical route, started on 2018-08-12, presumably until 2019-02-14, with intended 0 refill(s). Instructions: 1 Spray by Topical route 2 times a day\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-11-02, presumably until 2018-11-02\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-11-02, presumably until 2018-11-02\n- iodine, through Topical route, started on 2018-08-12, presumably until 2019-02-14, with intended 0 refill(s). Instructions: 1 Spray by Topical route 2 times a day\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2019-04-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2018-11-02, presumably until 2018-11-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-05 00:00:00, ended at 2018-11-05 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-09 00:00:00, ended at 2018-11-09 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-12 00:00:00, ended at 2018-11-12 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- MCH [Entitic mass] by Automated count: 24.9 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 7065 (cells per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.4 (percent)\n- MCV [Entitic volume] by Automated count: 79.3 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 78.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 16 (calculated)\n- Basophils [#/volume] in Blood by Automated count: 36 (cells per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.68 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 837 (cells per microliter)\n- Platelets [#/volume] in Blood by Automated count: 395 (thousand per microliter)\n- Tacrolimus [Mass/volume] in Blood by LC/MS/MS: 10.3 (microgram per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.5 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 252 (cells per microliter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter calculated)\n- Glucose [Mass/volume] in Serum or Plasma: 130 (milligram per deciliter)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.3 (calculated)\n- Hemoglobin [Mass/volume] in Blood: 8.9 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 140 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.0 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 810 (cells per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.58 (million per liter)\n- MCHC [Mass/volume] by Automated count: 31.3 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 12.4 (femtoliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-16 00:00:00, ended at 2018-11-16 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Drug-induced constipation\n\n### Drug\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2018-11-16, presumably until 2018-11-26, with intended 11 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2018-11-16, presumably until 2018-11-26, with intended 5 refill(s). Instructions: take 17 g by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-16 00:00:00, ended at 2018-11-16 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-19 00:00:00, ended at 2018-11-19 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-23 00:00:00, ended at 2018-11-23 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Peripheral vascular disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-23 00:00:00, ended at 2018-11-23 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Pure hypercholesterolemia\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-23 00:00:00, ended at 2018-11-23 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-26 00:00:00, ended at 2018-11-26 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-26 09:57:00, ended at 2018-11-26 10:28:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 70.3 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study\n\n### Condition\n- Chronic kidney disease\n- Disorder of transplanted heart\n- Hyperlipidemia\n- Pure hypercholesterolemia\n- Essential hypertension\n- Hypomagnesemia\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-26 10:29:00, ended at 2018-11-26 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin [Mass/volume] in Blood: 9.1 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 75.3 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 47 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 3.8 (ratio)\n- Eosinophils [#/volume] in Blood by Automated count: 0.30 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 235 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.13 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 115 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.02 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.76 (million per microliter)\n- MCV [Entitic volume] by Automated count: 79.0 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 364 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.6 (percent)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.7 (percent)\n- MCH [Entitic mass] by Automated count: 24.3 (picogram)\n- Tacrolimus [Mass/volume] in Blood: 4.3 (nanogram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 110 (milligram per deciliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 133 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Everolimus [Mass/volume] in Blood: 1.7 (nanogram per milliliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 179 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 180 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 30.7 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n\n### Procedure\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n- Collection of venous blood by venipuncture\n\n### Condition\n- Transplanted heart present\n- Hypomagnesemia\n- Pure hypercholesterolemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-11-26 11:10:25, ended at 2018-11-26 12:19:19\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Transplanted heart present\n- Essential hypertension\n- Hyperlipidemia\n- Chronic kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-11-27 00:00:00, ended at 2018-11-27 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Absence of toe\n- Primary diagnosis: Acquired absence of organ\n- Disorder of transplanted heart\n- Hyperlipidemia\n\n### Drug\n- bumetanide 2 MG Oral Tablet, through Oral route, started on 2018-11-27, presumably until 2019-07-05, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day 2nd prescription, please dispense!\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, started on 2018-11-27, presumably until 2019-02-14, with intended 11 refill(s). Instructions: Take 40mEq in the AM, 20mEq in the PM.\n- hydralazine hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-11-27, presumably until 2019-11-22, with intended 3 refill(s). Instructions: take 1 Tab by mouth 3 times a day\n- pravastatin sodium 40 MG Oral Tablet, through Oral route, presumably until 2019-07-05, with intended 11 refill(s). Instructions: take 1 Tab by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-11-28 00:00:00, ended at 2018-11-28 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n\n### Drug\n- everolimus 0.5 MG Oral Tablet, started on 2018-11-28, presumably until 2018-12-07, with intended 3 refill(s). Instructions: Take 1.5mg BID; Cytotoxic. Take with  food. Swallow whole. do not break, chew or crush tablets.  Z94.1  DOT: 06/06/2018\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-30 00:00:00, ended at 2018-11-30 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-03 00:00:00, ended at 2018-12-03 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-03 10:32:00, ended at 2018-12-03 10:49:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.1 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 78.3 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 120 (unit per liter)\n- Everolimus [Mass/volume] in Blood: 7.9 (nanogram per milliliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.23 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 373 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- MCH [Entitic mass] by Automated count: 24.7 (picogram)\n- Tacrolimus [Mass/volume] in Blood: 11.8 (nanogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.73 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.98 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.0 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.2 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.73 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 125 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.2 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.1 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.9 (percent)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 31.6 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-03 10:50:00, ended at 2018-12-03 23:59:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording \n- Duplex scan of lower extremity arteries or arterial bypass grafts; unilateral or limited study\n\n### Condition\n- Peripheral vascular disease\n- Disorder of transplanted heart\n- Transplanted heart present\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-12-03 10:50:06, ended at 2018-12-03 12:27:12\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Peripheral vascular disease\n\n### Drug\n- collagenase 0.25 UNT/MG Topical Ointment, through Topical route, started on 2018-12-03, presumably until 2019-02-14, with intended 0 refill(s). Instructions: by Topical route daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-05 00:00:00, ended at 2018-12-05 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Peripheral vascular disease\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-12-05, presumably until 2018-12-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-07 00:00:00, ended at 2018-12-07 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-12-07 00:00:00, ended at 2018-12-07 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n\n### Drug\n- tacrolimus 1 MG Oral Capsule, started on 2018-12-07, presumably until 2019-01-20, with intended 11 refill(s). Instructions: Take 2mg in Am and 2 mg in PM\n- everolimus 0.5 MG Oral Tablet, started on 2018-12-07, presumably until 2019-01-20, with intended 3 refill(s). Instructions: Take 1mg BID; Cytotoxic. Take with  food. Swallow whole. do not break, chew or crush tablets.  Z94.1  DOT: 06/06/2018\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-10 00:00:00, ended at 2018-12-10 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.3 (calculated)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter calculated)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 12.3 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.2 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 783 (cells per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Tacrolimus [Mass/volume] in Blood by LC/MS/MS: 6.2 (microgram per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 249 (cells per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.63 (million per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.8 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 76.6 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.5 (percent)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 9 (calculated)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 6 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 8.7 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.16 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.3 (percent)\n- MCH [Entitic mass] by Automated count: 24.0 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 3602 (cells per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 119 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.5 (percent)\n- MCHC [Mass/volume] by Automated count: 31.3 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1114 (cells per microliter)\n- Basophils [#/volume] in Blood by Automated count: 52 (cells per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 62.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 370 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-14 00:00:00, ended at 2018-12-14 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2019-02-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-14 00:00:00, ended at 2018-12-14 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-17 00:00:00, ended at 2018-12-17 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.11 (million per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 163 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4744 (cells per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 9 (calculated)\n- Basophils [#/volume] in Blood by Automated count: 40 (cells per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 23.1 (picogram)\n- MCV [Entitic volume] by Automated count: 76.9 (femtoliter)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 12.0 (femtoliter)\n- Tacrolimus [Mass/volume] in Blood by LC/MS/MS: 3.9 (microgram per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.1 (percent)\n- Everolimus [Mass/volume] in Blood: 4.0 (nanogram per milliliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 998 (cells per microliter)\n- Platelets [#/volume] in Blood by Automated count: 355 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.71 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.9 (percent)\n- MCHC [Mass/volume] by Automated count: 30.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 650 (cells per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 8 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 268 (cells per microliter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter calculated)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.6 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 70.8 (percent)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.3 (calculated)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 112 (unit per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.7 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-19 00:00:00, ended at 2018-12-19 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-21 00:00:00, ended at 2018-12-21 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-24 00:00:00, ended at 2018-12-24 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-25 00:00:00, ended at 2018-12-25 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-28 00:00:00, ended at 2018-12-28 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-31 00:00:00, ended at 2018-12-31 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-04 00:00:00, ended at 2019-01-04 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-07 00:00:00, ended at 2019-01-07 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.4 (percent)\n- MCH [Entitic mass] by Automated count: 22.6 (picogram)\n- MCV [Entitic volume] by Automated count: 77.1 (femtoliter)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 13.0 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter calculated)\n- Glucose [Mass/volume] in Serum or Plasma: 328 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.3 (percent)\n- MCHC [Mass/volume] by Automated count: 29.3 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.1 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 865 (cells per microliter)\n- Tacrolimus [Mass/volume] in Blood by LC/MS/MS: 1.2 (microgram per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 94 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 59 (cells per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.70 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 370 (cells per microliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 714 (cells per microliter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 16 (calculated)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.1 (calculated)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.33 (million per liter)\n- Platelets [#/volume] in Blood by Automated count: 319 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.4 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6392 (cells per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.4 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.5 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-11 00:00:00, ended at 2019-01-11 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-11 00:00:00, ended at 2019-01-11 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2019-01-12 23:47:00, ended at 2019-01-20 14:28:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: 34.10 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 31.0 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.6 (millimole per liter)\n- Tacrolimus [Mass/volume] in Blood: 8.4 (nanogram per milliliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 3.731 (nanogram per milliliter)\n- Albumin [Mass/volume] in Urine: 203 (milligram per liter)\n- Body height: 5' 5\" (inch (US))\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.13 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma: >70000 (picogram per milliliter)\n- Platelets [#/volume] in Blood by Automated count: 273 (thousand per microliter)\n- Prothrombin time (PT): 14.3 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 95.8 (second)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.67 (million per microliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 10.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.6 (thousand per microliter)\n- Microalbumin/Creatinine [Mass Ratio] in Urine: 595 (milligram per gram)\n- Sodium/Creatinine [Molar ratio] in Urine: <20 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Anion gap in Serum or Plasma: 21 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 375 (milligram per deciliter)\n- Lactate [Moles/volume] in Blood: 1.9 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 23.2 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 85.9 (percent)\n- Salicylates [Presence] in Urine: <0.3 (milligram per deciliter)\n- Base excess in Arterial blood by calculation: -8.0 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.20 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Glucose [Mass/volume] in Blood: 96 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.9 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 60 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Everolimus [Mass/volume] in Blood: 9.3 (nanogram per milliliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCV [Entitic volume] by Automated count: 76.7 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.93 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 79 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 3.88 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.0 (percent)\n- Heparin unfractionated [Units/volume] in Platelet poor plasma: <0.10 (unit per milliliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Bicarbonate [Moles/volume] in Specimen: 18.6 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Left ventricular Ejection fraction: 41.4 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.5 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Ultrasound, retroperitoneal (eg, renal, aorta, nodes), real time with image documentation; complete\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Collection of venous blood by venipuncture\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements f\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging)\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes (List separately in addition to code for primary service)\n- Radiologic examination, chest; single view\n- Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right heart catheterization\n- Hospital discharge day management; 30 minutes or less\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Excision of Right Ventricle, Percutaneous Approach, Diagnostic\n- Fluoroscopy of Multiple Coronary Arteries using Low Osmolar Contrast\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Medical decision making that is straightforward or o\n- Endomyocardial biopsy\n\n### Condition\n- Cardiac transplant failure\n- Chronic kidney disease stage 3\n- Open wound of foot\n- Renal disorder due to type 2 diabetes mellitus\n- Sepsis\n- Acute on chronic combined systolic and diastolic heart failure\n- Acute tubular necrosis\n- Anemia in chronic kidney disease\n- Electrocardiogram abnormal\n- Hyperglycemia due to type 2 diabetes mellitus\n- Obesity\n- Peripheral vascular disease\n- Severe protein-calorie malnutrition (Gomez: less than 60 percent of standard weight)\n- Tachycardia\n- Transplanted heart present\n- Acidosis\n- Acute non-ST segment elevation myocardial infarction\n- Acute renal failure syndrome\n- Cardiogenic shock\n- Coronary thrombosis not resulting in myocardial infarction\n- Chronic pulmonary edema\n- Hyperkalemia\n- Localized edema\n- Pulmonary hypertension\n- Viral pneumonia\n- Atherosclerosis of coronary artery without angina pectoris\n- Blood coagulation disorder\n- Cardiomegaly\n- Chronic kidney disease stage 4\n- Hypertensive heart and renal disease with (congestive) heart failure\n- Acquired absence of organ\n- Acute ischemic heart disease\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Disorder of immune function\n- Heart disease\n- Old myocardial infarction\n- Atrial fibrillation\n- Cardiac transplant rejection\n- Primary diagnosis: Chronic ischemic heart disease\n- Disorder of transplanted heart\n- Hypokalemia\n- Late effect of complications of procedure\n- Septic shock\n- Absence of toe\n- Acute on chronic hypoxemic respiratory failure\n- Congestive heart failure\n- Hypo-osmolality and or hyponatremia\n- Pneumonia and influenza\n- Takotsubo cardiomyopathy\n- Type 2 diabetes mellitus\n- Upper respiratory tract infection due to Influenza\n- Backache\n- Dehydration\n\n### Drug\n- bumetanide 2 MG Oral Tablet, through Oral route, started on 2019-01-20, presumably until 2019-01-20\n- sodium bicarbonate 650 MG Oral Tablet, through Oral route, started on 2019-01-15, presumably until 2019-01-19\n- chlorothiazide 500 MG Oral Tablet, through Oral route, started on 2019-01-14, presumably until 2019-01-15\n- acyclovir 200 MG Oral Capsule, through Oral route, started on 2019-01-15, presumably until 2019-03-06, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day for 30 days\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Cartridge, started on 2019-01-17, presumably until 2019-01-18\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2019-01-17, presumably until 2019-01-17\n- methylprednisolone 40 MG Injection, started on 2019-01-13, presumably until 2019-01-15\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-20\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2019-01-13, presumably until 2019-01-14\n- tacrolimus 1 MG Oral Capsule, through Oral route, started on 2019-01-13, presumably until 2019-01-15\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-13\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-13\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-13\n- aspirin 325 MG Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-14\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-19\n- dextromethorphan hydrobromide 2 MG/ML / guaifenesin 20 MG/ML Oral Solution, through Oral route, started on 2019-01-13, presumably until 2019-01-13\n- clonidine hydrochloride 0.1 MG Oral Tablet, through Oral route, started on 2019-01-20, presumably until 2019-01-20\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2019-01-17, presumably until 2019-01-20\n- insulin isophane, human 100 UNT/ML Injectable Suspension, through Subcutaneous route, started on 2019-01-14, presumably until 2019-01-20\n- 250 ML dopamine hydrochloride 1.6 MG/ML Injection, through Intravenous route, started on 2019-01-13, presumably until 2019-01-19\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2019-01-13, presumably until 2019-01-13\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2019-01-15, presumably until 2019-01-16\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-02-01, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2019-01-13, presumably until 2019-01-13\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2019-01-18, presumably until 2020-01-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning with breakfast\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2019-01-14, presumably until 2019-01-15\n- tacrolimus 0.5 MG Oral Capsule, through Oral route, started on 2019-01-18, presumably until 2019-02-15, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-01-13, presumably until 2019-01-19\n- everolimus 0.75 MG Oral Tablet, through Oral route, started on 2019-01-20, presumably until 2019-02-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day Cytotoxic. Take with or without food. Swallow whole. do not break, chew or crush tablets.\n- lidocaine hydrochloride 0.02 MG/MG Topical Gel, through Submucosal route, started on 2019-01-13, presumably until 2019-01-13\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2019-01-13, presumably until 2019-01-13\n- oseltamivir 6 MG/ML Oral Suspension, through Oral route, started on 2019-01-13, presumably until 2019-01-16\n- benzonatate 100 MG Oral Capsule, through Oral route, started on 2019-01-13, presumably until 2019-01-13\n- sulfamethoxazole 400 MG / trimethoprim 80 MG Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-19\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-20\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-19\n- bumetanide 0.25 MG/ML Injectable Solution, through Intravenous route, started on 2019-01-13, presumably until 2019-01-19\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-19\n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-20\n- ondansetron 8 MG Disintegrating Oral Tablet, through Oral route, started on 2019-01-16, presumably until 2019-01-16\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2019-01-13, presumably until 2019-01-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2019-01-13 00:00:00, ended at 2019-01-13 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2019-01-13, presumably until 2019-01-13\n- iodixanol, through Intravenous route, started on 2019-01-13, presumably until 2019-01-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-14 00:00:00, ended at 2019-01-14 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-18 00:00:00, ended at 2019-01-18 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-21 00:00:00, ended at 2019-01-21 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-23 00:00:00, ended at 2019-01-23 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2019-01-23, presumably until 2019-02-19, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day Cytotoxic. Take with or without food. Swallow whole. do not break, chew or crush tablets.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-25 00:00:00, ended at 2019-01-25 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-28 00:00:00, ended at 2019-01-28 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-02-01 00:00:00, ended at 2019-02-01 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-02-01, presumably until 2019-02-19, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-01 00:00:00, ended at 2019-02-01 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-04 00:00:00, ended at 2019-02-04 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-08 00:00:00, ended at 2019-02-08 00:00:00\nThe patient in this visit was 55 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-11 00:00:00, ended at 2019-02-11 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-13 00:00:00, ended at 2019-02-13 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-14 00:00:00, ended at 2019-02-14 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-02-14 08:38:00, ended at 2019-02-14 10:14:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 4.28 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.9 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.1 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.5 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 23.4 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 5.44 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 312 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.42 (milligram per deciliter)\n- Everolimus [Mass/volume] in Blood: 2.6 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.4 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.3 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 85 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 94 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.00 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 79.2 (femtoliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.6 (percent)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 51 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 15 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 29.5 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.9 (percent)\n- Tacrolimus [Mass/volume] in Blood: 1.7 (nanogram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n\n### Condition\n- Essential hypertension\n- Disorder of transplanted heart\n- Transplanted heart present\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-14 09:01:55, ended at 2019-02-14 10:07:14\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2019-02-14 10:15:00, ended at 2019-02-14 23:59:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 68.0 (percent)\n\n### Procedure\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging)\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-15 00:00:00, ended at 2019-02-15 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-02-15 00:00:00, ended at 2019-02-15 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- tacrolimus 1 MG Oral Capsule, through Oral route, started on 2019-02-15, presumably until 2019-10-04, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day Total dose of 1mg Am, 1.5mg PM\n- tacrolimus 0.5 MG Oral Capsule, through Oral route, started on 2019-02-15, presumably until 2019-10-04, with intended 1 refill(s). Instructions: take 1 Cap by mouth PM Total dose of 1mg AM, 1.5mg PM; Z94.1, Fax: 999-999-9999\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-18 00:00:00, ended at 2019-02-18 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-02-19 00:00:00, ended at 2019-02-19 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n\n### Drug\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2019-02-19, presumably until 2019-05-01, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day Take 0.5 mg in AM and 1 mg in PM\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-19 00:00:00, ended at 2019-02-19 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 2.5 MG Oral Tablet, through Oral route, started on 2019-02-19, presumably until 2019-04-03, with intended 6 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-22 00:00:00, ended at 2019-02-22 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-25 00:00:00, ended at 2019-02-25 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-01 00:00:00, ended at 2019-03-01 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-04 00:00:00, ended at 2019-03-04 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.4 (percent)\n- MCV [Entitic volume] by Automated count: 76.2 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 200 (cells per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 842 (cells per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4802 (cells per microliter)\n- Tacrolimus [Mass/volume] in Blood by LC/MS/MS: 3.4 (microgram per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 24 (calculated)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter calculated)\n- Lymphocytes [#/volume] in Blood by Automated count: 987 (cells per microliter)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.0 (calculated)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.05 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.9 (thousand per microliter)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 12.5 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 50 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.2 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 69 (cells per microliter)\n- MCHC [Mass/volume] by Automated count: 31.3 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 85 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 82 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.2 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.86 (million per liter)\n- MCH [Entitic mass] by Automated count: 23.8 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 301 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.0 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.3 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-03-06 00:00:00, ended at 2019-03-06 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- acyclovir 200 MG Oral Capsule, through Oral route, started on 2019-03-06, presumably until 2019-07-05, with intended 6 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-08 00:00:00, ended at 2019-03-08 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-11 00:00:00, ended at 2019-03-11 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-11 00:00:00, ended at 2019-03-11 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-15 00:00:00, ended at 2019-03-15 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-18 00:00:00, ended at 2019-03-18 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-22 00:00:00, ended at 2019-03-22 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-25 00:00:00, ended at 2019-03-25 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-29 00:00:00, ended at 2019-03-29 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-01 00:00:00, ended at 2019-04-01 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-03 00:00:00, ended at 2019-04-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- prednisone 2.5 MG Oral Tablet, through Oral route, started on 2019-04-03, presumably until 2019-10-03, with intended 6 refill(s). Instructions: take 1 Tab (2.5 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-04-03 00:00:00, ended at 2019-04-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-04-03 00:00:00, ended at 2019-04-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-04-04 00:00:00, ended at 2019-04-04 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperglycemia due to type 2 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-05 00:00:00, ended at 2019-04-05 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-08 00:00:00, ended at 2019-04-08 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-12 00:00:00, ended at 2019-04-12 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-15 00:00:00, ended at 2019-04-15 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-19 00:00:00, ended at 2019-04-19 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-22 00:00:00, ended at 2019-04-22 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-26 00:00:00, ended at 2019-04-26 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-26 00:00:00, ended at 2019-04-26 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-29 00:00:00, ended at 2019-04-29 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-29 09:45:00, ended at 2019-04-29 23:59:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 91 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 29.8 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.89 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 330 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.2 (percent)\n- MCV [Entitic volume] by Automated count: 82.0 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.8 (percent)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.0 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.7 (percent)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.2 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.1 (thousand per microliter)\n- Tacrolimus [Mass/volume] in Blood: 2.7 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 69 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.4 (percent)\n- Everolimus [Mass/volume] in Blood: 1.8 (nanogram per milliliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.11 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.17 (million per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.5 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 24.5 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 4.01 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n- Essential hypertension\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-04-30 00:00:00, ended at 2019-04-30 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-04-30 00:00:00, ended at 2019-04-30 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-05-01 00:00:00, ended at 2019-05-01 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n\n### Drug\n- everolimus 1 MG Oral Tablet, through Oral route, started on 2019-05-01, presumably until 2019-07-09, with intended 11 refill(s). Instructions: take 1 mg by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-05-03 00:00:00, ended at 2019-05-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-05-06 00:00:00, ended at 2019-05-06 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-05-06 00:00:00, ended at 2019-05-06 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.5 (percent)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 12.2 (femtoliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.90 (million per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 951 (cells per microliter)\n- MCV [Entitic volume] by Automated count: 77.4 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.2 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Tacrolimus [Mass/volume] in Blood by LC/MS/MS: 3.0 (microgram per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 161 (cells per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4904 (cells per microliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter calculated)\n- Potassium [Moles/volume] in Serum or Plasma: 5.2 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 22 (calculated)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.45 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 24.4 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.6 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.2 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 40 (cells per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 127 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 31.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 643 (cells per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 54 (milligram per deciliter)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.2 (calculated)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 299 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-05-10 00:00:00, ended at 2019-05-10 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-05-13 00:00:00, ended at 2019-05-13 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-05-17 00:00:00, ended at 2019-05-17 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-05-20 00:00:00, ended at 2019-05-20 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-05-24 00:00:00, ended at 2019-05-24 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-05-27 00:00:00, ended at 2019-05-27 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-05-31 00:00:00, ended at 2019-05-31 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-31 09:30:00, ended at 2019-05-31 23:59:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of lower extremity arteries or arterial bypass grafts; unilateral or limited study\n- Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording \n\n### Condition\n- Gangrenous disorder\n- Peripheral vascular disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-31 09:30:15, ended at 2019-05-31 11:29:56\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Gangrenous disorder\n- Primary diagnosis: Peripheral vascular disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-03 00:00:00, ended at 2019-06-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-07 00:00:00, ended at 2019-06-07 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-10 00:00:00, ended at 2019-06-10 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-14 00:00:00, ended at 2019-06-14 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-17 00:00:00, ended at 2019-06-17 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-21 00:00:00, ended at 2019-06-21 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-24 00:00:00, ended at 2019-06-24 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-28 00:00:00, ended at 2019-06-28 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-01 00:00:00, ended at 2019-07-01 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-03 00:00:00, ended at 2019-07-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Fatigue\n- Pure hypercholesterolemia\n- Type 1 diabetes mellitus without complication\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-03 00:00:00, ended at 2019-07-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-03 00:00:00, ended at 2019-07-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-04 00:00:00, ended at 2019-07-04 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Iron saturation [Mass Fraction] in Serum or Plasma: 9 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Iron deficiency anemia\n\n### Drug\n- rosuvastatin calcium 20 MG Oral Tablet, through Oral route, presumably until 2019-07-12, with intended 11 refill(s). Instructions: take 1 Tab (20 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-04 07:37:00, ended at 2019-07-04 09:47:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 4.0 (ratio)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.10 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hemoglobin [Mass/volume] in Blood: 10.2 (gram per deciliter)\n- Tacrolimus [Mass/volume] in Blood: 2.8 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.2 (percent)\n- Everolimus [Mass/volume] in Blood: 2.7 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 20.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 242 (thousand per microliter)\n- Protein/Creatinine [Mass Ratio] in Urine: 0.89 (milligram per milligram)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Cholesterol [Mass/volume] in Serum or Plasma: 259 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.22 (million per microliter)\n- MCH [Entitic mass] by Automated count: 24.2 (picogram)\n- MCV [Entitic volume] by Automated count: 78.9 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.16 (thousand per microliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 202 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 100 (unit per liter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 9.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.3 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.10 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 52 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 116 (unit per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 60.1 (percent)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 171 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 30.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 158 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.3 (thousand per microliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 49.0 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 65 (milligram per deciliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 194 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 55.28 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n\n### Condition\n- Pure hypercholesterolemia\n- Fatigue\n- Disorder of transplanted heart\n- Transplanted heart present\n- Type 1 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-07-04 08:10:26, ended at 2019-07-04 09:43:16\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Acute ST segment elevation myocardial infarction\n- Disorder of transplanted heart\n- Transplanted heart present\n- Conduction disorder of the heart\n- Electrocardiogram abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-04 09:48:00, ended at 2019-07-04 23:59:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 67.2 (percent)\n\n### Procedure\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; supervision only, without interpretation and report\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; tracing only, without interpretation and report\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation \n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; interpretation and report only\n\n### Condition\n- Cardiomegaly\n- Pure hypercholesterolemia\n- Transplanted heart present\n- Disorder of transplanted heart\n- Type 1 diabetes mellitus without complication\n- Iron deficiency anemia\n- Fatigue\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-05 00:00:00, ended at 2019-07-05 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-07-05 00:00:00, ended at 2019-07-05 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Primary diagnosis: Transplanted heart present\n\n### Drug\n- bumetanide 2 MG Oral Tablet, through Oral route, started on 2019-07-05, presumably until 2019-10-04, with intended 3 refill(s). Instructions: take 1 Tab (2 mg total) by mouth daily 2nd prescription, please dispense!\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2019-07-05, presumably until 2020-07-30, with intended 3 refill(s). Instructions: take 1 Tab by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-08 00:00:00, ended at 2019-07-08 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-09 00:00:00, ended at 2019-07-09 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2019-07-09, presumably until 2019-10-22, with intended 11 refill(s). Instructions: take 1 Tab (0.5 mg total) by mouth 2 times a day Take 1 mg in AM and 1.5mg in PM.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-07-09 00:00:00, ended at 2019-07-09 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n\n### Drug\n- everolimus 1 MG Oral Tablet, through Oral route, started on 2019-07-09, presumably until 2019-12-23, with intended 11 refill(s). Instructions: take 2 mg by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-07-12 00:00:00, ended at 2019-07-12 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n\n### Drug\n- rosuvastatin calcium 20 MG Oral Tablet, through Oral route, started on 2019-07-12, presumably until 2020-08-21, with intended 11 refill(s). Instructions: take 1 Tab (20 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-12 00:00:00, ended at 2019-07-12 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-15 00:00:00, ended at 2019-07-15 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-19 00:00:00, ended at 2019-07-19 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-22 00:00:00, ended at 2019-07-22 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-25 00:00:00, ended at 2019-07-25 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-26 00:00:00, ended at 2019-07-26 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-29 00:00:00, ended at 2019-07-29 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2019-07-31 00:00:00, ended at 2019-07-31 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Endomyocardial biopsy\n\n### Condition\n- Transplanted heart present\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2019-07-31, presumably until 2019-07-31\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-31 00:00:00, ended at 2019-07-31 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-31 11:18:00, ended at 2019-07-31 12:26:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 253 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 30.7 (gram per deciliter)\n- Tacrolimus [Mass/volume] in Blood: 4.4 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.5 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.24 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.0 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.6 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.28 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 68 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Everolimus [Mass/volume] in Blood: 5.6 (nanogram per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 24.6 (picogram)\n- MCV [Entitic volume] by Automated count: 79.9 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.88 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 213 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 17.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 104 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.48 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.8 (percent)\n\n### Procedure\n- Endomyocardial biopsy\n- Excision of Right Ventricle, Percutaneous Approach, Diagnostic\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Collection of venous blood by venipuncture\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n- Cardiac transplant rejection\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-01 00:00:00, ended at 2019-08-01 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2019-08-01, presumably until 2020-09-04, with intended 11 refill(s). Instructions: take 1 Cap (250 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-02 00:00:00, ended at 2019-08-02 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-05 00:00:00, ended at 2019-08-05 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-09 00:00:00, ended at 2019-08-09 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-12 00:00:00, ended at 2019-08-12 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-16 00:00:00, ended at 2019-08-16 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-19 00:00:00, ended at 2019-08-19 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-23 00:00:00, ended at 2019-08-23 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-26 00:00:00, ended at 2019-08-26 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-30 00:00:00, ended at 2019-08-30 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-02 00:00:00, ended at 2019-09-02 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-06 00:00:00, ended at 2019-09-06 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-09 00:00:00, ended at 2019-09-09 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Disorder of fluid AND/OR electrolyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-11 00:00:00, ended at 2019-09-11 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-13 00:00:00, ended at 2019-09-13 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-13 00:00:00, ended at 2019-09-13 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-16 00:00:00, ended at 2019-09-16 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of fluid AND/OR electrolyte\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-10-02 00:00:00, ended at 2019-10-02 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-10-03 00:00:00, ended at 2019-10-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- mycophenolate mofetil 500 MG Oral Tablet, through Oral route, started on 2019-10-03, presumably until 2020-10-16, with intended 11 refill(s). Instructions: take 2 Tabs (1,000 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-10-03 00:00:00, ended at 2019-10-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-03 09:51:00, ended at 2019-10-03 10:28:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 63.7 (percent)\n\n### Procedure\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging)\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study\n\n### Condition\n- Disorder of transplanted heart\n- Pure hypercholesterolemia\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-03 10:29:00, ended at 2019-10-03 23:59:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.80 (million per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67.5 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 77 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.46 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 54 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.82 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- Tacrolimus [Mass/volume] in Blood: 1.0 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.0 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 184 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 30.7 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.19 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 81.3 (femtoliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.9 (percent)\n- MCH [Entitic mass] by Automated count: 25.0 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 172 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-03 11:26:41, ended at 2019-10-03 12:14:25\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pure hypercholesterolemia\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- clonidine hydrochloride 0.1 MG Oral Tablet, through Oral route, presumably until 2020-10-20, with intended 11 refill(s). Instructions: take 0.1-0.2 mg by mouth as directed Take 0.1mg QAM and 0.2mg QPM\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-10-04 00:00:00, ended at 2019-10-04 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- bumetanide 1 MG Oral Tablet, through Oral route, started on 2019-10-04, presumably until 2019-11-26, with intended 3 refill(s). Instructions: take 1 Tab (1 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2019-10-15 00:00:00, ended at 2019-10-15 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2019-10-15, presumably until 2019-10-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-15 09:46:00, ended at 2019-10-15 12:19:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 85 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 158 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.49 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.4 (percent)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Anion gap in Serum or Plasma: 15 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 79.9 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.65 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.1 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22.0 (percent)\n- MCH [Entitic mass] by Automated count: 25.1 (picogram)\n- MCHC [Mass/volume] by Automated count: 31.5 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 40 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.02 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.33 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 64.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 264 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.1 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Endomyocardial biopsy\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n\n### Condition\n- Acquired absence of organ\n- Absence of toe\n- Chronic kidney disease due to hypertension\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Chronic kidney disease\n- Disorder of transplanted heart\n- Hyperlipidemia\n- Type 2 diabetes mellitus\n- Transplanted heart present\n- Cardiac transplant rejection\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-10-16 00:00:00, ended at 2019-10-16 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Everolimus [Mass/volume] in Blood: 9.4 (nanogram per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-10-19 00:00:00, ended at 2019-10-19 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-10-22 00:00:00, ended at 2019-10-22 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2019-10-22, presumably until 2020-04-24, with intended 11 refill(s). Instructions: take 1 mg by mouth 2 times a day \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-11-21 00:00:00, ended at 2019-11-21 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Complication due to diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- 3 ML insulin lispro 100 UNT/ML Pen Injector, started on 2019-11-22, presumably until 2022-06-10, with intended 11 refill(s). Instructions: INJECT 17 UNITS SUB-CUTANEOUSLY( UNDER THE SKIN) THREE TIMES DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-11-22 00:00:00, ended at 2019-11-22 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydralazine hydrochloride 100 MG Oral Tablet, through Oral route, started on 2019-11-22, presumably until 2021-06-04, with intended 11 refill(s). Instructions: take 1 Tab (100 mg total) by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-11-22 00:00:00, ended at 2019-11-22 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Complication due to diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- 3 ML insulin lispro 100 UNT/ML Pen Injector, started on 2019-11-22, presumably until 2019-11-22, with intended 11 refill(s). Instructions: INJECT 17 UNITS UNDER THE SKIN(UNDER THE SKIN) THREE TIMES DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-11-26 00:00:00, ended at 2019-11-26 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- 24 HR isosorbide mononitrate 30 MG Extended Release Oral Tablet, through Oral route, presumably until 2019-12-23, with intended 2 refill(s). Instructions: take 1 Tab (30 mg total) by mouth as directed\n- bumetanide 1 MG Oral Tablet, through Oral route, started on 2019-11-26, presumably until 2020-09-10, with intended 3 refill(s). Instructions: take 2 Tabs (2 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-11-27 00:00:00, ended at 2019-11-27 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Complication due to diabetes mellitus\n\n### Drug\n- 3 ML insulin isophane, human 100 UNT/ML Pen Injector, started on 2019-11-27, presumably until 2021-02-02, with intended 6 refill(s). Instructions: Inject subcutaneously 22 units AM, 22 units PM\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-04 00:00:00, ended at 2019-12-04 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Peripheral vascular disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-12-07 00:00:00, ended at 2019-12-07 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperosmolarity\n- Type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-10 00:00:00, ended at 2019-12-10 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Hyperosmolarity\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-20 00:00:00, ended at 2019-12-20 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-23 09:55:00, ended at 2019-12-23 23:59:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.99 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 46 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 17 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.8 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 25.3 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 3.69 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.19 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 30.3 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 209 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.67 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.3 (percent)\n- MCV [Entitic volume] by Automated count: 83.5 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.7 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 89 (unit per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.2 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.13 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.1 (gram per deciliter)\n\n### Procedure\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n- Collection of venous blood by venipuncture\n\n### Condition\n- Pure hypercholesterolemia\n- Disorder of transplanted heart\n- Hyperlipidemia\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-23 10:19:13, ended at 2019-12-23 11:39:05\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n- Everolimus [Mass/volume] in Blood: 1.4 (nanogram per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Pure hypercholesterolemia\n- Transplanted heart present\n\n### Drug\n- 24 HR isosorbide mononitrate 30 MG Extended Release Oral Tablet, through Oral route, started on 2019-12-23, presumably until 2020-12-10, with intended 3 refill(s). Instructions: take 1 Tab (30 mg total) by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-24 00:00:00, ended at 2019-12-24 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.4 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 224 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 45 (milligram per deciliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- C reactive protein [Mass/volume] in Serum or Plasma by High sensitivity method: 3.0 (milligram per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.3 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 827 (cells per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 157 (milligram per deciliter)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.2 (calculated)\n- MCHC [Mass/volume] by Automated count: 31.7 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3631 (cells per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 233 (cells per microliter)\n- Homocysteine [Moles/volume] in Serum or Plasma: 12.3 (micromole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.6 (percent)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 13.5 (femtoliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.05 (million per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.1 (percent)\n- MCH [Entitic mass] by Automated count: 25.9 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 42 (cells per microliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 77 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter calculated)\n- Monocytes [#/volume] in Blood by Automated count: 567 (cells per microliter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 27 (calculated)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 86 (unit per liter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 51 (milligram per deciliter)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 1.5 (ratio)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.66 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 116 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 81.7 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 159 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 3.1 (ratio)\n- Lipoprotein a [Mass/volume] in Serum or Plasma: 221.8 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hyperlipidemia\n- Hypomagnesemia\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2019-12-24, presumably until 2020-10-06, with intended 3 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-26 00:00:00, ended at 2019-12-26 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-30 00:00:00, ended at 2019-12-30 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-01-02 00:00:00, ended at 2020-01-02 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperosmolarity\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-03 00:00:00, ended at 2020-01-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-06 00:00:00, ended at 2020-01-06 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-10 00:00:00, ended at 2020-01-10 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-10 08:12:00, ended at 2020-01-10 09:59:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of lower extremity arteries or arterial bypass grafts; unilateral or limited study\n- Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording \n\n### Condition\n- Peripheral vascular disease\n- Disorder of soft tissue\n- Localized edema\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-10 08:12:54, ended at 2020-01-10 14:56:11\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Peripheral vascular disease\n- Disorder of soft tissue\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-10 10:00:00, ended at 2020-01-10 23:59:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study\n\n### Condition\n- Localized edema\n- Disorder of soft tissue\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-13 00:00:00, ended at 2020-01-13 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-17 00:00:00, ended at 2020-01-17 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-20 00:00:00, ended at 2020-01-20 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-24 00:00:00, ended at 2020-01-24 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-27 00:00:00, ended at 2020-01-27 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-31 00:00:00, ended at 2020-01-31 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-03 00:00:00, ended at 2020-02-03 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-07 00:00:00, ended at 2020-02-07 00:00:00\nThe patient in this visit was 56 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-10 00:00:00, ended at 2020-02-10 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-14 00:00:00, ended at 2020-02-14 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-17 00:00:00, ended at 2020-02-17 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-21 00:00:00, ended at 2020-02-21 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-24 00:00:00, ended at 2020-02-24 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-28 00:00:00, ended at 2020-02-28 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-02 00:00:00, ended at 2020-03-02 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-06 00:00:00, ended at 2020-03-06 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-09 00:00:00, ended at 2020-03-09 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-13 00:00:00, ended at 2020-03-13 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-16 00:00:00, ended at 2020-03-16 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-20 00:00:00, ended at 2020-03-20 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-23 00:00:00, ended at 2020-03-23 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-27 00:00:00, ended at 2020-03-27 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-30 00:00:00, ended at 2020-03-30 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-30 00:00:00, ended at 2020-03-30 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperosmolarity\n- Primary diagnosis: Type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-03 00:00:00, ended at 2020-04-03 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-06 00:00:00, ended at 2020-04-06 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-10 00:00:00, ended at 2020-04-10 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-13 00:00:00, ended at 2020-04-13 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 148 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.9 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 31.7 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 214 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 44 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 3202 (cells per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 26 (calculated)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 49 (cells per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.18 (million per liter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter calculated)\n- MCH [Entitic mass] by Automated count: 25.1 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.3 (calculated)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 80 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.1 (percent)\n- MCV [Entitic volume] by Automated count: 79.2 (femtoliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.69 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 259 (cells per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.8 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.1 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.5 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.4 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 751 (cells per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1139 (cells per microliter)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 13.0 (femtoliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-15 14:40:50, ended at 2020-04-15 15:07:23\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperosmolarity\n- Primary diagnosis: Type 2 diabetes mellitus\n\n### Drug\n- 0.5 ML dulaglutide 1.5 MG/ML Auto-Injector, through Subcutaneous route, started on 2020-04-15, presumably until 2020-11-03, with intended 11 refill(s). Instructions: inject 0.75 mg subcutaneous (under the skin) once a week\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-17 00:00:00, ended at 2020-04-17 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-20 00:00:00, ended at 2020-04-20 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-21 00:00:00, ended at 2020-04-21 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.6 (percent)\n- Everolimus [Mass/volume] in Blood: 1.9 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 10.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 25.3 (picogram)\n- MCV [Entitic volume] by Automated count: 79.8 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 31.7 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.9 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3819 (cells per microliter)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 12.7 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 239 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 102 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 202 (cells per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 34 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.15 (million per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 16.8 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 610 (cells per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.1 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 19 (calculated)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.75 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 28 (cells per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 941 (cells per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-24 00:00:00, ended at 2020-04-24 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2020-04-24, presumably until 2020-07-16, with intended 11 refill(s). Instructions: take 3 Tabs (1.5 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-24 00:00:00, ended at 2020-04-24 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-27 00:00:00, ended at 2020-04-27 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-01 00:00:00, ended at 2020-05-01 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-04 00:00:00, ended at 2020-05-04 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-06 00:00:00, ended at 2020-05-06 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-06 00:00:00, ended at 2020-05-06 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-06 00:00:00, ended at 2020-05-06 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-08 00:00:00, ended at 2020-05-08 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-11 00:00:00, ended at 2020-05-11 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-15 00:00:00, ended at 2020-05-15 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-18 00:00:00, ended at 2020-05-18 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-22 00:00:00, ended at 2020-05-22 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-25 00:00:00, ended at 2020-05-25 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-29 00:00:00, ended at 2020-05-29 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-01 00:00:00, ended at 2020-06-01 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-05 00:00:00, ended at 2020-06-05 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-08 00:00:00, ended at 2020-06-08 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-12 00:00:00, ended at 2020-06-12 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-15 00:00:00, ended at 2020-06-15 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypomagnesemia\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-16 00:00:00, ended at 2020-07-16 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2020-07-16, presumably until 2021-04-27, with intended 11 refill(s). Instructions: take 1 Tab (0.5 mg total) by mouth 2 times a day Total dose of 1.5mg twice daily\n- everolimus 1 MG Oral Tablet, through Oral route, started on 2020-07-16, presumably until 2020-07-29, with intended 11 refill(s). Instructions: take 1 Tab (1 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-23 10:45:04, ended at 2020-07-23 11:09:56\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose mean value [Mass/volume] in Blood Estimated from glycated hemoglobin: 183 (milligram per deciliter calculated)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 7.3 (percent hemoglobin)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Complication due to diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n- Postprocedural asymptomatic ovarian failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-24 00:00:00, ended at 2020-07-24 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 109 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.9 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1056 (cells per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 622 (cells per microliter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 16 (calculated)\n- Neutrophils [#/volume] in Blood by Automated count: 3625 (cells per microliter)\n- Platelets [#/volume] in Blood by Automated count: 223 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.09 (million per liter)\n- MCH [Entitic mass] by Automated count: 26.2 (picogram)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.2 (percent)\n- MCV [Entitic volume] by Automated count: 80.4 (femtoliter)\n- Basophils [#/volume] in Blood by Automated count: 39 (cells per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 160 (cells per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.9 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.34 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.3 (percent)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 12.3 (femtoliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.7 (gram per deciliter)\n- Everolimus [Mass/volume] in Blood: 2.7 (nanogram per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-29 00:00:00, ended at 2020-07-29 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-07-29 00:00:00, ended at 2020-07-29 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n\n### Drug\n- ferrous sulfate 325 MG Oral Tablet, started on 2020-07-30, presumably until 2022-06-09, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-29 00:00:00, ended at 2020-07-29 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- everolimus 1 MG Oral Tablet, through Oral route, started on 2020-07-29, presumably until 2021-04-29, with intended 11 refill(s). Instructions: take 1-2 Tabs (1-2 mg total) by mouth 2 times a day Take 1.5 mg in AM and 2 mg in PM\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-13 00:00:00, ended at 2020-08-13 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.44 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 181 (cells per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.7 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.8 (percent)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.5 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.4 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.12 (million per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 36 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 69 (cells per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.9 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 902 (cells per microliter)\n- MCV [Entitic volume] by Automated count: 79.6 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3136 (cells per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 64 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 613 (cells per microliter)\n- Platelets [#/volume] in Blood by Automated count: 205 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 25 (calculated)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.8 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Everolimus [Mass/volume] in Blood: 3.2 (nanogram per milliliter)\n- MCH [Entitic mass] by Automated count: 26.2 (picogram)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 12.5 (femtoliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-21 00:00:00, ended at 2020-08-21 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Primary diagnosis: Transplanted heart present\n- Pure hypercholesterolemia\n\n### Drug\n- rosuvastatin calcium 20 MG Oral Tablet, through Oral route, started on 2020-08-21, presumably until 2021-02-02, with intended 3 refill(s). Instructions: take 1 Tab (20 mg total) by mouth daily\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2020-08-21, presumably until 2021-09-28, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-09-03 00:00:00, ended at 2020-09-03 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- docusate sodium 250 MG Oral Capsule, started on 2020-09-04, presumably until 2021-05-03, with intended 11 refill(s). Instructions: TAKE 1 CAPSULE(250 MG) BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-09-09 00:00:00, ended at 2020-09-09 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Peripheral vascular disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-09-10 00:00:00, ended at 2020-09-10 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- bumetanide 1 MG Oral Tablet, through Oral route, started on 2020-09-10, presumably until 2021-02-26, with intended 3 refill(s). Instructions: take 2 Tabs (2 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-11 12:09:00, ended at 2020-09-11 23:59:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of lower extremity arteries or arterial bypass grafts; unilateral or limited study\n- Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording \n\n### Condition\n- Peripheral vascular disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-09-25 00:00:00, ended at 2020-09-25 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-02 00:00:00, ended at 2020-10-02 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-05 00:00:00, ended at 2020-10-05 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-06 00:00:00, ended at 2020-10-06 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Primary diagnosis: Transplanted heart present\n\n### Drug\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2020-10-06, presumably until 2021-02-26, with intended 3 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-10-07 00:00:00, ended at 2020-10-07 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperosmolarity\n- Type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-09 00:00:00, ended at 2020-10-09 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-12 00:00:00, ended at 2020-10-12 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-10-12 00:00:00, ended at 2020-10-12 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- mycophenolate mofetil 500 MG Oral Tablet, started on 2020-10-16, presumably until 2020-10-16, with intended 11 refill(s). Instructions: TAKE 2 TABLETS BY MOUTH 2 TIMES A DAY.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-16 00:00:00, ended at 2020-10-16 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Blood glucose abnormal\n- Pure hypercholesterolemia\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-16 00:00:00, ended at 2020-10-16 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- mycophenolate mofetil 500 MG Oral Tablet, through Oral route, started on 2020-10-16, presumably until 2021-11-18, with intended 11 refill(s). Instructions: take 2 Tabs (1,000 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-19 00:00:00, ended at 2020-10-19 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-19 06:12:00, ended at 2020-10-19 06:50:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 187 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 25.8 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.16 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.49 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 26.48 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.57 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 116 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.0 (percent)\n- MCHC [Mass/volume] by Automated count: 31.2 (gram per deciliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 78.0 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 106 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.6 (percent)\n- Everolimus [Mass/volume] in Blood: 7.6 (nanogram per milliliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 7.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.8 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.04 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 82.7 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 220 (thousand per microliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 236 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.49 (micro-international unit per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 88 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.49 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Cholesterol [Mass/volume] in Serum or Plasma: 169 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 53 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 84 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.8 (percent)\n- Anion gap in Serum or Plasma: 15 (millimole per liter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 3.2 (ratio)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.9 (thousand per microliter)\n- Protein/Creatinine [Mass Ratio] in Urine: 2.95 (milligram per milligram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 30 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 74.3 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n\n### Procedure\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n- Pure hypercholesterolemia\n- Blood glucose abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-19 06:51:00, ended at 2020-10-19 07:12:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest; 2 views\n\n### Condition\n- Blood glucose abnormal\n- Transplanted heart present\n- Disorder of transplanted heart\n- Pure hypercholesterolemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-19 07:13:00, ended at 2020-10-19 10:34:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 68.9 (percent)\n\n### Procedure\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; tracing only, without interpretation and report\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; supervision only, without interpretation and report\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; interpretation and report only\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation \n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n- Blood glucose abnormal\n- Pure hypercholesterolemia\n- Cardiomegaly\n\n### Drug\n- 250 ML dobutamine 1 MG/ML Injection, through Intravenous route, started on 2020-10-19, presumably until 2020-10-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-10-19 09:24:19, ended at 2020-10-19 11:16:33\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Blood glucose abnormal\n- Pure hypercholesterolemia\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-19 10:35:00, ended at 2020-10-19 23:59:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-20 00:00:00, ended at 2020-10-20 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- clonidine hydrochloride 0.2 MG Oral Tablet, through Oral route, started on 2020-10-20, presumably until 2022-06-10, with intended 3 refill(s). Instructions: take 1 Tab (0.2 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-23 00:00:00, ended at 2020-10-23 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-26 00:00:00, ended at 2020-10-26 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-30 00:00:00, ended at 2020-10-30 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-02 00:00:00, ended at 2020-11-02 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-03 13:19:42, ended at 2020-11-03 14:16:55\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Complication due to diabetes mellitus\n\n### Drug\n- 0.5 ML dulaglutide 3 MG/ML Auto-Injector, through Subcutaneous route, started on 2020-11-03, presumably until 2021-09-06, with intended 4 refill(s). Instructions: inject 1.5 mg subcutaneous (under the skin) once a week\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-06 00:00:00, ended at 2020-11-06 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-09 00:00:00, ended at 2020-11-09 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-11-11 00:00:00, ended at 2020-11-11 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, started on 2020-11-11, presumably until 2020-11-25, with intended 0 refill(s). Instructions: Take 2L by mouth night before and 2L morning of procedure. Stop fluids 4hr before procedure. Instructions are forwarded to patient.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-13 00:00:00, ended at 2020-11-13 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-16 00:00:00, ended at 2020-11-16 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-20 00:00:00, ended at 2020-11-20 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-23 00:00:00, ended at 2020-11-23 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-27 00:00:00, ended at 2020-11-27 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-30 00:00:00, ended at 2020-11-30 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-02 08:00:00, ended at 2020-12-02 08:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-04 00:00:00, ended at 2020-12-04 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-07 00:00:00, ended at 2020-12-07 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-08 00:00:00, ended at 2020-12-08 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-09 00:00:00, ended at 2020-12-09 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-10 00:00:00, ended at 2020-12-10 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- 24 HR isosorbide mononitrate 30 MG Extended Release Oral Tablet, through Oral route, started on 2020-12-10, presumably until 2021-09-06, with intended 3 refill(s). Instructions: take 1 Tab (30 mg total) by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-11 00:00:00, ended at 2020-12-11 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-14 00:00:00, ended at 2020-12-14 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-12-17 08:46:02, ended at 2020-12-17 09:44:25\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Unlisted procedure, dentoalveolar structures\n- Alveoloplasty, each quadrant (specify)\n\n### Condition\n- Transplanted heart present\n- Dental caries\n- Primary diagnosis: Diastolic heart failure\n- Periapical abscess\n- Type 2 diabetes mellitus without complication\n- Primary diagnosis: Congestive heart failure\n- Primary diagnosis: Valvular endocarditis\n\n### Drug\n- chlorhexidine gluconate 1.2 MG/ML Mouthwash, through Oral route, started on 2020-12-17, presumably until 2021-02-25, with intended 3 refill(s). Instructions: take 15 mL by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-18 00:00:00, ended at 2020-12-18 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-21 00:00:00, ended at 2020-12-21 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-23 08:55:59, ended at 2020-12-23 09:01:45\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-25 00:00:00, ended at 2020-12-25 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-28 00:00:00, ended at 2020-12-28 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-01 00:00:00, ended at 2021-01-01 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-04 00:00:00, ended at 2021-01-04 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-01-05 00:00:00, ended at 2021-01-05 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Complication due to diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-01-07 00:00:00, ended at 2021-01-07 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-08 00:00:00, ended at 2021-01-08 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-11 00:00:00, ended at 2021-01-11 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-15 00:00:00, ended at 2021-01-15 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-18 00:00:00, ended at 2021-01-18 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-22 00:00:00, ended at 2021-01-22 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-25 00:00:00, ended at 2021-01-25 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-29 00:00:00, ended at 2021-01-29 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-01 00:00:00, ended at 2021-02-01 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-02 00:00:00, ended at 2021-02-02 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Pure hypercholesterolemia\n- Transplanted heart present\n\n### Drug\n- rosuvastatin calcium 20 MG Oral Tablet, through Oral route, started on 2021-02-02, presumably until 2021-12-15, with intended 3 refill(s). Instructions: take 1 Tab (20 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-02-02 00:00:00, ended at 2021-02-02 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Complication due to diabetes mellitus\n\n### Drug\n- 3 ML insulin isophane, human 100 UNT/ML Pen Injector, started on 2021-02-03, presumably until 2022-06-10, with intended 6 refill(s). Instructions: Inject subcutaneously 14 units twice daily. (Total 28 units per day).\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-05 00:00:00, ended at 2021-02-05 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-08 00:00:00, ended at 2021-02-08 00:00:00\nThe patient in this visit was 57 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-12 00:00:00, ended at 2021-02-12 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-15 00:00:00, ended at 2021-02-15 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-19 00:00:00, ended at 2021-02-19 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-22 00:00:00, ended at 2021-02-22 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-24 00:00:00, ended at 2021-02-24 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-25 00:00:00, ended at 2021-02-25 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-02-25 09:03:00, ended at 2021-02-25 09:34:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 15 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.1 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.74 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 17.5 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.6 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.33 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 82.6 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.62 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 227 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.48 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 42 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- Everolimus [Mass/volume] in Blood: 2.9 (nanogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 151 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.9 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.47 (million per microliter)\n- MCH [Entitic mass] by Automated count: 26.2 (picogram)\n- MCHC [Mass/volume] by Automated count: 31.7 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n- Hypomagnesemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-02-25 09:35:00, ended at 2021-02-25 23:59:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 75.0 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study\n\n### Condition\n- Transplanted heart present\n- Essential hypertension\n- Diabetes mellitus without complication\n- Hypomagnesemia\n- Disorder of transplanted heart\n- Hyperlipidemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-02-25 10:02:17, ended at 2021-02-25 11:09:14\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Transplanted heart present\n- Disorder of transplanted heart\n- Essential hypertension\n- Hyperlipidemia\n- Diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-02-26 00:00:00, ended at 2021-02-26 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- amlodipine 10 MG Oral Tablet, through Oral route, started on 2021-02-26, presumably until 2022-03-24, with intended 3 refill(s). Instructions: take 1 Tab (10 mg total) by mouth daily\n- bumetanide 1 MG Oral Tablet, through Oral route, started on 2021-02-26, presumably until 2021-10-04, with intended 3 refill(s). Instructions: take 1 Tab (1 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-26 00:00:00, ended at 2021-02-26 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-01 00:00:00, ended at 2021-03-01 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-05 00:00:00, ended at 2021-03-05 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-08 00:00:00, ended at 2021-03-08 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-12 00:00:00, ended at 2021-03-12 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-15 00:00:00, ended at 2021-03-15 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-19 00:00:00, ended at 2021-03-19 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-22 00:00:00, ended at 2021-03-22 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-26 00:00:00, ended at 2021-03-26 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-29 00:00:00, ended at 2021-03-29 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-02 00:00:00, ended at 2021-04-02 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-05 00:00:00, ended at 2021-04-05 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-09 00:00:00, ended at 2021-04-09 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-12 00:00:00, ended at 2021-04-12 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-16 00:00:00, ended at 2021-04-16 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-19 00:00:00, ended at 2021-04-19 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-23 00:00:00, ended at 2021-04-23 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-26 00:00:00, ended at 2021-04-26 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-04-27 00:00:00, ended at 2021-04-27 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2021-04-28, presumably until 2021-04-29, with intended 11 refill(s). Instructions: take 1 Tablet (0.5 mg total) by mouth 2 times a day Total dose of 1.5mg twice daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-04-29 00:00:00, ended at 2021-04-29 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2021-04-29, presumably until 2021-05-11, with intended 3 refill(s). Instructions: take 1 Tablet (0.5 mg total) by mouth 2 times a day Total dose of 1.5mg BID, Rx 2 of 2. Fax 999-999-9999.\n- everolimus 1 MG Oral Tablet, through Oral route, started on 2021-04-29, presumably until 2021-05-11, with intended 3 refill(s). Instructions: take 1 Tablet (1 mg total) by mouth 2 times a day Take 1.5 mg BID. Rx 1 of 2. Fax 999-999-9999.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-30 00:00:00, ended at 2021-04-30 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-03 00:00:00, ended at 2021-05-03 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2021-05-03, presumably until 2022-05-05, with intended 11 refill(s). Instructions: take 1 Capsule (250 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-03 00:00:00, ended at 2021-05-03 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.7 (percent)\n- MCH [Entitic mass] by Automated count: 26.5 (picogram)\n- MCV [Entitic volume] by Automated count: 79.8 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 37 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.2 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1097 (cells per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 17.7 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 676 (cells per microliter)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 12.4 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 24 (calculated)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.4 (calculated)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 69 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 37 (cells per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 217 (cells per microliter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter calculated)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67.3 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.56 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.2 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4173 (cells per microliter)\n- Platelets [#/volume] in Blood by Automated count: 192 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Everolimus [Mass/volume] in Blood: 13.8 (nanogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.41 (million per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.9 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-07 00:00:00, ended at 2021-05-07 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n\n### Drug\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2021-05-07, presumably until 2021-09-14, with intended 3 refill(s). Instructions: take 1-2 Tablets by mouth daily as needed for Constipation\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-07 00:00:00, ended at 2021-05-07 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-10 00:00:00, ended at 2021-05-10 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-05-11 00:00:00, ended at 2021-05-11 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n\n### Drug\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2021-05-11, presumably until 2021-05-26, with intended 3 refill(s). Instructions: take 1 Tablet (0.5 mg total) by mouth PM Total dose of 1mg in am and 1.5mg in pm, Rx 2 of 2. Fax 999-999-9999.\n- everolimus 1 MG Oral Tablet, through Oral route, started on 2021-05-11, presumably until 2021-05-26, with intended 3 refill(s). Instructions: take 1 Tablet (1 mg total) by mouth 2 times a day Total dose of 1mg in am and 1.5mg in pm, Rx 1 of 2. Fax 999-999-9999.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-14 00:00:00, ended at 2021-05-14 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-17 00:00:00, ended at 2021-05-17 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-17 00:00:00, ended at 2021-05-17 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-20 00:00:00, ended at 2021-05-20 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-21 00:00:00, ended at 2021-05-21 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-24 00:00:00, ended at 2021-05-24 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-05-24 09:06:00, ended at 2021-05-24 11:19:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.45 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 137 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 25.6 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 3.12 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.38 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 31.0 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 79 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.19 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.62 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 212 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.2 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 31 (milligram per deciliter)\n- Everolimus [Mass/volume] in Blood: 8.0 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 11.2 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 82.4 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.9 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.94 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-05-24 10:07:28, ended at 2021-05-24 11:42:39\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-05-24 11:20:00, ended at 2021-05-24 23:59:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging)\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-25 00:00:00, ended at 2021-05-25 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Capsule, through Oral route, started on 2021-05-25, presumably until 2021-08-30, with intended 0 refill(s). Instructions: take 25 mg by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-05-25 00:00:00, ended at 2021-05-25 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n\n### Drug\n- everolimus 1 MG Oral Tablet, through Oral route, started on 2021-05-26, presumably until 2022-05-23, with intended 3 refill(s). Instructions: take 1 mg by mouth 2 times a day Rx 1/2: Total dose of 1mg in am and 1.5 mg in pm.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-25 00:00:00, ended at 2021-05-25 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-28 00:00:00, ended at 2021-05-28 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-31 00:00:00, ended at 2021-05-31 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-04 00:00:00, ended at 2021-06-04 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-04 00:00:00, ended at 2021-06-04 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Essential hypertension\n\n### Drug\n- hydralazine hydrochloride 100 MG Oral Tablet, through Oral route, started on 2021-06-04, presumably until 2022-06-09, with intended 3 refill(s). Instructions: take 1 Tablet (100 mg total) by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-07 00:00:00, ended at 2021-06-07 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-11 00:00:00, ended at 2021-06-11 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-14 00:00:00, ended at 2021-06-14 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-18 00:00:00, ended at 2021-06-18 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-21 00:00:00, ended at 2021-06-21 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-25 00:00:00, ended at 2021-06-25 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-28 00:00:00, ended at 2021-06-28 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-07-02 00:00:00, ended at 2021-07-02 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-07-05 00:00:00, ended at 2021-07-05 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-07-09 00:00:00, ended at 2021-07-09 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-07-12 00:00:00, ended at 2021-07-12 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-07-16 00:00:00, ended at 2021-07-16 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-07-19 00:00:00, ended at 2021-07-19 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-07-23 00:00:00, ended at 2021-07-23 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-07-26 00:00:00, ended at 2021-07-26 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-07-30 00:00:00, ended at 2021-07-30 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-02 00:00:00, ended at 2021-08-02 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-06 00:00:00, ended at 2021-08-06 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-09 00:00:00, ended at 2021-08-09 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-13 00:00:00, ended at 2021-08-13 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-16 00:00:00, ended at 2021-08-16 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-20 00:00:00, ended at 2021-08-20 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-23 00:00:00, ended at 2021-08-23 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-08-24 00:00:00, ended at 2021-08-24 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-27 00:00:00, ended at 2021-08-27 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of thyroid gland\n- Disorder of transplanted heart\n- Primary diagnosis: Impaired glucose tolerance\n- Hyperlipidemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-08-30 00:00:00, ended at 2021-08-30 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Transplanted heart present\n- Disorder of transplanted heart\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-08-30 06:47:00, ended at 2021-08-30 07:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.13 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.9 (percent)\n- Protein/Creatinine [Mass Ratio] in Urine: 4.36 (milligram per milligram)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- Everolimus [Mass/volume] in Blood: 3.5 (nanogram per milliliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 7.2 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 3 - 5 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.9 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 122 (unit per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 170 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.0 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 31.8 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 190 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.22 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 82.5 (femtoliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 143 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- Creatinine [Mass/volume] in Urine: 25.45 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.52 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.3 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 4.0 (ratio)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.58 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 20.0 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 111.0 (milligram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 3.00 (micro-international unit per milliliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 323 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.1 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 90 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.96 (million per microliter)\n- MCH [Entitic mass] by Automated count: 26.2 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 70.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 245 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 47 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.49 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.2 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Pretreatment of serum for use in RBC antibody identification; incubation with inhibitors, each\n\n### Condition\n- Disorder of thyroid gland\n- Disorder of transplanted heart\n- Transplanted heart present\n- Hyperlipidemia\n- Impaired glucose tolerance\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-08-30 07:01:00, ended at 2021-08-30 23:59:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 61.4 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation \n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; supervision only, without interpretation and report\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; interpretation and report only\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; tracing only, without interpretation and report\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n\n### Condition\n- Transplanted heart present\n- Type 2 diabetes mellitus\n- Cardiomegaly\n- Disorder of transplanted heart\n- Hyperglycemia due to type 2 diabetes mellitus\n- Ventricular premature complex\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-08-30 10:28:13, ended at 2021-08-30 11:49:46\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Hyperlipidemia\n- Electrocardiogram abnormal\n- Primary diagnosis: Essential hypertension\n- Chronic kidney disease\n- Transplanted heart present\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-08-31 00:00:00, ended at 2021-08-31 00:00:00\nThe patient in this visit was 58 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of transplanted heart\n- Transplanted heart present\n\n### Drug\n- everolimus 0.5 MG Oral Tablet, through Oral route, started on 2021-08-31, presumably until 2022-08-25, with intended 3 refill(s). Instructions: take 1 Tablet (0.5 mg total) by mouth daily in the evening Rx 2/2: Dose is 1 mg in am and 1.5 mg every evening\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Malignant tumor of breast within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of breast_cancer means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "c0492fe7f720a62dab6ceeffd9bdcb911b145dc4323f93d54327dd44737c50e7", "prompt_hash": "d18e2cfd628bec4bc754538ed481c481bc770b34a33eb74081a28dea7f9390c7", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 5, "doc": {"person_id": 115967779, "visit_occurrence_id": 45453450, "death_date": null, "visit_concept_name": "Inpatient Visit", "visit_start_datetime": "2011-09-17 14:12:00", "visit_end_datetime": "2011-09-18 12:45:00", "visit_length_in_hours": 22.55, "integrated_visit_record": "## Visit\nThis visit record, was from Inpatient Visit, started at 2011-09-17 14:12:00, ended at 2011-09-18 12:45:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n- Platelets [#/volume] in Blood by Automated count: 141 (thousand per microliter)\n\n### Procedure\n- Removal of breast implant\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Unilateral breast implant\n- Collection of venous blood by venipuncture\n- Other local excision or destruction of lesion or tissue of skin and subcutaneous tissue\n\n### Condition\n- Acquired absence of breast\n- Mechanical complication due to breast prosthesis\n- Late effect of medical and surgical care complication\n- Scar conditions and fibrosis of skin\n- Complication of internal device\n- Primary malignant neoplasm of female breast\n\n### Drug\n- cefazolin 1000 MG Injection, through Intravenous route, started on 2011-09-17, presumably until 2011-09-18\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-09-18, presumably until 2012-09-17, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily.\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2011-09-18, presumably until 2012-09-17, with intended 0 refill(s). Instructions: take 1 Cap by mouth every 6 hours.\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2011-09-18, presumably until 2011-09-18\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2011-09-18, presumably until 2011-09-18\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-09-17, presumably until 2011-09-18\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2011-09-18, presumably until 2012-03-16, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 6 hours as needed for Pain.\n\n", "approximate_token_count": 531, "patient_first_visit_date": "2010-02-27 15:30:00", "patient_last_visit_date": "2015-03-26 12:15:00", "end_obs_date": "2012-09-17", "hypertension_type": "new", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "new", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "recurrent", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 17, "cumulated_visit_num": 17, "cumulated_approximate_token_count": 2724, "visit_cumulated": "## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-27 15:30:00, ended at 2010-02-27 16:44:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-27 16:45:00, ended at 2010-02-27 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Fibrocystic disease of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-03-10 00:00:00, ended at 2010-03-10 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-03-10 13:50:00, ended at 2010-03-10 14:50:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred slides prepared elsewhere\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-03-10 14:51:00, ended at 2010-03-10 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computer-aided detection (computer algorithm analysis of digital image data for lesion detection) with further review for interpretation, with or without digitization of film radiographic images; diagnostic mammography (List separately in addition to code\n- Mammography; bilateral\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-03-27 14:00:56, ended at 2010-03-27 15:45:53\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-04-10 13:49:00, ended at 2010-04-10 16:52:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-04-10 16:53:00, ended at 2010-04-10 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2010-04-11 11:40:00, ended at 2010-04-13 10:40:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- Insertion of tissue expander into breast\n- Local excision of lesion of breast\n- Bilateral simple mastectomy\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Radiological examination, surgical specimen\n\n### Condition\n- Acquired hypothyroidism\n- Carcinoma in situ of breast\n- Scar conditions and fibrosis of skin\n- Cardiac arrhythmia\n- Primary malignant neoplasm of female breast\n- Acquired absence of cervix and uterus\n\n### Drug\n- 500 ML hetastarch 60 MG/ML Injection, through Intravenous route, started on 2010-04-11, presumably until 2010-04-11\n- diazepam 5 MG Oral Tablet, through Oral route, started on 2010-04-13, presumably until 2010-10-10, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed \n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2010-04-13, presumably until 2010-12-31, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day. \n- cefazolin 1000 MG Injection, through Intravenous route, started on 2010-04-12, presumably until 2010-04-13\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2010-04-13, presumably until 2010-12-31, with quantity of 40.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth every 6 hours. \n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2010-04-12, presumably until 2010-04-13\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2010-04-12, presumably until 2010-04-12\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2010-04-11, presumably until 2010-04-11\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2010-04-12, presumably until 2010-04-12\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2010-04-12, presumably until 2010-10-10, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 6 hours as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-01 09:15:00, ended at 2010-05-01 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-05-22 14:42:38, ended at 2010-05-22 16:14:30\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-06-17 13:15:23, ended at 2010-06-17 14:15:16\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-07-15 13:21:42, ended at 2010-07-15 14:36:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-08-05 13:24:05, ended at 2010-08-05 14:52:46\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-05 10:10:00, ended at 2011-01-05 17:30:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Peri-implant capsulectomy, breast, complete, including removal of all intracapsular contents\n- Removal of skin expander from subcutaneous tissue of breast\n- Insertion of breast implant on same day of mastectomy (ie, immediate)\n- Insertion of bilateral breast prostheses\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Capsular breast contracture of breast implant\n- Acquired absence of breast\n- Complication of internal device\n- Late effect of medical and surgical care complication\n\n### Drug\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2011-01-05, presumably until 2011-09-18, with quantity of 40.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-01-15 11:54:26, ended at 2011-01-15 13:53:31\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acquired absence of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-09-17 14:12:00, ended at 2011-09-18 12:45:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n- Platelets [#/volume] in Blood by Automated count: 141 (thousand per microliter)\n\n### Procedure\n- Removal of breast implant\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Unilateral breast implant\n- Collection of venous blood by venipuncture\n- Other local excision or destruction of lesion or tissue of skin and subcutaneous tissue\n\n### Condition\n- Acquired absence of breast\n- Mechanical complication due to breast prosthesis\n- Late effect of medical and surgical care complication\n- Scar conditions and fibrosis of skin\n- Complication of internal device\n- Primary malignant neoplasm of female breast\n\n### Drug\n- cefazolin 1000 MG Injection, through Intravenous route, started on 2011-09-17, presumably until 2011-09-18\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-09-18, presumably until 2012-09-17, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily.\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2011-09-18, presumably until 2012-09-17, with intended 0 refill(s). Instructions: take 1 Cap by mouth every 6 hours.\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2011-09-18, presumably until 2011-09-18\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2011-09-18, presumably until 2011-09-18\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-09-17, presumably until 2011-09-18\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2011-09-18, presumably until 2012-03-16, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 6 hours as needed for Pain.\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Malignant tumor of breast within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-27 15:30:00, ended at 2010-02-27 16:44:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-27 16:45:00, ended at 2010-02-27 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Fibrocystic disease of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-03-10 00:00:00, ended at 2010-03-10 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-03-10 13:50:00, ended at 2010-03-10 14:50:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred slides prepared elsewhere\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-03-10 14:51:00, ended at 2010-03-10 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computer-aided detection (computer algorithm analysis of digital image data for lesion detection) with further review for interpretation, with or without digitization of film radiographic images; diagnostic mammography (List separately in addition to code\n- Mammography; bilateral\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-03-27 14:00:56, ended at 2010-03-27 15:45:53\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-04-10 13:49:00, ended at 2010-04-10 16:52:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-04-10 16:53:00, ended at 2010-04-10 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2010-04-11 11:40:00, ended at 2010-04-13 10:40:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- Insertion of tissue expander into breast\n- Local excision of lesion of breast\n- Bilateral simple mastectomy\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Radiological examination, surgical specimen\n\n### Condition\n- Acquired hypothyroidism\n- Carcinoma in situ of breast\n- Scar conditions and fibrosis of skin\n- Cardiac arrhythmia\n- Primary malignant neoplasm of female breast\n- Acquired absence of cervix and uterus\n\n### Drug\n- 500 ML hetastarch 60 MG/ML Injection, through Intravenous route, started on 2010-04-11, presumably until 2010-04-11\n- diazepam 5 MG Oral Tablet, through Oral route, started on 2010-04-13, presumably until 2010-10-10, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed \n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2010-04-13, presumably until 2010-12-31, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day. \n- cefazolin 1000 MG Injection, through Intravenous route, started on 2010-04-12, presumably until 2010-04-13\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2010-04-13, presumably until 2010-12-31, with quantity of 40.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth every 6 hours. \n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2010-04-12, presumably until 2010-04-13\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2010-04-12, presumably until 2010-04-12\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2010-04-11, presumably until 2010-04-11\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2010-04-12, presumably until 2010-04-12\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2010-04-12, presumably until 2010-10-10, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 6 hours as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-01 09:15:00, ended at 2010-05-01 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-05-22 14:42:38, ended at 2010-05-22 16:14:30\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-06-17 13:15:23, ended at 2010-06-17 14:15:16\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-07-15 13:21:42, ended at 2010-07-15 14:36:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-08-05 13:24:05, ended at 2010-08-05 14:52:46\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-05 10:10:00, ended at 2011-01-05 17:30:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Peri-implant capsulectomy, breast, complete, including removal of all intracapsular contents\n- Removal of skin expander from subcutaneous tissue of breast\n- Insertion of breast implant on same day of mastectomy (ie, immediate)\n- Insertion of bilateral breast prostheses\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Capsular breast contracture of breast implant\n- Acquired absence of breast\n- Complication of internal device\n- Late effect of medical and surgical care complication\n\n### Drug\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2011-01-05, presumably until 2011-09-18, with quantity of 40.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-01-15 11:54:26, ended at 2011-01-15 13:53:31\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acquired absence of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-09-17 14:12:00, ended at 2011-09-18 12:45:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n- Platelets [#/volume] in Blood by Automated count: 141 (thousand per microliter)\n\n### Procedure\n- Removal of breast implant\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Unilateral breast implant\n- Collection of venous blood by venipuncture\n- Other local excision or destruction of lesion or tissue of skin and subcutaneous tissue\n\n### Condition\n- Acquired absence of breast\n- Mechanical complication due to breast prosthesis\n- Late effect of medical and surgical care complication\n- Scar conditions and fibrosis of skin\n- Complication of internal device\n- Primary malignant neoplasm of female breast\n\n### Drug\n- cefazolin 1000 MG Injection, through Intravenous route, started on 2011-09-17, presumably until 2011-09-18\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-09-18, presumably until 2012-09-17, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily.\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2011-09-18, presumably until 2012-09-17, with intended 0 refill(s). Instructions: take 1 Cap by mouth every 6 hours.\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2011-09-18, presumably until 2011-09-18\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2011-09-18, presumably until 2011-09-18\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-09-17, presumably until 2011-09-18\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2011-09-18, presumably until 2012-03-16, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 6 hours as needed for Pain.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Malignant tumor of breast within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of breast_cancer means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "ba07c55321e560115a08f94d95f2eb88930803a55cb884bf46dd1a2cbe31bd88", "prompt_hash": "15f5b0ef930f8a0f1ac5b77f3f2a647302c21f18451307bb542b34584a32aeee", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 6, "doc": {"person_id": 115969214, "visit_occurrence_id": 37066945, "death_date": null, "visit_concept_name": "Case Management Visit", "visit_start_datetime": "2009-10-19 00:00:00", "visit_end_datetime": "2009-10-19 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Case Management Visit, started at 2009-10-19 00:00:00, ended at 2009-10-19 00:00:00\nThe patient in this visit was 38 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 93, "patient_first_visit_date": "2008-07-28 00:00:00", "patient_last_visit_date": "2011-01-31 10:45:00", "end_obs_date": "2010-10-19", "hypertension_type": "new", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "new", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "recurrent", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "recurrent", "breast_cancer_one_year_diagnosis": 1, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 11, "cumulated_visit_num": 11, "cumulated_approximate_token_count": 4743, "visit_cumulated": "## Visit\nThis visit record, was from Case Management Visit, started at 2008-07-28 00:00:00, ended at 2008-07-28 00:00:00\nThe patient in this visit was 36 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-08-25 00:00:00, ended at 2008-08-25 00:00:00\nThe patient in this visit was 37 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.6 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.23 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.5 (percent)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 217 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 95.7 (femtoliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2008-08-26 05:39:00, ended at 2008-09-01 12:00:00\nThe patient in this visit was 37 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 4.0 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Body height: 5' 7\" (inch (US))\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n\n### Procedure\n- Prophylactic mastectomy\n- Prophylactic oophorectomy\n\n### Condition\n- Disorder of breast\n- Fibrocystic disease of breast\n- Depressive disorder\n- Gastroesophageal reflux disease\n- Retention of urine\n- Primary malignant neoplasm of female breast\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2008-08-26, presumably until 2008-08-30\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2008-08-28, presumably until 2008-09-01\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2008-08-30, presumably until 2008-12-19, with quantity of 30.0, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 6 hours. \n- cefazolin 1000 MG Injection, through Intravenous route, started on 2008-08-26, presumably until 2008-08-31\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2008-08-28, presumably until 2008-08-28\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2008-08-28, presumably until 2008-08-30\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2008-08-31, presumably until 2008-09-23, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth every 6 hours. \n- oxycodone hydrochloride 1 MG/ML Oral Solution, through Oral route, started on 2008-08-31, presumably until 2008-12-19, with intended 0 refill(s). Instructions: take 5-10 mL by mouth every 4 hours as needed for Pain. \n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2008-08-31, presumably until 2008-08-31\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2008-08-30, presumably until 2008-12-19, with intended 0 refill(s). Instructions: take 2 Caps by mouth 3 times a day. \n- 2 ML ondansetron 2 MG/ML Injection, started on 2008-08-28, presumably until 2008-08-28\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2008-08-30, presumably until 2008-08-30\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2008-08-26, presumably until 2008-08-30\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, started on 2008-08-29, presumably until 2008-08-30\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2008-08-27, presumably until 2008-08-28\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2008-08-28, presumably until 2008-08-30\n- morphine sulfate 1 MG/ML Injection, through Intravenous route, started on 2008-08-26, presumably until 2008-08-28\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2008-08-31, presumably until 2008-12-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours. \n- 2 ML metoclopramide 5 MG/ML Injection, started on 2008-08-28, presumably until 2008-08-30\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2008-08-26, presumably until 2008-08-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2008-09-23 11:20:00, ended at 2008-09-23 19:30:00\nThe patient in this visit was 37 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- cefazolin 1000 MG Injection, through Intravenous route, started on 2008-09-23, presumably until 2008-09-23\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2008-10-17 08:07:00, ended at 2008-10-17 11:20:00\nThe patient in this visit was 37 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Sodium [Moles/volume] in Blood: 137 (millimole per liter)\n- Potassium [Moles/volume] in Blood: 4.0 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood: 43 (percent)\n- Hemoglobin [Mass/volume] in Blood by calculation: 14.6 (gram per deciliter)\n- Body height: 4' 6.134\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- cefazolin 1000 MG Injection, started on 2008-10-17, presumably until 2008-10-17\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2008-10-17, presumably until 2008-10-17\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2008-10-17, presumably until 2008-10-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-10-27 00:00:00, ended at 2008-10-27 00:00:00\nThe patient in this visit was 37 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.7 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 38.9 (percent)\n- MCV [Entitic volume] by Automated count: 92.0 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 46.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.7 (percent)\n- MCH [Entitic mass] by Automated count: 30.9 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 188 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.10 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.60 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 83 (unit per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.49 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.91 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.1 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 89 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-11-09 00:00:00, ended at 2008-11-09 00:00:00\nThe patient in this visit was 37 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.5 (percent)\n- MCH [Entitic mass] by Automated count: 30.6 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 79.7 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: <5 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 102 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.97 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.7 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.9 (femtoliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 112 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.86 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.75 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.1 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.10 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 239 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.3 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-11-17 00:00:00, ended at 2008-11-17 00:00:00\nThe patient in this visit was 37 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 95 (unit per liter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.23 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.26 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.7 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.2 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.7 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.4 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.5 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 388 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.37 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 47 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.1 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.6 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2008-12-29 18:15:00, ended at 2008-12-30 11:20:00\nThe patient in this visit was 37 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acquired absence of breast\n- Primary malignant neoplasm of female breast\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2008-12-29, presumably until 2008-12-30\n- diphenhydramine hydrochloride 2.5 MG/ML Oral Solution, through Oral route, started on 2008-12-29, presumably until 2008-12-29\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2008-12-30, presumably until 2008-12-30\n- 1 ML meperidine hydrochloride 25 MG/ML Cartridge, started on 2008-12-29, presumably until 2008-12-29\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, presumably until 2009-04-07. Instructions: take 20 mg by mouth 2 times a day. \n- cefazolin 1000 MG Injection, through Intravenous route, started on 2008-12-29, presumably until 2008-12-29\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2008-12-29, presumably until 2009-01-05, with quantity of 40.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day. \n- oxycodone hydrochloride 1 MG/ML Oral Solution, through Oral route, started on 2008-12-29, presumably until 2008-12-30\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2008-12-29, presumably until 2008-12-30\n- gabapentin 600 MG Oral Tablet, through Oral route, started on 2008-12-29, presumably until 2009-04-07, with quantity of 40.0, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth 3 times a day. \n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2008-12-29, presumably until 2008-12-30\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2008-12-29, presumably until 2008-12-29\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2008-12-29, presumably until 2009-04-07, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-04-07 05:39:00, ended at 2009-04-07 12:10:00\nThe patient in this visit was 37 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- cefazolin 1000 MG Injection, through Intravenous route, started on 2009-04-07, presumably until 2010-04-07, with quantity of 1.0, with intended 0 refill(s). Instructions: 50 mL by Intravenous route One Time. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-10-19 00:00:00, ended at 2009-10-19 00:00:00\nThe patient in this visit was 38 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Malignant tumor of breast within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-07-28 00:00:00, ended at 2008-07-28 00:00:00\nThe patient in this visit was 36 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-08-25 00:00:00, ended at 2008-08-25 00:00:00\nThe patient in this visit was 37 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.6 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.23 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.5 (percent)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 217 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 95.7 (femtoliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2008-08-26 05:39:00, ended at 2008-09-01 12:00:00\nThe patient in this visit was 37 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 4.0 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Body height: 5' 7\" (inch (US))\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n\n### Procedure\n- Prophylactic mastectomy\n- Prophylactic oophorectomy\n\n### Condition\n- Disorder of breast\n- Fibrocystic disease of breast\n- Depressive disorder\n- Gastroesophageal reflux disease\n- Retention of urine\n- Primary malignant neoplasm of female breast\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2008-08-26, presumably until 2008-08-30\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2008-08-28, presumably until 2008-09-01\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2008-08-30, presumably until 2008-12-19, with quantity of 30.0, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 6 hours. \n- cefazolin 1000 MG Injection, through Intravenous route, started on 2008-08-26, presumably until 2008-08-31\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2008-08-28, presumably until 2008-08-28\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2008-08-28, presumably until 2008-08-30\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2008-08-31, presumably until 2008-09-23, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth every 6 hours. \n- oxycodone hydrochloride 1 MG/ML Oral Solution, through Oral route, started on 2008-08-31, presumably until 2008-12-19, with intended 0 refill(s). Instructions: take 5-10 mL by mouth every 4 hours as needed for Pain. \n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2008-08-31, presumably until 2008-08-31\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2008-08-30, presumably until 2008-12-19, with intended 0 refill(s). Instructions: take 2 Caps by mouth 3 times a day. \n- 2 ML ondansetron 2 MG/ML Injection, started on 2008-08-28, presumably until 2008-08-28\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2008-08-30, presumably until 2008-08-30\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2008-08-26, presumably until 2008-08-30\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, started on 2008-08-29, presumably until 2008-08-30\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2008-08-27, presumably until 2008-08-28\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2008-08-28, presumably until 2008-08-30\n- morphine sulfate 1 MG/ML Injection, through Intravenous route, started on 2008-08-26, presumably until 2008-08-28\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2008-08-31, presumably until 2008-12-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours. \n- 2 ML metoclopramide 5 MG/ML Injection, started on 2008-08-28, presumably until 2008-08-30\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2008-08-26, presumably until 2008-08-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2008-09-23 11:20:00, ended at 2008-09-23 19:30:00\nThe patient in this visit was 37 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- cefazolin 1000 MG Injection, through Intravenous route, started on 2008-09-23, presumably until 2008-09-23\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2008-10-17 08:07:00, ended at 2008-10-17 11:20:00\nThe patient in this visit was 37 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Sodium [Moles/volume] in Blood: 137 (millimole per liter)\n- Potassium [Moles/volume] in Blood: 4.0 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood: 43 (percent)\n- Hemoglobin [Mass/volume] in Blood by calculation: 14.6 (gram per deciliter)\n- Body height: 4' 6.134\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- cefazolin 1000 MG Injection, started on 2008-10-17, presumably until 2008-10-17\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2008-10-17, presumably until 2008-10-17\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2008-10-17, presumably until 2008-10-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-10-27 00:00:00, ended at 2008-10-27 00:00:00\nThe patient in this visit was 37 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.7 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 38.9 (percent)\n- MCV [Entitic volume] by Automated count: 92.0 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 46.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.7 (percent)\n- MCH [Entitic mass] by Automated count: 30.9 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 188 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.10 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.60 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 83 (unit per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.49 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.91 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.1 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 89 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-11-09 00:00:00, ended at 2008-11-09 00:00:00\nThe patient in this visit was 37 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.5 (percent)\n- MCH [Entitic mass] by Automated count: 30.6 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 79.7 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: <5 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 102 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.97 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.7 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.9 (femtoliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 112 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.86 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.75 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.1 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.10 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 239 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.3 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-11-17 00:00:00, ended at 2008-11-17 00:00:00\nThe patient in this visit was 37 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 95 (unit per liter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.23 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.26 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.7 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.2 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.7 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.4 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.5 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 388 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.37 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 47 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.1 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.6 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2008-12-29 18:15:00, ended at 2008-12-30 11:20:00\nThe patient in this visit was 37 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acquired absence of breast\n- Primary malignant neoplasm of female breast\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2008-12-29, presumably until 2008-12-30\n- diphenhydramine hydrochloride 2.5 MG/ML Oral Solution, through Oral route, started on 2008-12-29, presumably until 2008-12-29\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2008-12-30, presumably until 2008-12-30\n- 1 ML meperidine hydrochloride 25 MG/ML Cartridge, started on 2008-12-29, presumably until 2008-12-29\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, presumably until 2009-04-07. Instructions: take 20 mg by mouth 2 times a day. \n- cefazolin 1000 MG Injection, through Intravenous route, started on 2008-12-29, presumably until 2008-12-29\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2008-12-29, presumably until 2009-01-05, with quantity of 40.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day. \n- oxycodone hydrochloride 1 MG/ML Oral Solution, through Oral route, started on 2008-12-29, presumably until 2008-12-30\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2008-12-29, presumably until 2008-12-30\n- gabapentin 600 MG Oral Tablet, through Oral route, started on 2008-12-29, presumably until 2009-04-07, with quantity of 40.0, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth 3 times a day. \n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2008-12-29, presumably until 2008-12-30\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2008-12-29, presumably until 2008-12-29\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2008-12-29, presumably until 2009-04-07, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-04-07 05:39:00, ended at 2009-04-07 12:10:00\nThe patient in this visit was 37 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- cefazolin 1000 MG Injection, through Intravenous route, started on 2009-04-07, presumably until 2010-04-07, with quantity of 1.0, with intended 0 refill(s). Instructions: 50 mL by Intravenous route One Time. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-10-19 00:00:00, ended at 2009-10-19 00:00:00\nThe patient in this visit was 38 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Malignant tumor of breast within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of breast_cancer means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "a7db31f85f9b5fed0e7e25a640de9abad3edfaf767eec9067122eb434998c409", "prompt_hash": "733c5436706d73c2d1ac42e5965aa51c61536fa3c00eb6cf4008660ef79d5e60", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 0.0, "f1_gu_yn": [1, 0], "recall_gu_yn": [1, 0]}
{"doc_id": 7, "doc": {"person_id": 115969239, "visit_occurrence_id": 97880316, "death_date": null, "visit_concept_name": "Outpatient Visit", "visit_start_datetime": "2017-01-08 13:45:00", "visit_end_datetime": "2017-01-08 23:59:00", "visit_length_in_hours": 10.233333333333333, "integrated_visit_record": "## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-08 13:45:00, ended at 2017-01-08 23:59:00\nThe patient in this visit was 59 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, breast, unilateral, real time with image documentation, including axilla when performed; limited\n\n### Condition\n- Breast lump\n- Solitary cyst of breast\n- Disorder of breast\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 115, "patient_first_visit_date": "2015-10-05 00:00:00", "patient_last_visit_date": "2020-05-29 00:00:00", "end_obs_date": "2018-01-08", "hypertension_type": "new", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "new", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "recurrent", "breast_cancer_one_year_diagnosis": 1, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 33, "cumulated_visit_num": 33, "cumulated_approximate_token_count": 5377, "visit_cumulated": "## Visit\nThis visit record, was from Case Management Visit, started at 2015-10-05 00:00:00, ended at 2015-10-05 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-10-05 00:00:00, ended at 2015-10-05 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-10-05 12:44:04, ended at 2015-10-05 14:55:22\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-10-05 13:31:14, ended at 2015-10-05 15:12:55\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-10-09 00:00:00, ended at 2015-10-09 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2015-11-22 00:00:00, ended at 2015-11-22 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; single level\n- Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; second level (List separately in addition to code for primary proced\n\n### Condition\n- Persistent pain following procedure\n\n### Drug\n- 10 ML bupivacaine hydrochloride 5 MG/ML Injection, started on 2015-11-22, presumably until 2015-11-22\n- midazolam 1 MG/ML Injectable Solution, started on 2015-11-22, presumably until 2015-11-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2015-11-22 00:00:00, ended at 2015-11-22 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bacitracin 5000 UNT/ML Injectable Solution, through Intramuscular route, started on 2015-11-22, presumably until 2015-11-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2015-11-22 00:00:00, ended at 2015-11-22 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on the integumentary system on the extremities, anterior trunk and perineum; reconstructive procedures on breast (eg, reduction or augmentation mammoplasty, muscle flaps)\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2015-11-22, presumably until 2015-11-22\n- cefazolin 1000 MG Injection, started on 2015-11-22, presumably until 2015-11-22\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2015-11-22, presumably until 2015-11-22\n- 2 ML ondansetron 2 MG/ML Injection, started on 2015-11-22, presumably until 2015-11-22\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2015-11-22, presumably until 2015-11-22\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2015-11-22, presumably until 2015-11-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-11-22 11:16:52, ended at 2015-11-22 13:16:22\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Lymphatics and lymph nodes imaging\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2015-11-22 13:40:00, ended at 2015-11-23 11:05:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Radiological examination, surgical specimen\n- Pathology consultation during surgery; first tissue block, with frozen section(s), single specimen\n- Tissue expander placement in breast reconstruction, including subsequent expansion(s)\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Excision of Left Breast, Open Approach\n- Morphometric analysis, tumor\n- Insertion of Tissue Expander into Left Breast, Open Approach\n- Excision of Left Axillary Lymphatic, Open Approach, Diagnostic\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2015-11-22, presumably until 2015-11-22\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2015-11-22, presumably until 2016-01-08, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily\n- cefazolin 1000 MG Injection, started on 2015-11-22, presumably until 2015-11-23\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2015-11-23, presumably until 2015-11-30, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day for 7 days\n- bacitracin zinc 0.5 UNT/MG Topical Ointment, started on 2015-11-23, presumably until 2016-01-08, with intended 0 refill(s). Instructions: Apply as directed\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2015-11-23, presumably until 2016-01-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth Every Day\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-11-22, presumably until 2015-11-22\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2015-11-22, presumably until 2016-01-08, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-12-04 13:05:48, ended at 2015-12-04 14:46:05\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.717\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-12-04 13:06:10, ended at 2015-12-04 14:45:44\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-12-19 14:35:54, ended at 2015-12-19 16:05:54\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-01-08 08:28:43, ended at 2016-01-08 09:52:20\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- anastrozole 1 MG Oral Tablet, through Oral route, started on 2016-01-08, presumably until 2016-04-08, with intended 6 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-01-08 14:57:31, ended at 2016-01-08 16:17:41\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.717\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-02-25 10:30:38, ended at 2016-02-25 11:09:33\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.126\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-03-17 00:00:00, ended at 2016-03-17 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 0.154 MEQ/ML Irrigation Solution, through Topical route, started on 2016-03-17, presumably until 2016-03-17\n- bacitracin 5000 UNT/ML Injectable Solution, through Intramuscular route, started on 2016-03-17, presumably until 2016-03-17\n- 10 ML bupivacaine hydrochloride 2.5 MG/ML / epinephrine 0.005 MG/ML Injection, started on 2016-03-17, presumably until 2016-03-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-17 00:00:00, ended at 2016-03-17 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on the integumentary system on the extremities, anterior trunk and perineum; reconstructive procedures on breast (eg, reduction or augmentation mammoplasty, muscle flaps)\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- cefazolin 1000 MG Injection, started on 2016-03-17, presumably until 2016-03-17\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2016-03-17, presumably until 2016-03-17\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-03-17, presumably until 2016-03-17\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-03-17, presumably until 2016-03-17\n- midazolam 1 MG/ML Injectable Solution, started on 2016-03-17, presumably until 2016-03-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-17 05:55:00, ended at 2016-03-17 13:23:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.992\" (inch (US))\n\n### Procedure\n- Removal of Synthetic Substitute from Left Breast, Open Approach\n- Replacement of Bilateral Breast with Synthetic Substitute, Open Approach\n- Revision of peri-implant capsule, breast, including capsulotomy, capsulorrhaphy, and/or partial capsulectomy\n- Breast augmentation with implant\n- Release Bilateral Breast, Open Approach\n- Removal of Synthetic Substitute from Right Breast, Open Approach\n- Replacement of tissue expander with permanent implant\n\n### Condition\n- Displacement of breast implant\n- Deformity of reconstructed breast\n- Late effect of complications of procedure\n- Primary malignant neoplasm of female breast\n- Disproportion of reconstructed breast\n- Capsular breast contracture of breast implant\n\n### Drug\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2016-03-17, presumably until 2016-03-17\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2016-03-17, presumably until 2016-03-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-03-25 13:17:12, ended at 2016-03-25 14:16:37\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-04-08 11:22:07, ended at 2016-04-08 12:45:40\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.78\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- 24 HR venlafaxine 37.5 MG Extended Release Oral Capsule, through Oral route, started on 2016-04-08, presumably until 2016-07-31, with intended 11 refill(s). Instructions: take 1 Akmal by mouth every bedtime\n- exemestane 25 MG Oral Tablet, through Oral route, started on 2016-04-08, presumably until 2017-01-08, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-04-30 10:34:15, ended at 2016-04-30 12:04:56\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-03 08:03:36, ended at 2016-06-03 09:16:32\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.78\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-07-31 10:40:47, ended at 2016-07-31 13:18:55\nThe patient in this visit was 59 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- 24 HR venlafaxine 37.5 MG Extended Release Oral Capsule, through Oral route, started on 2016-07-31, presumably until 2017-01-08, with intended 11 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-18 00:00:00, ended at 2016-08-18 00:00:00\nThe patient in this visit was 59 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Paravertebral block (PVB) (paraspinous block), thoracic; single injection site (includes imaging guidance, when performed)\n- Paravertebral block (PVB) (paraspinous block), thoracic; second and any additional injection site(s) (includes imaging guidance, when performed) (List separately in addition to code for primary procedure)\n\n### Condition\n- Persistent pain following procedure\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2016-08-18, presumably until 2016-08-18\n- 10 ML bupivacaine hydrochloride 2.5 MG/ML Injection, started on 2016-08-18, presumably until 2016-08-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-08-18 00:00:00, ended at 2016-08-18 00:00:00\nThe patient in this visit was 59 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 10 ML bupivacaine hydrochloride 2.5 MG/ML / epinephrine 0.005 MG/ML Injection, started on 2016-08-18, presumably until 2016-08-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-18 00:00:00, ended at 2016-08-18 00:00:00\nThe patient in this visit was 59 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on the integumentary system on the extremities, anterior trunk and perineum; reconstructive procedures on breast (eg, reduction or augmentation mammoplasty, muscle flaps)\n\n### Condition\n- Deformity of reconstructed breast\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2016-08-18, presumably until 2016-08-18\n- cefazolin 1000 MG Injection, started on 2016-08-18, presumably until 2016-08-18\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2016-08-18, presumably until 2016-08-18\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2016-08-18, presumably until 2016-08-18\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-08-18, presumably until 2016-08-18\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-08-18, presumably until 2016-08-18\n- ketamine 100 MG/ML Injectable Solution, started on 2016-08-18, presumably until 2016-08-18\n- midazolam 1 MG/ML Injectable Solution, started on 2016-08-18, presumably until 2016-08-18\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2016-08-18, presumably until 2016-08-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-18 06:22:00, ended at 2016-08-18 12:20:00\nThe patient in this visit was 59 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Breast reconstruction with other technique\n- Extraction of Abdomen Subcutaneous Tissue and Fascia, Percutaneous Approach\n- Tissue grafts, other (eg, paratenon, fat, dermis)\n- Supplement Left Breast with Autologous Tissue Substitute, Percutaneous Approach\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Disproportion of reconstructed breast\n- Deformity of reconstructed breast\n- Primary diagnosis: Primary malignant neoplasm of upper inner quadrant of female breast\n- Hypothyroidism\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2016-08-18, presumably until 2016-08-18\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2016-08-18, presumably until 2016-08-23, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day for 5 days\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2016-08-18, presumably until 2016-08-18\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2016-08-18, presumably until 2016-08-26, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-26 14:01:09, ended at 2016-08-26 14:54:48\nThe patient in this visit was 59 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.992\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of upper inner quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-07 09:40:18, ended at 2016-10-07 10:47:47\nThe patient in this visit was 59 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.992\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of upper inner quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-06 13:57:00, ended at 2017-01-06 23:59:00\nThe patient in this visit was 59 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation on X-ray examination made elsewhere, written report\n\n### Condition\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-08 12:34:53, ended at 2017-01-08 13:50:38\nThe patient in this visit was 59 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.99\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Overlapping malignant neoplasm of female breast\n\n### Drug\n- 24 HR venlafaxine 75 MG Extended Release Oral Capsule, through Oral route, started on 2017-01-08, presumably until 2017-03-12, with intended 3 refill(s). Instructions: take 1 Durbin by mouth every bedtime\n- tamoxifen 20 MG Oral Tablet, through Oral route, started on 2017-01-08, presumably until 2018-01-08, with intended 3 refill(s). Instructions: take 20 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-08 13:45:00, ended at 2017-01-08 23:59:00\nThe patient in this visit was 59 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, breast, unilateral, real time with image documentation, including axilla when performed; limited\n\n### Condition\n- Breast lump\n- Solitary cyst of breast\n- Disorder of breast\n\n### Drug\n- No drugs.\n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Malignant tumor of breast within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-10-05 00:00:00, ended at 2015-10-05 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-10-05 00:00:00, ended at 2015-10-05 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-10-05 12:44:04, ended at 2015-10-05 14:55:22\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-10-05 13:31:14, ended at 2015-10-05 15:12:55\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-10-09 00:00:00, ended at 2015-10-09 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2015-11-22 00:00:00, ended at 2015-11-22 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; single level\n- Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; second level (List separately in addition to code for primary proced\n\n### Condition\n- Persistent pain following procedure\n\n### Drug\n- 10 ML bupivacaine hydrochloride 5 MG/ML Injection, started on 2015-11-22, presumably until 2015-11-22\n- midazolam 1 MG/ML Injectable Solution, started on 2015-11-22, presumably until 2015-11-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2015-11-22 00:00:00, ended at 2015-11-22 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bacitracin 5000 UNT/ML Injectable Solution, through Intramuscular route, started on 2015-11-22, presumably until 2015-11-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2015-11-22 00:00:00, ended at 2015-11-22 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on the integumentary system on the extremities, anterior trunk and perineum; reconstructive procedures on breast (eg, reduction or augmentation mammoplasty, muscle flaps)\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2015-11-22, presumably until 2015-11-22\n- cefazolin 1000 MG Injection, started on 2015-11-22, presumably until 2015-11-22\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2015-11-22, presumably until 2015-11-22\n- 2 ML ondansetron 2 MG/ML Injection, started on 2015-11-22, presumably until 2015-11-22\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2015-11-22, presumably until 2015-11-22\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2015-11-22, presumably until 2015-11-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-11-22 11:16:52, ended at 2015-11-22 13:16:22\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Lymphatics and lymph nodes imaging\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2015-11-22 13:40:00, ended at 2015-11-23 11:05:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Radiological examination, surgical specimen\n- Pathology consultation during surgery; first tissue block, with frozen section(s), single specimen\n- Tissue expander placement in breast reconstruction, including subsequent expansion(s)\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Excision of Left Breast, Open Approach\n- Morphometric analysis, tumor\n- Insertion of Tissue Expander into Left Breast, Open Approach\n- Excision of Left Axillary Lymphatic, Open Approach, Diagnostic\n\n### Condition\n- Primary malignant neoplasm of upper outer quadrant of female breast\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2015-11-22, presumably until 2015-11-22\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2015-11-22, presumably until 2016-01-08, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily\n- cefazolin 1000 MG Injection, started on 2015-11-22, presumably until 2015-11-23\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2015-11-23, presumably until 2015-11-30, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day for 7 days\n- bacitracin zinc 0.5 UNT/MG Topical Ointment, started on 2015-11-23, presumably until 2016-01-08, with intended 0 refill(s). Instructions: Apply as directed\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2015-11-23, presumably until 2016-01-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth Every Day\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-11-22, presumably until 2015-11-22\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2015-11-22, presumably until 2016-01-08, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-12-04 13:05:48, ended at 2015-12-04 14:46:05\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.717\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-12-04 13:06:10, ended at 2015-12-04 14:45:44\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-12-19 14:35:54, ended at 2015-12-19 16:05:54\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-01-08 08:28:43, ended at 2016-01-08 09:52:20\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- anastrozole 1 MG Oral Tablet, through Oral route, started on 2016-01-08, presumably until 2016-04-08, with intended 6 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-01-08 14:57:31, ended at 2016-01-08 16:17:41\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.717\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-02-25 10:30:38, ended at 2016-02-25 11:09:33\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.126\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-03-17 00:00:00, ended at 2016-03-17 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 0.154 MEQ/ML Irrigation Solution, through Topical route, started on 2016-03-17, presumably until 2016-03-17\n- bacitracin 5000 UNT/ML Injectable Solution, through Intramuscular route, started on 2016-03-17, presumably until 2016-03-17\n- 10 ML bupivacaine hydrochloride 2.5 MG/ML / epinephrine 0.005 MG/ML Injection, started on 2016-03-17, presumably until 2016-03-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-17 00:00:00, ended at 2016-03-17 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on the integumentary system on the extremities, anterior trunk and perineum; reconstructive procedures on breast (eg, reduction or augmentation mammoplasty, muscle flaps)\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- cefazolin 1000 MG Injection, started on 2016-03-17, presumably until 2016-03-17\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2016-03-17, presumably until 2016-03-17\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-03-17, presumably until 2016-03-17\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-03-17, presumably until 2016-03-17\n- midazolam 1 MG/ML Injectable Solution, started on 2016-03-17, presumably until 2016-03-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-17 05:55:00, ended at 2016-03-17 13:23:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.992\" (inch (US))\n\n### Procedure\n- Removal of Synthetic Substitute from Left Breast, Open Approach\n- Replacement of Bilateral Breast with Synthetic Substitute, Open Approach\n- Revision of peri-implant capsule, breast, including capsulotomy, capsulorrhaphy, and/or partial capsulectomy\n- Breast augmentation with implant\n- Release Bilateral Breast, Open Approach\n- Removal of Synthetic Substitute from Right Breast, Open Approach\n- Replacement of tissue expander with permanent implant\n\n### Condition\n- Displacement of breast implant\n- Deformity of reconstructed breast\n- Late effect of complications of procedure\n- Primary malignant neoplasm of female breast\n- Disproportion of reconstructed breast\n- Capsular breast contracture of breast implant\n\n### Drug\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2016-03-17, presumably until 2016-03-17\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2016-03-17, presumably until 2016-03-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-03-25 13:17:12, ended at 2016-03-25 14:16:37\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-04-08 11:22:07, ended at 2016-04-08 12:45:40\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.78\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- 24 HR venlafaxine 37.5 MG Extended Release Oral Capsule, through Oral route, started on 2016-04-08, presumably until 2016-07-31, with intended 11 refill(s). Instructions: take 1 Akmal by mouth every bedtime\n- exemestane 25 MG Oral Tablet, through Oral route, started on 2016-04-08, presumably until 2017-01-08, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-04-30 10:34:15, ended at 2016-04-30 12:04:56\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-03 08:03:36, ended at 2016-06-03 09:16:32\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.78\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-07-31 10:40:47, ended at 2016-07-31 13:18:55\nThe patient in this visit was 59 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- 24 HR venlafaxine 37.5 MG Extended Release Oral Capsule, through Oral route, started on 2016-07-31, presumably until 2017-01-08, with intended 11 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-18 00:00:00, ended at 2016-08-18 00:00:00\nThe patient in this visit was 59 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Paravertebral block (PVB) (paraspinous block), thoracic; single injection site (includes imaging guidance, when performed)\n- Paravertebral block (PVB) (paraspinous block), thoracic; second and any additional injection site(s) (includes imaging guidance, when performed) (List separately in addition to code for primary procedure)\n\n### Condition\n- Persistent pain following procedure\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2016-08-18, presumably until 2016-08-18\n- 10 ML bupivacaine hydrochloride 2.5 MG/ML Injection, started on 2016-08-18, presumably until 2016-08-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-08-18 00:00:00, ended at 2016-08-18 00:00:00\nThe patient in this visit was 59 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 10 ML bupivacaine hydrochloride 2.5 MG/ML / epinephrine 0.005 MG/ML Injection, started on 2016-08-18, presumably until 2016-08-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-18 00:00:00, ended at 2016-08-18 00:00:00\nThe patient in this visit was 59 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on the integumentary system on the extremities, anterior trunk and perineum; reconstructive procedures on breast (eg, reduction or augmentation mammoplasty, muscle flaps)\n\n### Condition\n- Deformity of reconstructed breast\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2016-08-18, presumably until 2016-08-18\n- cefazolin 1000 MG Injection, started on 2016-08-18, presumably until 2016-08-18\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2016-08-18, presumably until 2016-08-18\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2016-08-18, presumably until 2016-08-18\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-08-18, presumably until 2016-08-18\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-08-18, presumably until 2016-08-18\n- ketamine 100 MG/ML Injectable Solution, started on 2016-08-18, presumably until 2016-08-18\n- midazolam 1 MG/ML Injectable Solution, started on 2016-08-18, presumably until 2016-08-18\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2016-08-18, presumably until 2016-08-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-18 06:22:00, ended at 2016-08-18 12:20:00\nThe patient in this visit was 59 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Breast reconstruction with other technique\n- Extraction of Abdomen Subcutaneous Tissue and Fascia, Percutaneous Approach\n- Tissue grafts, other (eg, paratenon, fat, dermis)\n- Supplement Left Breast with Autologous Tissue Substitute, Percutaneous Approach\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Disproportion of reconstructed breast\n- Deformity of reconstructed breast\n- Primary diagnosis: Primary malignant neoplasm of upper inner quadrant of female breast\n- Hypothyroidism\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2016-08-18, presumably until 2016-08-18\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2016-08-18, presumably until 2016-08-23, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day for 5 days\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2016-08-18, presumably until 2016-08-18\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2016-08-18, presumably until 2016-08-26, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-26 14:01:09, ended at 2016-08-26 14:54:48\nThe patient in this visit was 59 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.992\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of upper inner quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-07 09:40:18, ended at 2016-10-07 10:47:47\nThe patient in this visit was 59 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.992\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of upper inner quadrant of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-06 13:57:00, ended at 2017-01-06 23:59:00\nThe patient in this visit was 59 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation on X-ray examination made elsewhere, written report\n\n### Condition\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-08 12:34:53, ended at 2017-01-08 13:50:38\nThe patient in this visit was 59 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.99\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Overlapping malignant neoplasm of female breast\n\n### Drug\n- 24 HR venlafaxine 75 MG Extended Release Oral Capsule, through Oral route, started on 2017-01-08, presumably until 2017-03-12, with intended 3 refill(s). Instructions: take 1 Durbin by mouth every bedtime\n- tamoxifen 20 MG Oral Tablet, through Oral route, started on 2017-01-08, presumably until 2018-01-08, with intended 3 refill(s). Instructions: take 20 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-08 13:45:00, ended at 2017-01-08 23:59:00\nThe patient in this visit was 59 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, breast, unilateral, real time with image documentation, including axilla when performed; limited\n\n### Condition\n- Breast lump\n- Solitary cyst of breast\n- Disorder of breast\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Malignant tumor of breast within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of breast_cancer means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "2db08abe69accb1ea377bb2b1b48105cf66d5c5a9f163a8b3cd94419052e5811", "prompt_hash": "42ad1388c014466da7658c3eb60e4097690e30b8401ca2806c14ec28831fec83", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 0.0, "f1_gu_yn": [1, 0], "recall_gu_yn": [1, 0]}
{"doc_id": 8, "doc": {"person_id": 115969394, "visit_occurrence_id": 166176421, "death_date": null, "visit_concept_name": "Telehealth", "visit_start_datetime": "2020-11-09 08:25:16", "visit_end_datetime": "2020-11-09 09:07:52", "visit_length_in_hours": 0.71, "integrated_visit_record": "## Visit\nThis visit record, was from Telehealth, started at 2020-11-09 08:25:16, ended at 2020-11-09 09:07:52\nThe patient in this visit was 49 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Primary diagnosis: Hemoptysis\n- Disorder of thyroid gland\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 101, "patient_first_visit_date": "2008-04-12 14:45:00", "patient_last_visit_date": "2022-12-04 09:08:18", "end_obs_date": "2021-11-09", "hypertension_type": "new", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "new", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "recurrent", "breast_cancer_one_year_diagnosis": 1, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 167, "cumulated_visit_num": 167, "cumulated_approximate_token_count": 24000, "visit_cumulated": "## Visit\nThis visit record, was from Hospital, started at 2008-04-12 14:45:00, ended at 2008-04-12 23:59:00\nThe patient in this visit was 36 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Female infertility\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-09 10:44:43, ended at 2015-08-09 12:00:33\nThe patient in this visit was 43 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.25\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Insomnia\n- Primary diagnosis: Goiter\n- Congenital hypothyroidism\n- Cyst of kidney\n- Gastro-esophageal reflux disease with esophagitis\n\n### Drug\n- lansoprazole 30 MG Delayed Release Oral Capsule, through Oral route, started on 2015-06-21, presumably until 2015-09-18, with intended 0 refill(s). Instructions: take 30 mg by mouth 2 times a day\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2015-06-18, presumably until 2015-09-18, with intended 0 refill(s). Instructions: take 50,000 Units by mouth once a week\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-09-04 10:47:39, ended at 2015-09-04 11:30:57\nThe patient in this visit was 43 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.25\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hashimoto thyroiditis\n\n### Drug\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2015-09-04, presumably until 2016-05-13, with intended 6 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-09-18 12:55:35, ended at 2015-09-18 14:26:30\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cyst of kidney\n\n### Drug\n- dexlansoprazole 60 MG Delayed Release Oral Capsule, through Oral route, presumably until 2016-05-20, with intended 0 refill(s). Instructions: take by mouth\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-13 11:34:20, ended at 2016-05-13 12:27:05\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.25\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Menopausal syndrome\n- Primary diagnosis: Autoimmune thyroiditis\n\n### Drug\n- evening primrose oil, started on 2016-05-13, presumably until 2016-05-20, with intended 1 refill(s). Instructions: daily\n- ethyl linoleate, started on 2016-05-13, presumably until 2016-05-20, with intended 1 refill(s). Instructions: daily\n- gamma-linolenate, started on 2016-05-13, presumably until 2016-05-20, with intended 1 refill(s). Instructions: daily\n- linoleate, started on 2016-05-13, presumably until 2016-05-20, with intended 1 refill(s). Instructions: daily\n- evening primrose extract, started on 2016-05-13, presumably until 2016-05-20, with intended 1 refill(s). Instructions: daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-16 00:00:00, ended at 2016-05-16 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign mammary dysplasia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-16 15:37:00, ended at 2016-05-16 23:59:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred slides prepared elsewhere\n\n### Condition\n- Fibroadenosis of left breast\n- Benign mammary dysplasia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-20 10:23:54, ended at 2016-05-20 11:57:02\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.173\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign mammary dysplasia\n- Hypertrophy of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-27 15:30:00, ended at 2016-05-27 23:59:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Morphometric analysis, tumor\n- Consultation and report on referred material requiring preparation of slides\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-30 13:12:20, ended at 2016-05-30 17:18:58\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.173\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypertrophy of breast\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-30 15:17:09, ended at 2016-05-30 17:18:49\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.173\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign mammary dysplasia\n- Hypertrophy of breast\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-03 10:27:52, ended at 2016-06-03 13:10:56\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.173\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-03 13:13:11, ended at 2016-06-03 13:13:33\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-06-04 00:00:00, ended at 2016-06-04 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 0.154 MEQ/ML Irrigation Solution, through Topical route, started on 2016-06-04, presumably until 2016-06-04\n- bacitracin 5000 UNT/ML Injectable Solution, through Intramuscular route, started on 2016-06-04, presumably until 2016-06-04\n- thrombin, bovine 2000 UNT/ML Topical Solution, through Topical route, started on 2016-06-04, presumably until 2016-06-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2016-06-04 00:00:00, ended at 2016-06-04 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on the integumentary system on the extremities, anterior trunk and perineum; reconstructive procedures on breast (eg, reduction or augmentation mammoplasty, muscle flaps)\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2016-06-04, presumably until 2016-06-04\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2016-06-04, presumably until 2016-06-04\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2016-06-04, presumably until 2016-06-04\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2016-06-04, presumably until 2016-06-04\n- cefazolin 1000 MG Injection, started on 2016-06-04, presumably until 2016-06-04\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2016-06-04, presumably until 2016-06-04\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2016-06-04, presumably until 2016-06-04\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2016-06-04, presumably until 2016-06-04\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2016-06-04, presumably until 2016-06-04\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2016-06-04, presumably until 2016-06-04\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-06-04, presumably until 2016-06-04\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-06-04, presumably until 2016-06-04\n- 250 ML lidocaine hydrochloride 8 MG/ML Injection, through Intravenous route, started on 2016-06-04, presumably until 2016-06-04\n- midazolam 1 MG/ML Injectable Solution, started on 2016-06-04, presumably until 2016-06-04\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2016-06-04, presumably until 2016-06-04\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2016-06-04, presumably until 2016-06-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2016-06-04 10:49:00, ended at 2016-06-06 19:43:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Level III - Surgical pathology, gross and microscopic examination Abortion, induced Abscess Aneurysm - arterial/ventricular Anus, tag Appendix, other than incidental Artery, atheromatous plaque Bartholin's gland cyst Bone fragment(s), other than pathologi\n- Insertion of Tissue Expander into Bilateral Breast, Open Approach\n- Lymphatics and lymph nodes imaging\n- Radiological examination, surgical specimen\n- Tissue expander placement in breast reconstruction, including subsequent expansion(s)\n- Removal of Synthetic Substitute from Right Breast, Open Approach\n- Removal of Synthetic Substitute from Left Breast, Open Approach\n- Mastectomy, simple, complete\n- Pathology consultation during surgery; cytologic examination (eg, touch prep, squash prep), initial site\n- Excision of Bilateral Breast, Open Approach\n- Excision of Left Axillary Lymphatic, Open Approach, Diagnostic\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Pathology consultation during surgery; first tissue block, with frozen section(s), single specimen\n\n### Condition\n- Benign mammary dysplasia\n- Primary malignant neoplasm of upper inner quadrant of female breast\n- Primary diagnosis: Primary malignant neoplasm of female breast\n- Autoimmune thyroiditis\n- Primary malignant neoplasm of central portion of female breast\n- Fibrocystic disease of breast\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2016-06-04, presumably until 2016-06-04\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2016-06-05, presumably until 2016-06-06\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2016-06-04, presumably until 2016-06-04\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2016-06-06, presumably until 2016-08-13, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day as needed (constipation)\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2016-06-06, presumably until 2016-06-16, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day for 10 days\n- cholecalciferol 0.01 MG Oral Tablet, through Oral route, started on 2016-06-05, presumably until 2016-06-06\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2016-06-04, presumably until 2016-06-06\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, started on 2016-06-04, presumably until 2016-06-04\n- methocarbamol 750 MG Oral Tablet, through Oral route, started on 2016-06-05, presumably until 2016-06-06\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2016-06-06, presumably until 2016-06-17, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed for Nausea\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2016-06-05, presumably until 2016-06-06\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2016-06-06, presumably until 2016-06-17, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed for Pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-06-04 11:55:00, ended at 2016-06-04 23:59:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 105 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-07 00:00:00, ended at 2016-06-07 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- diazepam 2 MG Oral Tablet, through Oral route, started on 2016-06-07, presumably until 2016-12-04, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-10 15:32:58, ended at 2016-06-10 17:26:10\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.173\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-17 00:00:00, ended at 2016-06-17 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ferrous gluconate 240 MG Oral Tablet, through Oral route, presumably until 2017-06-19, with intended 0 refill(s). Instructions: take 240 mg by mouth\n- calcium polycarbophil 625 MG Chewable Tablet, through Oral route, presumably until 2017-01-29, with intended 0 refill(s). Instructions: take 500 mg by mouth\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-17 10:27:40, ended at 2016-06-17 11:33:10\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Body height: 5' 4.17\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Shoulder joint pain\n- Spontaneous ecchymosis\n- Melanocytic nevus\n- Skin finding\n- Primary diagnosis: Autoimmune thyroiditis\n- Non-neoplastic nevus\n- Anemia\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-06-20 09:13:00, ended at 2016-06-20 09:13:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Bone and/or joint imaging; tomographic (SPECT)\n- Bone and/or joint imaging; whole body\n\n### Condition\n- Shoulder joint pain\n- Primary malignant neoplasm of female breast\n- Imaging of musculoskeletal system abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-21 00:00:00, ended at 2016-06-21 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-01 00:00:00, ended at 2016-07-01 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Skin finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-07-01 10:53:24, ended at 2016-07-01 11:33:43\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.173\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Postoperative state\n- Spontaneous ecchymosis\n- Anemia\n- Skin finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-03 00:00:00, ended at 2016-07-03 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-03 00:00:00, ended at 2016-07-03 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- von Willebrand factor (vWf) Ag actual/normal in Platelet poor plasma by Immunoassay: 71 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Skin finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-04 00:00:00, ended at 2016-07-04 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-10 08:42:00, ended at 2016-07-10 23:59:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Disorder of bone\n- Solitary nodule of lung\n- Primary malignant neoplasm of female breast\n- Disease of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-16 00:00:00, ended at 2016-07-16 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-17 00:00:00, ended at 2016-07-17 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: von Willebrand disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-07-18 10:46:14, ended at 2016-07-18 14:22:37\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.567\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- von Willebrand disorder\n- Irregular periods\n- Microscopic hematuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-07-18 14:46:16, ended at 2016-07-18 16:04:32\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- von Willebrand disorder\n- Microscopic hematuria\n- Irregular periods\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-30 00:00:00, ended at 2016-07-30 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Irregular periods\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-05 11:18:58, ended at 2016-08-05 14:38:25\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.567\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-06 11:19:00, ended at 2016-08-06 23:59:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, pelvic (nonobstetric), real time with image documentation; complete\n- Ultrasound, transvaginal\n\n### Condition\n- Uterine leiomyoma\n- Irregular periods\n- Intramural leiomyoma of uterus\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-12 00:00:00, ended at 2016-08-12 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: von Willebrand disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-12 00:00:00, ended at 2016-08-12 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: von Willebrand disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-13 00:00:00, ended at 2016-08-13 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Irregular periods\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-13 12:18:00, ended at 2016-08-13 23:59:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.65 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- MCHC [Mass/volume] by Automated count: 32.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.84 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 0.73 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.16 (thousand per microliter)\n- Prothrombin time (PT): 14.1 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 87.5 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.1 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay: 64.5 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.4 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 208 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 33.8 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 42 (unit per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 68 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.9 (percent)\n- MCH [Entitic mass] by Automated count: 28.0 (picogram)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.6 (percent)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.80 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 102 (milligram per deciliter)\n- Reticulocytes [#/volume] in Blood by Automated count: 35.1 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- von Willebrand disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-13 13:14:22, ended at 2016-08-13 14:10:40\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3.976\" (inch (US))\n- Ferritin [Mass/volume] in Serum or Plasma: 34.3 (nanogram per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: von Willebrand disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-12 08:15:15, ended at 2016-09-12 08:56:07\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Noninflammatory disorder of the vagina\n- Primary diagnosis: Genitourinary tract hemorrhage\n\n### Drug\n- metronidazole 0.0075 MG/MG Vaginal Gel, through Vaginal route, started on 2016-09-12, presumably until 2016-10-02, with intended 2 refill(s). Instructions: insert 1 Applicator into the vagina every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-17 15:08:52, ended at 2016-09-17 15:40:35\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2.992\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Coag./bleeding tests abnormal\n- von Willebrand disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-19 13:57:01, ended at 2016-09-19 16:59:18\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.252\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-01 11:37:12, ended at 2016-10-01 12:05:07\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute upper respiratory infection\n- Primary diagnosis: Viral disease\n\n### Drug\n- codeine phosphate 2 MG/ML / promethazine hydrochloride 1.25 MG/ML Oral Solution, started on 2016-10-01, presumably until 2016-10-17, with intended 0 refill(s). Instructions: TAke 5ml PO at night PRN cough\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-02 10:00:06, ended at 2016-10-02 10:38:38\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute upper respiratory infection\n- Autoimmune thyroiditis\n- Microscopic hematuria\n- Primary diagnosis: Hematuria syndrome\n- Viral disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-10-03 00:00:00, ended at 2016-10-03 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Microscopic hematuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-17 08:54:34, ended at 2016-10-17 09:46:56\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging\n\n### Condition\n- Primary diagnosis: Hematuria syndrome\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-30 07:58:00, ended at 2016-10-30 23:59:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Bone and/or joint imaging; whole body\n- Bone and/or joint imaging; tomographic (SPECT)\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Chest pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-01 00:00:00, ended at 2016-11-01 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-11-01 10:57:00, ended at 2016-11-01 23:59:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, retroperitoneal (eg, renal, aorta, nodes), real time with image documentation; complete\n\n### Condition\n- Noninflammatory disorder of the female genital organs\n- Primary malignant neoplasm of female breast\n- Coag./bleeding tests abnormal\n- Hematuria syndrome\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-05 00:00:00, ended at 2016-11-05 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cyst of ovary\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-11-05 13:15:00, ended at 2016-11-05 23:59:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, transvaginal\n- Ultrasound, pelvic (nonobstetric), real time with image documentation; complete\n\n### Condition\n- Intramural leiomyoma of uterus\n- Noninflammatory disorder of the female genital organs\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-11-21 11:58:27, ended at 2016-11-21 12:21:41\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Generalized anxiety disorder\n- Primary diagnosis: Cough\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-11-21, presumably until 2017-01-29, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 8 hours as needed\n- azithromycin 250 MG Oral Tablet, through Oral route, started on 2016-11-21, presumably until 2016-11-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth as directed for 5 days 2 tabs on day 1, then 1 tab daily thereafter\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-11-27 11:35:26, ended at 2016-11-27 17:28:38\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute upper respiratory infection\n- Viral disease\n- Primary diagnosis: Cough\n\n### Drug\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2016-11-27, presumably until 2016-11-27, with intended 0 refill(s). Instructions: 3 mL by Inhalation route One Time\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2016-11-27, presumably until 2017-01-29, with intended 0 refill(s). Instructions: 2 Puffs by Inhalation route every 4 hours as needed for Bronchospasm/Wheezing\n- 12 HR dextromethorphan hydrobromide 30 MG / guaifenesin 600 MG Extended Release Oral Tablet, through Oral route, started on 2016-11-27, presumably until 2017-01-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-11-27 13:25:24, ended at 2016-11-27 14:51:07\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.3 (percent)\n- MCH [Entitic mass] by Automated count: 29.0 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Body height: 5' 4\" (inch (US))\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.33 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.3 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 176 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.8 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.67 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 146 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Benign mammary dysplasia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-11-27 14:53:15, ended at 2016-11-27 16:24:38\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Cystourethroscopy (separate procedure)\n\n### Condition\n- Primary diagnosis: Hematuria syndrome\n- Cough\n- Benign mammary dysplasia\n- Acute upper respiratory infection\n- Viral disease\n\n### Drug\n- cephalexin 500 MG Oral Tablet, started on 2016-11-27, presumably until 2016-11-27, with intended 0 refill(s). Instructions: Take one capsule by mouth prior to procedure.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-11-28 00:00:00, ended at 2016-11-28 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for intraperitoneal procedures in lower abdomen including laparoscopy; not otherwise specified\n\n### Condition\n- Cyst of ovary\n\n### Drug\n- cefazolin 1000 MG Injection, started on 2016-11-28, presumably until 2016-11-28\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2016-11-28, presumably until 2016-11-28\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2016-11-28, presumably until 2016-11-28\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-11-28, presumably until 2016-11-28\n- midazolam 1 MG/ML Injectable Solution, started on 2016-11-28, presumably until 2016-11-28\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2016-11-28, presumably until 2016-11-28\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2016-11-28, presumably until 2016-11-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-11-28 00:00:00, ended at 2016-11-28 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 0.154 MEQ/ML Irrigation Solution, through Topical route, started on 2016-11-28, presumably until 2016-11-28\n- 20 ML bupivacaine liposome 13.3 MG/ML Injection, through Infiltration route, started on 2016-11-28, presumably until 2016-11-28\n- bupivacaine hydrochloride 5 MG/ML Injectable Solution, started on 2016-11-28, presumably until 2016-11-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2016-11-28 13:15:00, ended at 2016-11-29 13:19:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Resection of Bilateral Ovaries, Percutaneous Endoscopic Approach\n- Collection of venous blood by venipuncture\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Resection of Bilateral Fallopian Tubes, Percutaneous Endoscopic Approach\n- Pathology consultation during surgery\n\n### Condition\n- Autoimmune thyroiditis\n- Cyst of ovary\n- Follicular cyst of left ovary\n- Follicular cyst of right ovary\n- Corpus luteum cyst\n- Noninflammatory disorder of the female genital organs\n- Gastroesophageal reflux disease without esophagitis\n- Primary malignant neoplasm of female breast\n\n### Drug\n- oxycodone hydrochloride 5 MG Oral Capsule, through Oral route, started on 2016-11-28, presumably until 2017-01-29, with intended 0 refill(s). Instructions: take 5 mg by mouth every 4 hours as needed\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2016-11-29, presumably until 2016-11-29\n- ibuprofen 200 MG Oral Tablet, through Oral route, started on 2016-11-29, presumably until 2016-11-29\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2016-11-28, presumably until 2017-01-29, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day as needed (constipation)\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2016-11-29, presumably until 2016-11-29\n- ibuprofen 600 MG Oral Tablet, through Oral route, started on 2016-11-28, presumably until 2017-01-29, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-02 00:00:00, ended at 2016-12-02 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- anastrozole 1 MG Oral Tablet, through Oral route, started on 2016-12-02, presumably until 2017-02-25, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-29 09:28:21, ended at 2017-01-29 14:50:46\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-25 00:00:00, ended at 2017-02-25 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, through Oral route, started on 2017-02-25, presumably until 2017-06-19, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-11 13:12:23, ended at 2017-03-11 15:21:55\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Ganglion of wrist\n- Abdominal distension, gaseous\n- Arthralgia of the ankle and/or foot\n- Chest pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-05-26 00:00:00, ended at 2017-05-26 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Microscopic hematuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-05-28 11:19:44, ended at 2017-05-28 11:55:27\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Microscopic hematuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-05-29 10:37:12, ended at 2017-05-29 11:40:22\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Thyroperoxidase Ab [Units/volume] in Serum or Plasma: >1000.0 (international unit per milliliter)\n- Body height: 5' 4\" (inch (US))\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.6 (nanogram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 29.30 (micro-international unit per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic multinodular goiter\n- Menopause present\n- Simple goiter\n- Primary diagnosis: Autoimmune thyroiditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-04 11:12:08, ended at 2017-06-04 11:54:13\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congenital hypothyroidism with diffuse goiter\n- Autoimmune thyroiditis\n\n### Drug\n- levothyroxine sodium 0.075 MG Oral Tablet, through Oral route, started on 2017-06-04, presumably until 2017-06-17, with intended 4 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-09 00:00:00, ended at 2017-06-09 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on the integumentary system on the extremities, anterior trunk and perineum; reconstructive procedures on breast (eg, reduction or augmentation mammoplasty, muscle flaps)\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- citric acid 66.8 MG/ML / sodium citrate 100 MG/ML Oral Solution, through Oral route, started on 2017-06-09, presumably until 2017-06-09\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2017-06-09, presumably until 2017-06-09\n- cefazolin 1000 MG Injection, started on 2017-06-09, presumably until 2017-06-09\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-06-09, presumably until 2017-06-09\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2017-06-09, presumably until 2017-06-09\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-06-09, presumably until 2017-06-09\n- midazolam 1 MG/ML Injectable Solution, started on 2017-06-09, presumably until 2017-06-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-06-09 00:00:00, ended at 2017-06-09 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 0.154 MEQ/ML Irrigation Solution, through Topical route, started on 2017-06-09, presumably until 2017-06-09\n- bacitracin 5000 UNT/ML Injectable Solution, through Intramuscular route, started on 2017-06-09, presumably until 2017-06-09\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2017-06-09, presumably until 2017-06-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-09 06:46:00, ended at 2017-06-09 14:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- Tissue grafts, other (eg, paratenon, fat, dermis)\n- Removal of Tissue Expander from Left Breast, Open Approach\n- Removal of Tissue Expander from Right Breast, Open Approach\n- Breast reconstruction with other technique\n- Replacement of tissue expander with permanent implant\n- Replacement of Bilateral Breast with Autologous Tissue Substitute, Open Approach\n- Mastopexy\n- Level III - Surgical pathology, gross and microscopic examination Abortion, induced Abscess Aneurysm - arterial/ventricular Anus, tag Appendix, other than incidental Artery, atheromatous plaque Bartholin's gland cyst Bone fragment(s), other than pathologi\n- Replacement of Bilateral Breast with Synthetic Substitute, Open Approach\n\n### Condition\n- Autoimmune thyroiditis\n- Gastroesophageal reflux disease without esophagitis\n- Deformity of reconstructed breast\n\n### Drug\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2017-06-09, presumably until 2017-06-19, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 6 hours as needed for Pain\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2017-06-09, presumably until 2017-06-16, with intended 0 refill(s). Instructions: take 1 Cap by mouth every 6 hours for 7 days\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2017-06-09, presumably until 2017-06-09\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2017-06-09, presumably until 2017-06-09\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2017-06-09, presumably until 2017-06-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed (nausea)\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-06-09, presumably until 2017-06-19, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2017-06-09, presumably until 2017-06-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-16 12:15:48, ended at 2017-06-16 13:49:14\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-06-17 00:00:00, ended at 2017-06-17 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levothyroxine sodium 0.075 MG Oral Tablet, through Oral route, started on 2017-06-17, presumably until 2017-06-19, with intended 6 refill(s). Instructions: take 1 Tab by mouth daily in the evening\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-06-24 00:00:00, ended at 2017-06-24 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 0.154 MEQ/ML Irrigation Solution, through Topical route, started on 2017-06-24, presumably until 2017-06-24\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2017-06-24, presumably until 2017-06-24\n- bacitracin 5000 UNT/ML Injectable Solution, through Intramuscular route, started on 2017-06-24, presumably until 2017-06-24\n- thrombin, bovine 2000 UNT/ML Topical Solution, through Topical route, started on 2017-06-24, presumably until 2017-06-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-24 10:35:00, ended at 2017-06-24 17:13:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n- Glucose [Mass/volume] in Blood: 196 (milligram per deciliter)\n\n### Procedure\n- Peri-implant capsulectomy, breast, complete, including removal of all intracapsular contents\n- Level III - Surgical pathology, gross and microscopic examination Abortion, induced Abscess Aneurysm - arterial/ventricular Anus, tag Appendix, other than incidental Artery, atheromatous plaque Bartholin's gland cyst Bone fragment(s), other than pathologi\n- Removal of Synthetic Substitute from Left Breast, Open Approach\n- Removal of Synthetic Substitute from Right Breast, Open Approach\n\n### Condition\n- Hypothyroidism\n- Non-toxic multinodular goiter\n- Primary diagnosis: Postoperative state\n- Gastroesophageal reflux disease without esophagitis\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2017-06-24, presumably until 2017-06-24\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2017-06-09, presumably until 2017-06-30, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day for 10 days\n- ondansetron 4 MG Oral Tablet, started on 2017-06-09, presumably until 2017-06-24, with intended 0 refill(s). Instructions: TAKE 1 TAB BY MOUTH EVERY 6 HOURS AS NEEDED (NAUSEA)\n- exemestane 25 MG Oral Tablet, through Oral route, presumably until 2017-06-27, with intended 0 refill(s). Instructions: take 25 mg by mouth daily\n- levothyroxine sodium 0.075 MG Oral Tablet, through Oral route, presumably until 2017-08-07, with intended 0 refill(s). Instructions: take 75 mcg by mouth every morning before breakfast\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2017-06-24, presumably until 2017-08-07, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 to 6 hours as needed for Pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-06-26 00:00:00, ended at 2017-06-26 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, started on 2017-06-27, presumably until 2017-10-23, with intended 3 refill(s). Instructions: TAKE 1 TAB BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-06-27 00:00:00, ended at 2017-06-27 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Iron [Mass/volume] in Serum or Plasma: 54 (microgram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 16 (percent)\n- Ferritin [Mass/volume] in Serum or Plasma: 67.7 (nanogram per milliliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.31 (micro-international unit per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Autoimmune thyroiditis\n- Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-27 12:29:48, ended at 2017-06-27 13:01:50\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tachycardia\n- Congenital hypothyroidism with diffuse goiter\n- Autoimmune thyroiditis\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2017-06-27, presumably until 2017-09-25, with intended 3 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-30 15:50:14, ended at 2017-06-30 16:56:59\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2017-06-30, presumably until 2018-06-30, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2017-06-30, presumably until 2017-07-10, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-07-02 15:06:31, ended at 2017-07-02 15:50:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-07 15:58:27, ended at 2017-08-07 16:55:45\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-18 13:14:00, ended at 2017-08-18 23:59:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Non-toxic multinodular goiter\n- Simple goiter\n- Autoimmune thyroiditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-20 14:14:21, ended at 2017-08-20 15:42:01\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- General finding of observation of patient\n- Primary diagnosis: Low back pain\n- Localized enlarged lymph nodes\n- Dermatographic urticaria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-10 14:19:29, ended at 2017-09-10 16:52:34\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements f\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-12 00:00:00, ended at 2017-09-12 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congenital hypothyroidism without goiter\n- Iron deficiency anemia due to blood loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-23 15:49:40, ended at 2017-09-23 16:38:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-25 09:35:44, ended at 2017-09-25 10:46:05\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Autoimmune thyroiditis\n- Gastro-esophageal reflux disease with esophagitis\n- Benign mammary dysplasia\n- Iron deficiency anemia due to blood loss\n- Congenital hypothyroidism with diffuse goiter\n- Lymphadenopathy\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2017-09-25, presumably until 2018-09-25, with intended 12 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast\n- ranitidine 150 MG Oral Capsule, through Oral route, started on 2017-09-25, presumably until 2018-09-25, with intended 3 refill(s). Instructions: take 150 mg by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-25 11:16:03, ended at 2017-09-25 12:09:37\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-07 13:13:49, ended at 2017-10-07 14:14:56\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of head\n- Swelling / lump finding\n- Low back pain\n- Localized swelling, mass and lump, neck\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-10-07 14:14:29, ended at 2017-10-07 16:32:19\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of head\n- Localized swelling, mass and lump, neck\n- Primary diagnosis: Low back pain\n- Swelling / lump finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-20 10:28:00, ended at 2017-10-20 23:59:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Swelling / lump finding\n- Disorder of head\n- Localized swelling, mass and lump, neck\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-21 13:22:55, ended at 2017-10-21 14:08:28\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-10-23 00:00:00, ended at 2017-10-23 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, started on 2017-10-24, presumably until 2018-01-05, with intended 2 refill(s). Instructions: TAKE 1 TAB BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-24 09:30:00, ended at 2017-10-24 23:59:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine)\n\n### Condition\n- Menopause present\n- Disorder of bone\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-06 00:00:00, ended at 2017-11-06 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of head\n- Primary diagnosis: Localized swelling, mass and lump, neck\n- Primary diagnosis: Swelling / lump finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-06 13:14:00, ended at 2017-11-06 15:02:06\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-07 00:00:00, ended at 2017-11-07 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Swelling / lump finding\n- Primary diagnosis: Localized swelling, mass and lump, neck\n- Primary diagnosis: Disorder of head\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-13 08:45:44, ended at 2017-11-13 09:36:56\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Posterior rhinorrhea\n- Chronic pharyngitis\n- Gastro-esophageal reflux disease with esophagitis\n\n### Drug\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2017-11-13, presumably until 2019-06-09, with intended 3 refill(s). Instructions: 2 Sprays by Nasal route daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-18 09:48:01, ended at 2017-11-18 11:44:26\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Edema\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-01-05 00:00:00, ended at 2018-01-05 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, through Oral route, started on 2018-01-05, presumably until 2018-02-04, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-02-01 00:00:00, ended at 2018-02-01 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, started on 2018-02-13, presumably until 2018-02-13, with intended 2 refill(s). Instructions: TAKE 1 TAB BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-02-04 00:00:00, ended at 2018-02-04 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, through Oral route, started on 2018-02-04, presumably until 2018-05-05, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-20 14:11:03, ended at 2018-04-20 15:27:58\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3.976\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n- Cyst of ovary\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-27 00:00:00, ended at 2018-04-27 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-27 15:30:00, ended at 2018-04-27 23:59:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, abdominal, real time with image documentation; complete\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Abdominal pain\n- Imaging of gastrointestinal tract abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-28 07:08:00, ended at 2018-04-28 23:59:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Disease of liver\n- Primary malignant neoplasm of female breast\n- Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-04-30 00:00:00, ended at 2018-04-30 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, started on 2018-05-12, presumably until 2018-05-12, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-05 00:00:00, ended at 2018-05-05 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, through Oral route, started on 2018-05-05, presumably until 2018-08-06, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-06-02 00:00:00, ended at 2018-06-02 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-07-30 00:00:00, ended at 2018-07-30 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, started on 2018-08-11, presumably until 2018-08-14, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-08-06 00:00:00, ended at 2018-08-06 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, through Oral route, started on 2018-08-11, presumably until 2018-08-11, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-08-14 00:00:00, ended at 2018-08-14 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, through Oral route, started on 2018-08-17, presumably until 2018-12-09, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-10-23 14:21:20, ended at 2018-10-23 14:50:35\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Viral disease\n- Primary diagnosis: Acute upper respiratory infection\n\n### Drug\n- 12 HR guaifenesin 600 MG Extended Release Oral Tablet, through Oral route, started on 2018-10-23, presumably until 2019-06-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-13 00:00:00, ended at 2018-11-13 00:00:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-13 00:00:00, ended at 2018-11-13 00:00:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localized swelling, mass and lump, upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-13 15:58:00, ended at 2018-11-13 23:59:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Localized swelling, mass and lump, upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-16 13:47:00, ended at 2018-11-16 23:59:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, limited, joint or other nonvascular extremity structure(s) (eg, joint space, peri-articular tendon[s], muscle[s], nerve[s], other soft-tissue structure[s], or soft-tissue mass[es]), real-time with image documentation\n\n### Condition\n- Lump in left breast\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-11-23 14:23:46, ended at 2018-11-23 17:23:17\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3.976\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-12-09 00:00:00, ended at 2018-12-09 00:00:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, through Oral route, started on 2018-12-10, presumably until 2019-09-01, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-02-16 13:59:00, ended at 2019-02-16 23:59:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, limited, joint or other nonvascular extremity structure(s) (eg, joint space, peri-articular tendon[s], muscle[s], nerve[s], other soft-tissue structure[s], or soft-tissue mass[es]), real-time with image documentation\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Localized swelling, mass and lump, trunk\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-16 15:55:23, ended at 2019-02-16 16:43:46\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3.543\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-05-06 00:00:00, ended at 2019-05-06 00:00:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hemoptysis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-17 11:39:00, ended at 2019-05-17 23:59:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n- Primary malignant neoplasm of female breast\n- Hemoptysis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-17 13:57:06, ended at 2019-05-17 15:08:39\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3.543\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-03 07:48:23, ended at 2019-06-03 08:32:02\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3.543\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hemoptysis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-09 00:00:00, ended at 2019-06-09 00:00:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for closed chest procedures; (including bronchoscopy) not otherwise specified\n\n### Condition\n- Hemoptysis\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2019-06-09, presumably until 2019-06-09\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-06-09, presumably until 2019-06-09\n- remifentanil 2 MG Injection, through Intravenous route, started on 2019-06-09, presumably until 2019-06-09\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2019-06-09, presumably until 2019-06-09\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-06-09, presumably until 2019-06-09\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2019-06-09, presumably until 2019-06-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-09 08:45:00, ended at 2019-06-09 14:39:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Inspection of Tracheobronchial Tree, Via Natural or Artificial Opening Endoscopic\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; diagnostic, with cell washing, when performed (separate procedure)\n\n### Condition\n- Insomnia\n- Autoimmune thyroiditis\n- Primary diagnosis: Benign mammary dysplasia\n- Solitary nodule of lung\n- Gastroesophageal reflux disease without esophagitis\n- Hemoptysis\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2019-06-09, presumably until 2019-06-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-25 00:00:00, ended at 2019-06-25 00:00:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Solitary nodule of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-28 00:00:00, ended at 2019-06-28 00:00:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hemoptysis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-08-12 10:25:00, ended at 2019-08-12 23:59:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Solitary nodule of lung\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-08-16 12:39:00, ended at 2019-08-16 23:59:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, limited, joint or other nonvascular extremity structure(s) (eg, joint space, peri-articular tendon[s], muscle[s], nerve[s], other soft-tissue structure[s], or soft-tissue mass[es]), real-time with image documentation\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Lump of axillary tail of left breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-08-16 14:40:06, ended at 2019-08-16 15:55:10\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3.543\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-24 00:00:00, ended at 2019-08-24 00:00:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hemoptysis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-08-24 10:51:51, ended at 2019-08-24 11:37:55\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hemoptysis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-08-31 10:19:00, ended at 2019-08-31 23:59:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hemoptysis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-01 00:00:00, ended at 2019-09-01 00:00:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, through Oral route, started on 2019-09-01, presumably until 2020-08-30, with intended 3 refill(s). Instructions: take 1 Tab (25 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-03 00:00:00, ended at 2019-09-03 00:00:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hemoptysis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-19 10:53:56, ended at 2019-10-19 11:29:11\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-20 00:00:00, ended at 2019-10-20 00:00:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for closed chest procedures; (including bronchoscopy) not otherwise specified\n\n### Condition\n- Hemoptysis\n\n### Drug\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-10-20, presumably until 2019-10-20\n- remifentanil 2 MG Injection, through Intravenous route, started on 2019-10-20, presumably until 2019-10-20\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-10-20, presumably until 2019-10-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2019-10-20 00:00:00, ended at 2019-10-20 00:00:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial alveolar lavage\n\n### Condition\n- Hemoptysis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-20 08:58:00, ended at 2019-10-20 11:10:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial alveolar lavage\n\n### Condition\n- Hemoptysis\n- Autoimmune thyroiditis\n- Gastroesophageal reflux disease without esophagitis\n- Pneumonia\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2019-10-20, presumably until 2019-10-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-10-22 00:00:00, ended at 2019-10-22 00:00:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localized swelling, mass and lump, neck\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-27 11:07:00, ended at 2019-10-27 23:59:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Localized swelling, mass and lump, neck\n- Localized enlarged lymph nodes\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-10 13:56:41, ended at 2019-11-10 15:03:17\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; manual screening under physician supervision\n\n### Condition\n- Noninflammatory disorder of the vagina\n- Postmenopausal bleeding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-11-16 09:44:00, ended at 2019-11-16 23:59:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, pelvic (nonobstetric), real time with image documentation; complete\n- Ultrasound, transvaginal\n\n### Condition\n- Postmenopausal bleeding\n- Intramural leiomyoma of uterus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-25 10:13:36, ended at 2019-11-25 11:41:23\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Fine needle aspiration biopsy, including ultrasound guidance; first lesion\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n- Localized enlarged lymph nodes\n- Mycobacteriosis\n- Hemoptysis\n- Generalized enlarged lymph nodes\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-26 09:12:06, ended at 2019-11-26 11:46:58\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- Endometrial sampling (biopsy) with or without endocervical sampling (biopsy), without cervical dilation, any method (separate procedure)\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Noninflammatory disorder of uterus\n- Atrophic vaginitis\n- Primary diagnosis: Postmenopausal bleeding\n\n### Drug\n- estradiol 0.1 MG/ML Vaginal Cream, through Vaginal route, started on 2019-11-26, presumably until 2020-11-25, with intended 0 refill(s). Instructions: insert 2 g into the vagina daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-11 00:00:00, ended at 2019-12-11 00:00:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrophic vaginitis\n\n### Drug\n- estradiol 0.1 MG/ML Vaginal Cream, started on 2019-12-11, presumably until 2020-08-22, with intended 0 refill(s). Instructions: Apply small amount to skin outside of vagina, and to vaginal skin, once or twice a week at night.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-16 10:48:32, ended at 2019-12-16 11:50:04\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Generalized enlarged lymph nodes\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-24 00:00:00, ended at 2020-01-24 00:00:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-02 00:00:00, ended at 2020-02-02 00:00:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-02 08:31:00, ended at 2020-02-02 23:59:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Generalized enlarged lymph nodes\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-08 09:03:52, ended at 2020-02-08 09:36:12\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Mycobacteriosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-21 12:47:00, ended at 2020-02-21 23:59:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, limited, joint or other nonvascular extremity structure(s) (eg, joint space, peri-articular tendon[s], muscle[s], nerve[s], other soft-tissue structure[s], or soft-tissue mass[es]), real-time with image documentation\n\n### Condition\n- Lump of axillary tail of left breast\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-22 08:54:56, ended at 2020-02-22 09:46:01\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3.346\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Staphylococcal infectious disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-25 00:00:00, ended at 2020-02-25 00:00:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n- Cyst of ovary\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-03-13 16:03:47, ended at 2020-03-13 17:14:04\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Epigastric pain\n- Digestive system finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-21 09:18:00, ended at 2020-03-21 23:59:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, pelvic (nonobstetric), real time with image documentation; complete\n- Ultrasound, transvaginal\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Cyst of ovary\n- Intramural leiomyoma of uterus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-03-28 00:00:00, ended at 2020-03-28 00:00:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, started on 2020-03-28, presumably until 2020-04-11, with intended 0 refill(s). Instructions: Take 2L by mouth night before and 2L morning of procedure. Stop fluids 4hr before procedure. Instructions are forwarded to patient.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-03 11:46:35, ended at 2020-05-03 11:55:26\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrophic vaginitis\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-22 09:25:33, ended at 2020-08-22 10:04:54\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-08-26 00:00:00, ended at 2020-08-26 00:00:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, started on 2020-08-30, presumably until 2021-09-21, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-09-15 08:25:30, ended at 2020-09-15 08:33:12\nThe patient in this visit was 49 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Mycobacteriosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-30 00:00:00, ended at 2020-10-30 00:00:00\nThe patient in this visit was 49 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Mycobacteriosis\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-03 00:00:00, ended at 2020-11-03 00:00:00\nThe patient in this visit was 49 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mycobacteriosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-09 00:00:00, ended at 2020-11-09 00:00:00\nThe patient in this visit was 49 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hemoptysis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-09 08:25:16, ended at 2020-11-09 09:07:52\nThe patient in this visit was 49 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Primary diagnosis: Hemoptysis\n- Disorder of thyroid gland\n\n### Drug\n- No drugs.\n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Malignant tumor of breast within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Hospital, started at 2008-04-12 14:45:00, ended at 2008-04-12 23:59:00\nThe patient in this visit was 36 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Female infertility\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-09 10:44:43, ended at 2015-08-09 12:00:33\nThe patient in this visit was 43 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.25\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Insomnia\n- Primary diagnosis: Goiter\n- Congenital hypothyroidism\n- Cyst of kidney\n- Gastro-esophageal reflux disease with esophagitis\n\n### Drug\n- lansoprazole 30 MG Delayed Release Oral Capsule, through Oral route, started on 2015-06-21, presumably until 2015-09-18, with intended 0 refill(s). Instructions: take 30 mg by mouth 2 times a day\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2015-06-18, presumably until 2015-09-18, with intended 0 refill(s). Instructions: take 50,000 Units by mouth once a week\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-09-04 10:47:39, ended at 2015-09-04 11:30:57\nThe patient in this visit was 43 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.25\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hashimoto thyroiditis\n\n### Drug\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2015-09-04, presumably until 2016-05-13, with intended 6 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-09-18 12:55:35, ended at 2015-09-18 14:26:30\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cyst of kidney\n\n### Drug\n- dexlansoprazole 60 MG Delayed Release Oral Capsule, through Oral route, presumably until 2016-05-20, with intended 0 refill(s). Instructions: take by mouth\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-13 11:34:20, ended at 2016-05-13 12:27:05\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.25\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Menopausal syndrome\n- Primary diagnosis: Autoimmune thyroiditis\n\n### Drug\n- evening primrose oil, started on 2016-05-13, presumably until 2016-05-20, with intended 1 refill(s). Instructions: daily\n- ethyl linoleate, started on 2016-05-13, presumably until 2016-05-20, with intended 1 refill(s). Instructions: daily\n- gamma-linolenate, started on 2016-05-13, presumably until 2016-05-20, with intended 1 refill(s). Instructions: daily\n- linoleate, started on 2016-05-13, presumably until 2016-05-20, with intended 1 refill(s). Instructions: daily\n- evening primrose extract, started on 2016-05-13, presumably until 2016-05-20, with intended 1 refill(s). Instructions: daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-16 00:00:00, ended at 2016-05-16 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign mammary dysplasia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-16 15:37:00, ended at 2016-05-16 23:59:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred slides prepared elsewhere\n\n### Condition\n- Fibroadenosis of left breast\n- Benign mammary dysplasia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-20 10:23:54, ended at 2016-05-20 11:57:02\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.173\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign mammary dysplasia\n- Hypertrophy of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-27 15:30:00, ended at 2016-05-27 23:59:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Morphometric analysis, tumor\n- Consultation and report on referred material requiring preparation of slides\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-30 13:12:20, ended at 2016-05-30 17:18:58\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.173\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypertrophy of breast\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-30 15:17:09, ended at 2016-05-30 17:18:49\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.173\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign mammary dysplasia\n- Hypertrophy of breast\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-03 10:27:52, ended at 2016-06-03 13:10:56\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.173\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-03 13:13:11, ended at 2016-06-03 13:13:33\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-06-04 00:00:00, ended at 2016-06-04 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 0.154 MEQ/ML Irrigation Solution, through Topical route, started on 2016-06-04, presumably until 2016-06-04\n- bacitracin 5000 UNT/ML Injectable Solution, through Intramuscular route, started on 2016-06-04, presumably until 2016-06-04\n- thrombin, bovine 2000 UNT/ML Topical Solution, through Topical route, started on 2016-06-04, presumably until 2016-06-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2016-06-04 00:00:00, ended at 2016-06-04 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on the integumentary system on the extremities, anterior trunk and perineum; reconstructive procedures on breast (eg, reduction or augmentation mammoplasty, muscle flaps)\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2016-06-04, presumably until 2016-06-04\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2016-06-04, presumably until 2016-06-04\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2016-06-04, presumably until 2016-06-04\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2016-06-04, presumably until 2016-06-04\n- cefazolin 1000 MG Injection, started on 2016-06-04, presumably until 2016-06-04\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2016-06-04, presumably until 2016-06-04\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2016-06-04, presumably until 2016-06-04\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2016-06-04, presumably until 2016-06-04\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2016-06-04, presumably until 2016-06-04\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2016-06-04, presumably until 2016-06-04\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-06-04, presumably until 2016-06-04\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-06-04, presumably until 2016-06-04\n- 250 ML lidocaine hydrochloride 8 MG/ML Injection, through Intravenous route, started on 2016-06-04, presumably until 2016-06-04\n- midazolam 1 MG/ML Injectable Solution, started on 2016-06-04, presumably until 2016-06-04\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2016-06-04, presumably until 2016-06-04\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2016-06-04, presumably until 2016-06-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2016-06-04 10:49:00, ended at 2016-06-06 19:43:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Level III - Surgical pathology, gross and microscopic examination Abortion, induced Abscess Aneurysm - arterial/ventricular Anus, tag Appendix, other than incidental Artery, atheromatous plaque Bartholin's gland cyst Bone fragment(s), other than pathologi\n- Insertion of Tissue Expander into Bilateral Breast, Open Approach\n- Lymphatics and lymph nodes imaging\n- Radiological examination, surgical specimen\n- Tissue expander placement in breast reconstruction, including subsequent expansion(s)\n- Removal of Synthetic Substitute from Right Breast, Open Approach\n- Removal of Synthetic Substitute from Left Breast, Open Approach\n- Mastectomy, simple, complete\n- Pathology consultation during surgery; cytologic examination (eg, touch prep, squash prep), initial site\n- Excision of Bilateral Breast, Open Approach\n- Excision of Left Axillary Lymphatic, Open Approach, Diagnostic\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Pathology consultation during surgery; first tissue block, with frozen section(s), single specimen\n\n### Condition\n- Benign mammary dysplasia\n- Primary malignant neoplasm of upper inner quadrant of female breast\n- Primary diagnosis: Primary malignant neoplasm of female breast\n- Autoimmune thyroiditis\n- Primary malignant neoplasm of central portion of female breast\n- Fibrocystic disease of breast\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2016-06-04, presumably until 2016-06-04\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2016-06-05, presumably until 2016-06-06\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2016-06-04, presumably until 2016-06-04\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2016-06-06, presumably until 2016-08-13, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day as needed (constipation)\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2016-06-06, presumably until 2016-06-16, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day for 10 days\n- cholecalciferol 0.01 MG Oral Tablet, through Oral route, started on 2016-06-05, presumably until 2016-06-06\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2016-06-04, presumably until 2016-06-06\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, started on 2016-06-04, presumably until 2016-06-04\n- methocarbamol 750 MG Oral Tablet, through Oral route, started on 2016-06-05, presumably until 2016-06-06\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2016-06-06, presumably until 2016-06-17, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed for Nausea\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2016-06-05, presumably until 2016-06-06\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2016-06-06, presumably until 2016-06-17, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed for Pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-06-04 11:55:00, ended at 2016-06-04 23:59:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 105 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-07 00:00:00, ended at 2016-06-07 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- diazepam 2 MG Oral Tablet, through Oral route, started on 2016-06-07, presumably until 2016-12-04, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-10 15:32:58, ended at 2016-06-10 17:26:10\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.173\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-17 00:00:00, ended at 2016-06-17 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ferrous gluconate 240 MG Oral Tablet, through Oral route, presumably until 2017-06-19, with intended 0 refill(s). Instructions: take 240 mg by mouth\n- calcium polycarbophil 625 MG Chewable Tablet, through Oral route, presumably until 2017-01-29, with intended 0 refill(s). Instructions: take 500 mg by mouth\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-17 10:27:40, ended at 2016-06-17 11:33:10\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Body height: 5' 4.17\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Shoulder joint pain\n- Spontaneous ecchymosis\n- Melanocytic nevus\n- Skin finding\n- Primary diagnosis: Autoimmune thyroiditis\n- Non-neoplastic nevus\n- Anemia\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-06-20 09:13:00, ended at 2016-06-20 09:13:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Bone and/or joint imaging; tomographic (SPECT)\n- Bone and/or joint imaging; whole body\n\n### Condition\n- Shoulder joint pain\n- Primary malignant neoplasm of female breast\n- Imaging of musculoskeletal system abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-21 00:00:00, ended at 2016-06-21 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-01 00:00:00, ended at 2016-07-01 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Skin finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-07-01 10:53:24, ended at 2016-07-01 11:33:43\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.173\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Postoperative state\n- Spontaneous ecchymosis\n- Anemia\n- Skin finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-03 00:00:00, ended at 2016-07-03 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-03 00:00:00, ended at 2016-07-03 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- von Willebrand factor (vWf) Ag actual/normal in Platelet poor plasma by Immunoassay: 71 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Skin finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-04 00:00:00, ended at 2016-07-04 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-10 08:42:00, ended at 2016-07-10 23:59:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Disorder of bone\n- Solitary nodule of lung\n- Primary malignant neoplasm of female breast\n- Disease of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-16 00:00:00, ended at 2016-07-16 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-17 00:00:00, ended at 2016-07-17 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: von Willebrand disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-07-18 10:46:14, ended at 2016-07-18 14:22:37\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.567\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- von Willebrand disorder\n- Irregular periods\n- Microscopic hematuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-07-18 14:46:16, ended at 2016-07-18 16:04:32\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- von Willebrand disorder\n- Microscopic hematuria\n- Irregular periods\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-30 00:00:00, ended at 2016-07-30 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Irregular periods\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-05 11:18:58, ended at 2016-08-05 14:38:25\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.567\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-06 11:19:00, ended at 2016-08-06 23:59:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, pelvic (nonobstetric), real time with image documentation; complete\n- Ultrasound, transvaginal\n\n### Condition\n- Uterine leiomyoma\n- Irregular periods\n- Intramural leiomyoma of uterus\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-12 00:00:00, ended at 2016-08-12 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: von Willebrand disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-12 00:00:00, ended at 2016-08-12 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: von Willebrand disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-13 00:00:00, ended at 2016-08-13 00:00:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Irregular periods\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-13 12:18:00, ended at 2016-08-13 23:59:00\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.65 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- MCHC [Mass/volume] by Automated count: 32.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.84 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 0.73 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.16 (thousand per microliter)\n- Prothrombin time (PT): 14.1 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 87.5 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.1 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay: 64.5 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.4 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 208 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 33.8 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 42 (unit per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 68 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.9 (percent)\n- MCH [Entitic mass] by Automated count: 28.0 (picogram)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.6 (percent)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.80 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 102 (milligram per deciliter)\n- Reticulocytes [#/volume] in Blood by Automated count: 35.1 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- von Willebrand disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-13 13:14:22, ended at 2016-08-13 14:10:40\nThe patient in this visit was 44 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3.976\" (inch (US))\n- Ferritin [Mass/volume] in Serum or Plasma: 34.3 (nanogram per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: von Willebrand disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-12 08:15:15, ended at 2016-09-12 08:56:07\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Noninflammatory disorder of the vagina\n- Primary diagnosis: Genitourinary tract hemorrhage\n\n### Drug\n- metronidazole 0.0075 MG/MG Vaginal Gel, through Vaginal route, started on 2016-09-12, presumably until 2016-10-02, with intended 2 refill(s). Instructions: insert 1 Applicator into the vagina every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-17 15:08:52, ended at 2016-09-17 15:40:35\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2.992\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Coag./bleeding tests abnormal\n- von Willebrand disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-19 13:57:01, ended at 2016-09-19 16:59:18\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.252\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-01 11:37:12, ended at 2016-10-01 12:05:07\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute upper respiratory infection\n- Primary diagnosis: Viral disease\n\n### Drug\n- codeine phosphate 2 MG/ML / promethazine hydrochloride 1.25 MG/ML Oral Solution, started on 2016-10-01, presumably until 2016-10-17, with intended 0 refill(s). Instructions: TAke 5ml PO at night PRN cough\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-02 10:00:06, ended at 2016-10-02 10:38:38\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute upper respiratory infection\n- Autoimmune thyroiditis\n- Microscopic hematuria\n- Primary diagnosis: Hematuria syndrome\n- Viral disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-10-03 00:00:00, ended at 2016-10-03 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Microscopic hematuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-17 08:54:34, ended at 2016-10-17 09:46:56\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging\n\n### Condition\n- Primary diagnosis: Hematuria syndrome\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-30 07:58:00, ended at 2016-10-30 23:59:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Bone and/or joint imaging; whole body\n- Bone and/or joint imaging; tomographic (SPECT)\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Chest pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-01 00:00:00, ended at 2016-11-01 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-11-01 10:57:00, ended at 2016-11-01 23:59:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, retroperitoneal (eg, renal, aorta, nodes), real time with image documentation; complete\n\n### Condition\n- Noninflammatory disorder of the female genital organs\n- Primary malignant neoplasm of female breast\n- Coag./bleeding tests abnormal\n- Hematuria syndrome\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-05 00:00:00, ended at 2016-11-05 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cyst of ovary\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-11-05 13:15:00, ended at 2016-11-05 23:59:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, transvaginal\n- Ultrasound, pelvic (nonobstetric), real time with image documentation; complete\n\n### Condition\n- Intramural leiomyoma of uterus\n- Noninflammatory disorder of the female genital organs\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-11-21 11:58:27, ended at 2016-11-21 12:21:41\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Generalized anxiety disorder\n- Primary diagnosis: Cough\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-11-21, presumably until 2017-01-29, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 8 hours as needed\n- azithromycin 250 MG Oral Tablet, through Oral route, started on 2016-11-21, presumably until 2016-11-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth as directed for 5 days 2 tabs on day 1, then 1 tab daily thereafter\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-11-27 11:35:26, ended at 2016-11-27 17:28:38\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute upper respiratory infection\n- Viral disease\n- Primary diagnosis: Cough\n\n### Drug\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2016-11-27, presumably until 2016-11-27, with intended 0 refill(s). Instructions: 3 mL by Inhalation route One Time\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2016-11-27, presumably until 2017-01-29, with intended 0 refill(s). Instructions: 2 Puffs by Inhalation route every 4 hours as needed for Bronchospasm/Wheezing\n- 12 HR dextromethorphan hydrobromide 30 MG / guaifenesin 600 MG Extended Release Oral Tablet, through Oral route, started on 2016-11-27, presumably until 2017-01-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-11-27 13:25:24, ended at 2016-11-27 14:51:07\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.3 (percent)\n- MCH [Entitic mass] by Automated count: 29.0 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Body height: 5' 4\" (inch (US))\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.33 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.3 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 176 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.8 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.67 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 146 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Benign mammary dysplasia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-11-27 14:53:15, ended at 2016-11-27 16:24:38\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Cystourethroscopy (separate procedure)\n\n### Condition\n- Primary diagnosis: Hematuria syndrome\n- Cough\n- Benign mammary dysplasia\n- Acute upper respiratory infection\n- Viral disease\n\n### Drug\n- cephalexin 500 MG Oral Tablet, started on 2016-11-27, presumably until 2016-11-27, with intended 0 refill(s). Instructions: Take one capsule by mouth prior to procedure.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-11-28 00:00:00, ended at 2016-11-28 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for intraperitoneal procedures in lower abdomen including laparoscopy; not otherwise specified\n\n### Condition\n- Cyst of ovary\n\n### Drug\n- cefazolin 1000 MG Injection, started on 2016-11-28, presumably until 2016-11-28\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2016-11-28, presumably until 2016-11-28\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2016-11-28, presumably until 2016-11-28\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-11-28, presumably until 2016-11-28\n- midazolam 1 MG/ML Injectable Solution, started on 2016-11-28, presumably until 2016-11-28\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2016-11-28, presumably until 2016-11-28\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2016-11-28, presumably until 2016-11-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-11-28 00:00:00, ended at 2016-11-28 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 0.154 MEQ/ML Irrigation Solution, through Topical route, started on 2016-11-28, presumably until 2016-11-28\n- 20 ML bupivacaine liposome 13.3 MG/ML Injection, through Infiltration route, started on 2016-11-28, presumably until 2016-11-28\n- bupivacaine hydrochloride 5 MG/ML Injectable Solution, started on 2016-11-28, presumably until 2016-11-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2016-11-28 13:15:00, ended at 2016-11-29 13:19:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Resection of Bilateral Ovaries, Percutaneous Endoscopic Approach\n- Collection of venous blood by venipuncture\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Resection of Bilateral Fallopian Tubes, Percutaneous Endoscopic Approach\n- Pathology consultation during surgery\n\n### Condition\n- Autoimmune thyroiditis\n- Cyst of ovary\n- Follicular cyst of left ovary\n- Follicular cyst of right ovary\n- Corpus luteum cyst\n- Noninflammatory disorder of the female genital organs\n- Gastroesophageal reflux disease without esophagitis\n- Primary malignant neoplasm of female breast\n\n### Drug\n- oxycodone hydrochloride 5 MG Oral Capsule, through Oral route, started on 2016-11-28, presumably until 2017-01-29, with intended 0 refill(s). Instructions: take 5 mg by mouth every 4 hours as needed\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2016-11-29, presumably until 2016-11-29\n- ibuprofen 200 MG Oral Tablet, through Oral route, started on 2016-11-29, presumably until 2016-11-29\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2016-11-28, presumably until 2017-01-29, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day as needed (constipation)\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2016-11-29, presumably until 2016-11-29\n- ibuprofen 600 MG Oral Tablet, through Oral route, started on 2016-11-28, presumably until 2017-01-29, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-02 00:00:00, ended at 2016-12-02 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- anastrozole 1 MG Oral Tablet, through Oral route, started on 2016-12-02, presumably until 2017-02-25, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-29 09:28:21, ended at 2017-01-29 14:50:46\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-25 00:00:00, ended at 2017-02-25 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, through Oral route, started on 2017-02-25, presumably until 2017-06-19, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-11 13:12:23, ended at 2017-03-11 15:21:55\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Ganglion of wrist\n- Abdominal distension, gaseous\n- Arthralgia of the ankle and/or foot\n- Chest pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-05-26 00:00:00, ended at 2017-05-26 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Microscopic hematuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-05-28 11:19:44, ended at 2017-05-28 11:55:27\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Microscopic hematuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-05-29 10:37:12, ended at 2017-05-29 11:40:22\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Thyroperoxidase Ab [Units/volume] in Serum or Plasma: >1000.0 (international unit per milliliter)\n- Body height: 5' 4\" (inch (US))\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.6 (nanogram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 29.30 (micro-international unit per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic multinodular goiter\n- Menopause present\n- Simple goiter\n- Primary diagnosis: Autoimmune thyroiditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-04 11:12:08, ended at 2017-06-04 11:54:13\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congenital hypothyroidism with diffuse goiter\n- Autoimmune thyroiditis\n\n### Drug\n- levothyroxine sodium 0.075 MG Oral Tablet, through Oral route, started on 2017-06-04, presumably until 2017-06-17, with intended 4 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-09 00:00:00, ended at 2017-06-09 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on the integumentary system on the extremities, anterior trunk and perineum; reconstructive procedures on breast (eg, reduction or augmentation mammoplasty, muscle flaps)\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- citric acid 66.8 MG/ML / sodium citrate 100 MG/ML Oral Solution, through Oral route, started on 2017-06-09, presumably until 2017-06-09\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2017-06-09, presumably until 2017-06-09\n- cefazolin 1000 MG Injection, started on 2017-06-09, presumably until 2017-06-09\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-06-09, presumably until 2017-06-09\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2017-06-09, presumably until 2017-06-09\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-06-09, presumably until 2017-06-09\n- midazolam 1 MG/ML Injectable Solution, started on 2017-06-09, presumably until 2017-06-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-06-09 00:00:00, ended at 2017-06-09 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 0.154 MEQ/ML Irrigation Solution, through Topical route, started on 2017-06-09, presumably until 2017-06-09\n- bacitracin 5000 UNT/ML Injectable Solution, through Intramuscular route, started on 2017-06-09, presumably until 2017-06-09\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2017-06-09, presumably until 2017-06-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-09 06:46:00, ended at 2017-06-09 14:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- Tissue grafts, other (eg, paratenon, fat, dermis)\n- Removal of Tissue Expander from Left Breast, Open Approach\n- Removal of Tissue Expander from Right Breast, Open Approach\n- Breast reconstruction with other technique\n- Replacement of tissue expander with permanent implant\n- Replacement of Bilateral Breast with Autologous Tissue Substitute, Open Approach\n- Mastopexy\n- Level III - Surgical pathology, gross and microscopic examination Abortion, induced Abscess Aneurysm - arterial/ventricular Anus, tag Appendix, other than incidental Artery, atheromatous plaque Bartholin's gland cyst Bone fragment(s), other than pathologi\n- Replacement of Bilateral Breast with Synthetic Substitute, Open Approach\n\n### Condition\n- Autoimmune thyroiditis\n- Gastroesophageal reflux disease without esophagitis\n- Deformity of reconstructed breast\n\n### Drug\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2017-06-09, presumably until 2017-06-19, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 6 hours as needed for Pain\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2017-06-09, presumably until 2017-06-16, with intended 0 refill(s). Instructions: take 1 Cap by mouth every 6 hours for 7 days\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2017-06-09, presumably until 2017-06-09\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2017-06-09, presumably until 2017-06-09\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2017-06-09, presumably until 2017-06-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed (nausea)\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-06-09, presumably until 2017-06-19, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2017-06-09, presumably until 2017-06-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-16 12:15:48, ended at 2017-06-16 13:49:14\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-06-17 00:00:00, ended at 2017-06-17 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levothyroxine sodium 0.075 MG Oral Tablet, through Oral route, started on 2017-06-17, presumably until 2017-06-19, with intended 6 refill(s). Instructions: take 1 Tab by mouth daily in the evening\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-06-24 00:00:00, ended at 2017-06-24 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 0.154 MEQ/ML Irrigation Solution, through Topical route, started on 2017-06-24, presumably until 2017-06-24\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2017-06-24, presumably until 2017-06-24\n- bacitracin 5000 UNT/ML Injectable Solution, through Intramuscular route, started on 2017-06-24, presumably until 2017-06-24\n- thrombin, bovine 2000 UNT/ML Topical Solution, through Topical route, started on 2017-06-24, presumably until 2017-06-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-24 10:35:00, ended at 2017-06-24 17:13:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n- Glucose [Mass/volume] in Blood: 196 (milligram per deciliter)\n\n### Procedure\n- Peri-implant capsulectomy, breast, complete, including removal of all intracapsular contents\n- Level III - Surgical pathology, gross and microscopic examination Abortion, induced Abscess Aneurysm - arterial/ventricular Anus, tag Appendix, other than incidental Artery, atheromatous plaque Bartholin's gland cyst Bone fragment(s), other than pathologi\n- Removal of Synthetic Substitute from Left Breast, Open Approach\n- Removal of Synthetic Substitute from Right Breast, Open Approach\n\n### Condition\n- Hypothyroidism\n- Non-toxic multinodular goiter\n- Primary diagnosis: Postoperative state\n- Gastroesophageal reflux disease without esophagitis\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2017-06-24, presumably until 2017-06-24\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2017-06-09, presumably until 2017-06-30, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day for 10 days\n- ondansetron 4 MG Oral Tablet, started on 2017-06-09, presumably until 2017-06-24, with intended 0 refill(s). Instructions: TAKE 1 TAB BY MOUTH EVERY 6 HOURS AS NEEDED (NAUSEA)\n- exemestane 25 MG Oral Tablet, through Oral route, presumably until 2017-06-27, with intended 0 refill(s). Instructions: take 25 mg by mouth daily\n- levothyroxine sodium 0.075 MG Oral Tablet, through Oral route, presumably until 2017-08-07, with intended 0 refill(s). Instructions: take 75 mcg by mouth every morning before breakfast\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2017-06-24, presumably until 2017-08-07, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 to 6 hours as needed for Pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-06-26 00:00:00, ended at 2017-06-26 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, started on 2017-06-27, presumably until 2017-10-23, with intended 3 refill(s). Instructions: TAKE 1 TAB BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-06-27 00:00:00, ended at 2017-06-27 00:00:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Iron [Mass/volume] in Serum or Plasma: 54 (microgram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 16 (percent)\n- Ferritin [Mass/volume] in Serum or Plasma: 67.7 (nanogram per milliliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.31 (micro-international unit per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Autoimmune thyroiditis\n- Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-27 12:29:48, ended at 2017-06-27 13:01:50\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tachycardia\n- Congenital hypothyroidism with diffuse goiter\n- Autoimmune thyroiditis\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2017-06-27, presumably until 2017-09-25, with intended 3 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-30 15:50:14, ended at 2017-06-30 16:56:59\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2017-06-30, presumably until 2018-06-30, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2017-06-30, presumably until 2017-07-10, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-07-02 15:06:31, ended at 2017-07-02 15:50:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-07 15:58:27, ended at 2017-08-07 16:55:45\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-18 13:14:00, ended at 2017-08-18 23:59:00\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Non-toxic multinodular goiter\n- Simple goiter\n- Autoimmune thyroiditis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-20 14:14:21, ended at 2017-08-20 15:42:01\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- General finding of observation of patient\n- Primary diagnosis: Low back pain\n- Localized enlarged lymph nodes\n- Dermatographic urticaria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-10 14:19:29, ended at 2017-09-10 16:52:34\nThe patient in this visit was 45 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements f\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-12 00:00:00, ended at 2017-09-12 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Congenital hypothyroidism without goiter\n- Iron deficiency anemia due to blood loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-23 15:49:40, ended at 2017-09-23 16:38:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-25 09:35:44, ended at 2017-09-25 10:46:05\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Autoimmune thyroiditis\n- Gastro-esophageal reflux disease with esophagitis\n- Benign mammary dysplasia\n- Iron deficiency anemia due to blood loss\n- Congenital hypothyroidism with diffuse goiter\n- Lymphadenopathy\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2017-09-25, presumably until 2018-09-25, with intended 12 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast\n- ranitidine 150 MG Oral Capsule, through Oral route, started on 2017-09-25, presumably until 2018-09-25, with intended 3 refill(s). Instructions: take 150 mg by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-25 11:16:03, ended at 2017-09-25 12:09:37\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-07 13:13:49, ended at 2017-10-07 14:14:56\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of head\n- Swelling / lump finding\n- Low back pain\n- Localized swelling, mass and lump, neck\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-10-07 14:14:29, ended at 2017-10-07 16:32:19\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of head\n- Localized swelling, mass and lump, neck\n- Primary diagnosis: Low back pain\n- Swelling / lump finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-20 10:28:00, ended at 2017-10-20 23:59:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Swelling / lump finding\n- Disorder of head\n- Localized swelling, mass and lump, neck\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-21 13:22:55, ended at 2017-10-21 14:08:28\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n\n### Condition\n- Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-10-23 00:00:00, ended at 2017-10-23 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, started on 2017-10-24, presumably until 2018-01-05, with intended 2 refill(s). Instructions: TAKE 1 TAB BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-24 09:30:00, ended at 2017-10-24 23:59:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine)\n\n### Condition\n- Menopause present\n- Disorder of bone\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-06 00:00:00, ended at 2017-11-06 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of head\n- Primary diagnosis: Localized swelling, mass and lump, neck\n- Primary diagnosis: Swelling / lump finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-06 13:14:00, ended at 2017-11-06 15:02:06\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-07 00:00:00, ended at 2017-11-07 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Swelling / lump finding\n- Primary diagnosis: Localized swelling, mass and lump, neck\n- Primary diagnosis: Disorder of head\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-13 08:45:44, ended at 2017-11-13 09:36:56\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Posterior rhinorrhea\n- Chronic pharyngitis\n- Gastro-esophageal reflux disease with esophagitis\n\n### Drug\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2017-11-13, presumably until 2019-06-09, with intended 3 refill(s). Instructions: 2 Sprays by Nasal route daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-18 09:48:01, ended at 2017-11-18 11:44:26\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Edema\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-01-05 00:00:00, ended at 2018-01-05 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, through Oral route, started on 2018-01-05, presumably until 2018-02-04, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-02-01 00:00:00, ended at 2018-02-01 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, started on 2018-02-13, presumably until 2018-02-13, with intended 2 refill(s). Instructions: TAKE 1 TAB BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-02-04 00:00:00, ended at 2018-02-04 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, through Oral route, started on 2018-02-04, presumably until 2018-05-05, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-20 14:11:03, ended at 2018-04-20 15:27:58\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3.976\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n- Cyst of ovary\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-27 00:00:00, ended at 2018-04-27 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-27 15:30:00, ended at 2018-04-27 23:59:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, abdominal, real time with image documentation; complete\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Abdominal pain\n- Imaging of gastrointestinal tract abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-28 07:08:00, ended at 2018-04-28 23:59:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Disease of liver\n- Primary malignant neoplasm of female breast\n- Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-04-30 00:00:00, ended at 2018-04-30 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, started on 2018-05-12, presumably until 2018-05-12, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-05 00:00:00, ended at 2018-05-05 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, through Oral route, started on 2018-05-05, presumably until 2018-08-06, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-06-02 00:00:00, ended at 2018-06-02 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-07-30 00:00:00, ended at 2018-07-30 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, started on 2018-08-11, presumably until 2018-08-14, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-08-06 00:00:00, ended at 2018-08-06 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, through Oral route, started on 2018-08-11, presumably until 2018-08-11, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-08-14 00:00:00, ended at 2018-08-14 00:00:00\nThe patient in this visit was 46 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, through Oral route, started on 2018-08-17, presumably until 2018-12-09, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-10-23 14:21:20, ended at 2018-10-23 14:50:35\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Viral disease\n- Primary diagnosis: Acute upper respiratory infection\n\n### Drug\n- 12 HR guaifenesin 600 MG Extended Release Oral Tablet, through Oral route, started on 2018-10-23, presumably until 2019-06-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-13 00:00:00, ended at 2018-11-13 00:00:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-13 00:00:00, ended at 2018-11-13 00:00:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localized swelling, mass and lump, upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-13 15:58:00, ended at 2018-11-13 23:59:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Localized swelling, mass and lump, upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-16 13:47:00, ended at 2018-11-16 23:59:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, limited, joint or other nonvascular extremity structure(s) (eg, joint space, peri-articular tendon[s], muscle[s], nerve[s], other soft-tissue structure[s], or soft-tissue mass[es]), real-time with image documentation\n\n### Condition\n- Lump in left breast\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-11-23 14:23:46, ended at 2018-11-23 17:23:17\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3.976\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-12-09 00:00:00, ended at 2018-12-09 00:00:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, through Oral route, started on 2018-12-10, presumably until 2019-09-01, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-02-16 13:59:00, ended at 2019-02-16 23:59:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, limited, joint or other nonvascular extremity structure(s) (eg, joint space, peri-articular tendon[s], muscle[s], nerve[s], other soft-tissue structure[s], or soft-tissue mass[es]), real-time with image documentation\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Localized swelling, mass and lump, trunk\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-16 15:55:23, ended at 2019-02-16 16:43:46\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3.543\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-05-06 00:00:00, ended at 2019-05-06 00:00:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hemoptysis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-17 11:39:00, ended at 2019-05-17 23:59:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n- Primary malignant neoplasm of female breast\n- Hemoptysis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-17 13:57:06, ended at 2019-05-17 15:08:39\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3.543\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-03 07:48:23, ended at 2019-06-03 08:32:02\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3.543\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hemoptysis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-09 00:00:00, ended at 2019-06-09 00:00:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for closed chest procedures; (including bronchoscopy) not otherwise specified\n\n### Condition\n- Hemoptysis\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2019-06-09, presumably until 2019-06-09\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-06-09, presumably until 2019-06-09\n- remifentanil 2 MG Injection, through Intravenous route, started on 2019-06-09, presumably until 2019-06-09\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2019-06-09, presumably until 2019-06-09\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-06-09, presumably until 2019-06-09\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2019-06-09, presumably until 2019-06-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-09 08:45:00, ended at 2019-06-09 14:39:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Inspection of Tracheobronchial Tree, Via Natural or Artificial Opening Endoscopic\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; diagnostic, with cell washing, when performed (separate procedure)\n\n### Condition\n- Insomnia\n- Autoimmune thyroiditis\n- Primary diagnosis: Benign mammary dysplasia\n- Solitary nodule of lung\n- Gastroesophageal reflux disease without esophagitis\n- Hemoptysis\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2019-06-09, presumably until 2019-06-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-25 00:00:00, ended at 2019-06-25 00:00:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Solitary nodule of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-28 00:00:00, ended at 2019-06-28 00:00:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hemoptysis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-08-12 10:25:00, ended at 2019-08-12 23:59:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Solitary nodule of lung\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-08-16 12:39:00, ended at 2019-08-16 23:59:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, limited, joint or other nonvascular extremity structure(s) (eg, joint space, peri-articular tendon[s], muscle[s], nerve[s], other soft-tissue structure[s], or soft-tissue mass[es]), real-time with image documentation\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Lump of axillary tail of left breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-08-16 14:40:06, ended at 2019-08-16 15:55:10\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3.543\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-24 00:00:00, ended at 2019-08-24 00:00:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hemoptysis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-08-24 10:51:51, ended at 2019-08-24 11:37:55\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hemoptysis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-08-31 10:19:00, ended at 2019-08-31 23:59:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hemoptysis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-01 00:00:00, ended at 2019-09-01 00:00:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, through Oral route, started on 2019-09-01, presumably until 2020-08-30, with intended 3 refill(s). Instructions: take 1 Tab (25 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-03 00:00:00, ended at 2019-09-03 00:00:00\nThe patient in this visit was 47 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hemoptysis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-19 10:53:56, ended at 2019-10-19 11:29:11\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-20 00:00:00, ended at 2019-10-20 00:00:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for closed chest procedures; (including bronchoscopy) not otherwise specified\n\n### Condition\n- Hemoptysis\n\n### Drug\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-10-20, presumably until 2019-10-20\n- remifentanil 2 MG Injection, through Intravenous route, started on 2019-10-20, presumably until 2019-10-20\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-10-20, presumably until 2019-10-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2019-10-20 00:00:00, ended at 2019-10-20 00:00:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial alveolar lavage\n\n### Condition\n- Hemoptysis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-20 08:58:00, ended at 2019-10-20 11:10:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial alveolar lavage\n\n### Condition\n- Hemoptysis\n- Autoimmune thyroiditis\n- Gastroesophageal reflux disease without esophagitis\n- Pneumonia\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2019-10-20, presumably until 2019-10-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-10-22 00:00:00, ended at 2019-10-22 00:00:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localized swelling, mass and lump, neck\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-27 11:07:00, ended at 2019-10-27 23:59:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Localized swelling, mass and lump, neck\n- Localized enlarged lymph nodes\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-10 13:56:41, ended at 2019-11-10 15:03:17\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; manual screening under physician supervision\n\n### Condition\n- Noninflammatory disorder of the vagina\n- Postmenopausal bleeding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-11-16 09:44:00, ended at 2019-11-16 23:59:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, pelvic (nonobstetric), real time with image documentation; complete\n- Ultrasound, transvaginal\n\n### Condition\n- Postmenopausal bleeding\n- Intramural leiomyoma of uterus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-25 10:13:36, ended at 2019-11-25 11:41:23\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Fine needle aspiration biopsy, including ultrasound guidance; first lesion\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n- Localized enlarged lymph nodes\n- Mycobacteriosis\n- Hemoptysis\n- Generalized enlarged lymph nodes\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-26 09:12:06, ended at 2019-11-26 11:46:58\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- Endometrial sampling (biopsy) with or without endocervical sampling (biopsy), without cervical dilation, any method (separate procedure)\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Noninflammatory disorder of uterus\n- Atrophic vaginitis\n- Primary diagnosis: Postmenopausal bleeding\n\n### Drug\n- estradiol 0.1 MG/ML Vaginal Cream, through Vaginal route, started on 2019-11-26, presumably until 2020-11-25, with intended 0 refill(s). Instructions: insert 2 g into the vagina daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-11 00:00:00, ended at 2019-12-11 00:00:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrophic vaginitis\n\n### Drug\n- estradiol 0.1 MG/ML Vaginal Cream, started on 2019-12-11, presumably until 2020-08-22, with intended 0 refill(s). Instructions: Apply small amount to skin outside of vagina, and to vaginal skin, once or twice a week at night.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-16 10:48:32, ended at 2019-12-16 11:50:04\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Generalized enlarged lymph nodes\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-24 00:00:00, ended at 2020-01-24 00:00:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-02 00:00:00, ended at 2020-02-02 00:00:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-02 08:31:00, ended at 2020-02-02 23:59:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Generalized enlarged lymph nodes\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-08 09:03:52, ended at 2020-02-08 09:36:12\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Mycobacteriosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-21 12:47:00, ended at 2020-02-21 23:59:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, limited, joint or other nonvascular extremity structure(s) (eg, joint space, peri-articular tendon[s], muscle[s], nerve[s], other soft-tissue structure[s], or soft-tissue mass[es]), real-time with image documentation\n\n### Condition\n- Lump of axillary tail of left breast\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-22 08:54:56, ended at 2020-02-22 09:46:01\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3.346\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Staphylococcal infectious disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-25 00:00:00, ended at 2020-02-25 00:00:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n- Cyst of ovary\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-03-13 16:03:47, ended at 2020-03-13 17:14:04\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Epigastric pain\n- Digestive system finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-21 09:18:00, ended at 2020-03-21 23:59:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, pelvic (nonobstetric), real time with image documentation; complete\n- Ultrasound, transvaginal\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Cyst of ovary\n- Intramural leiomyoma of uterus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-03-28 00:00:00, ended at 2020-03-28 00:00:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, started on 2020-03-28, presumably until 2020-04-11, with intended 0 refill(s). Instructions: Take 2L by mouth night before and 2L morning of procedure. Stop fluids 4hr before procedure. Instructions are forwarded to patient.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-03 11:46:35, ended at 2020-05-03 11:55:26\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrophic vaginitis\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-22 09:25:33, ended at 2020-08-22 10:04:54\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-08-26 00:00:00, ended at 2020-08-26 00:00:00\nThe patient in this visit was 48 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- exemestane 25 MG Oral Tablet, started on 2020-08-30, presumably until 2021-09-21, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-09-15 08:25:30, ended at 2020-09-15 08:33:12\nThe patient in this visit was 49 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Mycobacteriosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-30 00:00:00, ended at 2020-10-30 00:00:00\nThe patient in this visit was 49 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Mycobacteriosis\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-03 00:00:00, ended at 2020-11-03 00:00:00\nThe patient in this visit was 49 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mycobacteriosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-09 00:00:00, ended at 2020-11-09 00:00:00\nThe patient in this visit was 49 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hemoptysis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-09 08:25:16, ended at 2020-11-09 09:07:52\nThe patient in this visit was 49 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Primary diagnosis: Hemoptysis\n- Disorder of thyroid gland\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Malignant tumor of breast within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of breast_cancer means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "d451a6fccee2fcb3f2207a19498e2b3665a079ddfdc2658abdad9de3ae031ffc", "prompt_hash": "8536556af9a812d61c2e47bf308dde059096507c8b8ff72b2f2d74c9ebe1f5d7", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 0.0, "f1_gu_yn": [1, 0], "recall_gu_yn": [1, 0]}
{"doc_id": 9, "doc": {"person_id": 115973289, "visit_occurrence_id": 80481944, "death_date": null, "visit_concept_name": "Office Visit", "visit_start_datetime": "2015-11-11 10:33:02", "visit_end_datetime": "2015-11-11 13:20:11", "visit_length_in_hours": 2.785833333333333, "integrated_visit_record": "## Visit\nThis visit record, was from Office Visit, started at 2015-11-11 10:33:02, ended at 2015-11-11 13:20:11\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Postoperative state\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 85, "patient_first_visit_date": "2009-09-22 09:56:00", "patient_last_visit_date": "2022-10-14 07:15:16", "end_obs_date": "2016-11-10", "hypertension_type": "new", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "new", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "recurrent", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 69, "cumulated_visit_num": 69, "cumulated_approximate_token_count": 11218, "visit_cumulated": "## Visit\nThis visit record, was from Outpatient Visit, started at 2009-09-22 09:56:00, ended at 2009-09-22 23:59:00\nThe patient in this visit was 60 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.319\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign neoplasm of major salivary gland\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-10-09 10:46:00, ended at 2009-10-09 13:22:00\nThe patient in this visit was 60 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 96.5 (femtoliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.0 (thousand per microliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 77 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.4 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Body height: 5' 1.22\" (inch (US))\n- MCH [Entitic mass] by Automated count: 32.9 (picogram)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.08 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 256 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.4 (percent)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign neoplasm of major salivary gland\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-10-09 13:23:00, ended at 2009-10-09 23:59:00\nThe patient in this visit was 60 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2009-10-14 06:35:00, ended at 2009-10-15 13:15:00\nThe patient in this visit was 60 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1\" (inch (US))\n\n### Procedure\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Partial excision of salivary gland\n\n### Condition\n- Gastroesophageal reflux disease\n- Swelling / lump finding\n- Benign neoplasm of major salivary gland\n- Finding of head and neck region\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2009-10-14, presumably until 2009-10-14\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2009-10-14, presumably until 2009-10-14\n- acetaminophen 300 MG / codeine phosphate 30 MG Oral Tablet, through Oral route, started on 2009-10-14, presumably until 2010-04-13, with quantity of 20.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed for Pain. \n- bacitracin 0.5 UNT/MG / polymyxin B 10 UNT/MG Topical Ointment, through Topical route, started on 2009-10-14, presumably until 2009-10-15\n- hypromellose 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2009-10-14, presumably until 2009-10-14\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2009-10-14, presumably until 2009-10-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-10-27 09:45:00, ended at 2009-10-27 23:59:00\nThe patient in this visit was 60 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.22\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign neoplasm of major salivary gland\n- Finding of head and neck region\n- Swelling / lump finding\n\n### Drug\n- acetaminophen 300 MG / codeine phosphate 30 MG Oral Tablet, through Oral route, started on 2009-10-27, presumably until 2010-04-25, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-11-24 09:00:00, ended at 2009-11-24 23:59:00\nThe patient in this visit was 60 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.22\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign neoplasm of major salivary gland\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-12-08 09:03:00, ended at 2009-12-08 23:59:00\nThe patient in this visit was 60 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.22\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign neoplasm of major salivary gland\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-23 09:00:00, ended at 2010-02-23 23:59:00\nThe patient in this visit was 60 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.22\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign neoplasm of major salivary gland\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-08-31 10:45:00, ended at 2010-08-31 23:59:00\nThe patient in this visit was 61 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.75\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign tumor of soft tissue of head, face and neck\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-27 10:00:00, ended at 2011-09-27 23:59:00\nThe patient in this visit was 62 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Finding of head and neck region\n- Swelling / lump finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-13 09:40:00, ended at 2012-11-13 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Finding of head and neck region\n- Primary diagnosis: Swelling / lump finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-11 02:40:00, ended at 2013-04-11 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Morphometric analysis, tumor\n- Consultation and report on referred material requiring preparation of slides\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-15 13:07:00, ended at 2013-04-15 15:55:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.811\" (inch (US))\n\n### Procedure\n- Consultation and report on referred material requiring preparation of slides\n- Morphometric analysis, tumor\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-15 15:56:00, ended at 2013-04-15 15:57:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 80 (unit per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 51 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- MCV [Entitic volume] by Automated count: 95.4 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.44 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.2 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.63 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.2 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 4.61 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.09 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.2 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 24.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 298 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-15 15:58:00, ended at 2013-04-15 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, breast(s) (unilateral or bilateral), real time with image documentation\n- Ultrasound, limited, joint or other nonvascular extremity structure(s) (eg, joint space, peri-articular tendon[s], muscle[s], nerve[s], other soft-tissue structure[s], or soft-tissue mass[es]), real-time with image documentation\n- Mammography; unilateral\n- Computer-aided detection (computer algorithm analysis of digital image data for lesion detection) with further review for interpretation, with or without digitization of film radiographic images; diagnostic mammography (List separately in addition to code\n\n### Condition\n- Inflammatory disorder of breast\n- Edema\n- Primary malignant neoplasm of female breast\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-24 00:00:00, ended at 2013-04-24 00:00:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for all procedures on nerves, muscles, tendons, fascia, and bursae of shoulder and axilla\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, started on 2013-04-24, presumably until 2013-04-24\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2013-04-24, presumably until 2013-04-24\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2013-04-24, presumably until 2013-04-24\n- cefazolin 1000 MG Injection, started on 2013-04-24, presumably until 2013-04-24\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-04-24, presumably until 2013-04-24\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-04-24, presumably until 2013-04-24\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-04-24, presumably until 2013-04-24\n- midazolam 1 MG/ML Injectable Solution, started on 2013-04-24, presumably until 2013-04-24\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2013-04-24, presumably until 2013-04-24\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2013-04-24, presumably until 2013-04-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2013-04-24 00:00:00, ended at 2013-04-24 00:00:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- indocyanine green, started on 2013-04-24, presumably until 2013-04-24\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2013-04-24, presumably until 2013-04-24\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2013-04-24, presumably until 2013-04-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-24 06:01:00, ended at 2013-04-25 09:45:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.75\" (inch (US))\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Excision of breast lesion identified by preoperative placement of radiological marker, open; single lesion\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Mammographic guidance for needle placement, breast (eg, for wire localization or for injection), each lesion, radiological supervision and interpretation (Deprecated)\n- Excision of breast lesion identified by preoperative placement of radiological marker, open; each additional lesion separately identified by a preoperative radiological marker (List separately in addition to code for primary procedure)\n- Local excision of lesion of breast\n- Biopsy or excision of lymph node(s); open, deep axillary node(s)\n- Biopsy of lymphatic structure\n- Radiological examination, surgical specimen\n- Preoperative placement of needle localization wire, breast\n- Lymphatics and lymph nodes imaging\n- Preoperative placement of needle localization wire, breast; each additional lesion (List separately in addition to code for primary procedure)\n\n### Condition\n- Carcinoma in situ of breast\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2013-04-24, presumably until 2013-04-24\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2013-04-24, presumably until 2013-04-24\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2013-04-25, presumably until 2013-05-07, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed for Pain.\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2013-04-25, presumably until 2013-05-14, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-02 10:00:00, ended at 2013-05-02 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2.795\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- acetaminophen 300 MG / codeine phosphate 30 MG Oral Tablet, through Oral route, started on 2013-05-02, presumably until 2013-10-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-07 00:00:00, ended at 2013-05-07 00:00:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on the integumentary system on the extremities, anterior trunk and perineum; not otherwise specified\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- cefazolin 1000 MG Injection, started on 2013-05-07, presumably until 2013-05-07\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2013-05-07, presumably until 2013-05-07\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-05-07, presumably until 2013-05-07\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-05-07, presumably until 2013-05-07\n- 250 ML lidocaine hydrochloride 8 MG/ML Injection, through Intravenous route, started on 2013-05-07, presumably until 2013-05-07\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2013-05-07, presumably until 2013-05-07\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2013-05-07, presumably until 2013-05-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2013-05-07 00:00:00, ended at 2013-05-07 00:00:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2013-05-07, presumably until 2013-05-07\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2013-05-07, presumably until 2013-05-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-07 05:34:00, ended at 2013-05-07 11:28:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- Radiological examination, surgical specimen\n- Mastectomy, partial (eg, lumpectomy, tylectomy, quadrantectomy, segmentectomy)\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Local excision of lesion of breast\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n- Gastroesophageal reflux disease\n- Carcinoma in situ of breast\n\n### Drug\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2013-05-07, presumably until 2013-05-07\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-05-07, presumably until 2013-05-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-14 09:00:00, ended at 2013-05-14 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' .984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-16 07:56:00, ended at 2013-05-16 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.811\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-27 12:58:00, ended at 2013-05-27 15:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.811\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-27 16:00:00, ended at 2013-05-27 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology treatment planning; complex\n- Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, onl\n- Computed tomography guidance for placement of radiation therapy fields\n- 3-dimensional radiotherapy plan, including dose-volume histograms\n- Therapeutic radiology simulation-aided field setting; complex\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-29 09:30:00, ended at 2013-05-29 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- 3-dimensional radiotherapy plan, including dose-volume histograms\n- Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, onl\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-05-30 00:00:00, ended at 2013-05-30 00:00:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-17 11:30:00, ended at 2013-06-17 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.811\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-06-27 00:00:00, ended at 2013-06-27 00:00:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-28 10:01:00, ended at 2013-06-28 10:57:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology simulation-aided field setting; simple\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-28 10:58:00, ended at 2013-06-28 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.417\" (inch (US))\n\n### Procedure\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-06-28, presumably until 2013-06-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-01 09:57:00, ended at 2013-07-01 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n- Radiation treatment management, 5 treatments\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-02 09:52:00, ended at 2013-07-02 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-03 09:48:00, ended at 2013-07-03 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-04 10:07:00, ended at 2013-07-04 12:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n- Therapeutic radiology port image(s)\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- nystatin 100 UNT/MG Topical Powder, through Topical route, started on 2013-07-04, presumably until 2014-02-04, with intended 0 refill(s). Instructions: by Topical route 4 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-04 13:00:00, ended at 2013-07-04 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-05 09:45:00, ended at 2013-07-05 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-08 09:47:00, ended at 2013-07-08 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n- Radiation treatment management, 5 treatments\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-09 09:37:00, ended at 2013-07-09 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-10 09:38:00, ended at 2013-07-10 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-11 09:45:00, ended at 2013-07-11 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-12 09:23:00, ended at 2013-07-12 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-15 07:54:00, ended at 2013-07-15 08:56:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment management, 5 treatments\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-15 08:57:00, ended at 2013-07-15 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.811\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-16 09:40:00, ended at 2013-07-16 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology port image(s)\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-17 07:24:00, ended at 2013-07-17 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-18 09:29:00, ended at 2013-07-18 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-19 07:34:00, ended at 2013-07-19 08:19:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-19 08:20:00, ended at 2013-07-19 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-03 14:00:00, ended at 2013-10-03 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.811\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-10-10 00:00:00, ended at 2013-10-10 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-04 11:18:00, ended at 2014-02-04 13:37:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computer-aided detection (computer algorithm analysis of digital image data for lesion detection) with further review for interpretation, with or without digitization of film radiographic images; screening mammography (List separately in addition to code \n- Screening mammography, bilateral (2-view study of each breast)\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-04 13:38:00, ended at 2014-02-04 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.811\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-04 12:56:00, ended at 2014-09-04 23:59:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.811\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-12-30 00:00:00, ended at 2014-12-30 00:00:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-04 12:15:00, ended at 2015-02-04 23:59:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.811\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Swelling / lump finding\n- Primary diagnosis: Finding of head and neck region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-26 10:36:00, ended at 2015-02-26 13:40:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Screening digital breast tomosynthesis, bilateral (List separately in addition to code for primary procedure)\n- Computer-aided detection (computer algorithm analysis of digital image data for lesion detection) with further review for interpretation, with or without digitization of film radiographic images; screening mammography (List separately in addition to code \n\n### Condition\n- Postmenopausal state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-26 13:41:00, ended at 2015-02-26 23:59:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-03-02 00:00:00, ended at 2015-03-02 00:00:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-09-14 12:51:31, ended at 2015-09-14 16:22:09\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.417\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Radiation-induced disorder\n- Disorder of breast\n- Postprocedural state finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-10-15 09:53:08, ended at 2015-10-15 15:02:31\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.417\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of breast\n- Radiation sickness\n- Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2015-11-03 00:00:00, ended at 2015-11-03 00:00:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bacitracin 5000 UNT/ML Injectable Solution, through Intramuscular route, started on 2015-11-03, presumably until 2015-11-03\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2015-11-03, presumably until 2015-11-03\n- bacitracin zinc 0.5 UNT/MG Topical Ointment, through Topical route, started on 2015-11-03, presumably until 2015-11-03\n- 1 ML epinephrine 1 MG/ML Injection, started on 2015-11-03, presumably until 2015-11-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-11-03 00:00:00, ended at 2015-11-03 00:00:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on the integumentary system on the extremities, anterior trunk and perineum; reconstructive procedures on breast (eg, reduction or augmentation mammoplasty, muscle flaps)\n\n### Condition\n- Deformity of reconstructed breast\n- Disproportion of reconstructed breast\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2015-11-03, presumably until 2015-11-03\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2015-11-03, presumably until 2015-11-03\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2015-11-03, presumably until 2015-11-03\n- cefazolin 1000 MG Injection, started on 2015-11-03, presumably until 2015-11-03\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2015-11-03, presumably until 2015-11-03\n- 2 ML ondansetron 2 MG/ML Injection, started on 2015-11-03, presumably until 2015-11-03\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-11-03, presumably until 2015-11-03\n- midazolam 1 MG/ML Injectable Solution, started on 2015-11-03, presumably until 2015-11-03\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2015-11-03, presumably until 2015-11-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-11-03 12:45:00, ended at 2015-11-03 20:28:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1\" (inch (US))\n\n### Procedure\n- Excision of Left Breast, Open Approach\n- Alteration of Right Breast with Autologous Tissue Substitute, Open Approach\n- Excision of Abdomen Subcutaneous Tissue and Fascia, Open Approach\n- Breast reconstruction with other technique\n- Breast reduction\n- Level III - Surgical pathology, gross and microscopic examination Abortion, induced Abscess Aneurysm - arterial/ventricular Anus, tag Appendix, other than incidental Artery, atheromatous plaque Bartholin's gland cyst Bone fragment(s), other than pathologi\n\n### Condition\n- Disorder caused by alcohol\n- Disorder of breast\n- Late effect of complications of procedure\n- Late effect of radiation\n- Deformity of reconstructed breast\n- Primary diagnosis: Radiation sickness\n- Disproportion of reconstructed breast\n- Postoperative state\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2015-11-03, presumably until 2015-11-03\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2015-11-03, presumably until 2016-02-04, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2015-11-03, presumably until 2015-11-10, with intended 0 refill(s). Instructions: take 1 Cap by mouth every 6 hours for 7 days\n- bacitracin zinc 0.5 UNT/MG Topical Ointment, started on 2015-11-03, presumably until 2016-02-04, with intended 0 refill(s). Instructions: Please place over bruised areas as needed\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2015-11-03, presumably until 2015-11-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-11-10 00:00:00, ended at 2015-11-10 00:00:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2015-11-10, presumably until 2015-11-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-11-10 00:00:00, ended at 2015-11-10 00:00:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2015-11-10, presumably until 2015-11-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-11-10 00:00:00, ended at 2015-11-10 00:00:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2015-11-10, presumably until 2015-11-17, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-11-11 10:33:02, ended at 2015-11-11 13:20:11\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Postoperative state\n\n### Drug\n- No drugs.\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Malignant tumor of breast within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-09-22 09:56:00, ended at 2009-09-22 23:59:00\nThe patient in this visit was 60 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.319\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign neoplasm of major salivary gland\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-10-09 10:46:00, ended at 2009-10-09 13:22:00\nThe patient in this visit was 60 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 96.5 (femtoliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.0 (thousand per microliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 77 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.4 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Body height: 5' 1.22\" (inch (US))\n- MCH [Entitic mass] by Automated count: 32.9 (picogram)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.08 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 256 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.4 (percent)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign neoplasm of major salivary gland\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-10-09 13:23:00, ended at 2009-10-09 23:59:00\nThe patient in this visit was 60 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2009-10-14 06:35:00, ended at 2009-10-15 13:15:00\nThe patient in this visit was 60 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1\" (inch (US))\n\n### Procedure\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Partial excision of salivary gland\n\n### Condition\n- Gastroesophageal reflux disease\n- Swelling / lump finding\n- Benign neoplasm of major salivary gland\n- Finding of head and neck region\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2009-10-14, presumably until 2009-10-14\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2009-10-14, presumably until 2009-10-14\n- acetaminophen 300 MG / codeine phosphate 30 MG Oral Tablet, through Oral route, started on 2009-10-14, presumably until 2010-04-13, with quantity of 20.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed for Pain. \n- bacitracin 0.5 UNT/MG / polymyxin B 10 UNT/MG Topical Ointment, through Topical route, started on 2009-10-14, presumably until 2009-10-15\n- hypromellose 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2009-10-14, presumably until 2009-10-14\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2009-10-14, presumably until 2009-10-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-10-27 09:45:00, ended at 2009-10-27 23:59:00\nThe patient in this visit was 60 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.22\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign neoplasm of major salivary gland\n- Finding of head and neck region\n- Swelling / lump finding\n\n### Drug\n- acetaminophen 300 MG / codeine phosphate 30 MG Oral Tablet, through Oral route, started on 2009-10-27, presumably until 2010-04-25, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-11-24 09:00:00, ended at 2009-11-24 23:59:00\nThe patient in this visit was 60 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.22\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign neoplasm of major salivary gland\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-12-08 09:03:00, ended at 2009-12-08 23:59:00\nThe patient in this visit was 60 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.22\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign neoplasm of major salivary gland\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-23 09:00:00, ended at 2010-02-23 23:59:00\nThe patient in this visit was 60 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.22\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign neoplasm of major salivary gland\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-08-31 10:45:00, ended at 2010-08-31 23:59:00\nThe patient in this visit was 61 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.75\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign tumor of soft tissue of head, face and neck\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-27 10:00:00, ended at 2011-09-27 23:59:00\nThe patient in this visit was 62 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Finding of head and neck region\n- Swelling / lump finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-13 09:40:00, ended at 2012-11-13 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Finding of head and neck region\n- Primary diagnosis: Swelling / lump finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-11 02:40:00, ended at 2013-04-11 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Morphometric analysis, tumor\n- Consultation and report on referred material requiring preparation of slides\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-15 13:07:00, ended at 2013-04-15 15:55:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.811\" (inch (US))\n\n### Procedure\n- Consultation and report on referred material requiring preparation of slides\n- Morphometric analysis, tumor\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-15 15:56:00, ended at 2013-04-15 15:57:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 80 (unit per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 51 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- MCV [Entitic volume] by Automated count: 95.4 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.44 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.2 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.63 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.2 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 4.61 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.09 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.2 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 24.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 298 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-15 15:58:00, ended at 2013-04-15 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, breast(s) (unilateral or bilateral), real time with image documentation\n- Ultrasound, limited, joint or other nonvascular extremity structure(s) (eg, joint space, peri-articular tendon[s], muscle[s], nerve[s], other soft-tissue structure[s], or soft-tissue mass[es]), real-time with image documentation\n- Mammography; unilateral\n- Computer-aided detection (computer algorithm analysis of digital image data for lesion detection) with further review for interpretation, with or without digitization of film radiographic images; diagnostic mammography (List separately in addition to code\n\n### Condition\n- Inflammatory disorder of breast\n- Edema\n- Primary malignant neoplasm of female breast\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-24 00:00:00, ended at 2013-04-24 00:00:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for all procedures on nerves, muscles, tendons, fascia, and bursae of shoulder and axilla\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, started on 2013-04-24, presumably until 2013-04-24\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2013-04-24, presumably until 2013-04-24\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2013-04-24, presumably until 2013-04-24\n- cefazolin 1000 MG Injection, started on 2013-04-24, presumably until 2013-04-24\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-04-24, presumably until 2013-04-24\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-04-24, presumably until 2013-04-24\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-04-24, presumably until 2013-04-24\n- midazolam 1 MG/ML Injectable Solution, started on 2013-04-24, presumably until 2013-04-24\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2013-04-24, presumably until 2013-04-24\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2013-04-24, presumably until 2013-04-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2013-04-24 00:00:00, ended at 2013-04-24 00:00:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- indocyanine green, started on 2013-04-24, presumably until 2013-04-24\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2013-04-24, presumably until 2013-04-24\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2013-04-24, presumably until 2013-04-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-24 06:01:00, ended at 2013-04-25 09:45:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.75\" (inch (US))\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Excision of breast lesion identified by preoperative placement of radiological marker, open; single lesion\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Mammographic guidance for needle placement, breast (eg, for wire localization or for injection), each lesion, radiological supervision and interpretation (Deprecated)\n- Excision of breast lesion identified by preoperative placement of radiological marker, open; each additional lesion separately identified by a preoperative radiological marker (List separately in addition to code for primary procedure)\n- Local excision of lesion of breast\n- Biopsy or excision of lymph node(s); open, deep axillary node(s)\n- Biopsy of lymphatic structure\n- Radiological examination, surgical specimen\n- Preoperative placement of needle localization wire, breast\n- Lymphatics and lymph nodes imaging\n- Preoperative placement of needle localization wire, breast; each additional lesion (List separately in addition to code for primary procedure)\n\n### Condition\n- Carcinoma in situ of breast\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2013-04-24, presumably until 2013-04-24\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2013-04-24, presumably until 2013-04-24\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2013-04-25, presumably until 2013-05-07, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed for Pain.\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2013-04-25, presumably until 2013-05-14, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-02 10:00:00, ended at 2013-05-02 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2.795\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- acetaminophen 300 MG / codeine phosphate 30 MG Oral Tablet, through Oral route, started on 2013-05-02, presumably until 2013-10-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-07 00:00:00, ended at 2013-05-07 00:00:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on the integumentary system on the extremities, anterior trunk and perineum; not otherwise specified\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- cefazolin 1000 MG Injection, started on 2013-05-07, presumably until 2013-05-07\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2013-05-07, presumably until 2013-05-07\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-05-07, presumably until 2013-05-07\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-05-07, presumably until 2013-05-07\n- 250 ML lidocaine hydrochloride 8 MG/ML Injection, through Intravenous route, started on 2013-05-07, presumably until 2013-05-07\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2013-05-07, presumably until 2013-05-07\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2013-05-07, presumably until 2013-05-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2013-05-07 00:00:00, ended at 2013-05-07 00:00:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2013-05-07, presumably until 2013-05-07\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2013-05-07, presumably until 2013-05-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-07 05:34:00, ended at 2013-05-07 11:28:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- Radiological examination, surgical specimen\n- Mastectomy, partial (eg, lumpectomy, tylectomy, quadrantectomy, segmentectomy)\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Local excision of lesion of breast\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n- Gastroesophageal reflux disease\n- Carcinoma in situ of breast\n\n### Drug\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2013-05-07, presumably until 2013-05-07\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-05-07, presumably until 2013-05-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-14 09:00:00, ended at 2013-05-14 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' .984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-16 07:56:00, ended at 2013-05-16 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.811\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-27 12:58:00, ended at 2013-05-27 15:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.811\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-27 16:00:00, ended at 2013-05-27 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology treatment planning; complex\n- Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, onl\n- Computed tomography guidance for placement of radiation therapy fields\n- 3-dimensional radiotherapy plan, including dose-volume histograms\n- Therapeutic radiology simulation-aided field setting; complex\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-29 09:30:00, ended at 2013-05-29 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- 3-dimensional radiotherapy plan, including dose-volume histograms\n- Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, onl\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-05-30 00:00:00, ended at 2013-05-30 00:00:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-17 11:30:00, ended at 2013-06-17 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.811\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-06-27 00:00:00, ended at 2013-06-27 00:00:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-28 10:01:00, ended at 2013-06-28 10:57:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology simulation-aided field setting; simple\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-28 10:58:00, ended at 2013-06-28 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.417\" (inch (US))\n\n### Procedure\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-06-28, presumably until 2013-06-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-01 09:57:00, ended at 2013-07-01 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n- Radiation treatment management, 5 treatments\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-02 09:52:00, ended at 2013-07-02 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-03 09:48:00, ended at 2013-07-03 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-04 10:07:00, ended at 2013-07-04 12:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n- Therapeutic radiology port image(s)\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- nystatin 100 UNT/MG Topical Powder, through Topical route, started on 2013-07-04, presumably until 2014-02-04, with intended 0 refill(s). Instructions: by Topical route 4 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-04 13:00:00, ended at 2013-07-04 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-05 09:45:00, ended at 2013-07-05 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-08 09:47:00, ended at 2013-07-08 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n- Radiation treatment management, 5 treatments\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-09 09:37:00, ended at 2013-07-09 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-10 09:38:00, ended at 2013-07-10 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-11 09:45:00, ended at 2013-07-11 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-12 09:23:00, ended at 2013-07-12 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-15 07:54:00, ended at 2013-07-15 08:56:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment management, 5 treatments\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-15 08:57:00, ended at 2013-07-15 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.811\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-16 09:40:00, ended at 2013-07-16 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology port image(s)\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-17 07:24:00, ended at 2013-07-17 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-18 09:29:00, ended at 2013-07-18 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-19 07:34:00, ended at 2013-07-19 08:19:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-19 08:20:00, ended at 2013-07-19 23:59:00\nThe patient in this visit was 63 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-03 14:00:00, ended at 2013-10-03 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.811\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-10-10 00:00:00, ended at 2013-10-10 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-04 11:18:00, ended at 2014-02-04 13:37:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computer-aided detection (computer algorithm analysis of digital image data for lesion detection) with further review for interpretation, with or without digitization of film radiographic images; screening mammography (List separately in addition to code \n- Screening mammography, bilateral (2-view study of each breast)\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-04 13:38:00, ended at 2014-02-04 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.811\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-04 12:56:00, ended at 2014-09-04 23:59:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.811\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-12-30 00:00:00, ended at 2014-12-30 00:00:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-04 12:15:00, ended at 2015-02-04 23:59:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.811\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Swelling / lump finding\n- Primary diagnosis: Finding of head and neck region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-26 10:36:00, ended at 2015-02-26 13:40:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Screening digital breast tomosynthesis, bilateral (List separately in addition to code for primary procedure)\n- Computer-aided detection (computer algorithm analysis of digital image data for lesion detection) with further review for interpretation, with or without digitization of film radiographic images; screening mammography (List separately in addition to code \n\n### Condition\n- Postmenopausal state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-26 13:41:00, ended at 2015-02-26 23:59:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-03-02 00:00:00, ended at 2015-03-02 00:00:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoma in situ of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-09-14 12:51:31, ended at 2015-09-14 16:22:09\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.417\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Radiation-induced disorder\n- Disorder of breast\n- Postprocedural state finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-10-15 09:53:08, ended at 2015-10-15 15:02:31\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.417\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of breast\n- Radiation sickness\n- Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2015-11-03 00:00:00, ended at 2015-11-03 00:00:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bacitracin 5000 UNT/ML Injectable Solution, through Intramuscular route, started on 2015-11-03, presumably until 2015-11-03\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2015-11-03, presumably until 2015-11-03\n- bacitracin zinc 0.5 UNT/MG Topical Ointment, through Topical route, started on 2015-11-03, presumably until 2015-11-03\n- 1 ML epinephrine 1 MG/ML Injection, started on 2015-11-03, presumably until 2015-11-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-11-03 00:00:00, ended at 2015-11-03 00:00:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on the integumentary system on the extremities, anterior trunk and perineum; reconstructive procedures on breast (eg, reduction or augmentation mammoplasty, muscle flaps)\n\n### Condition\n- Deformity of reconstructed breast\n- Disproportion of reconstructed breast\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2015-11-03, presumably until 2015-11-03\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2015-11-03, presumably until 2015-11-03\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2015-11-03, presumably until 2015-11-03\n- cefazolin 1000 MG Injection, started on 2015-11-03, presumably until 2015-11-03\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2015-11-03, presumably until 2015-11-03\n- 2 ML ondansetron 2 MG/ML Injection, started on 2015-11-03, presumably until 2015-11-03\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-11-03, presumably until 2015-11-03\n- midazolam 1 MG/ML Injectable Solution, started on 2015-11-03, presumably until 2015-11-03\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2015-11-03, presumably until 2015-11-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-11-03 12:45:00, ended at 2015-11-03 20:28:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1\" (inch (US))\n\n### Procedure\n- Excision of Left Breast, Open Approach\n- Alteration of Right Breast with Autologous Tissue Substitute, Open Approach\n- Excision of Abdomen Subcutaneous Tissue and Fascia, Open Approach\n- Breast reconstruction with other technique\n- Breast reduction\n- Level III - Surgical pathology, gross and microscopic examination Abortion, induced Abscess Aneurysm - arterial/ventricular Anus, tag Appendix, other than incidental Artery, atheromatous plaque Bartholin's gland cyst Bone fragment(s), other than pathologi\n\n### Condition\n- Disorder caused by alcohol\n- Disorder of breast\n- Late effect of complications of procedure\n- Late effect of radiation\n- Deformity of reconstructed breast\n- Primary diagnosis: Radiation sickness\n- Disproportion of reconstructed breast\n- Postoperative state\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2015-11-03, presumably until 2015-11-03\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2015-11-03, presumably until 2016-02-04, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2015-11-03, presumably until 2015-11-10, with intended 0 refill(s). Instructions: take 1 Cap by mouth every 6 hours for 7 days\n- bacitracin zinc 0.5 UNT/MG Topical Ointment, started on 2015-11-03, presumably until 2016-02-04, with intended 0 refill(s). Instructions: Please place over bruised areas as needed\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2015-11-03, presumably until 2015-11-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-11-10 00:00:00, ended at 2015-11-10 00:00:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2015-11-10, presumably until 2015-11-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-11-10 00:00:00, ended at 2015-11-10 00:00:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2015-11-10, presumably until 2015-11-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-11-10 00:00:00, ended at 2015-11-10 00:00:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2015-11-10, presumably until 2015-11-17, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-11-11 10:33:02, ended at 2015-11-11 13:20:11\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Postoperative state\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Malignant tumor of breast within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of breast_cancer means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "4f26b0fd3bdf998f1381d910ead921fd7b902282cfe9f3b8f77187869d43eb5c", "prompt_hash": "e795f2a9b68f5be050536bc94f24ddd881469b5fa6e9d7d395bdefa316f419a5", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
